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ABSTRACT
Eric F. Donaldson: Computational and Molecular Biology Approaches to Viral Replication
and Pathogenesis
(Under the direction of Ralph S. Baric)
The primary objective of this dissertation was to combine the power of bioinformatics
with synthetic genomics, reverse genetics, and molecular genetic approaches to generate a
platform technology, with which to empirically test well-informed hypotheses towards
understanding complex mechanisms of viral pathogenesis and replication.  This integrative
strategy was used to: 1) identify unique sequence signatures that were associated with
aberrant or altered gene function, focusing on replicase and structural proteins of the
Coronavirus family and the capsid protein of the Norovirus family; 2) use these sequence
signatures to generate hypotheses and predictions about gene function or evolution; and then
3) empirically test these models using reverse genetics, synthetic biology, molecular genetics,
and biochemistry in the laboratory setting.  Applying this integrative strategy allowed us to
generate three informative models.  First, we generated an informative model for the
pleiotropic role of a Coronavirus non-structural protein 10 in replication and proteolytic
processing, by demonstrating that this protein regulates RNA transcription during replication,
in addition to an essential role in polyprotein processing.  Second, we demonstrated that the
receptor-binding domain of the Coronavirus spike protein is the minimal domain requiring
adaptation for host range switching, which helps explain the evolutionary epidemiology of
SARS-CoV emergence from zoonotic reservoirs.  And finally, we generated an informative
iii
model for the molecular mechanisms governing the persistence of the GII.4 noroviruses in
human populations, whereby we demonstrated that these viruses persist by evolving unique
epitopes on the capsid protein surface to circumvent herd immunity and mediate receptor
switching.
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CHAPTER I: BIOINFORMATICS METHODS USED IN THIS DISSERTATION
1. GENERAL INTRODUCTION TO BIOINFORMATICS
The explosion of sequence information in the past several years has generated the
need for quality and novel computational tools which allow one to search through databases,
sift through hundreds to thousands of similar sequences, sort the sequences by any number of
parameters, compare a subset of those sequences, categorize the similarities and differences
between related clusters, and characterize sequences based on multiple characteristics; all
with the goal to integrate this important biological information into models for empirical
testing.  Although the field of bioinformatics originated prior to the explosion of sequences
brought on as a result of the golden age of genomics, this field took off in direct proportion to
the identification of more complex questions that could be answered by delving further into
the sequence information contained in the public databases.  As a result, a multitude of new
tools has been developed to answer general and specific questions about gene function and
the molecular mechanisms governing genome and proteome evolution and adaptation over
time.  Along the way, tools to further study the characteristics of important individual
molecules have also emerged, allowing molecular visualization, analyses of amino acid or
nucleic acid properties, and characterization of proteins based upon known and predicted
parameters.
In short, bioinformatics has provided the molecular biologist with an essential toolbox
of important tools which can be used to build informed hypotheses, to provide a logical
2framework for mutational design, to model mutational impacts on a structure, and even to
analyze and design genes with predicted phenotypes which can be synthesized with expert
precision and at costs which out compete conventional cloning costs and time.
The over-riding goal of this dissertation was to merge the power of bioinformatics,
synthetic genomics, and molecular biology and build informed, testable hypotheses, to guide
a rationale design of site directed mutagenesis targets, and to analyze mutational impacts on
putative and solved structures of the target proteins.  Moreover, we combined these
methodologies to build informative models on the evolutionary epidemiology of virus
disease emergence from zoonotic reservoirs and disease persistence in human populations.
These strategies were applied to two different families of RNA viruses, the Coronaviruses
and the Noroviruses, each of which will be introduced in detail in later chapters.
 Noroviruses and coronaviruses include a large group of mammalian plus stranded
RNA viruses that are major contributors to human and livestock disease worldwide.  Both
virus families evolve rapidly in the face of changing ecologies providing a definable
mutational landscape that can rapidly adapt to the human immune response, or other selective
pressures.  Although our studies focused on these two different RNA virus families, the
unifying foundation was the application of bioinformatics approaches to 1) identify unique
sequence signatures that were associated with aberrant or altered gene function, focusing on
replicase and structural proteins of the Coronavirus family and the capsid protein of the
Norovirus family, 2) use these sequence signatures to generate hypotheses and models of
gene function or evolution, and then 3) empirically test these models using reverse genetics,
synthetic biology, molecular genetics and biochemistry in the laboratory setting.
3The following bioinformatics tools were used to develop a strategy for investigating
specific problems in the fields of Coronavirus replication and Norovirus pathogenesis.
2. SEQUENCE DATABASE SEARCHING AND INITIAL ANALYSES OF SINGLE
    SEQUENCES
Many sequence databases have been established to store and maintain the millions of
nucleotide and protein sequences that have been identified and published. The National
Center for Biotechnology Information (NCBI) is a national resource in the United States for
molecular biology information (16, 24).  NCBI creates and maintains enormous databases of
nucleotide and protein sequences, and was used extensively in gathering sequences used in
this dissertation.  Along with the sequences, NCBI creates the tools necessary for searching
through these sequences using a variety of parameters from sequence name (Entrez)(19, 20),
to characteristics of the sequences themselves (Basic Local Alignment Search Tool, BLAST:
http://www.ncbi.nlm.nih.gov/blast/Blast.cgi)(2).  BLAST has become the most popular tool
used for searching for similar sequences, using a distance matrix to determine relatedness of
nucleotides or amino acids, and then searching for matches by matching with small
fragments and then extending the gaps (2).  Other search tools have been shown to be more
accurate, but at a cost of more computational time, and thus BLAST has remained the most
popular search tool.
Sequence annotation and verification are two major problems that exist in sequences
contained in NCBI databases (http://www.ncbi.nlm.nih.gov/)and other large repositories that
share information with NCBI.  In most cases, sequences are deposited by a researcher and
may contain sequence errors or have annotation problems that have not been identified or
corrected by the curators of the database(29, 45, 46).  Because of the large number of
4sequences in the database and the exponential rise in new sequences each year (Fig. 1), it is a
major problem that will not soon be solved.  Therefore one must exercise caution when
downloading and using sequences from public databases(29, 45, 46).
Figure 1: Growth of GenBank 1982-2005 (23).
Other more reliable databases exist, where sequence information is hand curated,
such as SwissProt (http://www.expasy.org/sprot/), however these databases often contain
fewer more reliable sequences, and thus serve more as a double check for sequences acquired
from the larger databases rather than a source of all available sequences for a given search.
Once a sequence or set of sequences is established, it is necessary to assign a name to each
such that it is informative in the final analyses.  While this can be a tedious process for
hundreds of sequences, it is essential as trees or alignments using accession numbers are
impossible to analyze with ease and speed.  The Bioperl (http://www.bioperl.org)project
provides a very useful toolkit for sequence manipulation, using the perl platform.  It provides
a series of modules that can be called from a script to do hundreds of processes such as
removing duplicate sequences from your file or database, removing sequences that do not
5meet a length requirement, renaming the sequences, removing sequences that do not meet a
similarity criterion, as well as then feeding those sequences into a variety of sequence
analysis packages for further study of the sequences, either by individual characteristics or as
alignments of multiple sequences (see section 3).  One important method facilitates a search
of a nucleotide sequence to DNA cleavage sites for specific restriction endonucleases.
Analyzing nucleotide sequences for restriction digestion sites using a restriction
enzyme database.  In addition to sequence databases, there are also restriction enzyme
databases that facilitate the identification of restriction sites in a sequence of interest.  This is
often necessary when trying to determine a cloning strategy for a gene to be synthesized or
mutated.  Type IIS restriction enzyme sites are often desirable for cloning as they leave a
unique uni-directional sticky end that allows for ligation in the correct orientation, when
piecing together fragments(42-44).  In addition to modules in the Bioperl package
(http://www.bioperl.org), New England Biolabs provides a restriction analysis tool called the
NEBcutter (http://tools.neb.com/NEBcutter2/index.php), a user friendly online tool that
analyzes a nucleotide sequence that is copied and pasted into a graphical user interface (GUI)
on line.  It performs an analysis to determine which restriction sites are found in the sequence
and how many of each is present.
Other tools, such Silent and Recode, two tools in the EMBOSS package
(http://emboss.sourceforge.net/)(31), allow one to alter the nucleotide sequence to contain
more or less of a restriction enzyme site without changing the protein sequence.  This is a
very effective way of adding additional restriction digestion sites flanking a region of
interest, which provides a mechanism for swapping that site by cutting it out and ligating it
with newly engineered fragments.
6Other important nucleotide tools include analyses of composition of each base,
determination if the sequence encodes a protein sequence (although this will likely be known
at the search stage)(EMBOSS), potential secondary structure if the sequence represents an
RNA molecule, etc (EMBOSS).  At the protein level, further analyses can be conducted on a
sequence of interest.  Some of the analyses that can provide clues as to function include:
determination of amino acid composition, determination secondary structure, and
identification of functional or structural domains that are found in your protein of interest,
but also conserved in proteins of known structure (programs available through EMBOSS).
Protein domains can be defined as key functional unit or as a key structural unit.  At
the structural level, a protein domain is a region that is independent of other regions, and may
even function separately from them.  These domains may have evolved independently of the
others present, and often domains in a protein evolve at different rates.
At the functional level, a domain is described as a region of the protein that is
involved in one or more identified functions and may include enzymatic activities,
phosphorylation, and other posttranslational modification sites, or transmembrane regions.
These are often important sites in predicting the function of a protein and/or predicting how
its function is activated, and these are critically important for generating a hypothesis about
the protein’s function.  There are several excellent tools for analyzing a protein sequence and
predicting if any known functional domains exist.
Using the Prosite database to predict functional domains.  Prosite (8, 14, 15, 36)
(http://www.expasy.ch/prosite/) is an online database of protein families and domains, which
is comprised of patterns and profiles that have been defined for more than a thousand protein
families or domains.  While there are an enormous number of different proteins, most can be
7categorized into a smaller number of families based on similarities in their sequences.
Proteins or protein domains that group into a particular family are likely to share similar
functions and are likely derived from a common ancestor.  Prosite currently provides access
to patterns and profiles specific for over one thousand protein families or domains.  Along
with each signature, Prosite provides background information on the structure and function
of these proteins (8, 14, 15, 36).  Searching this database with an amino acid sequence of
unknown function will map the known functional domains onto the sequence, and this
information not only provides insight into the function of the protein, but also provides a
framework for empirical model testing and design.
Using the SMART database and webtool to predict functional domains.  The
Simple Modular Architecture Research Tool (SMART)(18, 35) is an online tool
(http://smart.embl-heidelberg.de/) that determines if genetically mobile domains and domain
architectures are present in a protein sequence of interest.  SMART contains domains and
architectures that represent more than 500 domain families identified in signaling,
extracellular and chromatin-associated proteins, and these were annotated by phyletic
distributions, functional class, tertiary structure, and functionally important residues(18, 35).
The SMART tool allows for the identification of putative functional domains and motifs in a
protein of interest.
While functional domains are important clues, other regions of the protein sequence
may also be important.  Many proteins have been identified with small regions that do not
assume a secondary structure, and therefore named a disordered region.  Generally, these
regions do not assume a secondary structure until they come in contact with a binding
partner.  Often the binding partner will be another protein that interacts to form a homo- or
8heterodimers or other multimers; or it could be binding a nucleic acid or carbohydrate.
Identifying the binding partner can provide direct evidence for the function of the protein.
Using Predictors or Natural Disordered Regions (PONDR) to identify regions of
disorder in protein sequences of unknown function.  PONDR (32) is an online tool
(http://www.pondr.com/background.html) that analyzes an amino acid sequence to predict
which regions may be disordered in a three dimensional structure.  The program utilizes a
neural network to search an amino acid sequence for patterns of amino acids (such as pairs of
like charged amino acids occurring adjacent to one another) that have known disordering
qualities.  The different patterns identified are scored and compared to a threshold derived
from known protein structures with characterized disordered regions.  Matches scored above
the threshold indicate amino acids that comprise a region likely to be disordered(32).
In addition to these tools, there are a variety of other tools available to determine
specific characteristics of a single protein sequence.  For example, tools exist to determine
predicted molecular weight, to predict secondary structure, to determine hydrophobicity, to
predict the tertiary structure, and to determine transmembrane regions (EMBOSS (31)).
These tools are helpful for answering specific questions if necessary.  However, when an
investigator is interested in learning how sequences evolve, the most important starting point
is the multiple sequence alignment (MSA).
3. MULTIPLE SEQUENCE ANALYSIS
In many bioinformatics procedures, directly comparing related sequences in the form
of an alignment is not only the first step in the analysis pipeline, but is the most important
step.  The alignment is a comparison of DNA, RNA or protein sequences to identify
similarity between them that may be crucial in determining or predicting ancestry, function,
9and even structure(10).  Sequences are compared by aligning them on top of each other and
determining which columns are identical or similar enough to be a match.  In addition, most
alignment tools predict where insertions or deletions may have occurred during the evolution
of the sequences and these are shown as gaps in one or more sequences of the alignment(10).
The alignment is scored according to identical matches, conservative matches, and
mismatches as determined by which substitution matrix is selected.  Gaps are penalized by
two different strategies: 1) gap opening penalties are generally high to ensure that the
program only opens a gap as a last resort; and 2) gap extension penalties, which are lower,
are assessed based upon the length of the predicted gap(10).  The gap scoring schemes are
generally more expensive than a mismatch, which forces the program to assume that
insertions and deletions are more rare events than some mismatches(10).
The multiple sequence alignment establishes a baseline foundation upon which many
of the subsequent analyses are based.  An erroneous alignment means an incorrect starting
hypothesis, which will inevitably lead to incorrect assumptions later on.  Therefore much
care should be taken to ensure that the multiple alignment is as precise as possible(10).  This
can be accomplished by using a few safety checks: 1) Never assume that the alignment
provided by a program is correct, double check regions of high variability and
insertions/deletions.  Manually correct the alignment if necessary.  2) Never assume that the
default substitution matrix is the most accurate for your dataset.  The different substitution
matrices are hypotheses of how substitutions occur, and should be treated with caution.
Different matrices may provide different alignments, and these should be compared.  3)
Never assume that the gap opening and extension penalties built into the different programs
are accurate in every instance.  These parameters may greatly influence the alignment scores,
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resulting in differential optimal alignments. It is best to try a variety of parameters to
determine which are optimal(10).
Multiple alignments using ClustalX and TuneClustal.  ClustalX version 1.83(12)
is a widely used, freely available multiple sequence alignment tool with a user-friendly
graphical interface (http://www.ebi.ac.uk/Tools/clustalw2/index.html).   This program works
by dividing the computation of a multiple sequence alignment into three smaller steps.  First,
Clustal computes a pairwise alignment for all against all sequences and calculates similarity
scores for each, which are stored in a matrix. This similarity matrix is then converted into a
distance matrix, representing the evolutionary distance between each pair of sequences(12).
Second, Clustal generates a Neighbor-joining phylogenetic guide tree using the evolutionary
distance matrix generated by pairwise alignments(12).  Third, Clustal uses the phylogenetic
guide tree to compute the multiple alignment(12). The guide tree determines the order in
which pairs of sequences are aligned and combined with the previous alignment. The
sequences are progressively aligned at each branch point of the guide tree, starting from the
least distant pair of sequences (5, 11, 12, 38).
A variety of parameters and substitution matrices for the Clustal program can be
evaluated using the program TuneClustal version 1.0 (generously provided by Dr. Barry G.
Hall(10)).  This user-friendly tool recalculates the overall quality score of the alignment
based upon the varied parameter.  The quality score is a measure of the conservation of each
column, such that if a column has a quality score of 100, all characters in the column are
identical.  An overall quality score is calculated for each alignment, and comparing the scores
between alignments generated under different parameters indicates which parameters result
in an optimal alignment.   For example, changing the gap opening score from 7 to 8 would
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further restrict the alignment, making it more expensive to open a gap.  This would force the
alignment of more mismatches, and might result in a lower overall quality score.  If the first
alignment added gaps that were incorrect, the increased gap score might allow the program to
better predict the gaps resulting in an increased quality score.  In most cases, the gap scores
make little difference, however, determining which substitution matrix best fits the data using
TuneClustal is very informative.
Once a multiple alignment is generated and evaluated, there are often only a small
number of sites that are informative for a hypothesis.  For example, if the hypothesis is that
strictly conserved residues are important for a conserved function, then the informative sites
would be those that are conserved.  If the hypothesis is that variable sites are evolving to
avoid the human immune system, then obviously the variable sites would be the informative
sites.  In either case, the quality score can be used to evaluate and separate informative from
non-informative sites.
Generating evolutionary profiles.  Evolutionary profiles are tables of informative
sites (columns) that are exported from a multiple sequence alignment and ordered by cluster
and then by date of isolation.  In Clustal, this was accomplished by selecting the sequences to
be exported and selecting the ‘export quality scores’ option(10).  This created a file of those
sequences, with all of the positions and scores.  A perl script was written to further parse
these scores, selecting only scores that were less than 100 per column.  These were imported
into Excel, and transposed such that the sequence name was on the left, the column positions
were on top and the columns contained the amino acids.  The columns were then ordered by
cluster such that the amino acid changes were clustered together and colored. Each cluster
was further arranged by time.  In addition to the conserved sites removed, non-informative
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sites were removed based on the following criteria: 1) columns with single amino acid
replacements; 2) columns containing multiple single incongruous amino acid replacements;
3) columns containing random amino acid replacements not associated with a geographic
lineage or specific cluster; and 4) lineage specific replacements that were non-informative.
This resulted in a table of time ordered, cluster informative sites.
While a multiple alignment provides a visual representation of the differences
between sequences and exporting and analyzing informative sites can show how the
sequences are related based on the hypothesis, the best way to visualize the relationship of
one sequence to another is to generate a phylogenetic tree.
4. MOLECULAR PHYLOGENETICS
Molecular phylogenetics is the classification of nucleotide sequences encoding genes
and genomes or amino acid sequences encoding proteins based on inferred sequence
homology(10).  There are many computational methods and programs that make these
predictions, many of which make extensive use of the multiple sequence alignment in
constructing and refining a phylogenetic tree, which is a model of the predicted evolutionary
relatedness of the sequences.  The phylogenetic trees constructed by these computational
methods are unlikely to perfectly reproduce the evolutionary tree that represents the historical
relationships between the sequences, therefore the phylogenetic tree is a hypothesis about the
evolutionary ancestry of the sequences in the alignment(10).
Phylogenetic trees can be either rooted or unrooted depending on the sequences and
the method used(10).  A rooted tree is represented as a directed graph that models the
relatedness of the sequences to one another and explicitly identifies a Last Common Ancestor
(LCA), usually an inferred sequence not included in the input.  Genetic distance values are
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used to plot the tree with generally all of the input sequences becoming terminal nodes with
their distances from the root proportional to their genetic distance from the hypothesized
LCA.  At least one outgroup sequence, known to be only distantly related to the rest of the
sequences of interest, is used to root the tree(10).
In contrast, unrooted trees model the distances and relationships between input
sequences without making any assumptions regarding the order of their descent.   The total of
all possible phylogenetic trees for a given alignment of input sequences is referred to as "tree
space", and most molecular phylogenetics methods use optimization algorithms that search
through multidimensional tree space(10).  Counting the total number of trees for a nontrivial
number of input sequences can be computationally prohibitive as variations in tree topology
increase exponentially.  Several different molecular phylogenetics methods have been
described, however, it is generally accepted that similar topologies with more than one
method is necessary to substantiate any hypothesis on the evolution between the
sequences(10).
Generating trees by the Neighbor-joining method.  Neighbor-joining (NJ) is a
method that utilizes a data clustering technique whereby sequences in an alignment are
compared and given a genetic distance which is used to cluster and order all of the sequences
in a given alignment(10).  Thus, NJ is considered a distance method as it uses differences
between sequences to cluster them.  In most cases, the NJ tree is a useful first glance at the
data, however, more robust methods are required to substantiate any trends.
Bootstrapping(10) can be applied to the NJ method, whereby trees are generated from
random columns in an alignment and the number of times the branching order was the same
is assessed.  The bootstrap is generally conducted 100 or 1000 times and the branches on the
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tree would have a number that reflects the total number out of the iterations that branching
order was observed(10).  For example a bootstrap value of 70 would indicate that 700/1000
columns tested supported the consensus tree that was generated.  The cutoff for robust
representation is generally agreed to be 70 and above for bootstrap values.
Generating trees by the Maximum parsimony method.  Maximum parsimony
(MP) is a method that attempts to identify the phylogenetic tree that requires the smallest
total number of evolutionary events to explain the observed sequence data(10).  Depending
upon the scoring mechanism used, trees can include a cost associated with particular types of
evolutionary events, and so the MP program attempts to locate the tree with the lowest total
cost.   The simplest way of predicting the most parsimonious tree is by simple enumeration,
whereby each possible tree is considered in succession and the scores are compared, with the
most parsimonious tree being the tree with the lowest score.  Unfortunately, this manner of
scoring trees is only possible for a relatively small subset of sequences, as the problem of
identifying the most parsimonious tree is known to be computationally intense(10).   To
circumvent this limitation, several heuristic search methods have been developed that
optimize the search for an highly parsimonious tree, although these methods can not
guarantee that the tree identified is the most optimal in the set(10).  MP trees can also be
bootstrapped, although this can increase the computation of a tree by several days to weeks,
depending upon the number and length of the sequences in the alignment.  Phylogenetic
Analysis Using Parsimony (PAUP) (Sinauer Associates, Inc.) is a phylogenetic package that
infers MP trees, providing both exhaustive and heuristic search options.  It also allows
bootstrapping.
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Generating tree by the Maximum likelihood method.  Maximum Likelihood (ML)
infers an evolutionary tree by identifying the single best tree that maximizes the probability
of observing the sequence data presented in an alignment, given a model of evolution(10).  It
is a character-based method that calculates the log likelihood at each position in the
alignment and sums each position to derive the log likelihood for the tree.  The tree with the
largest log likelihood score meets the criteria of maximum likelihood.  Maximum Likelihood
searches all possible trees from point to point seeking higher points and more likely trees as it
goes(10).
This is similar to the MP method described above, in that both favor the least amount
of change to explain the data, however, ML builds in additional statistical flexibility by
allowing variable rates of evolution across lineages and sites.  ML requires that evolution at
different sites and along different lineages be statistically independent, therefore this method
is robust for the analysis of distantly related sequences.  However, the fact that it performs an
exhaustive search of all possible combinations of tree topology and branch length, it is
computationally intensive, and generally limited to no more than a few sequences(10).  One
caveat about ML trees is that the sampling algorithm can get trapped on a suboptimal peak
and report this peak as the maximum likelihood tree, while other more likely trees exist(10).
ML trees can also be bootstrapped to provide further statistical support to the branching order
of the tree.
 Generating trees by the Bayesian inference method.  Bayesian Inference (BI) is
also a character-based method which relies upon estimated posterior probabilities generated
using a model of evolution after deriving information about the data(10).  Both BI and ML
allow the user to determine the model of evolution and seek to identify the best trees that are
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consistent with both the model of evolution and the sequence alignment.  While ML seeks
the tree that maximizes the probability of observing the data given the tree, BI identifies a set
of trees that maximize the probability of the trees given the data (under the constraints of the
evolutionary model)(10).  This essentially rescales likelihoods to true probabilities(10).
Bayesian Inference, as implemented in the MrBayes program(13, 33), uses the
Metropolis-Coupled Markov Chain Monte Carlo (MCMCMC) algorithm that allows four
independent searches (chains) to occur simultaneously.  These chains are designed to
occasionally exchange information, which allows the method to avoid suboptimal peaks
while generating a set of trees.  The branches on a Bayesian tree are labeled with posterior
probabilities, which is a strong statistical measure.  Bootstrapping is not necessary for a BI
tree.
One caveat that is important to consider when analyzing molecular phylogenies, is
that different protein structural domains and subdomains may be evolving under different
evolutionary pressures.  In viruses for example, the most exposed region of a gene (protein)
that interacts with the human immune response may evolve much more quickly than a region
that is buried in the viral capsid or envelope.  We show in this dissertation that the P2
subdomain, which is the most exposed region of the capsid protein, evolves faster than the P1
and shell domains of the same protein.
In addition to molecular phylogenetics, which can demonstrate patterns of evolution
and descent, there are other important tools that can further characterizes the evolution
occurring in an alignment, by looking at rates of change over time.
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5. DETECTION OF POSITIVE SELECTION AND RECOMBINATION
Natural selection is the driving force of evolution.  A change in the environment,
selects for variants that have the highest fitness in the new environment, and are thus
‘selected’ for by the change in environment.  At the molecular genetic level, sites that are
changing in a gene at a higher rate than would be expected by chance are known to be
positively selected, or are undergoing positive selection.  Positive selection can be predicted
by looking at the changes that are occurring at the codon or gene level and comparing those
changes to the rest of the protein of interest(9).  If the rate of change for non-synonymous
replacements (dN) is the same as for synonymous replacements (dS) in an alignment at a
particular codon position, then that codon is evolving by neutral selection(9).  If the ratio of
dN/dS is larger than one, then this indicates that positive selection is occurring, while the
opposite dN/dS less than one would indicate negative or purifying selection(9).  Sites that are
evolving by positive selection are changing more rapidly than would be expected by chance,
due to the force of natural selection on the population(9).  In the case of a viral gene that
causes human sickness, if it has been evolving by positive selection, the sites operating under
positive selection would be candidates for interacting with and trying to evade the human
adaptive or innate immune responses.
Using the HyPhy package to detect positive selection.  The HyPHY package(26-
28) allows for the detection of positive selection at each position of an alignment, by three
different methods.  First, the Model Selection tool of the HyPhy Package
(http://www.hyphy.org/) was used to determine which model of evolution was the most
appropriate for conducting the analyses, and then three different codon-based maximum
likelihood methods were used to estimate the dN/dS ratio at every codon position in the
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alignment to determine if positive selection occurred.  These methods included: 1) single-
likelihood ancestor counting (SLAC), 2) fixed effects likelihood (FEL), and 3) random
effects likelihood (REL)(26-28).  All three of these methods use different strategies to predict
the dN/dS ratio at each position.  Ratios greater than one indicate positive selection.
Recombination is a process whereby the exchange of genetic material occurs between
two different DNA fragments which share homology.  This results in a DNA fragment
containing DNA characteristics of the two different DNAs.  This can lead to confounding
molecular phylogenetic results, as the recombinant will not cluster with of the original DNA
sequences.  Most often the recombinant sequence will appear as an outlier on a phylogenetic
tree, and the sequence will have definitive characteristics of both parents.  A recombination
break point is the position where one parental DNA ends and the other begins.
Using the HyPhy package to perform Recombination Analysis.  The Genetic
Algorithms for Recombination Detection (GARD) is a program developed as part of the
HyPhy package(26-28), which uses an efficient genetic algorithm to scan an alignment for
evidence of discordant phylogenetic signal.  This method determines:  1) if recombinant
sequences exist in the alignment; 2) the number of non-recombinant fragments present; 3)
where breakpoints occur and the confidence in their location; and 4) which phylogenetic tree
describes the evolution of each non-recombinant fragment.  In addition, a recombination
breakpoint is identified and tree generated on either side of the breakpoint(26-28).
Using the Recombination in Proteins tool to perform Recombination Analysis.
The Recombination Identification Program (RIP, http://www.hiv.lanl.gov/content/hiv-
db/RIPPER/rip_test.html) was used as an alternative approach to determine if recombination
occurred in an alignment.  This method utilizes parental sequences of known origin and
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integrity supplied by the user, to analyze putative recombinants by comparing them to the
known sequences.  This program generates an output that shows the sequence composition of
the putative recombinant such that if there is more than one of known sequences represented
in the sequence being tested, the output will show the signal from the two different sources.
For example, if a recombinant is predicted from DNA A and DNA B then the recombinant
would be displayed as having characteristics of both.
6. STRUCTURAL ANALYSIS OF PROTEINS
While using the tools described above can provide important clues about a protein’s
function and ancestry, the reality is that structural information is still one of the most
important determinants of a protein’s function.  Therefore in order to determine which
residues are important to function, and to learn more about the importance of the amino acids
properties, a structure is required to allow for the analysis of the amino acids in direct
relation to their structural loci.  The gold standards in the field are structures solved by X-ray
crystallography and Nuclear Magnetic Resonance (NMR), which provide reliable structural
coordinates and robust predictions of what structure a protein will assume in three-
dimensional space.
X-ray crystallography is the science, or often the art, of solving the atomic
arrangements within a crystal utilizing a beam of X-rays that scatters from the electrons
within that crystal(41). The crystal is generated from a concentrated, purified solution of the
protein of interest (or other mineral, salt, biological molecule, etc.)(41).  Further, the crystal
is a solid comprised of a repeating arrangement of atoms known as a unit cell(41). It is
generally the unit cell structure that is solved. This method generates a three-dimensional
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image of the density of the electrons within the crystal, which allows predictions of the mean
atomic positions, chemical bonds between atoms, etc.  These atomic coordinates can then be
used to generate 3D images of the crystal structure(41).
NMR spectroscopy is a second method capable of generating a 3D structure based on
predicted physical, chemical, electronic and structural information about proteins.  Basically,
NMR utilizes the phenomena that many atomic nuclei have spin and all nuclei are electrically
charged(40).  When a purified protein sample is exposed to an external magnetic field, an
energy transfer can be measured based on the difference between the base energy and a
higher energy state.  This transfer occurs at a wavelength that correlates to specific radio
frequency, and when the spin returns to its base state, energy is emitted at this same
frequency(40).  This emitted signal that matches the transfer is measured and processed to
yield an NMR spectrum.  The spectra of all atoms are then analyzed to determine atomic
positions of a 3D structure.  NMR is a powerful tool capable of providing detailed
information on the topology and three-dimensional structure of molecules in solution or as a
solid(40).  A protein structure is evaluated by its resolution, which is determined by analysis
of multiple isomorphous replacement techniques, and is reported in Angstroms difference
between the isomers(40).  The closer the isomers are, the smaller the Angstroms, the better
the resolution.  The best structures are solved to a resolution of less than 1 angstrom, while
low-resolution structures solved at 5 angstroms or higher may provide significant insights
into the structure, but will contain multiple errors, including wrong rotameric positions, and
even incorrect folds, and therefore must be studied with caution.  Generally, structures with
resolutions between 1 and 3 are reliable(41).
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  While a crystal structure provides evidence of what structure a molecule assumes,
the results must be analyzed with a few assumptions.  First, although the structure appears
rigid, biological molecules are dynamic, and thus a structure is simply a snapshot of an
instance or phase of the protein’s structure.
When comparing one structure or model by superimposing it on another structure or
model, the root mean square deviation (RMSD) is used to estimate the differences between
values predicted by the model and the values actually observed(41).  The smaller the RSMD,
the closer the two structures or models are predicted to be.
The main depository for three-dimensional structures, worldwide, is the Protein
Database (PDB)(17, 37, 39) (http://www.rcsb.org/pdb/home/home.do), which currently
contains 49,048 solved structures (90% of which were solved by X-ray crystallography) of
large biological molecules, including proteins and nucleic acids.  In addition, the PDB
provides tools and resources free of charge to the scientific community, which enables
research and education about the molecular basis of life.
While the number of solved structures is growing rapidly, we are a long way from
having solved structures for every protein.  Several strategies have been developed to
circumvent this problem by providing tools that provide reasonable predictions of what a
structure might look like, based upon an amino acid sequence, and homology shared between
the unknown and a protein or structural domain of known function.  Tools that use these
strategies are discussed in the next section.
7. HOMOLOGY MODELS
Homology modeling, also known as comparative modeling, is a method of predicting
an atomic-resolution structural model of a protein based on its amino acid sequence.  This
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method utilizes a template, which is a known protein structure that shares homology at the
amino acid sequence level with the protein of unknown structure, called the query sequence.
In many cases, a template can be selected and provided by the user, or determined by
searching a database of structures and identifying a template that shares homology with the
query sequence.  This is determined by generating an alignment between the query and the
template that compares residues in the query sequence to residues in the template sequence.
The sequence alignment and template structure are then used to produce the structural model
of the query sequence, by using the structural coordinates of the template. It is known that
protein structures are more conserved than protein sequences, therefore sequence similarity
strongly implies structural similarity (21).
Further, Chothia and Lesk showed in 1986 that many homologues share folds
depending upon sequence identity, indicating that the greater the sequence identity between
two protein sequences, the greater the agreement between the two structures. These authors
proposed a formula to calculate an expected average deviation per backbone atom from the
overall sequence identity:
deviation [angstroms] = 0.4 exp (1.87 x sequence difference)
Along with this natural limitation, modeling methods introduce more errors, particularly with
the less reliable parts of a model being the exposed loops, while secondary structure elements
tend to be more conserved.
While homology modeling is a powerful tool in structure prediction there are a couple
of important caveats that should be considered.  First, the predicted structural model is only
as good as the alignment between the template and the query sequences.  Thus, sequences
that are distantly related may not provide good models.  Most programs will generate a
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prediction regardless, and so it is important to analyze the alignment to determine if the
template is a good fit.  Second, homology models force the query sequence onto the template
structure, without adjusting the backbone.  This can be misleading if the changes in the query
sequence result in modifications to a proteins backbone.  Third, a model is generally less
reliable than the template from which it was derived, therefore templates of low-resolution
will generate models of even lower resolution.
Using 3Djigsaw to generate homology models.  3D-JIGSAW is an automated
online tool (http://www.3djigsaw.orf/) that predicts three-dimensional models for proteins
based on homologues of a known structure(3, 4, 6).  Using the Automatic mode the program,
allows searches for homologous templates in an online sequence database which includes
proteins from PFAM, PDB, and the nr of NCBI; and then splits the query sequence into
domains.   If reasonably good template structures are found, the most structurally
homologous domain is modeled using a maximum of two of the template structures. This
tool returns a predicted model as a PDB formatted set of coordinates, which can be displayed
with molecular visualization software such as PyMol.  A second option, the Interactive mode,
allows the user to choose the domains to model and select the templates and/or correct the
alignment before submitting the job. In both modes, the templates are ranked according to the
coverage of the query, their sequence identity and their crystallographic resolution.
One advantage to this method is that even if there are no good template structures to
model the sequence, the program can recognize folds of some domains that correspond to
PFAM proteins of known structure.
Using Modeller to generate homology models.  Modeller
(http://www.salilab.org/modeller) was a second method used in this dissertation for
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homology or comparative modeling of protein three-dimensional structures (21, 22). For this
program there is an online version (http://toolkit.tuebingen.mpg.de/) or a downloadable
package compatible for Macintosh that allowed more modification to parameters.  Modeller
requires that the user provide an alignment of the sequence to be modeled along with a
template sequence of a protein of known structure.  Modeller then calculates a structural
model containing all non-hydrogen atoms.
Modeller generates homology models by the satisfaction of spatial restraints method
(1, 34), and in addition to generating putative structures the Modeller package can perform
additional tasks, such as multiple alignment of protein sequences and/or structures and de
novo modeling of loops in protein structures.  One useful feature is that it allows one to
generate multiple predictions for each protein sequence, and these different iterations can be
compared with the structure having the lowest objective function score being the most robust.
Using Rosetta Design to generate mutated models.  Rosetta Design is an online
protein design program written and maintained by the Kuhlman lab at UNC.  It predicts the
lowest energy structure for an amino acid sequence of a known structure that has been
redesigned with one or multiple amino acid replacements (7). While this program does not
allow the backbone to be readjusted, it does allow for all amino acids within an interaction
distance to repack in the presence of the new amino acid(s).   This program is extremely
useful in generating models of a biological unit of the protein, especially if that biological
unit is a multimer, as it allows all chains of a pdb file to be manipulated simultaneously.
Most homology modeling programs are limited to a single chain, making it necessary to
piece together an entire prediction, whereas Rosetta Design allows a single design on the
entire biological unit.
Using Rosetta HMMster server to predict ab initio protein structures.  In addition to
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Rosetta Design, the Rosetta team has also developed a very successful ab initio protein
structure prediction tool called Rosetta HMMster
(http://www.bioinfo.rpi.edu/~bystrc/hmmstr/server.php).  This tool has consistently
performed well at the Computer Assisted Structure Prediction (CASP) competitions held
annually.  This tool works by comparing an amino acid sequence of unknown structure to a
database of hidden Markov models generated from analyzing known structures and
identifying conserved structural patterns based on small amino acid segments.  The structure
is then predicted by piecing together all of the predicted structural segments.  This ab initio
process is very good at predicting secondary structural elements such as helices and sheets,
but less robust at predicting loops.
8. MOLECULAR MODELING
Once the atomic coordinates of a protein structure have been solved, molecular
modeling is the process whereby these coordinates generated by x-ray crystallography or
NMR can be visualized in three-dimensional space.  It allows one to analyze a structure using
a variety of parameters, and it is very useful for examining a protein structure from a variety
of angles and positions.  Many tools have been developed for molecular visualization,
however only a handful have been made available as open source tools readily available to
the research community.  In addition, among the tools available, each has unique features,
such that in most cases more than one tool is required to fully analyze a protein of interest.
Using PyMOL to visualize structures.  PyMOL is an open-source, user-sponsored,
molecular visualization system created, maintained, and distributed by DeLano Scientific
LLC (http://pymol.sourceforge.net/).  Its strength is that is allows the user to produce high
quality 3D images of biological macromolecules such as proteins and carbohydrates, and it is
26
one of only a few open source visualization tools available for use in structural biology.  In
addition, it provides several features that many of the other open source tools lack, such as
movie making capabilities, ray tracing, mutagenesis tools, and command line accessibility on
a python platform.  In addition, PyMOL provides tools to incorporate mutations onto a
structure, alter rotameric positions of amino acids, measure distances between atoms of
interest, and to compare two structures by superimposing one upon the other and calculating
a RMSD to determine how close the two structures are to each other.
Using Chimera to visualize and compare structures.  Chimera is a highly
extensible molecular visualization package, developed by the Resource for Biocomputing,
Visualization, and Informatics at the University of California at San Francisco
(http://www.cgl.ucsf.edu/chimera/)(25).   Chimera is a great tool for interactive visualization
and analysis of molecular structures, generating supramolecular assemblies, analyzing
sequence alignments, and interpreting docking results. In addition, Chimera provides a
platform to generate high-quality images and animations.  However, using Chimera requires
a great deal of structural and computational expertise, making it a cumbersome tool for even
the most savvy molecular biologist.
9. BIOINFORMATICS STRATEGIES USED IN THIS DISSERTATION
There were a number of preliminary bioinformatics studies conducted to determine
what could be learned by comparing sequences with other known homologous sequences,
conducting multiple sequence alignments, and generating trees via molecular phylogenetics.
In each of the examples listed below, we developed a pipeline through which we conducted
the bioinformatics analyses, which guided our experimentation.  In many cases, testing
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hypothesis via experimentation resulted in more questions, which required further
bioinformatics analyses, and then more experimentation.
In some cases, genes were designed by bioinformatics analyses, and then generated
via synthetic biology.  Synthetic biology is the field of generating the actual DNA based
upon a published, engineered, or otherwise acquired sequence.  A webtool called DNA 2.0 is
a user-friendly tool that provides a platform for manipulating DNA sequences to design
genes for synthesis (http://www.dna20.com/).  There are several companies that synthesize
the DNA, and place it into a convenient vector for amplification.  Synthetic biology is
gaining in popularity because the cost to synthesize DNA has dropped in some cases to 65
cents per base for sequences that are verified and guaranteed to be free of point mutations.  In
many cases, multiple genes bearing alternate mutations can be synthesized from the first
synthetic sequence for even less.
In other cases, genes were designed to drop into the Venezuelan Equine Encephalitis
(VEE) viral replicon system developed by the Johnston lab at UNC (30).  This system allows
for the amplification of a protein of interest by adding its gene into the viral genome.
Briefly, the heterologous gene is inserted in place of the viral structural genes, and driven by
a 26S promoter.  This construct is co-transfected into cells along with the structural genes
provided in trans.  This allows for the recombinant viral RNA to be taken up in the viral
capsid and these VEE Replicon Particles (VRPs) are then capable of infecting cells and
producing copious amounts of the protein of interest (Fig. 2).  Since the VEE structural genes
are not encoded within the recombinant genome, this is a one-hit event.  This is a great
system for delivering an antigen of interest in an attempt to provoke an immune response in
vaccine studies.  A third overall strategy was to design mutated DNA fragments that could be
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engineered into an established infectious clone to determine the effect on viral replication.  In
addition, we used bioinformatics analyses to design two novel infectious clones.
Figure 2:  Depiction of VEE genome, RNA, replicons, and helpers (adapted from (30)).
An infectious clone is simply a system that allows one to generate an infectious full-
length viral RNA from manipulated cDNA fragments.  Prior to this work, the Baric lab had
established three infectious clones for Coronaviruses, including the Transmissible
Gastroenteritis Virus (TGEV) (42), the Mouse Hepatitis Virus (MHV) (44), and Severe
Acute Respiratory Syndrome Coronavirus (SARS-CoV) (43).  These will be detailed in later
chapters, but suffice it to say that each fragment of an infectious clone is small enough to
mutate with reasonable ease and speed, whereas working with an entire genome, particularly
a coronavirus genome, which is nearly 30kb, is tedious in most cases.
Below are the specific bioinformatics pipelines that were established and used to
generate hypotheses that resulted in the data presented in this dissertation.
Designing genes to be synthesized.  There were two strategies used to design genes.
First, genes were designed to drop into the already established SARS-CoV and MHV
infectious clones.  Many of the designed genes contained single codon changes that resulted
7546                     11329
transgene
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in mutation to an amino acid of interest, although whenever possible codons were changed in
as many positions as possible to limit reversion events.  To initiate the design, the known
gene sequence was analyzed and engineered to incorporate the mutant codon along with
unique restriction endonuclease sites to facilitate its insertion into the correct position of one
of the cDNA fragments of the infectious clone.  The design in this case was to identify
convenient restriction sites flanking the loci of the mutation, and then designing the sequence
so that after cloning it could be digested and ligated into the larger cDNA fragment.  In the
second strategy, genes were designed from sequences deposited in public databases, to create
reagents that were either not available, or not released to the research community.  In this
case, extensive sequence analysis was performed to determine if the sequence was legitimate
(Fig.3).
Figure 3.  Strategy for designing a gene from a downloaded sequence.
It is known that many sequences deposited in the public databases contain sequence errors,
insertions, deletions, or have problems with annotation.  Therefore, a consensus sequence
was generated using a multiple alignment of as many sequences as available (Fig. 3).  Once
consensus was established the gene was often designed with VEE linkers to allow quick and
easy cloning into the VEE vector for protein amplification.  In many cases, additional silent
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restriction sites were engineered into the gene sequence such that a specific domain could be
easily swapped if necessary.
Once genes were designed, they could either be created in the lab using traditional
PCR techniques, or they were submitted to companies, which specialize in synthesizing
DNA.  We found that in many cases it was cheaper to have the DNA generated by one of
these companies than it was to clone it ourselves (discussed in Chapters VI, VII, and IX).
 Designing full-length molecular clones.  The design of full-length molecular clones
from genomic sequences downloaded from public sequence databases was similar to
resurrecting a gene from a sequence database, just on a much larger scale with more complex
considerations.  The preliminary sequence analysis was to identify a consensus sequence,
which would serve as the template for design of the full-length clone (Fig. 4).
Figure 4: Strategy for generating an infectious clone.
However, in many cases there were not enough sequences available in the database to
determine a robust consensus sequence.  Therefore, we performed molecular phylogenetics
to determine the nearest neighbors to the sequence of interest and used that neighbor to help
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determine the correct bases at positions in question.  The nucleotide present in the majority of
sequences was selected as the consensus residue.
Once the consensus sequence was established, the genome was divided into
fragments (usually five or six), based upon a priori information about specific regions in the
genome.  For example, Coronaviruses are known to contain toxic regions that if left intact
will prevent cloning and amplification of the DNA containing that region.  Therefore, these
regions were targeted, such that the fragment junctions were engineered to interrupt the toxic
region.   Additional analyses were performed to ensure that the unique endonuclease sites did
not cut the vector, endogenous transcription sites (stretches of six or more T’s) contained in
the sequence were ablated by silent mutation, and that regulatory elements important for viral
subgenomic transcription remained intact after all other alterations are conducted.
Regulatory elements were then added to the appropriate fragment, such as a T7 promoter site
at the 5’ end of the genome to drive transcription, and a poly A tail at the 3’end.
Each fragment was then synthesized flanked by the unique class IIS restriction
endonuclease sites and placed in the appropriate vector.  The resulting plasmid DNAs were
amplified in bacteria, purified, and the fragments corresponding to the viral genome were
excised and ligated together to form a full-length cDNA of the viral genome.  Using the class
II restriction endonuclease sites ensured the generation of unique overhangs at each junction,
thus increasing the efficiency and specificity of the shotgun ligation.  Once a full-length
cDNA was isolated, it was transcribed into infectious RNA that was transfected into cells
competent for viral replication (discussed in Chapters III, IV, V, VI and VII).
Using protein domain searches and/or a structure to guide mutagenesis.  For
proteins of unknown function and structure, searching for known protein domains and
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functional motifs can provide important clues as to what the function might be.  To identify
targets in the sequence of a protein of unknown function that might help identify the
protein’s function, we ran a prosite search and conducted a SMART tool analysis on our
protein sequence to identify functional domains and motifs that were conserved.  We then
targeted these sites in a reverse genetics mutagenesis study that knocked out the predicted
motif or domain, to see if this had an impact on function.  In addition, we used PONDR to
identify disordered regions that might play an important role in protein:protein interactions.
Having a solved crystal structure of a protein of unknown function can provide
important clues as to the function of the protein, particularly if the protein structure is a close
match to a protein of known function.  However, even if no known homologue exists in the
database, the shape an amino acid configuration of a structure is a very useful guide for
determining which residues to target for mutagenesis.  Often charged residues found on the
surface of a protein are important for interacting with a variety of different ligands, from
other proteins, to a variety of biological regulators of all kinds.  Removing a charge, but
preserving the overall structure can provide significant insights into the function of an
unknown protein.  In addition, altering a known or predicted interaction site, or disrupting a
secondary structure element can be used to help determine a protein’s function, although with
these approaches it is possible to completely alter the protein, preventing it from folding.
Caution is required to select reasonable mutations without disrupting the overall structure.
These approaches are used in Chapters IV, V, VI and VII.
Mapping variation onto the structure.  Combining crystal structures and a rich
sequence database provides a unique opportunity to study variation as it occurred over time
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in the context of the structure (Fig. 5).  Our strategy was to first gather all of viral capsid
protein sequences, align them, order them by time, and export the informative sites (Fig. 5).
Figure 5: Strategy for mapping variation onto a structure.
In the case of the Norovirus capsid, a very clear pattern of evolution emerged over a 20 year
span, providing support for the hypothesis that the earliest cluster gave rise to a new cluster,
which gave rise to yet another subsequent cluster, such that in 20 years five distinct time-
ordered clusters emerged.  When evaluated in the context of the capsid structure, the
variation was predominantly located on the exposed surface of the capsid, at the interface of
where natural selection, driven by the immune system, would force a higher rate of
evolution.  The next step was to generate homology models of representative sequences from
each of these clusters, and determine what the effect of the cluster-specific mutations had on
the structure.  Interestingly, analysis of the capsid structural differences suggested that the
virus capsid structure was subtly changing over time, such that we predicted there would be
differences in antibody recognition and receptor binding.  As discussed in Chapter IX, these
predictions are strongly supported by empirical studies using synthetically derived genes,
virus like particles, carbohydrate ligands, and sera from human outbreaks.
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In the following chapters, I will introduce each of the virus families studied during
the course of this dissertation, outline the studies performed, and provide a discussion of the
results.  We provide a platform approach that uses bioinformatics to generate informed
hypotheses and molecular, genetic and biochemical studies to empirically test, validate
and/or refine models of Coronavirus evolution, replication and pathogenesis and Norovirus
molecular epidemiology.
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CHAPTER II: INTRODUCTION TO CORONAVIRUSES
1. INTRODUCTION
1.1 Coronaviruses are important human pathogens
In the past few years, Coronaviruses (CoV), which had mostly been associated with
the common cold in humans and more severe disease in many important domestic animals,
have emerged as major threats to human health(1).  The Severe Acute Respiratory Syndrome
CoV (SARS-CoV) erupted onto the scene in late 2003 from the Guangdong province of
China and rapidly expanded the SARS, an unusually severe pneumonia, to 19 countries in
less than a year infecting over 8,000 people, resulting in nearly 800 deaths(68).  It is now
thought that SARS-CoV is of zoonotic origin, most likely originating in Chinese horseshoe
bats, from which it was transmitted to palm civets and/or raccoon dogs in the live animal
markets, and then subsequently transmitted into the human population (37).
Even more recently, two previously unidentified human coronaviruses (HCoV),
HCoV-NL63(71) and HCoV-HKU-1(42, 53, 56, 76) have been identified as viruses
responsible for pneumonia, as well as upper and lower respiratory disease in humans,
respectively.  Interestingly, HCoV-NL63 was first isolated from children in the Netherlands
suffering from lower respiratory tract infections of unknown origin.  Since its discovery,
several studies have identified HCoV-NL63 as a major cause of lower respiratory disease in
children and adults, worldwide (9, 11, 15, 16, 18, 26, 31, 39, 81).  In 2005, a German study
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reported that among children 3-years of age and younger who presented with lower
respiratory tract infections, HCoV-NL63 was one of the most commonly isolated viruses,
following only Respiratory Syncytial Virus and Human Parainfluenza Virus-3, respectively.
More intriguingly, it was determined that HCoV-NL63 viral loads were higher in patients not
co-infected with other viruses, and that among those patients with high viral loads of HCoV-
NL63, 43% had croup(71, 72).  Croup is a group of conditions, that can be caused by a
variety of viruses, resulting in inflammation of the upper airway, which is characterized by a
whistling, obstructive stridor as the child breathes in followed by a “barking” cough.  Severe
cases can be fatal if not treated in a hospital(71, 72).
In addition to the human CoVs, many domestic and wild animals harbor
coronaviruses, with porcine epidemic diarrhea virus (PEDV), infectious bronchitis virus
(IBV) of birds, and transmissible gastroenteritis virus (TGEV) resulting in agricultural
economic losses approaching millions of dollars each year(1, 10, 40, 48).  Coronaviruses
have been found in nearly every animal tested, and during the search for the SARS-CoV
precursor in bats, several other non-SARS-CoV-like coronaviruses were isolated(46, 53).
With ubiquitous populations of coronaviruses found in nearly every natural and agricultural
population of animal, cross-species transmission from animal to human, such as occurred in
the emergence of SARS in 2003, is inevitable in the future, and may lead to the emergence of
dangerous new viruses.    Understanding the basic biology and pathogenesis of coronavirus
infection is of urgent importance.
1.2 Coronaviruses are the largest RNA viruses, with three distinct phylogenetic groups
Coronaviruses are the largest known RNA viruses encoding plus-sense, 5’capped, and
polyadenylated genomes of 27-32kb in length(40, 47).  They belong to the order Nidovirales,
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family Coronaviridae, and are divided into three groups based on serological and
phylogenetic categorization(40, 47).  Group 1 consists of HCoV-NL63, HCoV-HKU-1,
HCoV-229E, and TGEV of swine; Group 3 is comprised of IBV of birds; and Group 2 CoVs
include HCoV-OC43, Bovine-CoV, SARS-CoV, and Mouse Hepatitis Virus (MHV)(40, 47).
MHV is the most extensively studied CoV, with strain MHV-A59 being well characterized in
cell culture and a hepatic and neurological mouse model systems(51).  The close relationship
of MHV to SARS-CoV, makes MHV an ideal model for prototype studies on the biology and
pathogenesis of CoV infections in humans(51).
Figure 1:  Molecular Phylogenetic Analysis of the Coronaviridae family.  An unrooted
species tree generated using Bayesian Inference shows that the 10 complete coronavirus
genomes cluster into the three established groups, although SARS-CoV forms a separate
cluster along the group 2 lineage.  Thus the group 2 CoVs are further divided into subgroups
2A and 2B.
Although SARS-CoV is a group 2 coronavirus, it forms an independent node along
the group 2 lineage, where it establishes a new cluster.  Some argue that this indicates that
Group 1
Group 3
Group 2A
Group 2B
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SARS-CoV establishes a 4
th
 group of CoVs, while the predominant hypothesis accepted in
the field seems to be that the original members of group 2 should be renamed 2A and SARS-
CoV-like viruses would make up group 2B (Fig.1)(38, 65).  The SARS-CoV sequences have
been further divided into groups based upon the phase of the epidemic or animal of isolation.
These phases include early, middle, and late phases of the human epidemic strains and Palm
Civet, Bat, or Raccoon Dog as animals that the zoonotic viruses were isolated from(57, 58,
62).  These will be treated in detail later in this introduction.
1.3 Genomic organization and translation of the CoV genome
The first 2/3 of the CoV genome is organized as two overlapping open reading frames
(ORFs) which encode the replicase genes (ORF1a and ORF1ab) required to replicate the full-
length negative and positive strand viral RNAs (Fig.2)(40, 47).  The remaining 1/3 of the
CoV genome contains the genes which encode: 1) structural proteins common to all CoVs,
including Spike (S), Envelope (E), Membrane (M) and Nucleocapsid (N); and 2) accessory
ORFs which encode proteins unique to specific virus groups (usually indicated by the ORF
that encodes them) (Fig. 2)(40, 47).  The structural and accessory proteins are encoded by a
nested set of co-terminal subgenomic mRNAs that are generated by discontinuous
transcription of negative strands, followed by positive strand synthesis, and then
translation(40, 47).
In most cases, only the 5’ most gene is translated in each mRNA into a viral protein.
The process of mRNA synthesis is thought to be regulated by the process of transcription
attenuation, whereby the replicase complex pauses in precise body transcriptional regulatory
sequences, dissociates and re-associates with the template RNA near the 5’ end of the
genome to acquire leader RNA sequences(2, 3, 5, 17, 36, 50, 59). Thus, mRNAs encoded at
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the 3’ end of the genome are generally more abundant than upstream upstream mRNAs.  The
structural and accessory genes are translated from the subgenomic mRNAs by host
ribosomes, with the N protein being the most abundant(40, 48).  There is evidence that N
plays a role in viral replication, perhaps by transporting the viral RNA to the site of the
replication complex, functioning as a chaperon in mRNA synthesis or as part of a membrane
bound scaffold which assembles the replication complex.  Aside from this role, N is most
commonly found associated tightly with the single-strand viral RNA and the formation of
nucleocapsids which bud through internal membranes to acquire several virus encoded spike
glycoproteins(40, 48).
Figure 2.  Processing of the CoV polyprotein in MHV.  A. The replicase makes up 2/3 of
the CoV genome, while structural and accessory proteins, filled in black, comprise roughly
1/3 of the genome.  Upon entry into the cytoplasm of the infected cell the CoV genome is
translated and as either pp1a or pp1ab, which are then processed by two classes of virally
encoded proteinases into 15 mature proteins, plus a small linker region (nsp11). T1 =
transmembrane region-1, T2 = transmembrane region-2, T3 = transmembrane region-3, 3CL
= 3CLpro, PLP1/2 = papain-like proteinases 1 and 2, RdRp = RNA dependent RNA
Polymerase, Hel = Helicase, ExoN = Exoribonuclease, XendoU = Endonuclease, and MT =
Methyl transferase. Unmarked proteins have unknown functions.  B.  PLP1 and PLP2 cleave
the first three nsps, while Mpro cleaves nsp4-16.  Arrows indicated which sites are cleaved
by the proteinases.  Gray indicates the position of the proteinases.  Nsp5 encodes the Mpro,
while PLP1 and PLP2 are marked.
A
B
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All of the other structural proteins are translated and accumulate in the rough
endoplasmic reticulum (RER), where they embed in the membrane of the RER.  Newly
synthesized viral RNA, associated tightly with N, is targeted to the RER where it interacts
with M, which is embedded in the RER membrane (Fig. 3)(40, 48).  Egress occurs through
the RER-Golgi lumen, where the viral RNA and N are enveloped in the plasma membrane
acquired from the RER, which already has the S, E, and M proteins embedded within it (40,
48)(Fig. 3).
Figure 3: The Coronavirus lifecycle (68).
There have been recent reports that indicate other accessory proteins of SARS-CoV
may be embedded in the viral envelope, and these include ORF3A and ORF7A(68).
However, the S glycoprotein is the primary determinant of tropism as it interacts with the cell
receptor for attachment and entry into cells (See Attachment and entry below)(40, 48).
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The replicase genes are encoded in two large open reading frames, designated ORF1a
and ORF1b in the 5’ end of the genome.  Upon entry, the genomic RNA is translated by host
cell ribosomes into either an ~511 kDa polyprotein (pp1a) from ORF1a, or an 811kDa
polyprotein (pp1ab) ORF1a/b fusion protein, which is only translated when a premature stop
codon is ablated by a –1 ribosomal frameshift that opens the 3’ end of ORF1 to translation
(ORF1ab)(4, 19, 20, 73). ORF1ab translation occurs at a frequency of 25-30%, therefore
there is a greater than 3-fold enrichment of proteins translated from pp1a.  During and after
translation, pp1a and pp1ab are processed by virally encoded proteinases into active
intermediates and eventually into 10 and 15 mature proteins, respectively (Fig. 2)(4, 19, 20,
73).  In SARS-CoV the same general process of translation regulation is evident, however the
polyproteins are not identical in size, and some of the individual nsps differ.  The most
notable difference occurs in nsp3, where SARS-CoV contains a single functional Papain-like
protease (PLP), while MHV encodes two PLPs(55).
1.4 Processing of the replicase polyprotein by virally encoded proteases
Two viral proteinases process the nascent polyprotein into component intermediates
and mature proteins.  The first processing events have been shown to occur co-
translationally, with the first mediated by Papain-like Proteinase (PLP1), which cleaves the
junction between nsp1 and nsp2(7, 8, 21, 27).  In MHV, this liberates a 28kDa protein (nsp1)
from the ORF1 polyprotein and subsequently localizes to sites of viral replication at early
times and to sites of assembly at late times of infection(7, 8, 21, 27).  The second cleavage is
mediated by PLP2, which cleaves the junction between nsp3/4, resulting in two
intermediates: An nsp 2/3 encoding polyprotein intermediate of 275 kDa and an nsp4-10
polyprotein intermediate of ~150 kDa from ORF1a(7, 8, 21, 27).  The 275 kDa polyprotein is
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then processed into two mature nsps by the PLP1, resulting in nsp2 with a mass of 65 kDa
and nsp3, which includes the PLP1 and PLP2 activity with a mass of 210 kDa.  The
remaining intermediates nsp4-11 and nsp4-16 are processed by the Main proteinase (Mpro),
a 3C-like proteinases (Fig. 2).  In SARS-CoV, a single PLP liberates nsp1, nsp2 and nsp3 in
a similar manner.  Of note, the Mpro cleaves a small linker region called nsp 11from the c-
terminus of nsp10.  It is not known whether it encodes functions other than to span and
conserve the pseudo knot structure at the nucleotide level(7, 8, 21, 27).
Although the exact order and mechanism of processing of these intermediates is yet
to be determined, all 15 mature proteins have been observed in their mature form, and all
localize to sites of viral replication (Fig. 2)(7, 8, 21, 27).
1.5 Function of the replicase proteins
Non-structural protein (Nsp)1 has been shown to localize to sites of viral replication
at early times, but is detected at assembly sites later in infection. Further, nsp1 is required for
replication, as deletion mutagenesis resulted in a lethal phenotype in MHV and SARS-CoV.
However, partial deletions were tolerated at the C-terminal end of the protein suggesting the
functional domain resides in the N-terminal end (7).  A study using transiently expressed
nsp1 in different cell culture systems demonstrated that nsp1 arrests cell cycle progression
from G0/G1 to S phase.  In addition, with SARS-CoV, nsp1 has been found to suppress host
gene expression by promoting host mRNA degradation and inhibiting translation(49), and
nsp1 significantly inhibited IFN-dependent signaling by decreasing the phosphorylation
levels of STAT1 while having little effect on those of STAT2, JAK1, and TYK2(74).  These
data show that nsp1 is likely a virulence factor.
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Nsp2 has recently been shown to be dispensable for viral replication in MHV and
SARS-CoV, although deleting it attenuates replication in cell culture(28).  Nsp 2 is known to
co-localize to sites of viral replication(28), suggesting that it plays an important but not
essential role in replication.  Nsp3 encodes the papain-like proteinases (PLP1 and PLP2),
which cleave the N-terminal region of the nascent polyprotein.  In addition, a putative ADP-
ribose 1”-phosphatase activity, known as the X domain, is predicted to reside between the
two PLPs.  A recent report indicates that PLP of HCoV-CoV, also functions as an antagonist
of the innate immune response by blocking IRF3 translocation to the nucleus(13).
Nsp4 and nsp6 are transmembrane domains that flank the Mpro (nsp5).  The two
transmembrane domains are thought to play important roles in anchoring the entire
transcription/replication complex to the double membrane vesicles were these complexes are
thought to assemble and function.  It is possible that nsp4 and nsp6 help induce cellular
autophagy as part of the assembly process(54, 55). In a recent report it was shown that nsp4
is required for MHV replication, and that it contains four transmembrane-spanning regions
(TM1, -2, -3, and -4), demonstrates characteristics of an integral membrane protein, and is
thought to be essential for the formation and function of viral replication complexes on
cellular membranes(67).
Nsp5 (Mpro) liberates nsp4-nsp16 from the polyprotein precursors, with pp1ab being
cleaved at 11 conserved sites following P2-Leu-Gln  sequences, including the
autoproteolytic cleavage of itself (Mpro) from the nascent polyprotein(19, 64, 82).   It has
been demonstrated that continuous translation and processing of the replicase polyprotein(s)
is essential for RNA synthesis during MHV replication(19, 64, 82).  However, it is currently
unclear as to which order the cleavage occurs, and to what extent intermediates containing
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several of the unprocessed proteins participate in cleavage and/or replication complex
formation.
The X-ray crystal structure of the SARS-CoV Mpro has been solved by multiple
groups, under multiple conditions (33, 43, 70, 77, 78), and it has been reported to form a
homodimer both in the crystal and in solution (33, 43, 70, 77, 78), Both the homodimer and
to a lesser extent the monomer have proteolytic activity (33, 43, 70, 77, 78).  The Mpro
protomer can be divided into three domains (Yang, et al, 2003), of which domains I (residues
1-99) and domains II (residues 100-183) resemble chymotrypsin, while domain III (residues
184-302) is a comprised of five anti-parallel -helices .  The catalytic dyad has been
identified as amino acids His41 and Cys145 , and the substrate-binding pocket has been
mapped to a cleft between domains I and II.  An YMH motif from positions 161-163 has
been identified as the substrate binding region(33, 43, 70, 77, 78).
The MHV and SARS-CoV Mpro amino acid sequences share 50% sequence identity,
and when these sequences are aligned with Mpro sequences of CoV from all three groups,
the catalytic dyad residues, His41 and C145 are strictly conserved, as well as the Tyr-Met-
His motif that comprises the core of the active site cavity where the protease binds its
substrate.   Experiment resulting in mutation of the catalytic dyad His41 or Cys145 residues
of MHV Mpro completely abolished the proteolytic activity of the proteinase.
Nsp7 and nsp8 have recently been crystallized and shown to form an asymmetrical
hexadecamer unit(52, 80).  The biological unit is comprised of two hexadecamer
supercomplexes, which form a hollow cylinder postulated to protect dsRNA during
transcription/replication(52, 80).  The diameter and electrostatic properties of the
hexadecamer are similar to those of PCNA and beta-subunit, two processivity factors of
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DNA polymerase, which encircle the dsDNA and confer high processivity on it(52, 80).
Biochemical experiments with the SARS-CoV nsp8 have demonstrated that this protein
contains a second non-canonical RdRp activity, which may produce primers that are utilized
by the primer-dependent primary RdRp, found in nsp12, although it remains unclear whether
this activity is required for virus replication in vitro(52, 80).
The structure of nsp9 has also been solved and this protein was reported to be a
unique single-stranded RNA binding protein(25, 69).  In solution, nsp9 forms a dimer,
although it is currently not known if it assumes this oligermization state in vitro or in vivo.
Experiments in our lab have shown that introducing mutations to the nsp9 protein that force a
monomeric state without disrupting overall structure, results in a lethal phenotype.
Interestingly, low-level replication occurred in the mutant, but no virus was ever isolated.
This suggests that nsp9 functions as a dimer in vitro. Interestingly, the addition of nsp9 to the
nsp7-8 supercomplex reduced disorder in the supercomplex, suggesting that nsp9 interacts
with nsp7 or 8(25, 69, 80).  However, it is not clear if this association is as a monomer, a
dimer, or as a higher ordered structural subunit and the functional significance of this
interaction is not clear.
Nsp10 was first identified as a possible growth factor-like molecule based on gene
ontology classification, however, there is little homology between nsp10 and any proteins of
known function.  Biochemical assays have suggested that nsp10 interacts with cellular RNA
polymerase subunits BTF3 and ATF5, and specifically interacted with NADH 4L subunit
and cytochrome oxidase II, which resulted in depolarization of the inner mitochondrial
membrane(12).  Depolarization of the inner membrane can result in apoptosis, and this
implicates nsp10 as a potential virulence factor.  Work in our lab has demonstrated that
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nsp10 plays a dual role in MHV infection, as both a regulator of viral RNA synthesis and as
an important component of polyprotein processing(22, 23).  Mapping our mutations onto the
solved crystal structure of nsp10 suggested that a region on the exposed surface of this
protein, identified as a disordered region, is a key site, which may interact with other proteins
in the replication complex, may interact with the Mpro, or both(22, 23).
Work with IBV reported that nsp10 forms dimers, a result that was corroborated by
yeast-two-hybrid.  In the same yeast-two-hybrid system, nsp10 was shown to bind to nsp1
and nsp8, which taken together with the nsp7-9 data, suggests a larger complex which
includes multiple subunits of nsp7-10(8).   It is clear that nsps 7-10 co-localizes to sites of
viral replication with the viral RdRp(4).
Nsps processed from the C-terminal ORF1b region of pp1ab contain the RNA-
dependent-RNA-polymerase (RdRp) in nsp12(6), and the helicase function has been mapped
to nsp13(20, 65).  Nsp 14 is a putative 3’ to 5’ exonuclease (ExoN)(65), nsp15 is a putative
poly(U)-specific endoribonuclease (XendoU)(65), and  nsp16 is a putative S-
adenosylmethionine-dependent ribose 2’-O-methyltransferase (2-O-MT)(65).
Hypothetically, nsp14-16 and the ADP-ribose 1”-phosphatase activity of nsp3 comprise
putative enzymes which retain the ability to function in RNA proofreading and repair(65).
The most intriguing evidence for a putative proofreading mechanism was shown recently by
Eckerle, et al.(24), who disrupted the ExoN activity in MHV, and the resulting mutant
showed an increase in point mutations, which appeared to accumulate in a random fashion,
and increased with passage(24).
1.6 Coronavirus Replication
Coronavirus replication is currently thought to require three distinct phases: 1)
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negative strand synthesis of full length genomic RNA and subgenomic length transcripts; 2)
conversion from negative to positive strand synthesis; and 3) positive strand synthesis of
genomic length and subgenomic length transcripts. The exact mechanism and proteins or
intermediates required for negative and positive strand synthesis is currently not known.
However, it has been shown that continued processing of the viral polyprotein is essential for
continued negative strand synthesis, implying that polyprotein intermediates are required to
replicate negative strands, and that these are then processed into mature proteins that
presumably assemble and function as the positive strand replication complex(47, 50, 59, 60).
In fact, the positive strand replication complex does not appear to require additional
processing as positive strands synthesis continues after treatment of cells with cyclohexamide
(47, 50, 59, 60).
A recent model proposed that negative strand synthesis is facilitated by the use of a
replication protein intermediate, that is hypothetically processed into mature proteins that
may form the positive strand replication complex at later times during infection.  This model
is supported by classical complementation studies conducted with temperature-sensitive (TS)
mutants that suggest that the nsp4-11 intermediate with a molecular mass of ~150kDa (p150)
functions as a single polyprotein or functions in cis before processing to synthesize negative
strands, as mutations found in nsp4, nsp5, and nsp10 did not complement for each other(61).
A single point mutation in nsp10, a Gln to Glu change at position 65 of this protein, results in
a TS phenotype that was shown to halt negative strand synthesis upon shift from permissive
to non-permissive temperature (32-40C), an observation later characterized as a defect in
negative strand elongation.  An additional mutant in nsp5 (Mpro), also in complementation
group 1, was shown to synthesize negative strands but not convert them to positive strands
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suggesting a defect in conversion from negative to positive strand synthesis(61).  Taken
together, these data suggest that the p150 intermediate plays a functional role in negative
strand synthesis, and possibly conversion from the negative strand transcription complex to
the positive strand synthesis transcription/replication complex(61).
The nsp10 TS mutant behaves almost identically to infections treated with
Cyclohexamide (CH) to shut down protein synthesis.  The wt virus stops negative strand
synthesis within 30 minutes of the addition of CH, suggesting that the virus requires an
ongoing supply of proteins to continue negative strand synthesis.  Work reported in this
dissertation (See Chapter V) provides evidence that counters the established model.  We
show that the TS mutation in nsp10 completely ablates processing by the Mpro at the non-
permissive temperature(22).   That coupled with the fact that the TS mutation in nsp5 likely
ablates processing, too, suggests that concluding that the p150 is an essential intermediate
involved in RNA synthesis is premature and put forth alternative hypotheses to explain the
interesting phenotype of this TS mutant(22).
1.7 Attachment and entry
The CoVs derive the name Corona (Latin for crown) from the crown-like morphology
of the CoV particle when observed by Electron Microscopy.  The S glycoprotein protrudes
from the surface of the viral envelope to give the crown-like appearance, and the S
glycoprotein is the primary determinant of receptor binding and host range specificity.  In
addition to its role in attachment and entry, the S glycoprotein has also been implicated as a
major component of protective immunity, and is highly immunogenic containing three
known domains that have been shown to be targeted by neutralizing antibodies (29, 32, 41).
The SARS-CoV S glycoprotein is 1225 amino acids in length and is divided into two
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functional domains known as S1 and S2(40, 48).  The S1 domain, encodes from amino acid
17 to 756 and contains the receptor-binding domain (RBD) (from amino acid 318 to
510)(44), which is the site of interaction between S and the cellular receptor.  The S2
domain, encoded from amino acid position 757 to 1225, contains two heptad repeat regions
responsible for viral fusion, as well as a transmembrane domain positioned at 1189 to 1227,
which anchors S to the viral envelope(44).
The CoVs utilize a variety of different cellular receptors, which mediate uptake of the
virus into cells. The major receptor for MHV has been identified as the cell-adhesion
molecule 1 in the carcinoembryonic antigen family (CEACAM1)(75, 79), which is classified
as part of the immunoglobulin superfamily.  CEACAM1 is expressed on the epithelium and
is also found in endothelial cells of a variety of tissues.   CEACAM1 serves dual functions
for MHV attachment and entry into cells: 1) It binds directly to S; and 2) It triggers
conformational changes in S, which mediate virus-cell membrane fusion(75, 79).
For SARS-CoV and HCoV-NL63, the primary receptor for entry into the host cell is
the angiotensin converting enzyme-2 (ACE2) (35, 45).  A crystal structure has been solved
which shows this interaction (PDB: 2AJF) (44)(Fig.4).
ACE2 is found on ciliated cells within the lung epithelia, type 2 pneumocytes in
alveoli as well as cells of the kidney and colon(30).  After S attaches to the ACE2 receptor,
the virus enters the cell by receptor-mediated endocytosis.  Cleavage of the S by cathepsin L
within the endosome is required for SARS-CoV infection, and this event must occur prior to
fusion(63).
The amino acid sequence of the S glycoprotein of the different SARS-CoV isolates
segregates phylogenetically into four distinct clusters, which have been labeled: zoonotic,
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early, middle and late phase clusters.  This phylogenetic classification correlates with
molecular epidemiological studies (14), which reveal similar trends. Sequence analyses
conducted on SARS-CoV genomes from all four clusters demonstrated that the S
glycoprotein was operating under strong positive selection during the early phase of the
epidemic, but that this gene stabilized as the epidemic progressed (14).
Figure 4.  Structure of SARS-CoV RBD in complex with human ACE2.
1.8 Molecular epidemiology and evolution of the SARS-CoV pandemic
The earliest outbreaks of SARS occurred in the Foshan Province of China sometime
around October or November of 2002, but no isolates have been made publicly available
from those early cases(38).  The earliest available isolates were taken from Guangdong
Province in November.  Guangdong appears to be the epicenter of the early expansion of
SARS-CoV, as several independent outbreaks occurred and many subsequent transmissions
have been traced to that region.  Two early isolates, GZ02 and GD01, taken from the same
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patient in Guangzhou (the capital of Guangdong) were 99.8% similar to the strains isolated in
the spring of 2003 from civet cats (SZ16 and SZ03) and raccoon dogs (SZ13), and all contain
a 29 nucleotide (nt) segment in ORF8 that is absent in later viruses.  An isolate of civet,
HZ/SZ/61/03, taken from civet cats later in the fall of 2003, was more closely related to the
early strains of SARS-CoV and was the impetus for culling of civets in China(38).
Two major clusters arose from strains traced to early isolates in Guangdong,
including the Beijing and Vietnam clusters(38).  The index case for the Beijing cluster has
not been reported in the literature, although phylogenetic analyses suggest that it arose from
an isolate in Guangdong.  The Vietnam cluster actually comprised all pandemic strains that
originated in Hong Kong.   It appears that multiple index cases brought SARS-CoV to the
island of Hong Kong, with all of those strains having connections to and/or phylogenetic
relationships similar to Guangdong isolates.   One such isolate, HKU-33 was the index case
for the Metropole Hotel outbreak.  Most of the pandemic strains that occurred later  (late
phase) in the epidemic are traceable to transmission events that occurred between a single
patient and other hotel guests (38)(Fig. 5).
Multiple other outbreaks occurred within or were traceable to Guangdong, and appear to
have been localized.  In Zaungshou, the outbreak was contained with no further transmission
to other regions.  Isolates from that outbreak show an unusual genotype with an 82-
nucleotide deletion in ORF8, and several mutations that appear to be linked only to strains
emerging in Zaungshou (38)(Fig. 5).
These strains cluster phylogenetically with early human and animal strains, which
suggests that the outbreak may be one of several early attempts at virus adaptation and spread
through the human population (38).  The 82-nt deletion was also observed in some of the
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civet cat isolates.  Another cluster of sequences reported by The SARS epidemiology
consortium of Guangdong(38); HSZ-A, -B, and -C; contain the additional 29-nt segment in
ORF8 and cluster more closely with the pandemic strains.  In fact, the HSZ sequences are the
closet isolates to pandemic strains that contain the additional 29-nt segment(38) (Fig. 5).
Figure 5: Overview of the molecular epidemiology of the SARS-CoV Pandemic.  The
pandemic most likely really took off sometime in the fall or early winter of 2002 in
Guangdong province of China, when a super-spreader event (SSE, shown in red boxes)
occurred with virus GZ50 spreading it throughout the capital city and into Beijing and Hong
Kong.  In Hong Kong another super-spreader event occurred with virus HKU-33 spreading
and infecting several people at the Metropole Hotel in Hong Kong.  SSE, red framed boxes;
Zoonotic strains, teal; Early phase, beige; Middle phase, blue; Late phase, gray.  Arrows
indicate route of transmission, with dashed lines being hypothetical and solid lines being
verified my molecular epidemiology.  Red arrow indicates the probable route of emergence
from Early to Late phase.
Phylogenetically, isolates GZ50 and CUHK-W1, both originating in Guangdong, are
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the most reasonable precursors to viral strains that evolved from early Guangdong isolates to
pandemic strains.  Both of these isolates contain the 29-nt deletion which divides ORF8 into
ORF8a and 8b, and which is found in the majority of isolates from the late stages of the
pandemic (38)(Table 1).  Further, GZ50 and CUHK-W1 cluster between the early and the
late strains, containing mutations that originated in the early phase, and also being among the
first strains to contain mutations found in late phase strains (Table 1).  This is strong
evidence that GZ50 and CUHK-W1 are the isolates or are related to isolates that led to the
expansion of the SARS-CoV virus from early to middle phase strains.  Two markers appear
to definitively separate early and middle phase strains:  at position 3076 of ORF1a early
strains contain an Ala and all other strains a Val; and at position 779 of spike early isolates
contain Asp and all others Tyr (38)(Table 1).  CUHK-W1 contains an Ala at the first position
and Tyr at the second, while GZ50 contains a Val at the first marker position and an Asp at
the second.  This is further evidence that CUHK-W1 and/or GZ50 are ancestors to pandemic
strains.  All other differences found between early and late phase isolates are specific to
independent lineages, and do not represent changes that were fixed in the pandemic
population (38)(Table 1).
The molecular epidemiology and phylogenetic analyses suggest that several
independent transmissions occurred from the middle phase (GZ50/CUHK-W1) isolates.  The
first Super Spreader Event (SSE) is traceable to strains originating in the middle phase in
Guangdong (possibly GZ50, CUHK-W1 or a close relative) and this event led to a major
outbreak in a hospital in Guangzhou (38)(Fig.5).  Strains associated with that outbreak, HZS-
2, cluster between the middle phase isolates and strains associated with the late phase of the
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epidemic.  Whether there is a primary connection between HZS-2 strains (SSE-1) and the
second SSE, the Metropole Hotel index case (SSE-2) in Hong Kong, is unclear.
Table 1:  Amino Acid changes that occurred during the emergence of SARS-CoV from
zoonotic to late phase strains.
The Beijing cluster appears to have originated from middle phase isolates, as well as
additional isolates in Hong Kong found to have no epidemiological link to the Metropole
Hotel.  This suggests that the middle phase isolates evolved the genotype necessary for
efficient human-to-human transmission(38).
All of the late phase strains have been linked by direct or serial transmission from
strains originating at the Metropole Hotel (38)(Fig. 6).  The evolution from middle to late
phase is marked by two definitive mutations, the first of which occurs at position 5765 in
ORF1ab where all animal, early, and middle phase strains contain a Glu while all late phase
isolates contain Asp.  The second marker mutation occurs at position 244 in the spike gene,
with Thr found in animal, early, and middle strains and Ile in late phase isolates (Table 1).
Other mutations are found that are unique to middle and late phase strains, but do not include
all strains, and are almost exclusively found as markers for an independent lineage.  For
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example, all of the Beijing isolates contain two mutations that are not found in any other
isolates.  The first of these occurs at position 3201 of ORF1ab where Beijing isolates contain
a Val and all other isolates from all phases contain Ala.  The second marker at position 58 of
ORF3A contains a Leu for Beijing isolates and a Pro for all others (38)(Table 1).
The fact that these mutations are not found in any strains other than the specific
cluster suggests that they are independent events that occurred early in the Beijing lineage
and became fixed in that population only.  The fact that these changes did not evolve
independently in other lineages suggests that they are not essential for human-to-human
transmission, and may have little effect on viral fitness.  Whether or not these mutations alter
viral pathogenesis is yet to be determined(38).
Figure 6: Likely route of emergence of SARS-CoV from the zoonotic reservoir to a
human epidemic strain.  Zoonotic phase, teal; Early phase, beige; Middle phase, blue; and
Late phase; gray.  Red arrows represent likely route of emergence.  Dashed lines are
hypothetical, solid lines are verified by molecular epidemiology.  Red framed boxes indicate
SSE.
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Hypothetically, the pandemic strains of SARS-CoV evolved from the virus isolated
from civet cats and raccoon dogs (37, 66)(Fig. 6).  If this is the case, then there are 20 non-
synonymous substitutions essential for human transmission that must have occurred in the
civet virus and fixed in the viral population (Table 1).  Once these 20 mutations allowed
entry into the human population, then two essential mutations were required to evolve from
early to middle and two additional mutations necessary to evolve from middle to late.
Several other important mutations are noted in Table 1 that occurred at each phase, but only
those mentioned above were completely associated with transition between states.
1.9 Molecular evolution of the SARS-CoV spike glycoprotein
In total, 23 amino acid changes occurred within the spike gene between the zoonotic
and all human phases over the course of the epidemic (58).  These observations suggested
that the S-glycoprotein under went adaptive evolution, probably allowing for an expansion of
host range from Civet/Raccoon dog to humans (Table 2).  An outlier sequence named GD03
was isolated from a human during the epidemic in 2003, and this sequence clusters with and
resembles the sequences isolated from Civet cats(37, 66) (Table 2).
Table 2: Amino acid differences in the S glycoprotein.  Comparing the S amino acid
sequence of zoonotic Civet SARS-CoV to the different Human SARS-CoV from different
phases of the epidemic shows that several sites changed at different phases of the epidemic.
The representative sequences for each phase:  Zoonotic SARS-CoV: SZ16, Civet and
HC/SZ/61/03, Civet.  The human SARS-CoV: GD03, isolated from human, very close to
civet SARS-CoV; GZ02, early phase human; CUHK-W1, middle phase human; Urbani, late
phase human.
       Spike
AA change
D
-G
N
-D
A
-V
Q
-R
N
-K
S
-L
D
-G I-T
T
-K
G
-R
R
-K
F
-S
L
-P
N
-K
D
-G
T
-S
I-F
S
-P
A
-L
D
-E
L
-S
S
-L
T
-A
V
-A
A
-V
Y
-D
T
-A
N
-S
E
-K
Phase AA position
7
7
7
8
1
3
9
1
4
7
2
2
7
2
3
9
2
4
3
2
4
4
2
6
1
3
1
1
3
4
4
3
6
0
4
7
2
4
7
9
4
8
0
4
8
7
5
5
9
6
0
7
6
0
9
6
1
3
6
6
5
7
0
1
7
4
3
7
5
4
7
6
5
7
7
8
8
9
4
1
0
8
0
1
1
6
3
Civet SZ16 D N A Q K L D T K G R S L K  D S I P A D S L A A A D A N E
Civet   HC/SZ/61/03 D N V Q K S G T T G R S P R G S F S L E S S R V V D T S E
Human/Civet GD03 D D V R N S D T T G R S P N G S F S L E S S R V V D T N E
Early GZ02 D N A Q N L D T T R R F L N D T F S A D L S T V A D T N E
Middle CUHK-W1 D N A Q N S D T T G K F L N D T F S A D L S T V A Y T N K
Late Urbani G N A Q N S D I T G K F L N D T F S A D L S T V A Y T N K
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A crystal structure of a late phase SARS-CoV RBD in complex with the human
ACE2 molecule revealed that18 amino acids in ACE2 interact with 14 residues in the RBD
of SARS-CoV(44).  The authors of this study identify two amino acids in the RBD at
positions 479 and 487 as being critical for binding to ACE2.  However, other key residues
include positions 472 and 442, both of which have been identified as important residues by
our laboratory (62) (Fig. 7).
Interestingly, analysis of these amino acids at the interaction positions in the zoonotic
and all three phases of the epidemic strains revealed that position 479 changed from Lys or
Arg in the zoonotic strains to Asn in the human strains, while position 487 was Ser through
the zoonotic strains, and changed to Thr in all human strains (Table 2).  Of note, we and
others predicted that the Lys at position 479 of Urbani would cause a clash between the RBD
and the human ACE2, resulting in a block at the level of attachment and entry, and this
prediction was verified by our lab(62).  Briefly, the S protein of SZ16 containing the Lys at
position 479, was placed in the Urbani infectious clone and the resulting construct resulted in
replication as detectable by RT-PCR, however, no virus was recovered, and no CPE was
detected, suggesting a block at the level of attachment or entry(62). However, mutating the
Lys at position 479 to Asn resulted in detection of virus indicating that a single point
mutation (K479N) in the SZ16 S improved binding to ACE2, although the mutation was
insufficient for robust growth(62).  Interestingly, passing the SZ16-K479N chimeric virus in
cell culture resulted in adaptations within the RBD, which allowed for efficient attachment
and entry and therefore efficient replication.  The sites that adapted were Y442F and/or
L472F.  We predicted these changes allowed the zoonotic RBD to adapt to efficiently use the
human ACE2 for attachment and entry into host cells(62)(See Chapter VII).
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Figure 7: SARS-CoV RBD interacting with human ACE2.  The Urbani RBD is shown in
green, interacting with human ACE2 shown in red.  Only amino acids 19-86 of human ACE2
are shown as this region of hACE2 contains nearly all of the interactions.  Yellow indicates
the key residues important for binding; black indicates residues on hACE2 that interact.
Interestingly, the adapted SZ16-K479N chimera that was adapted to human ACE2, lost the
ability to infect cells expressing the civet ACE2, while the wild type SZ16 was capable of
infecting these cells.  Perhaps the most interesting observation with this experiment was that
the late phase SARS-CoV RBD had adapted to efficiently utilize both human and civet
ACE2 receptors(62). This result suggests that the human SARS-CoV rather than the Civet
SARS-CoV may have first evolved from the Bat reservoir (46).  This observation was further
corroborated by phylogenetic analysis, which suggests that the Bat SARS-CoV spike is more
closely related to the middle phase human SARS-CoV spike than to the civet or raccoon
variants of the virus (Fig. 8). In fact, this may also explain the outlier, GD03, which clusters
with the Civet SARS-COV, and may represent a Civet-to-human transmission.
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Figure 8: Bayesian Inference of the Spike amino acid sequence of representative SARS
viruses. The spike protein sequences of 36 SARS-CoV viruses representing the early,
middle, and late phases of the human epidemic, as well as representative SARS-CoVs
isolated from Palm Civets, Raccoon Dogs and Bats were aligned and analyzed using
MrBayes.  The tree, rooted with the bat sequences, suggests that the Bat SARS-CoV is more
closely related to the human SARS-CoV strains than those isolated from Civet or Raccoon
Dogs.  This implies that the emergence of SARS-CoV may have occurred by Bat-to-Human
transmissions, and that Civets and Raccoon Dogs may have been subsequently infected by
humans.  The GD03 human outlier case may be an isolated case of a Civet (or Raccoon
Dog)-to-Human transmission.  Node confidences are shown as posterior probabilities.
Further studies with the Bat SARS-CoV S revealed a similar barrier.  We resurrected
a Bat SARS-CoV that was unable to infect Vero cells with the Bat SARS-CoV RBD, but
when the Urbani RBD was placed into the Bat SARS-CoV backbone, the rescued virus was
capable of replication and spread to neighboring cells, indicating the primary block was at
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the level of viral attachment and entry (Becker, et.al., in press) (See Chapter VII).
Interestingly, inserting only the region of the RBD that interacts with the human ACE2 was
insufficient to overcome this barrier.  This observation, led us to speculate that sites distal to
the interaction region regulate binding of the RBD to the ACE2 receptor.  This observation
was further corroborated by molecular dynamics simulations, which suggested that the
binding interface of the RBD flexes open and closed in such away that upon binding, the
loop that contains binding residue 472 bends into position to interact with its partner on
hACE2.  Further support for this observation comes from a recent crystal structure of the
same late phase SARS-CoV RBD structure in solution and not in complex with hACE2,
which shows the non-bound RBD in an open conformation as compared to the structure
bound to hACE2(34).
Further evidence for a flexible binding interaction between the SARS-CoV RBD and
the ACE2 receptor was found in a study conducted by our lab using human monoclonal
antibodies.  In this study, escape mutants were generated in the presence of neutralizing
antibodies, and the adaptive sites that allowed escape were mapped onto the structure of the
SARS-CoV RBD.  Intriguingly, two newly identified epitopes were mapped to the binding
interface, while a third was mapped to a region distal to the interface (See Chapter VII).  We
hypothesized that antibodies binding to the distal epitope likely neutralized the virus by
preventing the RBD from adopting the conformation that allowed binding to the ACE2 (57).
1.10 Summary
Prior to the identification of SARS-CoV in 2003 as the etiologic agent that caused
SARS, only a dozen animal or human coronaviruses were known. The search for the
reservoir of SARS-CoV in nature resulted in identification of the civet and bat SARS-CoVs,
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as well as several other Bat CoVs, which cluster in all three phylogenetic groups of the
CoVs.   Shortly after SARS-CoV was discovered, two addition human coronaviruses, NL63
and HKU1, were discovered as respiratory pathogens that were previously unrecognized.
Surveillance of CoVs in a variety of animal species has increased the number of known
CoVs to at least 36.  The unexpected and explosive nature of the first SARS epidemic,
coupled with a high mortality rate, resulted in enormous economic implications in Southeast
Asia resulting in at least 50 billion dollars in economic losses.  Furthermore, this epidemic
led to a research boon starting with the rapid identification of SARS-CoV as the agent that
caused SARS, and which continued with over 4900 research papers describing studies
focusing on molecular evolutionary, epidemiological, clinical, pathological, immunological,
virological, and other basic scientific aspects of the virus and the disease.
Many of these studies have increased our understanding of the virus and the disease,
and have resulted in identifying the horseshoe bats as the probable natural reservoir for
SARS-CoV-like viruses and Civet Cats and Raccoon Dogs as potentially the amplification
hosts.  The experience with SARS-CoV has taught us that CoVs are ubiquitous in nature, that
emergence from the zoonotic reservoir to humans does occur, and that these viruses encode
the capacity to rapidly adapt to a new host, allowing human-to-human transmission.  These
observations make clear that Coronaviruses are an important family of viruses to study.
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  CHAPTER III: SYSTEMATIC ASSEMBLY AND GENETIC MANIPULATION OF
                             THE MOUSE HEPATITIS VIRUS A59 GENOME
(Currently in press as a book chapter in Cornavirus Protocols, Sinauer and associates, Inc.)
ABSTRACT
We have developed a DNA assembly platform that utilizes the non-specific, highly variable
sequence signatures of type IIs restriction enzymes to assemble a full length molecular clone
of murine hepatitis coronavirus (MHV) strain A59.  The approach also allows changes to be
engineered into a DNA fragment by designing primers that incorporate the restriction site
and the mutations of interest.  By adding the type IIs restriction site in the proper orientation,
subsequent digestion removes the restriction site and leaves a sticky end comprising the
mutation of interest ready to ligate to a second fragment generated in parallel as its
complement.  In this chapter, we discuss the details of the method to assemble a full-length
infectious clone of MHV, and then engineer a specific mutation into the clone to demonstrate
the power of this unique site-directed “No See’m” mutagenesis approach.
1. INTRODUCTION
Mouse hepatitis virus (MHV) strain A59 is an extensively studied group 2
coronavirus (CoV).  Its genome is an approximately 31.5 kb single-stranded positive-sense
RNA, which contains a 5’ cap and poly-A tail (1, 2).  The first two-thirds of the genome
encodes the non-structural proteins required for viral RNA replication and transcription, and
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Figure 1.  The MHV genome, subgenomic transcription, and strategy for infectious
clone assembly.  A.  The MHV genome is ~31.5 kb, with the first two-thirds comprising the
non-structural replicase genes required for viral RNA synthesis (gray rectangle), and the final
third encoding the structural genes important for assembly of the viral particle (large black
rectangle).  The 5’ end is capped and contains a leader sequence (small black box) and the
3’end has a poly-A tail.  B. The structural genes are encoded as a nested set of co-terminal
mRNAs, each of which contains the leader sequence derived from the 5’end of the genome
and a poly-A tail.  C.  For assembly of an infectious clone of MHV, the genome was divided
into seven stable contiguous cDNA fragments known as MHV-A, MHV-B, MHV-C, MHV-
D, MHV-E, MHV-F and MHV-G.  Unique type IIs restriction sites were used to generate
unique junctions, which when ligated together produce a full-length cDNA.  This allows
manipulation of any region of the genome by targeting the fragment of interest and
engineering No See’m sites to incorporate the mutation.  In this example we target genomic
position 13354-56 (indicated by ), which falls within the MHV-E fragment.  Numbers on
top of the assembled genome indicate fragment sizes, while bottom numbers represent
genomic positions.
A
B
C
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the final third comprises six additional open reading frames (ORFs) from which a nested set
of 3’ co-terminal subgenomic mRNAs are transcribed (Figs 1a, 1b, 3c).  Upon entry into the
cell, the N-encapsidated viral RNA is released form the virion and immediately translated by
host machinery, resulting in large polyprotein precursors which are autocleaved to generate
intermediates and eventually 16 mature proteins, most of which are thought to function in
viral RNA synthesis (3-6).  The subgenomic mRNAs are generated from a similar-sized
subgenomic negative strand, which is synthesized only after the viral replication complex is
functional.    The negative subgenomic RNA serves as a template for transcription of similar-
sized subgenomic mRNAs which contain the leader sequence as well as the ORF which
encodes the protein directly downstream of the leader sequence (7-10).  All subgenomic
mRNAs are co-terminal, with each subsequent mRNA containing the sequence for all
downstream ORFs, although only the 5’ most ORF is translated.  This allows for rapid
detection of viral replication by RT-PCR using primers that anneal to the leader and the N-
gene, which results in a ladder of different sized products (Fig. 1b and Fig. 3b,c) (7-10).
In cell culture, murine delayed brain tumor (DBT) cells infected with wild-type MHV
experience cytopathology characterized by the formation of syncytia, caused by interaction
of spike glycoproteins, which anchor in the cell membrane and interact with other spikes in
neighboring cells.  Wild-type infections generate uniform circular plaques of ~5mm in
diameter (Fig. 4a).
Prior to development of an infectious clone of MHV, reverse genetics of the viral
coding sequence was restricted to the ORFs downstream of the replicase.   Targeted
recombination was the primary method for manipulation of the structural and accessory
ORFs of MHV, and while extremely powerful, this methodology did not provide an approach
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to engineer changes into the viral replicase genes (2, 11). Moreover, RNA recombination can
result in aberrant recombination events resulting in 2
nd
 site changes (12), necessitating an
approach to manipulate the entire genome as a recombinant molecule.
Full-length cDNA constructs revolutionized reverse genetic applications in the entire
MHV genome. Our laboratory developed a full-length molecular clone of MHV-A59
(icMHV) by implementing a No See’m approach (Figs 1c and 2a,b) (13).  Our strategy was
to divide the genome into pieces that could be stably subcloned into E. coli-based plasmids to
facilitate targeted mutagenesis studies and for easy DNA storage and maintenance, using the
same approach that was successful with the transmissible gastroenteritis virus (TGEV)
infectious clone (13, 14) (Figs. 1c and 2a,b). However, the MHV molecular clone was
difficult to establish as several toxic regions existed in the genome.
  A                                                       B
             
Figure 2.  Engineering the clones of MHV.  A.  The MHV genome was divided into seven
contiguous fragments, named MHV-A through MHV-G, which are each flanked by unique
type IIs restriction endonuclease sites which when digested leave unique sticky ends which
facilitate unidirectional assembly. Top bands represent MHV fragments, while all other
bands represent digested vector. B. The cloning vectors used to stably clone the contiguous
fragments of MHV.
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Consequently, several of the MHV cDNA fragments required subdivision into smaller
subclones and cloning into transcription and translation negative vectors (Fig. 2b).
To ensure unidirectional ligation of all fragments native or engineered type IIs
restrictions sites were used to form junctions at the ends of each fragment, which allowed the
restriction site to be removed by restriction digestion (13). A T7 promoter site was added at
the 5’ end of the genome to facilitate in vitro transcription of the full-length cDNA fragment
after ligation, and a poly-A tail was included at the 3’ end (13) (Fig. 1c).  The purpose of this
review is to provide a detailed protocol that allows for efficient, systematic assembly and
mutagenesis of coronavirus full length cDNAs using class II S restriction enzymes and the
No See’m based mutagenesis approach. The pros and cons of this approach, and an appraisal
of what the future holds for this technology, are discussed at the end (see Note 8).
2. MATERIALS
2.1 Cell Culture and Lysis
1. Two cell lines are used for MHV full-length RNA transfection experiments: DBT
cells and baby hamster kidney cells expressing the MHV receptor (BHK-MHVr)(13).
2. Minimum essential medium (Gibco -Invitrogen, Carlsbad, CA) supplemented with
10% tryptose phosphate broth, 10% Fetal Clone II (HyClone, Logan, Utah), and 1%
gentamicin/kanamycin.  In addition, to select for BHK-MHVr cells expressing
MHVr, geneticin (0.8 mg/ml) is added to the medium.  The resistant clones were
selected by 3X cell sorting for CEACAM1a expression and are maintained in
geneticin as previously described by our group (13).
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3. Trypsin (0.25%) for removing cells from bottom of flask and versene (0.5 mM) for
washes.
2.2 Transformation and Amplification of Plasmids
1. Seven plasmids containing MHV fragments A-G cloned into pCR-XL-Topo
(Invitrogen, Carlsbad, CA) or pSMART (Lucigen, Middleton, WI) vectors, as
follows: pCR-XL-Topo-MHV-A, pSMART-MHV-B, pSMART-MHV-C, pSMART-
MHV-D, pSMART-MHV-E, pSMART-MHV-F, pSMART-MHV-G.
2. Chemically competent Top10 cells (Invitrogen) for transformations and maintenance
of plasmid DNA.
3. Super Optimal Catabolite-repression (SOC) medium (Invitrogen, Carlsbad, CA) is
used to stabilize the transformed chemically competent cells prior to plating them.
4. Luria-Bertani (LB) plates supplemented with ampicillin (75 mg/ml) for pSMART
vectors or kanamycin (50 mg/ml) for pCR-XL-Topo for growing colonies of bacteria
containing the transformed plasmids.
5. LB broth supplemented with ampicillin (75 mg/ml) for pSMART or kanamycin (50
mg/ml) for pCR-XL-Topo, 5 ml per colony for growing up individual colonies.
2.3 Plasmid Purification, Restriction Digestion Screen and Digestion
1. Qiaprep Spin Miniprep Kit (Qiagen, Valencia, CA.; Cat. no. 27106) is used to purify
plasmid DNA according to the manufacturer’s directions.
2. Restriction enzymes and reagents as follows (New England BioLabs, Ipswich, MA):
MluI (0.5-1U/ml final volume), BsmBI (0.5-1U/ml final volume), BglI (0.5-1U/ml
final volume), AhdI (0.5-1U/ml final volume), SfiI (0.5-1U/ml final volume), 10X
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bovine serum albumin (10 mg/ml), calf intestinal alkaline phosphatase (CIP) (1U/ml),
NEB 10X buffers 1-4 are used to digest the cDNA from the vector.
3. Agarose gel for electrophoresis (0.8-1.0% w/v) of restriction digestions.
4. LB broth supplemented with ampicillin (75 mg/ml) for pSMART or kanamycin (50
mg/ml) for pCR-XL-Topo vectors, 20 ml per culture for growing up larger stocks of
colonies that look correct by restriction screen.
2.4 Fragment Purification and Ligation
1. Qiaex II Gel Extraction Kit (Qiagen, Valencia, CA; Cat. no. 20010), 3M Sodium
Acetate pH5.2, elution buffer from Qiagen miniprep kit for purifying bands cut out of
the agarose gel.
2. Reagents for chloroform extraction/isopropanol precipitation of fragments:
Chloroform, isopropanol, 70% ethanol, 95% ethanol, and elution buffer.
3. A DNA spectrophotometer for quantifying the concentration of individual purified
cDNA fragments.
4. T4 DNA ligase plus 10X ligase buffer (New England Biolabs) for ligating the full-
length cDNA.
2.5 In Vitro Transcription and Electroporation
1. MHV N-gene amplified with SP6 promoter on the 5’end is used as a template for
generating N-gene transcripts.  Primers for Sp6-N have been published (13).
Transfecting in parallel with N-gene increases viral replication by roughly 15-fold.
2. mMessage mMachine T7 Transcription Kit (Ambion, Austin, TX; Cat. no. 1344) and
mMessage mMachine SP6 Transcription Kit (Ambion , Austin, TX; Cat. no. 1340)
for generating full-length MHV RNA or SP6-N-gene RNA.
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3. One 0.4 cm Gene Pulser Cuvette (Bio Rad, Hercules, CA) for each transfection.
4. BHK-MHVr cells are seeded at low density and grown in 150 cm
2
 flasks to 70%
confluence, washed three times in nuclease-free PBS and resuspended in cold PBS at
a concentration of 1.0 x 10
7
 cells/ml, and ~5x10
6
 DBT cells are infected by plating
the electroporated BHK-MHVrs on top.  We see greatly reduced transfection
efficiencies if cells are allowed to approach confluence prior to harvest.
5. Bio Rad (Hercules, CA) Gene Pulser Excel electroporator for doing the transfection.
2.6 Plaque Purification, Harvesting Viral RNA and RT-PCR
1. 2X DMEM media (Gibco)
2. Fetal Clone II (Hyclone) or fetal bovine serum (Gibco)
3. Low melting temperature cell culture grade agarose (Cambrex, Rockland, ME; Cat.
no. 50000)
4. Phosphate buffered saline (Gibco).
5. Trizol reagents (Invitrogen, Carlsbad, CA) for harvesting total RNA from infected
cells.
6. 75% ethanol prepared in DepC water (Invitrogen, Carlsbad, CA)
7. PCR/sequencing primers flanking the region of the mutation.
8. SuperScript III Reverse Transcription kit (Invitrogen; Cat. no. 18080-044) for reverse
transcription of viral RNA to cDNA.
9. pCR-XL-Topo cloning kit (Invitrogen, Carlsbad, CA; Cat. no. K4500) for cloning the
amplicon for sequencing.
2.7 Designing and Implementing Mutations
1. MHV genomic sequence (Accession no. NC_001846) for designing primers.
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2. NebCutter2.0 restriction digestion tool (New England BioLabs
http://tools.neb.com/NEBcutter2/index.php) for analyzing sequences to ensure that
the type IIs restriction site selected does not occur naturally in the wild-type
sequence, or is not introduced by the mutation.
3. Web Primer online primer design tool (http://seq.yeastgenome.org/cgi-bin/web-
primer) for development of primers for engineering mutations and for sequencing to
verify that the correct change was incorporated into the virus.
4. Expand Long PCR Kit (Roche, Basel, Switzerland; Cat. no. 11 681 834 001) for
amplification of the mutant fragments.
5. dNTPs (10mM) prepared in nuclease-free water.
6. Appropriate type IIs restriction enzyme for digestion of the two fragments.
7. T4 DNA ligase for assembling the full-length mutant fragment.
8. pCR-XL-Topo cloning kit for cloning the fragment into the pCR-XL-Topo vector,
and for transforming the new plasmid for growth in LB media.
3. METHODS
Assembling the full-length clone of MHV involves a series of steps, each of which is
important for amplifying and purifying the reagents necessary for the next step. Briefly,
plasmids are transformed into chemically competent E. coli and plated in the presence of
appropriate antibiotic selection.  Colonies are isolated, grown overnight at room temperature
(see Note 6), DNA harvested, and inserts verified by a screening restriction digestion.  It is
important to screen the DNA prior to setting up the large-scale preps to ensure plasmid
integrity. We typically harvest 50-75 μg of each plasmid DNA, restrict the DNA with the
83
appropriate restriction endonucleases, and purify the viral cDNAs from agarose gels.  It is
equally as important to keep the digested fragments free of contaminants, including residual
carbohydrates from the gel extraction procedure, or contamination with other fragments,
particularly a wild-type version of a mutated fragment (see Note 2).  Following gel
extraction, chloroform extractions are performed to ensure that all carbohydrate contaminants
are removed prior to preparing the ligation reaction (see Note 4).
It is also important to maintain an RNAse-free environment (as much as possible)
after ligation of the full-length clone.  Always wear gloves, keep the bench top RNAse free
by spraying with RNAse Zap (Ambion, Austin TX; Cat. no. 9780), and always use DepC
water (see Note 2) and barrier tips (see Note 3).  In addition, washing the BHK-MHVr cells
with PBS made with DepC water may help prevent degradation of the electroporated full-
length viral RNA (see Note 2).
3.1 Transformation and Restriction Screening of the Seven Clones of MHV
1. The seven fragments of MHV are maintained in either pCR-XL-Topo or pSMART
vectors, and each vector encodes a different antibiotic resistance cassette.  For pCR-
XL-Topo cloning vector encodes kanamycin resistance while the pSMART vector
encodes ampicillin resistance (pSMART vectors are available with kanamycin or
ampicillin resistance, in this case it is ampicillin).  LB broth and LB agar plates with
each antibiotic are required for growing the newly transformed bacteria.  Although
other vector-fragment combinations exist, we will focus on the following in this
report: pCR-XL-Topo-MHV-A, pSMART-MHV-B, pSMART-MHV-C, pSMART-
MHV-D, pSMART-MHV-E, pSMART-MHV-F, pSMART-MHV-G (13). Plasmids
are stored at approximately 20 ng/ml at –80°C.
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2. Thaw each plasmid and the chemically competent Top10 cells (one vial per plasmid)
on ice.  Add 100ng of each plasmid to an appropriately labeled vial of cells (50 ml)
and incubate for 30 minutes on ice.
3. Transform the cells by heat shock in a water bath maintained at 42°C for 2 minutes,
followed by two minutes on ice.
4. Add 200ml S.O.C. media (without antibiotic), and rock the vials at room temperature
for 2 hours.
5. Inoculate two LB plates (with appropriate antibiotic) for each plasmid, using 25 ml
and 100 ml of culture and incubate the plates at room temperature for 48 hours.
6. Pick at least five colonies of each plasmid (from one or both plates) and inoculate
each into a 15 ml conical containing 5 ml of LB broth with appropriate antibiotic.
Grow the colonies for 16-24 hours at 28.5°C in an incubator shaker set at 250 RPMs.
In our hands, plasmid stability is enhanced at the lower temperature.
7. Prepare a library plate by inoculating an LB agar plate (with appropriate selection)
with 25 ml of the supernatant of each colony.  The library plate should contain all of
the colonies for one plasmid, and is grown at room temperature for 16-24 hours and
then stored at 4°C.  Then spin the cultures at 3000g for 10 minutes at 4°C, aspirate
and discard the supernatant.
8. Plasmids are isolated from E. coli using the Qiagen miniprep kit, according to the
manufacturer’s instructions. Follow the plasmid DNA purification scheme using the
Qiaprep Spin Miniprep Kit and a microcentrifuge protocol, and elute the plasmid
DNA in 50 ml of elution buffer preheated to 70°C.
9. Screen each colony by restriction digestion to verify insert size and restriction map.
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a. pCR-XL-Topo-MHV-A: 10 ml plasmid, 1 ml MluI, 1 ml BsmBI, 2 ml NEB
Buffer 3, 6 ml water.  Incubate at 55°C for 1 hour.
b. pSMART-MHV-B: 10ml plasmid, 1 ml BglI, 2 ml NEB Buffer 3, 6 ml water.
Incubate at 37°C for 1 hour.  Add 1 ml BsmBI and incubate at 55°C for an
additional hour.
c. pSMART-MHV-C: 10 ml plasmid, 1 ml BglI, 2 ml NEB Buffer 3, 6 ml water.
Incubate at 37°C for 1 hour.  Add 1 ml BsmBI and incubate at 55°C for an
additional hour.
d. pSMART-MHV-D: 10 ml plasmid, 1 ml BsmBI, 1 ml BSA, 2 ml NEB Buffer
4, 5 ml water.  Incubate at 55°C for 1 hour.  Add 1 ml AhdI and incubate at
37°C for an additional hour.
e. pSMART-MHV-E: 10 ml plasmid, 1 ml BsmBI, 2 ml NEB Buffer 3, 7 ml
water.  Incubate at 55°C for 1 hour.
f. pSMART-MHV-F: 10 ml plasmid, 1 ml BsmBI, 2 ml NEB Buffer 3, 7 ml
water.  Incubate at 55°C for 1 hour.
g. pSMART-MHV-G: 10 ml plasmid, 1 ml SfiI, 1 ml BsmBI, 1 ml BSA, 2 ml
NEB Buffer 2, 5 ml water.  Incubate at 55°C for 1 hour.
10. Run the restriction digestions out on a 0.8-1.0% agarose gel in TAE buffer (4.84 g/l
Tris base, 2 ml/l 0.5M EDTA pH 8.0, 1.14ml/l glacial acetic acid; pH to 8.5) at 100
mA, and determine that the plasmid DNAs have the appropriate banding pattern (Fig.
2a).  The digests were designed to ensure that the desired MHV insert is the slowest
migrating band in the gel (Fig. 2a).  MHV-A is 5000 basepairs (bp), MHV-B is 4672
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bp, MHV-C is 1954 bp, MHV-D is 1451 bp, MHV-E is 2792 bp, MHV-F is 6985 bp,
and MHV-G is 8711 bp (Figs. 1c, 2a).
3.2 Amplification and Digestion of the Seven Fragments of MHV
1. Identify replicates on the library plate for each fragment that looked correct by
restriction screen.
2. Prepare a 50 ml conical containing 15 ml of LB broth with appropriate antibiotic and
inoculate it with a streak from the library plate for each plasmid to be amplified.  In
general, one 15 ml culture of each plasmid DNA insert is sufficient for assembling at
least two full-length MHV clones.  Incubate for 12-16 hours at 28.5°C in an incubator
shaker set at 250 RPMs.  Then add 5 ml of LB plus antibiotic and allow growth to
continue for an additional 4-6 hours under the same conditions.
3. Spin the cultures at 3000g for 10 minutes at 4°C and discard the supernatants.  Re-
suspend the pellet in 750ml of Qiagen miniprep P1 Buffer and transfer equally to
three 1.5 ml Microfuge tubes. Purify plasmids using the Qiaprep Miniprep Kit, and
elute to a final volume of 50 ml in elution buffer heated to 70°C.  Combine all three
50 ml aliquots of each fragment to a single tube.
4.  Digest the plasmids as follows:
a. pCR-XL-Topo-MHV-A: 150 ml plasmid, 10ml MluI, 20 ml NEB Buffer 3, 20
ml water.  Incubate at 55°C for 1.5 hours.  Add 5 ml of CIP and incubate at
37°C for 1 hour. CIP catalyzes the removal of 5´ phosphate groups from
DNA, which prevents concatamers of MHV-A from occurring during ligation
(15).   CIP cannot be completely heat inactivated, so the reaction is
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chloroform extracted and isopropanol precipitated at this point to remove the
CIP.
 i. For the chloroform extraction all steps are performed at room
temperature: Add 25 ml of water, 50 ml 3M sodium acetate and 275
ml of chloroform to the reaction.  Shake by hand for 2 minutes, and
then spin at full speed in a microcentrifuge for 2 minutes.  Remove the
aqueous phase to a fresh tube and add an equal volume of isopropanol.
Incubate at room temperature for 10 minutes, followed by
centrifugation at full speed in a microcentrifuge for 10 minutes.
Remove the supernatant and resuspend the pellet in 1 ml of 70%
ethanol.  Spin for 5 minutes at full speed, remove the supernatant and
resuspend in 95% ethanol. Spin for 5 minutes, remove supernatant,
and air-dry the pellet for no more than 5 minutes.  Re-suspend the
pellet in 170 ml elution buffer heated to 70°C.
 ii. Add 10 ml BsmBI and 20 ml NEB Buffer 3.  Incubate for 2 hours at
55°C.
b. pSMART-MHV-B: 150 ml plasmid, 10 ml BglI, 20ml NEB Buffer 3, 10 ml
water.  Incubate at 37°C for 1.5 hours.  Add 10 ml BsmBI and incubate at
55°C for an additional 2 hours.
c. pSMART-MHV-C: 150 ml plasmid, 10 ml BglI, 20 ml NEB Buffer 3, 10 ml
water.  Incubate at 37°C for 1.5 hours.  Add 10 ml BsmBI and incubate at
55°C for an additional 2 hours.
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d. pSMART-MHV-D: 150 ml plasmid, 10ml BsmBI, 2ml BSA, 20 ml NEB
Buffer 4, 8 ml water.  Incubate at 55°C for 2 hours.  Add 10 ml AhdI and
incubate at 37°C for an additional 1.5 hours.  AhdI cuts the vector into two
fragments, which allows the MHV-D fragment to be the largest band.
e. pSMART-MHV-E: 150 ml plasmid, 10 ml BsmBI, 20 ml NEB Buffer 3, 20
ml water.  Incubate at 55°C for 2 hours.
f. pSMART-MHV-F: 150 ml plasmid, 10 ml BsmBI, 20 ml NEB Buffer 3, 20
ml water.  Incubate at 55°C for 2 hours.
g. pSMART-MHV-G: 150 ml plasmid, 10 ml SfiI, 2 ml BSA, 20 ml NEB Buffer
2, 18 ml water.  Incubate at 55°C for 1.5 hours. Add 5 ml of CIP and incubate
at 37°C for 1 hour.  Do the chloroform extraction as described above
(3.2.4.a.i) and re-suspend the pellet in 170 ml of elution buffer.  Add 10 ml of
BsmBI and 20 ml NEB buffer 3, and incubate at 55°C for 2 hours.
5. Isolate the digested fragments by electrophoresis on a 0.8-1.0% gel in wells capable
of holding 75 ml each (3 wells per reaction) (Fig. 2a).  The restriction products should
be run for sufficient time to allow for high resolution of individual fragments.
6. Excise the top band of the correct size for each fragment from the gel, making sure
that it corresponds to the size of the MHV fragment (Fig. 2a) and is not undigested
vector-MHV fragment.  Place the excised band in a 1.5 ml microfuge tube.
7. Use the Qiaex II Gel Extraction Kit for extracting the DNA from the agarose as
follows:
a. Use the Qiaex II Agarose Gel Extraction Protocol with the following
modifications:
89
 i. Re-suspend the excised band in 620 ml of QX1 buffer, 12.5 ml 3M
sodium acetate, and 11 ml QIAEX II resin.  Incubate in a water bath at
55°C for a total of 12-16 minutes with agitation every 2 minutes.  For
fragments larger than 4kb (MHV-A, MHV-B, MHV-F, and MHV-G),
add 360 ml of water after 6 minutes of incubation.  Follow the protocol
for the remaining steps and elute to a final volume of 35ml.  Add the
three replicates for each extraction into one tube (~100ml).
8. A final chloroform only extraction is performed to remove any residual impurities
that remain after the DNA extraction (see Note 1). Use a 1:1 volume of chloroform,
shake for 2 minutes, and spin at top speed in a microcentrifuge at room temperature
for 2 minutes.  Remove the aqueous phase to a fresh tube.
3.3 Assembling the Viral Genome
1. Quantitate each purified MHV fragment with a UV spectrophotometer (optional).
2.  Set up a shotgun ligation by adding relatively equivalent amounts of each fragment
to a fresh 1.5 ml Microfuge tube.  For example, add 25 ml of each of the fragments
with the lowest concentrations, 20 ml for fragments of intermediate concentrations,
and only 15 ml of fragments with the highest concentrations, achieving a goal of
relatively equivalent numbers of molecules of each fragment in the ligation mix (1 μg
of 1000 bp DNA = 1.52 pMol = 9.1x10
11
 molecules). The reaction size will vary each
time but a typical reaction is similar to this:
a. 20 ml of MHV-A
b. 25 ml of MHV-B
c. 25 ml of MHV-C
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d. 25 ml of MHV-D
e. 25 ml of MHV-E
f. 15 ml of MHV-F
g. 20 ml of MHV-G
h. 15 ml of water
i. 20 ml of 10X ligation buffer
j. 10 ml of ligase.
k. Incubate the ligase reaction overnight at 4°C.
3. Chloroform extract and isopropanol precipitate the reaction as described above
(3.2.4.a.i), and re-suspend the cDNA pellet in 10 ml of DepC water heated to 70°C.
4. In vitro transcription of the full-length cDNA construct is conducted using the
mMessage mMachine T7 Transcription Kit using the following recipe per reaction:
a. 7.5 ml of GTP (30 mM)
b. 25 ml 2x NTP/CAP (15 mM ATP, 15 mM CTP, 15 mM UTP, 3 mM GTP,
and 12 mM cap analog)
c. 5 ml 10X Buffer
d. 7.5 ml of full-length cDNA template
e. 5 ml enzyme (RNA Polymerase)
f. Incubate the reaction at 40.5°C for 25 minutes, then 37°C for 50 minutes, and
then 40.5°C for 25 additional minutes.  Use a PCR-cycler for most consistent
results.
g. The remaining 2.5 ml of the ligation reaction and 5 μl of the RNA
transcription reaction can be run on a gel to determine if full-length ligation
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occurred and whether in vitro transcription was successful (Fig. 3a).  Use LE
Agar (0.5%w/v) for the gel with 10% SDS added to the gel buffer and the
running buffer.  Treat 5 μl of RNA with DNAse and then add 2 μl of 10%
SDS and 4 μl 5mM EDTA, prior to running the gel.  For optimal resolution
run the gel overnight at 30 mA.
5. Preparation of SP6-N-gene.  Primers for adding the SP6 promoter onto the N-gene
have been previously published (13).  Use these primers (10 mM) along with the 1 ml
of purified MHV-G fragment (step 3.2.8) per reaction and reagents from the Expand
Long Kit as follows:
a. 1 ml cDNA from MHV-G fragment
b. 1 ml sense primer (10 mM)
c. 1 ml anti-sense primer (10 mM)
d. 1.75 ml dNTP (10 mM)
e. 5 ml Buffer #1
f. 0.75 ml Expand Taq
g. 39.5 ml water
h. Then run PCR through the following cycles: 1 cycle of 94°C for 5 min,
followed by 30 cycles of 94°C for 1 min, 58°C for 1 min, 68°C for 3 min, and
then 1 cycle of 68°C for 10 min followed by 4°C until ready for gel
electrophoresis.
i. The PCR product is then purified as described above (3.2.5 through 3.2.8).
6. In vitro transcription of N-gene is conducted using the mMessage mMachine SP6
Transcription Kit using the following reaction recipe per reaction:
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a. 12.5 ml 2 x NTP/CAP (10 mM ATP, 10 mM CTP, 10mM UTP, 2 mM GTP,
and 8 mM cap analog)
b. 2.5 ml 10X Buffer
c. 3.5 ml SP6-N-gene template
d. 2.5 ml enzyme (RNA Polymerase)
e. 4 ml nuclease-free water
f. Incubate the reaction at 40.5°C for 25 minutes, then 37°C for 50 minutes, and
then 40.5°C for 25 additional minutes.  Use a PCR-cycler for most consistent
results.
g. Do one reaction for each transfection and one additional reaction for the
negative control.
3.4 Preparation of Cells
1. Cell culture must be planned a day or two in advance, as three T150 flasks of BHK-
MHVr cells at ~70% confluency and one T150 flask of DBTs at 80-90% confluency
are required to do one transfection and one negative control (see Note 5).
2. Cells are maintained in the media described above (2.1.1 through 2.1.3).  For passage,
the media is aspirated and the attached cells are washed.  Cells are removed from the
flask with 0.25% trypsin, and then re-suspended and passaged in media.  Splitting a
confluent T150 flask of BHK-MHVr cells (e.g., ~2-3 x 10
7
 cells) the night before at
1:5 will generally produce a T150 at ~70% confluency the next day.
3. Preparation of BHK-MHVr cells for transfection (per T150 flask):
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a. Remove media and wash cells.  Remove the cells from the flask with trypsin.
Add 2 ml of trypsin to the flask and incubate for 5 minutes at 37°C.  Remove
cells from flask by tapping gently.
b. Re-suspend the trypsinized cells in 8 ml of media and transfer cells from all
three flasks to a sterile 50 ml conical.
c. Spin the cells at ~2000g for 5 minutes and remove the media, leaving the
pellet in the conical.
d. Re-suspend the pellet in 10 ml of ice cold PBS and spin at 2000g for 5
minutes.
e. Remove the PBS and re-suspend the pellet in an additional 10 ml of ice-cold
PBS.
f. Transfer 10 ml of the cell suspension to a hemocytometer for counting, and
spin the remaining suspension at ~2000g for 5-10 minutes, while counting the
cells.
g. Remove the PBS from the cells and re-suspend the pellet in the volume of
PBS that will give a concentration of 10
7
 cells/ml.  Counting 10 ml of cells
from a 10 ml preparation translates into 10
4
 cells per 1mm square (grid of 16
squares arranged 4x4) on the hemocytometer.  So count all the cells in three of
the 16 square grids and average them.  Then, multiply this number by 1 x 10
4
.
This gives you the concentration in cells/ml.  In general, to get to a final
concentration of 1x10
7
 cells/ml re-suspend the final pellet in 1/100
th
 of the
final count.  For example, if the final average count is 200 cells, this would
calculate to 2.0 x 10
6
 cells/ml in 10ml volume for a total of 2.0 x 10
7
 cells.
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Re-suspend in 2 ml of PBS to get to a final concentration of 1x10
7
 cells/ml.
Keep cells on ice until ready for electroporation.  A total volume of 1.6 ml of
1x10
7
 cells/ml is required for one transfection and one negative control.
4. Preparation of DBT cells for infection.  Only one confluent T150 flask of DBT cells
is required.
a. Remove media and wash cells.  Remove the cells from the flask with trypsin.
b. Re-suspend the cells in 10 ml of media and transfer 1 ml of cells to a fresh
T75 flask labeled for infection (~5.0x10
6
 cells).  Bring up to 9.5 ml total
volume with media.  Make one flask per transfection and one for a negative
control.
3.5 Transfection
1. Add 800 ml of BHK-MHVr cells re-suspended in PBS (free of magnesium or
calcium) to a concentration of 10
7
 cells to each 0.4 cm Gene Pulser Cuvette labeled
for the appropriate transfection or control.  Do one for each transfection and one for a
negative control.
2. Add 22.5 ml of N-transcript from the SP6-N-gene transcription reaction to each
cuvette, including the negative control.
3. Add 45 ml of the full-length RNA from the transcription reaction to the appropriately
labeled cuvette.
a. The remaining 5 ml is saved to run on an RNA gel (Fig. 3a).
4. Set the Bio Rad Gene Pulser Excel electroporator at 25 mFerrads and 850 volts.
5. Place each cuvette into the Shock Pod™ shocking chamber and pulse three times.
6. Allow each cuvette to incubate at room temperature for 10 minutes.
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7. Remove the electroporated cells from the cuvette into the appropriately labeled T75
flask of DBT cells (optional).  Alternatively, allow the electroporated MHVr cells to
settle onto a T75 flask and incubate at 37°C for 1-2 days to allow for the development
of cytopathology.
8. Incubate the flasks at 37°C in an incubator with 5% CO2.
A                                           B                             C
Figure 3.  In vitro assembly of full length cDNAs and transcripts and the recovery of
infectious virus.  A.  Running the cDNA from an assembly ligation results in a ladder of
intermediates, as well as a full-length product ~31.5kb.  After in vitro transcription, running
RNA on a gel results in a smear of RNA including a full-length viral RNA which runs at 16-
17kb.  B.  Detecting viral replication can be accomplished using primers that anneal to the
leader sequence and the N-gene.  Using the anti-sense primer to perform reverse transcription
and then both primers to amplify the target via RT-PCR generates a series of bands
corresponding to several subgenomic mRNAs. C.  A northern blot showing the seven
mRNAs of icMHV, using a probe that anneals to the 5’ 300 nucleotides of the N-gene allows
detection of genomic and all subgenomic mRNAs.
3.6 Detection of Cytopathic Effect
1. Wild-type MHV from the clone will generally produce cytopathic effect (CPE) within
8-12 hours, and usually the syncytium across the monolayer is complete by 24 hours.
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We typically recover between 1,000 and 10,000 plaques (infectious center assay)
following electroporation of transcripts.  CPE is very obvious for DBT cells infected
with MHV.  Excess spike glycoproteins accumulate at and protrude from the cell
surface, which facilitates fusion with the neighboring cells. This creates large multi-
nucleated syncytia that are usually observed by 8-12 hours post-transfection.  As the
cells die, they lift off the flask, and so an efficient transfection of full-length viral
RNA will result in a rapid clearing of the monolayer, usually within 16-24 hours.
2. Mutants generally come up slower and may take up to 72 hours for CPE to be
obvious.  Highly debilitated mutants may not display obvious CPE.  Passage usually
selects for 2
nd
 site revertant viruses that replicate efficiently; so extensive passage
usually results in recombinant viruses containing multiple mutant alleles scattered
across the genome. Reversions at the site of mutation can be reduced by fixing each
engineered mutations with 2 or more nucleotide changes in the codon.
3. Harvest supernatants by spinning the at ~3000g for 10 minutes at room temperature
and aliquoting to fresh 2 ml screw cap tubes.  Store at –80°C.  These are labeled as
passage zero (P0).
3.7 Plaque Purification
1. Plaque purification allows isolation of single colonies of virus for propagation of
stocks and verification of genotype (Fig. 4).  This is done by plating a serial dilution
of supernatants from P0 onto 60 mm dishes of DBT cells and then adding an agar
overlay to prevent diffusion of the virus into the media.
2. One confluent T150 flask of DBT cells is sufficient to seed twenty 60 mm dishes
labeled by dilution and virus.  Re-suspend washed cells in a total of 61 or 81 ml of
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media and aliquot 3 or 4 ml of cells onto each of twenty 60 mm plates.  Repeat as
necessary for the correct number of plates.  The cells are then incubated at 37°C
overnight.  They are ready to use at ~95-100% confluency.
3. When the cells are confluent, remove the media.  Dilute the supernatant from P0
using dilutions of 1 part P0 supernatant to 9 parts PBS, ranging from 10
-1
 to 10
-7
dilutions.
4. Add 200 ml of the appropriate dilution onto a 60 mm plate of DBT cells, and spread
evenly by mixing back and forth every 15 minutes, while incubating at room
temperature for 1 hour.  This is passage one (P1).
5. Prepare the overlay ahead of time.  Make enough to aliquot 5 ml of overlay onto each
plate.  For 100 ml:
a. Autoclave 49 ml sterile water and 0.8 g of LE Agar (low melt) and
incubate in a water bath at 55°C for 15 minutes.
b. Add 40 ml 2 x media heated to 37°C.
c. Add 10 ml FCII or FBS heated to 37°C.
d. Add 1 ml of Gen/Kan heated to 37°C.
6. Carefully add 5 ml of overlay onto each plate.  This must be accomplished at close to
40-42°C as the media rapidly solidifies below these temperatures while hotter
temperatures will adversely affect cell viability.  Allow the plates to incubate 24-48
hours at 37°C.
7. Plaques for icMHV resemble wt MHV (Fig. 4a), while mutant plaques can vary
greatly (Fig. 4b).  Select 5 plaques for each virus.  For each plaque to be picked: use
sterile technique to cut ~1/3 of an inch off the end of a P1000 barrier tip, place the tip
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over the plaque and push through the agar, make sure the surface of the plate and the
agar are both manipulated so as to ensure that the entire plaque is extracted without
any neighboring plaques.  Place the picked media into 300 ml PBS and incubate at
4°C for 30 min.
Figure 4.  Plaques produced by infection with recombinant MHV and a mutant.  A.
DBT cells were infected with recombinant icMHV and overlaid with agar.  Plaques formed
at 24-36 hours, and cells were stained with neutral red.  MHV produces clear, uniform
plaques of approximately 5 mm in diameter.  B.  In contrast, some mutant forms of MHV
produce differential plaques sizes.  Here we show a mutant with a double amino acid change
in nsp10 (the lysines at positions 24 and 25 in nsp10 were changed to alanines), which results
in smaller overall plaque sizes, as well as a variety of different sizes, some with irregular
borders.
8. The 300 ml containing the plaque and PBS is then used to infect a 60 mm plate of
DBT cells, brought up as described above. To infect cells, remove media and pipette
all 300 ml of the plaque and PBS onto a 60 mm plate of DBT cells, spread evenly by
mixing back and forth every 10-15 minutes and incubate at room temperature for 1
hour.  Then add 4 ml of media to each plate. This is passage 2 (P2). Allow the
infections to proceed at 37°C until CPE is obvious (usually 24-36 hours). We
typically only plaque purifiy recombinant viruses 1X as additional passages increase
the probability of 2
nd
 site mutations or reversions (see Note 7).
A.                                                    B.
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9. Remove the media from the 60 mm dishes, centrifuge at ~3000g for 10 minutes at
room temperature and aliquot the supernatant into 1.5 ml Microfuge tubes labeled P2.
10. Re-suspend the cells in 1 ml of Trizol Reagents and dispense it into a 1.5 ml
microfuge tube for isolation of total RNA.
3.8 Harvesting RNA, Reverse Transcription and Verification of Viral Genotype
1. Total RNA is harvested using Trizol Reagents following the standard protocol.
Briefly, approximately 4x10
6
 cells are harvested in 1 ml of Trizol and the RNA is
frozen at -80°C until further use:
a. All steps are performed at room temperature.  Start by thawing the frozen cells
in Trizol and allowing them to sit at room temperature for 5 minutes.
b. Add 200 ml chloroform and shake by hand for 15 seconds.
c. Spin at 12,000g for 15 min.
d. Remove aqueous phase to a fresh tube
e. Add 500 ml of isopropanol and incubate for 10 minutes
f. Spin at 12,000g for 10 min
g. Remove supernatants and re-suspend the pellet in 1ml of 75% ethanol diluted
in DepC water
h. Spin at 7500g for 5 minutes
i. Remove ethanol and air-dry the pellet for 5-10 min.
j. Dissolve the pellet 100 ml of DepC water heated to 70°C and incubate at 55°C
for 10 minutes.
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2. Design PCR/sequencing primers flanking the region of the mutation.  Use the anti-
sense primer as the gene specific primer for SuperScript III reverse transcription with
modifications to the protocol:
a. Add 2 ml of RNA and 2 ml of anti-sense primer to a fresh tube and incubate at
70°C for 10 min.
b. Add 2 ml of 0.1 M DTT
c. Add 2 ml 10 mM dNTPs
d. Add 4 ml 5x First-strand Buffer
e. Add 7 ml of nuclease free water
f. Add 1 ml SuperScript III
g. Incubate at 55°C for 1 hour.
h. Incubate at 70°C for 20 min to inactivate the RT.
3. Amplify the region of interest with a 50 ml PCR reaction appropriate for the size and
composition of the cDNA target.
4. Isolate the DNA from PCR following the same procedures as described in 3.2.5
through 3.2.7.i modifying the recipes for the 50 ml reaction size.
5. Once isolated, clone the target into a vector of choice.  We use pCR-XL-Topo,
following the manufacturer’s recommend protocol.
6. Transform, grow-up, and screen as described in section 3.1.  Screen by restriction
digestion with EcoRI, and sequence clones that are of the appropriate size to verify
genotype.
3.9 Designing Mutants using the No See’m Technology
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1. Identify a target of interest.  This can be a single/double/triple codon change, a
deletion, etc.
2. Determine which type IIs restriction enzymes do not cut the vector, the target
fragment, and the fragment with the newly designed mutations incorporated into the
sequence.  This can be accomplished with any restriction analysis tool, however
NEBcutter2.0 works sufficiently and is user-friendly.
3. Select one of the non-cutters to add onto the end of each fragment.  In Figs. 1c and 5,
we selected a glutamate codon at position 13354-56 (CAG) and will change it to an
alanine (GTC).  To stabilize the mutation against reversion to the wt genotype, we
generally alter the codon at multiple positions.  This mutation maps to MHV-E as the
fragment target, and enzyme BbsI does not cut the sequence or the pCR-XL-Topo
vector.
4. Design primers that incorporate the mutation into the target fragment utilizing the
non-specific site of the restriction cut site to engineer a junction oriented such that
upon cleavage the restriction site is removed and complementing sticky ends remain
(Fig. 5).
5. Amplify both fragments by PCR using the newly designed primers along with vector
specific sequencing primers and reaction conditions appropriate for the size of each
target.  For MHV-E fragment in pCR-XL-Topo M13F and M13R are used.  Run PCR
reactions on a gel, extract and purify amplicons of the correct size, clone into pCR-
XL-Topo (or another vector of choice), transform, pick colonies and grow larger
cultures, screen by restriction digestion, and sequence verify each amplicon (as
described above).
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6. Digest each amplicon using the appropriate reaction conditions and enzymes.  In the
case of MHV-E in Fig. 5, we amplified with vector primers M13R and M13F, which
ensures that the BsmBI sites were preserved at both ends of the fragment, so each
amplicon will have a BsmBI site and a newly engineered BbsI site.  These amplicons
are digested first with BbsI and NEB buffer 2 for 1.5 hours at 37°C followed by
digestion with BsmBI at 55°C for 2 hours.  In addition, we digested wild-type MHV-
E with just BsmBI, and purified the vector band (the smaller of the two). All of these
digests are purified as described above.
7. Using this strategy, both amplicons and the vector are ligated in a single ligation
reaction:
a. 11 ml of each purified band (amplicon1, amplicon2, vector)
b. 4 ml Ligation buffer
c. 3 ml Ligase
d. Incubate at 4°C overnight.
8. Transform 5 ml of the ligation, plate, pick colonies and grow larger cultures, screen
by restriction digestion, and sequence verify each amplicon.
9. Build MHV virus using the newly mutated cDNA.
4. NOTES
1. Always do a chloroform-only extraction of the viral fragments after digestion as
impurities left behind by the extraction kit can interfere with the DNA ligase.
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Figure 5.  Engineering mutations with the No See’m approach.  A. The position of
interest, a Glutamate (CAG) to Alanine (GTC) mutation at position 13354-56, is targeted and
mapped to the MHV-E fragment.  The vector sequence, the wild-type fragment, and the
mutated fragment are analyzed to determine which type IIs restriction enzymes do not cut
any of them, and one of these is selected as the restriction site to add.  In this case BbsI is
selected.  B. Primers are designed that add the mutation and the restriction site in proper
orientation so that upon digestion the restriction site is eliminated and complementing sticky
ends are produced.  The BbsI cut sites are highlighted in gray.  The mutated codon is bold
and underlined.  C.  PCR is conducted using vector specific primers along with the newly
designed primers that incorporate the mutation of interest to produce two amplicons.  These
are cloned and purified, and then digested with BbsI and BsmBI to produce a mutated MHV-
E fragment that can then be incorporated into the full-length clone.
A
B
C
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2. Always use PBS prepared in DepC water for washing cells.  This reduces the
opportunity for RNAses in the media to degrade the full-length viral transcript prior
to electroporation.
3. Always use barrier tips for pipetting, particularly when working with wild-type MHV
along side a mutant.
4. Run digestions of wild-type fragment and mutant fragment on different gels with new
running buffer each time. Wild-type MHV is so efficient at replication that even very
low levels of cross contamination of fragments will result in wild type MHV out-
competing with any mutant.
5. For best results use BHK-MHVr cells at or below 80% confluency.
6. Clone stability is enhanced by growing everything at room temperature.
7. Avoid passage of highly attenuated mutant viruses because reversions to wildtype and
2
nd
 site reversions occur rapidly upon passage.
8. There are several strengths and a few weaknesses to the No See’m infectious clone
approach.  Strengths over a single full-length clone include a) rapid mutagenesis of
independent subclones in parallel, b) mixing and matching of existing mutants from
different subclones, c) increased stability of smaller cDNAs, d) safety of molecular
clone of highly pathogenic viruses, e) requirement for high individual expertise which
minimizes the chances of harmful use of the coronavirus molecular clone, f) high
recovery of recombinant viruses, g) speed of recovery of recombinant virus, and h)
reduced sequencing costs (sequence subclone only).  Weaknesses include: a)
technical expertise required for assembly, b) in vitro transcription of full length
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coronavirus RNAs is difficult, c) troubleshooting the lengthy assembly process, and
d) obtaining reliable sequence information for the wild type genome.
Well over a hundred mutants have been engineered into the clone of MHV
using this approach, which far exceeds all other coronavirus reverse genetic systems
reported.  In addition, this technology has been used to rapidly develop reagents in
response to newly identified emerging coronaviruses.  For example, SARS-CoV was
identified in the fall of 2002, and a full-length infectious clone was available the
summer of 2003 (16).  Piecemeal assembly of smaller subclones is within range of
commercial DNA synthesis companies, allowing for synthetic reconstruction of
coronavirus genomes. However, attempts to reconstruct other coronavirus genomes
using this method have proven more difficult.  Current problem areas that must be
solved for the advancement of this technology include: a) unreliable sequence
information in the public databases, b) mistake prone amplification and cloning of AT
rich genomes (such as in human coronavirus NL63), c) clone stability and sequence
toxicity issues with different viruses, d) size issues of the different fragments for
different viruses, and e) cell tropism issues with newly identified animal viruses (Bat
CoV).
Once an infectious clone is established for a virus, rapid production of
candidate vaccine strains (17-19) and vectors for therapeutic gene delivery in animals
and humans (20) is possible.  Attenuating mutations can be identified and
combinations engineered into the infectious clone, and recombinant viruses generated
and tested.  In SARS-CoV, this approach has identified zoonotic candidate vaccine
strains (17, 18) and a novel strategy for preventing recombination between wildtype
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and recombinant viruses by rewiring the viral communication network (19).  This
strategy provides a recombination safe vaccine platform that will likely redefine
coronavirus vaccinology.
A tremendous amount of creativity in the coronavirus field has resulted in four
independent and unique reverse genetic systems for a single virus family (11, 13, 14,
21, 22), all of which have helped pave the way for the emergence of the golden age of
coronavirus genetics.  We anticipate the discovery and genetic analysis of a large
number of unique genetic functions in the coronavirus genome, and that these
discoveries will translate to a better understanding of coronavirus replication,
transcription and assembly and mechanisms of pathogenesis of these important
human and animal pathogens.
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CHAPTER IV: MURINE HEPATITIS VIRUS REPLICASE PROTEIN NSP10 IS A
                            CRITICAL REGULATOR OF VIRAL RNA SYNTHESIS
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Denison, and R. S. Baric. 2007. Murine hepatitis virus replicase protein nsp10 is a critical
regulator of viral RNA synthesis. J Virol 81:6356-68.
ABSTRACT
Coronavirus replication requires proteolytic processing of the large polyprotein encoded by
ORF1a/ab into putative functional intermediates and eventually ~15 mature proteins.  The c-
terminal ORF1a protein, nsp10, colocalizes with viral replication complexes but its role in
transcription/replication is not well defined.  To investigate the role of nsp10 in coronavirus
transcription/replication, alanine substitutions were engineered into an MHV infectious clone
in place of conserved residues in predicted functional domains or charged amino acid
pairs/triplets, and rescued viruses analyzed for mutant phenotypes.  Of the sixteen engineered
clones, five viable viruses were rescued, three mutant viruses generated no cytopathic effect
but were competent to synthesize viral subgenomic RNAs, and eight were not viable.  All
viable mutants showed reductions in growth kinetics and overall viral RNA synthesis,
implicating nsp10 as a co-factor in positive or negative strand synthesis.  Viable mutant
nsp10-E2 was compromised in its ability to process the nascent polyprotein, as processing
intermediates were detected in cells infected with this virus that were not detectable in wild-
type infections.  Mapping the mutations onto the crystal structure of SARS nsp10, identified
a central core resistant to mutation.  Mutations targeting residues in or near either zinc-
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binding finger generated non-viable phenotypes, demonstrating that both domains are
essential to nsp10 function and MHV replication.  All mutations resulting in viable
phenotypes mapped to loops outside the central core, and were characterized by a global
decrease in RNA synthesis.  These results demonstrate that nsp10 is a critical regulator of
coronavirus RNA synthesis and may play an important role in polyprotein processing.
1. INTRODUCTION
Coronaviruses (CoVs) have historically been associated with severe disease in
important domestic animals, and mild upper respiratory tract infections in humans (Human
Coronavirus [HCoV]-229E and HCoV-OC43), rarely leading to severe disease(24).
However, the rapid identification of a CoV as the etiological agent responsible for Severe
Acute Respiratory Syndrome (SARS) redefined historic perceptions.  SARS-CoV spread
globally and infected over 8,000 people with mortality rates of about 10 percent (49).  More
recent studies have identified human CoVs HCoV-NL63 and HCoV HKU-1 as important
lower respiratory tract pathogens (25, 53). With ubiquitous populations of CoVs found in
many animals, it is not surprising that several newly identified CoVs have been described
that likely emerged from zoonotic reservoirs over the past 20 years.  Understanding the basic
biology and pathogenesis of coronavirus infection is of urgent importance.
Coronaviruses are the largest known RNA viruses encoding plus-sense, 5’capped, and
polyadenylated genomes of 27-31kb in length.  CoVs are classified as members of the order
Nidovirales, family Coronaviridae, genus Coronavirus, and are divided into three groups
based on serological and phylogenetic categorization(14, 29).  Group 1 consists of NL63,
HCoV-229E, and transmissible gastroenteritis virus (TGEV); Group 3 is composed of
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infectious bronchitis virus (IBV); and Group 2 CoVs include HCoV-OC43, HKU-1, Bovine-
CoV, SARS-CoV, and Murine Hepatitis Virus (MHV)(14).  MHV is an extensively studied
CoV, with strain MHV-A59 being well characterized in cell culture and mouse model
systems(33).  The close relationship of MHV to SARS-CoV, makes MHV an ideal model for
prototype studies on the biology and pathogenesis of CoV infections in humans.
The first ~22kb of the CoV genome is organized as two overlapping open reading
frames (ORFs) which encode the replicase genes (ORF1a and ORF1ab), while the remaining
5-9kb contains the genes which encode: 1) structural proteins common to all CoVs, including
Spike (S), Envelope (E), Matrix (M) and Nucleocapsid (N); and 2) accessory ORFs which
encode proteins unique to specific virus groups(24). The structural and accessory proteins are
encoded by a nested set of co-terminal subgenomic mRNAs that are generated by
discontinuous transcription of negative strands(1, 21, 39, 40, 42-44, 46, 57), followed by
positive strand synthesis, and then translation.
Immediately after entry, the genomic RNA is uncoated and translation of ORF1
generates either an ~500 kDa polyprotein (pp1a) from ORF1a, or an ~800kDa polyprotein
(pp1ab), which is only translated when the ORF1a stop codon is overridden by a –1
ribosomal frameshift that allows translation of an ORF1ab fusion protein (ORF1ab)(5).
ORF1ab translation occurs at an approximate frequency of 25-30%, which leads to a greater
than 3-fold enrichment of proteins translated from pp1a(4).  During and after translation,
pp1a and pp1ab are processed by three functionally active virally encoded proteinases into
active intermediates and eventually ~15 mature proteins (6).
Two distinct types of viral proteinases are required to process the nascent polyprotein
into component intermediates and mature proteins.  The first type is the Papain-like
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proteinases (PLP1 and PLP2), which cleave non-structural proteins (nsps)1-3 co-
translationally (7, 8,18, 45) resulting in mature proteins nsp1, nsp2 and nsp3 as well as
polyproteins nsp4-11 and nsp4-16.  These polyprotein intermediates are then processed both
co- and post-translationally by the second type, a 3C-like proteinase known as 3CLpro or
Main proteinase (Mpro) (11).  Although the exact order and mechanism of processing of
mature proteins from these intermediates is yet to be determined, most of these proteins have
been observed in their mature form, and co-localize with the viral RNA dependent RNA
polymerase to intracellular double-membrane vesicles, where they form the viral replication
complex (16).  The current model suggests larger unprocessed intermediates such as nsp4-
10/11 (p150) play a role in early negative strand synthesis, while positive strand replication is
thought to require mature proteins(41).  To date, only nsp2 has been shown to be dispensable
for replication(17).
In general, nsps 1 and 2 have unknown functions, nsp3 contains domains important
for transcriptional regulation as well as for PLP1 and PLP2 activity, nsp4 and nsp6 are
transmembrane domains which may aid in anchoring the replication complex to double
membrane vesicles, and nsp5 is the 3CLpro.  Nsps 7 through 10 are four small proteins of
unknown function found at the carboxy terminal end of pp1a.   The structures of nsp7 (34)
nsp7-nsp8 (56), nsp9 (13, 52) and nsp10 (22, 51) have been solved, and all four proteins have
been implicated in RNA synthesis.  Nsp7 and 8 are predicted to form a hollow cylinder
postulated to protect dsRNA during transcription/replication (56), nsp8 has a demonstrated
RNA primase activity (20), nsp9 has been shown to bind ssRNA (13, 52), and three studies
with nsp10 predict that it interacts with RNA, DNA, and/or other proteins(22, 28, 51). Nsp11
is a small ~36 nucleotide (nt) segment located at the 3’ end of ORF1a that encodes a small
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uncharacterized 12 amino acid peptide with no defined function.  Nsp12 is the RNA
dependent RNA polymerase (RdRp), nsp13 contains the helicase activity, and nsps14-16 are
enzymes which may function in RNA processing (48).
Studies with Nsp10 have shown that it is a 15-kDa protein of unknown function
shown to interact with itself, nsp1, and nsp7(8).  It co-localizes with N to sites of viral
replication(3), and is essential for replication (Deming, et. al. 2007, submitted).  Nsp10 was
first predicted to be a possible growth factor-like molecule as the concentration of nsp10
increased in response to epidermal growth factor(30), however, there is little homology
between nsp10 and any other proteins of known function.  Complementation studies using
TS mutants in several nsps of MHV, have purported that nsp10, along with nsp4, nsp5,
nsp12, nsp14, and nsp16 are essential for the assembly of a functional
replication/transcription complex(41).  Further characterization of the nsp10 TS mutant TS-
LA6 has suggested that nsp10 plays a critical role in negative strand elongation (41, 47, 54).
Recent crystallography studies have revealed the structure of nsp10 of SARS-CoV as a novel
zinc finger protein with two zinc finger domains (22, 51), whereas a second report suggests
the biological unit is a dodecamer that forms a hollow positively charged cylinder thought to
be a transcription factor (22, 51).
In this study, we employed a reverse genetics approach to generate mutants of nsp10
in the context of the entire virus to define the functions of nsp10 in CoV
replication/transcription.  We show that rescued viruses with mutations in nsp10 globally
reduce viral RNA synthesis.  Mutations resulting in lethal phenotypes mapped a central core
of nsp10 which is resistant to mutation, and verified that the zinc-binding fingers (ZFs),
including the surrounding residues to which they hydrogen bond, are critical to nsp10
114
function and coronavirus viability.  Finally, our study is the first to demonstrate that
mutations in nsp10 may affect processing of the ORF1a/1ab polyprotein.
2. METHODS
Virus and cells.   For this study we used an infectious clone of MHV-A59 developed
by our laboratory, comprised of seven fragments maintained in pSMART (Lucigen) or pCR-
XL-TopoA (Invitrogen) vectors, and amplified according to previously published protocols
(55).   Recombinant MHV generated by the infectious clone (wt-icMHV) was used as a
control in each experiment.   MHV sequence accession: NC_001846 was used for primer and
cloning design.
Delayed Brain Tumor (DBT) cells were maintained at 37°C in Minimum Essential
Media supplemented with 10% Fetal Clone II (Gibco), 10% tryptose phosphate broth, and
Gentamycin (0.05mg/ml)/Kanamycin (0.25mg/ml).  Baby Hamster Kidney (BHK) cells
exogenously expressing MHV receptor (BHK-MHVr) were maintained at 37°C in the same
media as above with the addition of Geneticin (0.8 mg/ml) to select for cells expressing
MHVr.
Bioinformatics analysis and mutant rationale.  A multiple sequence alignment
generated by the National Center for Biotechnology Information(NCBI)
(http://www.ncbi.nlm.nih.gov/genomes/SARS/nsP7.html) was used to map the conserved features of
nsp10.  Bioinformatic predictions were generated using Prosite(19) to predict conserved
protein domains, Predictors of Natural Disordered Regions (PONDR)(38) to determine
putative disordered domains, the SMART database(26) to search for similarity signatures,
and HMMSearch(12) to analyze potential structurally conserved subunits.
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Generating mutants.  A full-length molecular clone developed by our laboratory(55)
was used to engineer the appropriate mutations in the nsp10 sequence, which is found in the
MHV-E fragment (55).  Briefly, primers were designed (Table 2) that incorporated type IIS
restriction enzyme sites (BbsI) bearing each mutation onto the ends of two amplicons that
comprised MHV-E (55).  In all cases the wild-type residue(s) was changed to alanine by
altering two positions in each codon.  The mutants were generated by PCR, cloned into
TopoXL vector (Invitrogen), grown up in competent Top10 cells (Invitrogen), screened by
restriction digestion, and sequenced to verify that the correct changes were added on each
end.  Each amplicon was then digested with BbsI, and ligated to form the mutated MHV-E
fragment.  Full-length E-constructs were amplified, purified, and sequence verified.  For
assembling the infectious clone, plasmids incorporating cDNA fragments of MHV-A through
MHV-G for wt- icMHV and MHV-A to D, and MHV-F, MHV-G and the mutated E-
construct for each mutant were transformed into chemically competent Top 10 Cells
(Invitrogen) by heat shock at 42°C for 2 min, then plated on Luria Bertani (LB) plates with
appropriate selection (Kanamycin [25mg/ml] for Topo-XL and Ampicillin [50 mg/ml] for
pSMART).  Colonies were picked and grown under appropriate selection conditions in 5ml
of LB broth maintained at 28.5°C for 16-24 H, then purified and screened by restriction
digestion.   Larger 20 ml stocks were grown at 28.5°C for 24h for each of the cDNAs.
Purified plasmids were then digested with MluI and BsmBI for MHV-A, BglI and BsmBI for
MHV-B and MHV-C, BsmBI for MHV-D, MHV-E, and MHV-F, and SfiI and BsmBI for
MHV-G (55).  After digestion fragments were electroporated on 0.8% agarose gel, and
appropriate bands were excised and gel purified using a Qiaex II Gel Extraction Kit (Qiagen)
with modifications (55).  Briefly, all fragments were resuspended in 620 μl of QX1 buffer,
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11 μl QIAEX II silica-gel particles and 12.5 μl 3M sodium acetate, and eluted in 35 μl of
elution buffer heated to 70°C.   Purified fragments were ligated overnight at 4°C, in a total
reaction volume of ~200 μl.  The full-length cDNA was then further purified by chloroform
extraction and isopropanol precipitation, and transcribed using T7 transcription kit (Ambion)
and co-transfected into 8x106 BHK-MHVr cells in parallel with the N-gene driven by an SP6
promoter and transcribed with SP6 transcription kit (Ambion).  Electroporated BHKs were
poured onto ~2.5x105 DBT cells seeded in T75 flasks and incubated at 37°C for 24-72 hours.
Flasks were examined at regular intervals for cytopathic effect (CPE), and viable mutants
were verified by reverse transcriptase PCR (RT-PCR) of subgenomic RNA using primers
targeting the leader sequence and the 5’ end of the N gene (Table 2).  Plaque purified viruses
were sequenced to confirm that the correct mutations were present in the recombinant virus.
Growth kinetics and RNA analysis.  Viral stocks were propagated in DBT cells for
each viable mutant and titers were determined by plaque titration.   For growth curve
analysis, DBT cells were infected at an Multiplicity Of Infection (MOI) of 0.2 Plaque
Forming Units (PFU)/cell in 60 mm plates with an one hour adsorption period, followed by
three washes with PBS.  Three milliliters of media was added to each culture and the
infection was maintained at 37°C.  Supernatants were harvested at 2, 4, 8, 12, and 16 hours
post infection (h p.i.) and titers determined by plaque titration in DBT cells.  For analysis of
RNA, cells were infected at an MOI of 1 PFU/cell and total RNA was harvested at 8 and 12-
hours in Trizol Reagent (Invitrogen).  For northern blot analysis 1μg of total RNA from each
mutant and wt-icMHV was separated by gel electrophoresis on a 1% agarose gel, transferred
to a nitrocellulose membrane, and probed with a 300 nt biotinylated RNA probe designed to
detect the first ~300 nucleotides of mRNA-7 (N gene) using an Ambion (Austin, TX)
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Northern kit.   Bands were detected using the Bright Star Detection (Ambion) system, and
membranes were exposed to film.
Reverse transcription, RT-PCR, and real time PCR.  Viral RNA was reverse
transcribed to cDNA using SuperScript III (Invitrogen) with modification to the protocol as
follows:  Random hexamers (300ng) and total RNA (5μg) were incubated for 10 minutes at
70°C.  The remaining reagents were then added according to manufacturer’s
recommendation and the reaction was incubated at 55°C for 1 hour followed by 20 minutes
at 70°C to deactivate the RT.  For RT-PCR, a forward primer in the leader sequence and a
reverse primer ~200 nt into the N-gene (Table 2) were used to generate an ~220 base pair
product by PCR.
Quantitative real time RT-PCR was conducted using Smart Cycler II (Cepheid) with
SYBR green (Cepheid, diluted to .25X) to detect subgenomic cDNA with primers (7.5 pM)
optimized to detect ~120 nucleotides spanning from the leader sequence to the 5’ end of N
gene (Table 2) or genomic cDNA with primers (7.5 pM) optimized to detect ~120
nucleotides of ORF1a (Table 2).  The cDNA from the RT reaction of each virus was diluted
1:103, and 1μl was used for each reaction, with a total reaction volume of 25μl. Omnimix
beads (Cepheid) containing all reagents except SYBR green, primer, and template were used
to standardize the reaction conditions, and template concentrations were normalized by
housekeeping gene, GAPDH concentrations.  In addition, all products were verified by
melting curve analysis.
Statistical methods.  Three independent infections for each mutant were analyzed by
real time PCR and differences in copy number for genomic and subgenomic RNAs were
tested using the paired t-test with an -value of 0.05.
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Immunoprecipitation analysis.  DBT cells were infected at MOI of 2 PFU/ml for 2
hours, at which time the media was removed and replaced with media lacking Met/Cys but
containing 20mg/ml of Actinomycin D (Sigma), and incubated at 37°C for an additional two
hours.  At 4h p.i., [35S]methionine/cysteine (0.08mCi/ml) was added to the infections and
cells were harvested at 9 hours. Radiolabeled cells were washed in 1 ml of PBS and then
resuspended in 1 ml of ST buffer (200mM Sucrose, 10mM Tris pH 7.4, cold).  Next cells
were homogenized by 40 passes through a ball-bearing homogenizer, and transferred to fresh
tubes.  Homogenates were then spun at 6000g for 3 min at room temperature, and
supernatant was transferred to ultracentrifuge tubes and spun at 300,000g for 15 min at 4°C.
The supernatant was then transferred to a fresh tube (S100), and the pellet resuspended in 1
ml of ST buffer (P100).  The nuclear pellet was resuspended in 1 ml of ST buffer and the
DNA was sheared by passing 20 times through a 20-gauge needle.
Lysates were boiled for 5 min in SDS at a final concentration of one percent, then
combined with protein A-Sepharose beads and a 1:200 dilution of anti-nsp10 antibody
(VU128) in no-SDS lysis buffer (1% NP-40, 150 mM sodium chloride, 0.5% sodium
deoxycholate, and 50 mM Tris, pH 8.0) supplemented with 1% SDS. After incubation at 4°C
for 4 h, beads were pelleted and washed with low-salt lysis buffer (no-SDS lysis buffer plus
150 mM NaCl) followed by high-salt lysis buffer (no-SDS lysis buffer with 1 M NaCl) and a
final low-salt wash. After rinsing, 30 ml of 2X SDS loading buffer (8% SDS, 0.2 M Tris, pH
8.8, 4 mM EDTA, 0.1% bromophenol blue, 40% glycerol, 0.5 M dithiothreitol) was added to
the pelleted beads and boiled for 5 min prior to electrophoresis of the supernatant on 4 to
12% SDS-PAGE gels.
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Immunofluorescence assay. DBT cells were grown to 60-70% confluence on 12-
mm glass coverslips and infected with wt-icMHV or each of the viable mutants at an MOI of
5 PFU/cell. At 6.5h p.i. the media was aspirated, and the cells were fixed and permeabilized
in –20°C methanol overnight. Cells were rehydrated in PBS for 30 min, and blocked in
buffer comprised of PBS with 5% bovine serum albumin. All subsequent IFA steps were
conducted at 25°C in IFA assay wash buffer comprised of PBS containing 1% bovine serum
albumin and 0.05% Nonidet P-40. After blocking, cells were incubated in primary antibody
(anti-nsp10 (VU128), 1:200, and anti-N, 1:1,000 or anti-M, 1:1000) for 1 h. Cells were then
washed in IFA assay wash buffer three times at 10 min/wash. Next, cells were incubated in
secondary antibody (goat anti-rabbit-Alexa 488, 1:1,000, and goat anti-mouse-Alexa 546,
1:1,000, Molecular Probes) for 45 min. Next, cells were washed three times at 10 min/wash,
followed by a final wash of 30 min. in PBS. Coverslips were mounted to slides with
Aquapolymount (Polysciences) and dried for 1 hour, and then visualized by confocal
immunofluorescence microscopy using a Zeiss LSM 510 laser scanning confocal microscope
at 488 and 543 nm with a final magnification of 40X with the oil immersion lens. Images
were prepared for publication using Adobe Photoshop CS.
Analysis of structure.  The crystal structure coordinates of SARS nsp10 (PDB code
2FYG)(22) were used as a template to generate a homology model of MHV nsp10, which is
a predicted 3-D structure of this protein calculated from its sequence homology with SARS-
CoV nsp10.  Homology models were generated using the program Modeller version 8.2(15,
27), with the automodel class.  A pairwise alignment was generated using SARS nsp10
protein database (PDB) file and the MHV homologue sequence (Accession number:
NP_740615), and five models were generated from each alignment, with the best model
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selected based on the lowest objective function score.  Corresponding PDB files generated by
this program were visualized on molecular modeling tools MacPyMol (DeLano Scientific)
and Chimera(35).  In addition, homology models of each of 16 mutants were generated using
the same parameters.
3. RESULTS
Mutation Design and Rationale. To identify functional domains within MHV nsp10
and determine roles nsp10 plays in coronavirus replication, two different alanine scanning
mutagenesis strategies were devised.  The first targeted pairs and triplets of charged amino
acids, since charged residues often provide electrostatic surface potential required for
interaction of the protein with other proteins or nucleic acids.  These sites may play a crucial
role in inter- and intra-protein interactions, as well as nucleic acid binding, and these were
designated the E-series mutants (Table 1, Fig. 1).
Table 1.  Sites targeted for mutagenesis.
Mutant AA(s)/Pos Conservation Phenotype Structural location
nsp10-E1 K24 K25 KK in GIIa, not in SARS. K25 in mostb Viable N-terminus of H2c
nsp10-E2 D47 H48 DH in GII, H also in GId Viable Loop between H2 and H3
nsp10-E4 R78 S79 R80 R78 strictly conservede, pos 80 always (+)f Lethal H4 near ZF-1g
nsp10-E5 E82 H83 pos 82 mostlyb (–)f H83 identical in CoVs Lethal ZF-1
nsp10-E6 K104 D105 D strictly conserved Lethal Near N-terminus of H5
nsp10-E7 H113 D114 Mostly (-) at 114, H113 identical in GII Lethal C-terminus of H5 near ZF-2
nsp10-E8 D123 R124 conserved in GII, (+) at 124 also in SARS Lethal C-terminal loop near ZF-2
nsp10-U1 C41 Strictly conserved in CoVs Viable Loop between H2 and H3
nsp10-U2 G52 Strictly conserved in CoVs Viable-Dh Loop between B1i and B2
nsp10-U3 T56 Strictly conserved in CoVs Viable Loop between B1 and B2
nsp10-U4 P59 variable in CoVs Viable B3
nsp10-U5 G70 Strictly conserved in CoVs Viable-D H3
nsp10-U6 G50 Strictly conserved in CoVs Viable-D Loop between B1 and B2
nsp10-U7 Y68 conserved aromatic in CoVs Lethal H3
nsp10-U8 G69 Strictly conserved in CoVs Lethal H3
nsp10-U9 S72 Strictly conserved in CoVs Lethal H3
aGII= group II CoVs, bmostly conserved = some amino acid conservation, but not in every group, cH = -helix, dGI =
group I CoVs, estrictly conserved = identical, fCharge + for positive and – for negative, gZF = zinc binding finger, h D=
debilitated, iB = -sheet.
Table 1: Sites targeted for mutagenesis.
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Bioinformatic methods identified an highly active region from amino acids 50-75
which contains multiple predicted protein domains and a disordered region potentially
indicative of an interaction domain (Fig. 1, Table 1).  The disordered region was not
conserved at the amino acid level, however the same amino acid positions were predicted by
PONDR(38) to be disordered in all CoVs, indicating that the conserved disordered region
may play an important role in nsp10 function. Therefore, the second strategy targeted key
residues in this region of nsp10, in an attempt to alter potential protein:protein or
protein:nucleic acid interaction sites (Table 1, Figure 1) (38) or ablate putative functional
domains (myristoylation sites, phosphorylation sites, etc) (Table 1, Figure 1).  These mutants
were designated the U-series mutants. All U-series mutant amino acids were conserved in
nsp10 in all three groups of the Coronavirus genus (Fig. 1, Table 1), except mutant nsp10-
U4, which targeted a non-conserved proline present in MHV and SARS-CoV.  This change
was predicted to add order to the conserved disordered region.
Figure 1. Mutational design of nsp10 mutants.  Nsp10 mutants were selected using two
approaches.  The U-series of mutants targeted conserved residues in putative regulatory
motifs near a predicted disordered region, and the E-series targeted charged amino acid pairs
and triplets. Residues above the black box are predicted to comprise a disordered region.
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To determine the effects of nsp10 alanine scanning mutagenesis on MHV replication
the 16 mutations were engineered into the molecular clone of MHV, replacing the wild-type
amino acid(s) with alanine.  In all cases, two nucleotide changes were made to each codon to
reduce the likelihood of reversion to wild-type sequence.  The wild-type fragments of the
molecular clone were isolated by restriction endonuclease digestion and ligated with the
appropriate sequence verified mutant fragment, and full-length cDNAs were then transcribed
in vitro, transfected into replication competent cell lines, and monitored for CPE, i.e. syncytia
formation (55).
Isolation and Genotype of Mutant Viruses.  MHV mutant viruses containing
mutations nsp10-U1, nsp10-U3, nsp10-U4, nsp10-E1, and nsp10-E2 were rescued by 48h
post transfection and were categorized as the viable mutants.  Mutant nsp10-U1 grew with
similar characteristics as wt-icMHV, with plaque formation and size comparable to wild-
type.  Mutants nsp10-U3 and nsp10-U4 had reduced plaques sizes as compared to wt-
icMHV.  Mutant nsp10-E1 exhibited smaller plaque sizes, with irregular boundaries, whereas
viable mutant nsp10-E2 was the most difficult to observe in further analyses due to variable
sized plaques with irregular borders and sizes, many of which were much smaller than wild-
type (~2mm vs. ~5mm), and barely visible by eye.
Mutants nsp10-U2, nsp10-U5, and nsp10-U6 exhibited a CPE negative RNA positive
(CPE-/RNA+) phenotype characterized by no detectable CPE in the transfection flask by 48h
post transfection, although all three generated subgenomic mRNAs at a cycle threshold
slightly above the lower limit of detection by real time PCR (data not shown).  However,
leader-containing transcripts could not be detected after passage of nsp10-U2 and nsp10-U6.
Interestingly, by 72h post transfection, nsp10-U5 infections showed signs of CPE.
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Sequencing of nsp10-U5 from cells harvested at 48h post transfection confirmed the correct
mutation (G70A), while sequences generated from infections harvested after 72h
demonstrated a wild-type genotype at the mutant locus.  This was repeated with the exact
results both times, suggesting that nsp10-U5 reverts to wild-type at two nucleotide positions
after 48h of debilitated replication.  Mutants nsp10-E4, nsp10-E5, nsp10-E6, nsp10-E7,
nsp10-E8, nsp10-U7, nsp10-U8 and nsp10-U9 were non-viable as multiple attempts failed to
recover virus or detect leader-containing transcripts.
All of the viable mutants nsp10-U1, nsp10-U3, nsp10-U4, nsp10-E1, and nsp10-E2
were plaque purified and sequenced at the nsp10 locus to confirm that the appropriate mutant
allele had been incorporated into the molecular clone, and stocks were grown to high titer for
further analyses.
Phenotype Analyses.  To determine the effects of the nsp10 mutations on viral
growth kinetics and global viral RNA synthesis, we compared rescued mutant nsp10 viruses
to wt-icMHV via viral growth curves, Northern blot analysis, and quantitative PCR.  DBT
cells were infected with wild-type or recombinant viruses bearing the viable nsp10 mutations
at MOI of 0.2 PFU/cell for one hour and virus growth assayed over 16 hours.  All five viable
mutants grew to lower titers than wt-icMHV at all time points up to 16h p.i. (Fig. 2a).
However, nsp10-U1 growth was roughly equivalent to wild-type virus, while the other four
mutants displayed lower titers at 8h p.i.  By 12 and 16h p.i., mutants nsp10-E1 and nsp10-E2
were debilitated, replicating to titers about one log lower than wild-type, while mutants
nsp10-U3 and nsp10-U4 were characterized as having more extensive blocks in virus
replication (Fig. 2a).  As overall virus growth was reduced for many of the nsp10 mutant
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viruses, we next evaluated levels of subgenomic viral transcripts using Northern blot (Fig.
2b) and subgenomic and genomic RNA levels using real time PCR (Fig. 3b,c,d).
Figure 2.  Growth kinetics and Northern blot analysis of nsp10 mutants.  A. Cultures of
DBT cells were infected at a MOI of 0.2 PFU/cell.  Virus samples were taken at different
time points and measured by plaque assay.  All mutants showed reduced growth kinetics at
8h p.i, while nsp10-U1 recovered by 12h p.i. to near wt-icMHV growth.  All other viable
mutants reached lower titers, with nsp10-U3 and nsp10-U4 showing 2 logs difference at 16h
p.i.  =wt-icMHV, =nsp10-E1, =nsp10-E2, =nsp10-U1,  =nsp10-U3, and =nsp10-
U4. B. Northern blot. Cultures of cells were infected at a MOI of 1 PFU/cell, and
intracellular RNA isolated at 8h p.i.  The RNA was separated on 1% agarose gels, blotted to
a nitrocellulose membrane and probed with an N-gene specific probe. The results show that
all five mutants have reduced RNA synthesis as compared to wt-icMHV, whereas two
mutants, nsp10-E1 and nsp10-E2, have reduced subgenomic RNA at 8h p.i. G=Genomic,
H=Hemmaglutinin Esterase, S=spike, E=envelope, M=membrane and N=nucleocapsid.
By Northern blot, all mutants showed a reduction in subgenomic mRNA synthesis at
8h p.i., with nsp10-E1, nsp10-E2, and nsp10-U4 showing more extensive blocks in
subgenomic mRNA synthesis.  Nsp10-E2 showed an inordinate reduction in subgenomic
mRNA synthesis compared to all other mutants and wt-icMHV at 8h p.i. (Fig. 2b).
To confirm and extend the Northern blot analysis, real time PCR was used to quantify
viral plus strand transcripts using primers designed to amplify subgenomic RNA from the N-
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gene or genomic RNA from ORF1a.  In agreement with the Northern blot data, quantitative
PCR analyses demonstrated that all five mutants were reduced in subgenomic mRNA
synthesis at 8h p.i. as compared to wt-icMHV, with more extensive blocks occurring in
mutants nsp10-E2 which had a ~900-fold reduction and nsp10-U4 with a ~60-fold reduction
in mRNA synthesis (Fig. 3b,d).  All other mutants had reductions of less than 10-fold (Fig.
3d).  Analysis of genomic RNA showed the same trend, with reductions in all mutants, while
nsp10-E1 showed a ~7-fold reduction, nsp10-E2 a 900-fold reduction, and nsp10-U4 a 17-
fold reduction in genomic RNA at 8h p.i as compared to wt-icMHV (Fig. 3c,d).  All other
mutants were reduced by less than 10-fold (Fig. 3d).
A comparison of the reductions of subgenomic and genomic RNAs at 8h p.i.
demonstrated that mutants nsp10-E2 and nsp10-U1 had equivalent reductions of both
genomic and subgenomic RNAs (Fig. 3d).  Nsp10-E2 had reductions of 900-fold in both
genomic and subgenomic RNAs, whereas nsp10-U1 had 2-fold reductions of both (Fig. 3d).
In contrast, nsp10-E1, nsp10-U3 and nsp10-U4 showed differential effects on
subgenomic and genomic RNA synthesis (Fig. 3d).  Nsp10-E1 showed a larger reduction in
subgenomic than genomic RNA synthesis with a 7-fold reduction versus a 3.5- fold
reduction, respectively, although this difference was not statistically significant (p-value =
0.11).  Further, nsp10-U3 and nsp10-U4 demonstrated greater reductions in genomic RNA
than subgenomic mRNAs (Fig. 3d).  In the case of nsp10-U3, genomic RNA was reduced
3.5-fold, while subgenomic mRNA was reduced only 2-fold, and this difference was
statistically significant with a p-value of 0.043.  Nsp10-U4 also showed a greater decrease in
genomic RNAs with an ~60-fold reduction versus subgenomic mRNA synthesis with an ~17-
fold reduction (Fig. 3d).  This difference was statistically significant with a p-value of 0.024.
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Figure 3.  Real time PCR analysis of nsp10 mutants.  Three independent cultures of DBT
cells were infected for each of the nsp10 mutants or wt-icMHV at MOI of 1 PFU/cell, and
harvested at 8 and 12h p.i.  Total RNA was isolated, reverse transcribed using random
hexamers, and amplified by real time PCR using primers specific for genomic or subgenomic
cDNAs or the housekeeping gene GAPDH.  A.  Total RNA for each sample was normalized
to GAPDH levels by diluting samples until cycle threshold values, as determined by real time
PCR, were roughly equivalent indicating equivalent concentrations of starting template.  B.
Subgenomic mRNA for the N-gene of wt-icMHV and the viable mutant panel was compared,
and in agreement with the northern blot, all five viable mutants showed decreases in
subgenomic mRNA synthesis at 8h p.i., with more substantial blocks occurring in mutants
nsp10-E2 and nsp10-U4.  However, by 12h p.i. only nsp10-E2 and nsp10-U4 showed
reductions in subgenomic mRNA synthesis.  C. Genomic RNA analysis, using primers to
detect an ORF1 cDNA showed that all five mutants were compromised in generating
genomic RNA at 8h p.i., with mutants nsp10-E1, nsp10-E2, and nsp10-U4 exhibiting more
extensive blocks in genomic RNA synthesis.  Genomic RNA synthesis returned to wildtype
levels by 12h p.i. in all mutants except nsp10-E2.  D.  Reductions of subgenomic and
genomic RNAs were compared from three independent infections at the 8h time point, and
analyzed by the paired t-test to test the null hypothesis that the reduction in subgenomic
mRNAs minus the reduction of genomic RNAs was equal to zero.  The null hypothesis was
not rejected for mutants nsp10-E2 and nsp10-U1 suggesting that these mutants have an equal
reduction in subgenomic and genomic RNAs.  The null hypothesis was rejected with p-
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Figure 3 (cont.): values less than 0.05 for mutants nsp10-U3 and nsp10-U4, suggesting that
these mutants are significantly more defective in generating genomic RNAs than subgenomic
mRNAs.  Mutant nsp10-E1 appears to be more defective in subgenomic mRNA synthesis
than genomic, although this difference was not significant (p-value = 0.110).  black bar =
RNA harvested at 12h p.i., black and white hatched bar = reduction in genomic RNA.  * =
statistical significance.  Error bars represent standard error with a 95% confidence interval.
However, by 12h p.i., only steady state levels of nsp10-E2 RNA was significantly
reduced as compared to wt-icMHV.  While nsp10-U4 also displayed slightly reduced levels
of subgenomic RNA than wt-icMHV, all other mutants had recovered viral RNA synthesis to
wt-icMHV levels.  Nsp10-E2 maintained a ~3-log reduction through both time points.
These results suggest that in general, mutations to nsp10 result in global attenuation
of viral RNA synthesis, particularly early in infection.  In addition, some mutations
demonstrate greater defects in genomic and/or subgenomic mRNA synthesis, suggesting that
nsp10 plays a critical role in viral RNA regulation of subgenomic and genomic transcripts.
Replicase Protein Processing. To assess the impact of nsp10 mutations on
polyprotein processing of viral replicase proteins, we performed radio labeled
immunoprecipitations on infected cell lysates to evaluate the processing and expression
levels of nsp10.  DBTs cells were infected with wt-icMHV and the viable nsp10 mutants at
MOI of 2.0 PFU/cell, pretreated with actinomycin D, switched to Met-Cys minus media and
the cultures labeled with [35S] Cys/Meth for 4h between 8-9h p.i..  Cell lysates were
fractionated into a crude nuclear pellet and cytoplasmic supernatant.  Both the cytoplasmic
and nuclear fractions were probed with antibodies directed against nsp10 (VU128), separated
on SDS-PAGE gels and analyzed by autoradiography to detect radiolabeled viral proteins.
Nsp10 was expressed and processed during infection with each viable nsp10 mutant,
although some variation in the amounts of nsp10 was noted among the nsp10 mutant panel
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(Fig. 4a).  For example, mutant nsp10-E2 appeared to express more proteins than all other
viruses despite low levels of replication and the reduced transcription noted above (Fig. 4a).
Figure 4.  Immunoprecipitation analysis of nsp10 mutants.  Cultures of cells were
infected with various mutants, radiolabeled at 4h p.i. with [35S]methionine/cysteine, and
harvested at 9h p.i.  The lysates were immunoprecipitated with anti-nsp10 antibody, and
separated by SDS-PAGE.  A. Immunoprecipitation analysis of the cytoplasmic lysates
showed that nsp10 is expressed and processed in each mutant, however mutants nsp10-U3
and nsp10-E1 demonstrate a reduction in processed nsp10.  In addition, nsp10-E1 shows a
reduction in p150.  Additional products co-precipitated with nsp10-E2 that are not present in
any other virus.  These bands likely represent processing intermediates.  B. The crude nuclear
pellet was also immunoprecipitated with anti-nsp10 antibody, and mutant nsp10-E2 shows
accumulation of several novel products, which correspond in size to additional processing
intermediates.
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Current data suggests that nsp4-10/11 is expressed as a polyprotein processing
precursor of ~150 kDa known as p150, which is subsequently processed by 3CLpro via cis or
trans cleavage into the individual replicase proteins (41, 47, 54).  The nsp10-E2 mutant
contained two novel bands that registered at ~30 kDa and ~71 kDa, respectively.  By size
analyses, viral precursor polyproteins containing nsp9-11 (29 kDa) and nsp7-11(71 kDa)
would be the only appropriately sized intermediates to be immunoprecipitated with anti-
nsp10 antisera.  These data suggest that the nsp10-E2 mutation may cause subtle changes in
nsp4-10/11 polyprotein processing, allowing visualization of the polyprotein precursor
intermediates from the C-terminal end of pp1a.
In addition to cytoplasmic lysates, crude nuclear pellets were also probed with anti-
nsp10 antibody (Fig. 4b) to determine if ancillary processing intermediates were detectable.
Bands corresponding to nsp10 as well as putative intermediates nsp10-11 (~17kDa), nsp9-11
(~29kDa), nsp8-11(~51kDa), nsp7-11(~61kDa) and nsp6-11(~92kDa) were present in crude
nuclear lysates from nsp10-E2 (Fig. 4b).  In addition to altered processing of the polyprotein,
alternate subcellular targeting of mutant nsp10 could account for a reduction in RNA
synthesis.
Nsp10 Replicase Protein Subcellular Localization.  To determine if the alanine
scanning mutations in nsp10 altered its subcellular localization, immunofluorescence assays
were performed. Previous studies have demonstrated that wild-type nsp10 co-localizes with
N to distinct punctuate foci in perinuclear regions, thought to be the site of the coronavirus
replication complexes (Fig. 5a) (3) and not with M, which localizes to sites of assembly. We
probed mock-infected and infected cells with antisera directed against nsp10 and either M or
N specific antibodies to determine if the panel of nsp10 mutants targeted to sites of
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replication similar to the wild-type protein. The predominant nsp10 signal was localized in
perinuclear regions for each of the mutants (data not shown for all mutants, Figure 5b).
Nsp10 signal was also detected to a lesser extent in the nucleus of DBT cells infected with
nsp10-E2 (Fig. 5b), and is consistent with immunoprecipitation data from crude nuclear
lysates for nsp10-E2.  In all cases, nsp10 mutants appeared to predominantly co-localize to
sites of viral replication at 6.5h p.i. and was not found in sites of maturation and assembly.
Figure 5.  Confocal Immunofluorescence Assay of nsp10 mutants.  DBT cells were
infected with wt-icMHV and the panel of mutants at MOI of 5 PFU/cell for 6.5 hours, and
fixed in methanol.  Cells were then dual labeled with anti-nsp10 and anti-N or anti-M, to
determine if nsp10 colocalize with N to sites of replication, or with M at sites of viral
assembly.  A. In wt-icMHV, nsp10 predominantly co-localizes with N to perinuclear foci
where the viral replication complex is thought to assemble.  Nsp10 clearly does not co-
localize with M, a marker for viral assembly.  B. For the panel of mutants, it appeared that
nsp10 predominantly localized to the same perinuclear structures as wt-icMHV, with
incidental staining occurring in the nucleus in mutant nsp10-E2.
         
            
A.
B.
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Mapping the mutations onto the structure.  To identify key residues on the
structure of nsp10 that might alter its function, the viable,  CPE-/RNA+, and lethal mutants
were modeled onto the solved structure of SARS-CoV nsp10.  Homology models were
generated for wt-icMHV nsp10 and each of the 16 mutants.  The backbone of the SARS-CoV
nsp10 structure was then compared to the homology model of MHV nsp10 using the
MatchMaker tool under the structure comparison section of Chimera (15, 27), resulting in a
calculated Root Mean Square Distance of 0.207 Å.   Each mutant was then analyzed in two
contexts: 1) by studying the wild-type residues on the MHV homology model, and 2)
comparing those to changes predicted by the homology model for each mutant.
General trends.  Josephs, et. al., solved the SARS nsp10 structure at a resolution of
1.8 Å, and report that it is a single domain protein comprised of a pair of antiparallel N-
terminal helices stacked against an irregular-sheet, which contains a coil-rich C terminus, and
two ZFs.   Nsp10 represents a novel fold and is the first structural representative of this
family of Zinc finger proteins found so far exclusively in coronaviruses(22, 23).
Mapping of all of the mutations onto the homology model of wt-MHV provided
strong support for both ZFs being essential for nsp10 function, and therefore MHV
replication.  In general the core structure of nsp10 surrounding the ZFs was resistant to
mutagenesis and all mutations in the region were lethal (Fig. 6).  This central core, which
extends from amino acid 65 through the C-terminal half of nsp10 is also comprised of 27
residues that are identical among all known CoVs, and contains both ZFs.  Loops that extend
away from the central core, for the most part, tolerated mutation resulting in viable
phenotypes.  The CPE-/RNA+ mutants were all glycine to alanine substitutions that occurred
in the outer loops or in H3 (Fig. 6).
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Figure 6.  Topology map of MHV nsp10 showing a conserved core and all 16 mutations.
The homology modeled structure of nsp10 starts with two anti-parallel -helices 1 and 2 (H1
and H2) followed by four -sheets (B1-4) and long loops, and then two small -helices, H3
and H4 which are important for ZF-1.  Another small -sheet (B5) followed by -helix 5
(H5), and then ZF-2 at the C-terminal end of nsp10.  The central core is colored black,
numbers represent amino acid positions in nsp10 of MHV, =viable mutants;  =non-
viable mutants,  = CPE-/RNA+ mutants and =ZF-1 and ZF-2.  The central core is highly
conserved and resistant to mutagenesis, while the loops on either side tolerate mutagenesis.
4. DISCUSSION
Previous studies have predicted that nsp10 acts as a co-factor in the MHV replication
complex(3, 28, 30, 41, 44, 50), which led us to hypothesize that mutations to nsp10 could
impact several specific areas of viral RNA synthesis including but not limited to: 1) positive
strand synthesis, resulting in reductions of both subgenomic and genomic RNAs, 2) negative
strand synthesis, resulting in reductions of minus strand templates, and/or 3) polyprotein
processing, resulting in reductions of essential proteins or intermediates processed from the
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nascent polyprotein that are essential to the formation of the replication complex.  To further
examine the functional role of nsp10 in MHV RNA transcription/replication, we applied a
reverse genetics approach incorporating scanning alanine mutations into the nsp10 gene of
the molecular clone of MHV based upon two strategies.  First, we hypothesized that
conserved regions of nsp10 are essential to its function, so we targeted single residues and a
disordered region that are strictly conserved in all coronaviruses (Fig. 1 and Table 1).
Second, we hypothesized that charged residues may provide polar targets on the molecule’s
surface which facilitate binding to other proteins or nucleic acids, thus pairs and triplets of
charged amino acids were targeted.  In all cases, the targeted amino acid(s) were changed to
alanine, as alanine eliminates the side chain beyond the -carbon but does not alter the main-
chain conformation nor impose extreme electrostatic or steric effects (10).  Of the 16 full-
length mutant viral cDNAs generated, eight constructs resulted in no detectable virus, three
generated CPE-/RNA+ phenotypes that were lost with passage, and five viruses were rescued
with viable phenotypes and further characterized in this study. The high number of non-
viable constructs supports earlier arguments that nsp10 is essential for coronavirus
replication.
RNA synthesis of each viable mutant was evaluated by analyses of growth kinetics
over 16 hours and detection of subgenomic versus genomic plus-strand RNA quantities at 8
and 12 hours post-infection.  Growth curve analysis demonstrated that all five viable mutants
were compromised in RNA synthesis, with all showing reduced growth kinetics as compared
to wt-icMHV (Fig. 2).  This trend was confirmed by both Northern blot and real time PCR,
which demonstrated that all five mutants were reduced in RNA synthesis at 8h p.i., although
steady state levels of RNA became nearly equivalent by 12h p.i. in all mutants except nsp10-
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E2 and nsp10-U4.  Interestingly, mutant nsp10-E2 showed the largest reduction with a nearly
three-log reduction in subgenomic and genomic RNA at both time points, while nsp10-U4
showed a more extensive reduction in subgenomic RNA synthesis at the earlier time point.
MHV-A59 is known to produce ~100 subgenomic mRNAs per genomic RNA and
this ratio remains constant throughout the infectious cycle(39), although the ratio of the
different subgenomic mRNAs varies greatly with mRNA-7 (N-gene) being the most
abundant.  In addition, negative strands comprise approximately 1% of the total RNA at any
time(41).  Mutations that equally reduce subgenomic and genomic RNAs but maintain this
ratio, would likely introduce a defect in global positive strand RNA synthesis, or a defect in
negative strand template synthesis.  In our mutant panel we observed phenotypes that
preserved this ratio, as well as those that appeared to alter this ratio with specific reductions
in genomic and/or subgenomic RNA synthesis.
Comparing reductions of subgenomic and genomic RNAs for each mutant versus wt-
icMHV at 8h p.i. indicated that mutants nsp10-E1, nsp10-U3 and nsp10-U4 demonstrated
differential reductions in subgenomic and genomic RNA synthesis, suggesting that the ratio
of subgenomic mRNAs per genomic RNA was altered.  In contrast, mutants nsp10-E2 and
nsp10-U1 had reductions that were equal in both cases (Fig. 3d), suggesting that RNA
synthesis was reduced, but the ratio of subgenomic mRNAs per genomic RNA remained
constant at ~100-to-1.  However, by 12h p.i., only nsp10-E2 had subgenomic and genomic
RNA levels significantly lower than wt-icMHV, with nsp10-U4 genomic RNA synthesis
recovering to near wildtype levels and subgenomic RNA synthesis recovering to less than a
one-log reduction.
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 Although it appears that ratios of subgenomic versus genomic RNA eventually
recover to wildtype levels by 12h p.i., differential ratios are evident in mutants nsp10-E1,
nsp10-U3, and nsp10-U4 at earlier times of infection. It is worth noting that in similar studies
with arterivirus protein nsp11, some mutations produced moderate, but significant
differences between genomic and subgenomic RNA synthesis (36).  This may be occurring at
early times of infection in some nsp10 mutants, perhaps due to a defect in negative strand
template synthesis.  Alternatively, a mutation that altered the ability of RdRp template
switching could reduce subgenomic mRNA quantities and have no affect on genomic minus
or plus strand synthesis (31, 32).  We note that real time and Northern blot analysis measure
accumulated levels of RNA and do not measure the actual rates of subgenomic and genomic
mRNA transcription.
These data show that four-of-five mutants exhibited delays in global RNA synthesis
at 8h p.i. that were overcome by 12h p.i., whereas Nsp10-E2 maintained global ~3-log
reductions throughout.  There are at least four mechanisms which could account for global
reductions of viral RNA synthesis in the nsp10 mutants: 1) a specific defect in negative
strand or global positive strand synthesis, 2) a defect in polyprotein processing that impedes
maturation of the replication complex, 3) a reduction in the molar quantities of processed
nsp10 leading to a reduction in the number of functional replication complexes, or 4)
mislocalization of mutated nsp10 proteins to alternative cellular compartments.
Confocal IFA verified that mislocalization of the mutated forms of nsp10 did not
occur, although ancillary staining of nsp10 was detected in the nucleus of cells infected with
nsp10-E2 (Fig.5b).  This observation led us to examine viral processing in both the
cytoplasmic and nuclear fractions of infected cells.
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Operating under the hypothesis that mutations to nsp10 might impede processing of
pp1a/pp1ab by disrupting essential contact sites required for protein:protein cis interactions
or by interfering with the ability of the polyprotein to fold into a correct orientation to
facilitate 3CLpro cleavage, immunoprecipitations were performed to detect nsp10 in the
cytoplasmic and nuclear fractions of cells infected with each mutant.  In the cytoplasmic
fraction, mature forms of nsp10 were processed in each case, although at varying
concentrations (Fig. 4a), whereas in the nuclear fraction only mutant nsp10-E2 had detectable
proteins (Fig. 4b).  Interestingly, nsp10-E2 processed novel proteins of 65kDa and 29kDa in
the cytoplasmic fraction (Fig. 4a), while in the nuclear fraction proteins of 17kDa, 29kDa,
51kDa and 65kDa were detected (Fig. 4b).  These novel proteins correlate very well in mass
to putative intermediates nsps7-11 (~65kDa), nsps8-11 (~51kDa), nsp9-11 (~29kDa) and
nsps10-11 (~17kDa).
Although processing of mature proteins from the nascent polyprotein in MHV-A59 is
not completely understood, there is no evidence that these intermediates exist in wildtype or
mock infections (Fig. 4a).  We hypothesize that nsp10-E2 impedes viral processing of the
p150 intermediate, resulting in novel processing intermediates that are either transient or
non-existent in wildtype MHV.  These psuedoproforms probably accumulate in excess in the
cell, and likely aggregate with the membranes pulled down with the crude nuclear pellet,
although proteins 50kDa and smaller are capable of inefficiently traversing the nuclear pore
complex in the absence of active transport(2).  Further, the accumulation of aberrant
processing intermediates reduces the number of functional replication complexes, resulting in
a global (3-log) reduction of genomic and subgenomic RNAs.
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Support for this hypothesis was found in studies with Yellow Fever and Hepatitis A
viruses, which have shown that mutations distant from the polyprotein cleavage site and the
active site of the viral protease are capable of reducing proteolytic activity, hypothetically by
altering substrate conformation (9, 16).  We are currently generating the necessary reagents
to verify that these are intermediate forms, to further investigate the fate of the p150
polyprotein during processing in mutant nsp10-E2, and to discern the processing cascade and
the exact identity of the intermediates that are present at various times of infection.
Recent structural studies have solved the x-ray crystal structure of SARS-CoV nsp10,
and identified a protein with a novel fold containing two ZFs, predicted to be essential to
nsp10 function (22, 51).  We used the SARS nsp10 crystal structure and to generate
homology models of MHV nsp10, and then mapped our mutations onto the predicted
structure.  Of note, mutations responsible for the phenotype of nsp10-E2 (D47A, H48A)
removed two charged residues predicted to extend to the surface of nsp10.  Removing these
side chains appeared to alter the loop region, without ablating the nsp10 structure completely.
Interestingly, both nsp10-E2 and known Temperature Sensitive mutant TS-LA6
(nsp10:Q65E) map to the same region on the structure of nsp10, in the loop region proximal
to the first ZF.  In the case of nsp10-E2, substituting alanines for Asp47 and a His48 directly
alters hydrogen bonds: Lys43-His48, Asp47-Ala-49, and Asp47-Cys46, which allow the loop
to collapse inward, rearranging the surface.  Substituting a glutamine to glutamic acid at
position 65 as in TS-LA6, adds a negative charge to the surface of the protein and forces the
loop to extend outward, probably due to repulsion between Glu65, Asp66, and Glu60, which
are in the same proximity.  This allows a new hydrogen bond to form between Glu65 and
His48, which likely extend the loop outward.  TS-LA6 has been characterized as having a
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defect in negative strand synthesis (41), and we are currently investigating whether or not
TS-LA6 shows a reduction in processing efficiency similar to nsp10-E2.
Nsp10-U4 targeted a proline at position 59, which also maps to the same region as
nsp10-E2 and TS-LA6.  We hypothesized that changing this amino acid to alanine would
provide more helical character to this disordered region conserved throughout the
Coronavirus genus.  The fact that this mutation conferred differential reductions in genomic
and subgenomic RNA synthesis at 8h p.i. suggests that this disordered region is critical for
regulation of viral RNA synthesis, most likely by interacting with another cofactor or viral
RNA.  In fact, disordered regions have been implicated as binding interfaces in other
studies(37).
In addition, the mutation to nsp10-U4 might alter the formation of higher order
structures, particularly in conjunction with mutant nsp10-E1.  Changing the lysines to
alanines in mutant nsp10-E1 (K24A,K25A) removed positive potential from the surface of
nsp10, potentially reducing its binding capacity to another co-factor, or viral RNA.  In
addition, Lys25 has been implicated as a key aliphatic residue that interacts with Glu60 of a
second nsp10 monomer to stabilize the formation of a trimer.  Four of these trimers are
predicted to interact to form a large dodecamer, which is hypothesized to function as a
transcription factor (51).  However, substituting Lys25 to alanine would remove the
interacting side chain, and would likely ablate this interaction site.  Additional residues
stabilize this interface and they include Val21 from one monomer that interacts with Val57
and Thr58 of another(51).   Mutant nsp10-U4 (P59A) would also likely interfere with this
interface at the second interaction site because changing the proline to alanine at position 59
would alter the rotameric positions of neighboring residues 57, 58, and 60; all of which have
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been predicted to be crucial for trimer formation.  The fact that both mutants nsp10-E1 and
nsp10-U4 are viable, suggests that the dodecamer supercomplex may lack biological
relevance.  In fact, this structure was solved using the nsp10-nsp11 polyprotein, and
experiments in our laboratory have demonstrated that cleavage of nsp11 from nsp10 is
essential for replication (Deming, 2007, submitted).  Although the authors show that nsp11
extends away from the dodecamer (51), it is not known if this super complex can form in the
absence of nsp11.  A second solved structure of nsp10 suggests that nsp10 may form
homodimers or homotrimers (22).
Mapping all 16 of our mutations onto the homology model of MHV nsp10 provided
important insights into its structure.  First, mutations that resulted in lethal phenotypes
occurred within or near the ZF domains.  ZFs are protein domains in which Zn2+ contributes
to the structural stability by binding to residues in the structure to stabilize the domain.
There are several classes of ZFs, and these are found in a variety of proteins of diverse
function, including proteins involved in replication and repair of nucleic acids, transcription
and translation, cellular signaling and metabolism, and cell proliferation and apoptosis.  ZFs
most frequently function as interaction sites for binding of other proteins, nucleic acids, or
small molecules (For a recent review see reference (23)).  The residues that bind zinc in
SARS-CoV nsp10 are strictly conserved throughout the coronavirus genus and include
residues Cys74, Cys77, His83, and Cys90 which bind zinc to form ZF-1, and residues
Cys117, Cys120, Cys128, and Cys103 which bind zinc to form ZF-2.
The fact the lethal mutations occurred in or near the ZFs indicates that both ZF motifs
are critical for infectivity and RNA synthesis in cell culture.  Further, in agreement with Su,
et. al. (22, 51) our data suggests that the C-terminal half of nsp10 comprises a central core,
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which spans amino acids 65-130 and provides the structure necessary for the formation of
both ZFs (Fig. 6).  Analyses of the homology models suggest that lethal mutations that
mapped within the central core altered the local structural landscape, which prevented the
ZFs from forming.  We observed three such disruptions.  The first, replacement of the
essential residues involved in Zn2+ binding, as in mutant nsp10-E5 (Q82A, H83A), was
lethal. Second, targeting residues that hydrogen bond directly to the four residues that bind
Zn2+ in both ZFs appears to disrupt the formation of the domain.  Lethal mutant nsp10-E4
mutates an Arg78-Ser79-Arg80 motif near ZF-1, in which both arginine residues hydrogen
bond directly to the residues that bind Zn2+ (Arg78-Cys74, Arg80-Cys77).  Third, altering
residues proximal to each ZF probably disrupts the structure enough to prevent ZF formation.
Lethal mutants nsp10-E6 (K104A, D105A), nsp10-E7 (H113A, D114A) and nsp10-E8
(R123A, D124A) occur near the ZFs, and alter hydrogen bonding.  These observations
suggest that the structure of the central core is essential to the formation of the ZF domains,
and provides strong evidence that the ZFs are imperative to nsp10 function.
The N-terminal region of nsp10, which contains mostly loops that extend away from
the structural core of nsp10 tolerated mutagenesis.  All of the viable mutants were well away
from the ZFs, and targeted residues that were not involved in maintaining local structure
necessary for the folding of these domains.  However, in all cases, these viable mutations had
an impact on viral RNA synthesis suggesting that nsp10 is a critical regulator of viral RNA
synthesis.
The results presented in this paper suggest that nsp10 plays a critical role in the
regulation of viral RNA synthesis, as well as potential secondary role in polyprotein
processing (Fig. 7a,b). Future experiments designed to measure full length and subgenomic
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length replicative form (RF) RNAs and quantitation of negative strands for each viable
mutant will help elucidate the role of nsp10 in MHV plus and minus strand RNA synthesis.
Figure 7.  The pleiotropic roles of nsp10 in Coronavirus replication.  A.   After
translation, pp1a and pp1ab are processed into precursors and mature proteins.  Nsp10
appears to influence processing in mutant nsp10-E2, which shows evidence of processing
intermediates not seen in wt-icMHV.  These data suggest that nsp10 likely interacts with
another nsp to facilitate cleavage, or maintains a structure that allows the polyprotein to fold
into the proper orientation for 3CLpro activation.  B. Once processed, nsp10 functions in
replication, probably as a dimer or trimer that binds RNA and nsp7.  Our mutant panel
suggests nsp10 may function in both the negative and positive strand replicases.  The
numbers in the diagram represent nsp numbers.  The dotted line represents RNA.  The curved
line represents the double membrane structure.
The role of nsp10 in processing is likely by cis interactions with a binding partner within the
precursor polyprotein.  A putative binding site between amino acid positions 48 to 65, which
includes the conserved disordered region, may facilitate this interaction.  Another possibility
is that this region of nsp10 maintains the amino acids necessary for the p150 intermediate to
adopt the correct fold to allow other cis interactions, which facilitate autocleavage of the
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polyprotein by the 3CLpro.  Pulse chase experiments have been designed to further examine
the fate of the p150 intermediate in nsp10-E2 infection, to verify that processing is reduced in
that mutant.  Additionally, mapping the mutations generating lethal phenotypes onto the
structure of nsp10 supports the hypothesis that both ZFs are essential to replication, and
demonstrates that a conserved central core maintains the functional domain of nsp10.
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CHAPTER V: ANALYSIS OF MURINE HEPATITIS VIRUS STRAIN A59
 TEMPERATURE SENSITIVE MUTANT TS-LA6 SUGGESTS NSP10
 PLAYS A CRITICAL ROLE IN POLYPROTEIN PROCESSING
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ABSTRACT
Coronaviruses are the largest RNA viruses, and their genomes encode replication machinery
capable of efficient replication of both positive and negative strand viral RNAs, as well as
enzymes capable of processing large viral polyproteins into putative replication intermediates
and mature proteins.  A current model proposed by Sawicki, et al., based upon
complementation studies of known temperature sensitive mutants of MHV-A59, proposes
that an intermediate comprised of nsps 4-10/11 (~150kDa) is involved in negative strand
synthesis.  Further, the mature forms of nsps4-10 are thought to serve as co-factors with other
replicase proteins to assemble a larger replication complex specifically formed to transcribe
positive strand RNAs.  In this study, we introduced the single amino acid change
(nsp10:Q65E) associated with the TS-LA6 phenotype into nsp10 of the infectious clone of
MHV.  Growth kinetic studies demonstrated that this mutation was sufficient to generate the
TS phenotype at the permissive and non-permissive temperatures.  Our results demonstrate
that the TS mutant variant of nsp10 inhibits the main protease, 3CLpro, blocking its function
completely at the non-permissive temperature.  These results implicate nsp10 as a critical
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factor in the activation of 3CLpro function.  We discuss how these findings challenge the
current hypothesis that nsps4-10/11 functions as a single cistron in negative strand RNA
synthesis, and analyze recent complementation data in light of these new findings.
1. INTRODUCTION
Coronaviruses (CoV) are large single-stranded positive-sense RNA viruses of the
order Nidovirales, family Coronaviridae, genus Coronavirus(16, 30, 34).  They comprise
viruses known to cause severe disease in humans, such as the Severe Acute Respiratory
Syndrome CoV(SARS-CoV) which causes an atypical pneumonia with a ~10% mortality
rate(52).  In addition, newly discovered human coronaviruses HCoV-NL63 (57) and HCoV-
HKU-1(31) are associated with lower respiratory tract infections while HCoV-OC43 and
HCoV-229E are typically associated with milder infections similar to the common cold(3).
In addition, several CoVs are the etiological agents responsible for diseases affecting
important domestic animals including bovines (BCoV), swine (Porcine epidemic diarrhea
virus [PEDV] and Transmissible Gastroenteritis virus [TGEV]), and avians (Infectious
Bronchitis virus [IBV])(3, 12, 30, 33).  Murine Hepatitis Virus strain A59 (MHV) has been
extensively studied in cell culture and in the mouse model(38), and being a close relative of
SARS-CoV makes it a relevant model for studying human CoVs.
Upon entry into the cytoplasm of the infected cell, the viral RNA, which is tightly
associated with nucleocapsid protein (N), is uncoated and immediately translated by host
ribosomes into large polyproteins(30, 33).  Roughly the first 2/3s of the CoV genome
encodes the non-structural replicase proteins in a single open reading frame (ORF) (Fig. 1A).
The final 1/3 of the genome consists of the structural proteins spike (S), envelope (E), matrix
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(M) and N (Fig. 1A), as well as accessory proteins specific to different strains, which are
translated from a nested set of co-terminal subgenomic mRNAs(30, 33).
Two polyproteins are translated from the genome, with the most abundant comprised
of nsp1-10/11 known as polyprotein1a (pp1a), while the second is a fusion protein known as
pp1ab, comprised of nsps1-16(30, 33)(Fig. 1A), which is only translated following a
ribosomal frameshift that occurs with an approximate frequency of 25-30%(7, 8).
Figure 1.  Polyprotein processing of MHV-A59, and assembly of the MHV and TS-LA6
infectious clones.  A. Polyproteins 1a and 1ab, encoded by ORF1a and ORF1ab are
processed by two virally encoded proteinases into 16 mature proteins.  PLP1 and PLP2
cleave the first three nsps, while 3CLpro cleaves nsp4-16.  The P150 intermediate is
comprised of nsps4-10/11.  T1 = transmembrane region-1, T2 = transmembrane region-2, T3
= transmembrane region-3, 3CL = 3CLpro, PLP1/2 = papain-like proteinases 1 and 2, RdRp
= RNA dependent RNA Polymerase, Hel = Helicase, ExoN = Exoribonuclease, XendoU =
Endonuclease, and MT = Methyl transferase.  Block boxes indicate structural proteins which
comprise roughly 1/3 of the genome, and the hatched box represents the nsp which contains
of the mutations of interest.  B.  The MHV infectious clone is divided into seven fragments
which are assembled after unique restrictions sites are used to digest the cDNA from
plasmids, and appropriate sticky ends allow the fragments to ligate together in the proper
order and orientation.  The MHV-E fragment was mutated to generate the icTS-LA6 mutant.
A
B
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Processing of the polyproteins occurs both co- and post-translationally with two classes of
viral proteinases required to cleave the polyprotein into its component proteins and
intermediates (Fig. 1A).  The first cleavage events in MHV require the papain-like
proteinases (PLP1 and PLP2), which rapidly cleave nsps1-3 from the N-terminus.  Nsps4-16
are processed by a second 3C-like proteinase known as 3CLpro or Main proteinase (Mpro).
A precursor intermediate of 150 kDa, comprised of nsps4-10/11 (Fig. 1A), has been detected
in pulse chase experiments, and is thought to play a role in coronavirus replication(24, 50),
although its exact function is yet to be determined.  The mature processed proteins are
predicted to form the replication complex(9, 10, 15, 22, 50, 61).  To date, only nsp2 has been
shown to be dispensable for MHV replication(21).
Studies with 3CLpro inhibitor E64d have demonstrated that addition of this cysteine-
specific proteinase inhibitor to cells infected with MHV-A59 rapidly shuts off new viral
RNA synthesis, demonstrating that processing of pp1a/1ab is required throughout the
infection to sustain RNA synthesis necessary for viral replication(27).
Coronavirus replication is currently thought to require at least four distinct phases
including: 1) recruitment of viral RNA from translation to sites of negative strand synthesis;
2) negative strand synthesis of full length genomic RNA and subgenomic length transcripts;
3) conversion from negative to positive strand synthesis; and 4) positive strand synthesis of
genomic and subgenomic length transcripts(37, 46, 47, 61). The exact mechanism and
proteins or intermediates required for negative and positive strand synthesis is currently not
known(47).  However, it has been shown that continued processing of the viral polyprotein is
essential for continued negative strand synthesis(47, 59), suggesting that polyprotein
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intermediates are required to replicate negative strands, and that these are then processed into
mature proteins that presumably assemble and function as the positive strand replication
complex(47).  In contrast, the positive strand replication complex does not appear to require
additional polypeptide processing as positive strand synthesis continues unabated and slowly
decays after treatment of cells with cyclohexamide (CH), while negative strand synthesis
stops abruptly(47, 59).
A recent model proposes that negative strand synthesis is facilitated by the use of a
replication protein intermediate that is hypothetically processed into mature proteins that
form the positive strand replication complex at later times during infection(47).  This model
is supported by classical complementation studies conducted with temperature-sensitive (TS)
mutants that suggest that the nsp4-10/11 intermediate with a molecular mass of ~150kDa
(p150) functions as a single polyprotein or functions in cis before processing to synthesize
negative strands, as TS mutations found in nsp4, nsp5, and nsp10 did not complement for
each other(47).  A single point mutation in nsp10, a glutamine to glutamate change at
position 65 of this protein, was predicted to be responsible for the TS phenotype and halts
negative strand synthesis upon shift from permissive to non-permissive temperature (32ºC
and 39.5ºC, respectively), an observation later characterized as a defect in negative strand
elongation(47, 59). These data suggest that the p150 intermediate plays a functional role in
negative strand synthesis, that nsp10 functions in negative strand elongation as part of the
p150 intermediate, and that nsp10 in its mature form may play a role in positive strand
synthesis(47, 59).
The goal of this study was to further characterize the TS mutant of nsp10 to advance
our understanding of nsp10’s role in coronavirus replication.   Using a genetic approach, we
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demonstrate that a single glutamine to glutamic acid substitution at position 65 of nsp10
confers the TS phenotype characterized by a complete block in 3CLpro cleavage of the viral
polyprotein at the non-permissive temperature.
2. METHODS
Virus and cells.  For this study we used MHV-A59 virus generated from the infectious
clone (60)(wt-icMHV) as the wild-type control, and the TS mutant was engineered into the
MHV clone, which is comprised of seven fragments maintained in plasmids amplified and
assembled according to previously published protocols (60)(Fig. 1B).   Briefly, plasmids
were transformed into chemically competent Top 10 cells (Invitrogen) by heat shock at 42ºC
for 2 minutes (min), and then plated on Luria-Bertani plates.  Colonies were picked and
grown under appropriate selection in LB broth maintained at 28.5ºC for 16-24 hours (h).
Delayed Brain Tumor (DBT) cells were maintained at 37°C in Minimum Essential Media
supplemented with 10% Fetal Clone II (Gibco), 10% tryptose phosphate broth, and
Gentamycin (0.05μg/ml)/Kanamycin (0.25μg/ml).  Baby Hamster Kidney (BHK) cells
exogenously expressing MHV receptor (BHK-MHVr) were maintained at 37°C in the same
media as above with the addition of Geneticin (0.8 mg/ml) to select for cells expressing
MHVr.
Generating the TS mutant TS-LA6.  The mutation of interest, a glutamine to glutamate
change at amino acid position 65 in nsp10(51), located from 13359-13361 on the MHV-A59
genome (MHV-A59 genome accession NC_001846), was mapped to the MHV-E fragment
of the molecular clone (Fig. 1B, 2B).  This fragment was used to engineer the appropriate
mutation into the MHV backbone.  Primers were designed that incorporated a type IIs
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restriction endonuclease (BbsI) site flanking the mutation of interest, and which introduced
two nucleotide changes within the codon being targeted (Table 1). Mutated fragments were
generated by PCR, cloned into TopoXL vector (Invitrogen), grown up in competent Top10
cells, screened by restriction digestion, and sequenced to verify that the correct changes were
incorporated.  The full-length infectious clone was assembled as previously described (60),
as was the mutant incorporating the mutant MHV-E fragment (Fig. 1B).  The full-length
cDNA construct was transcribed and transfected into 8x10
6
 BHK-MHVr cells, poured onto
5x10
6
 DBT cells (60), and incubated at the permissive temperature of 32ºC for 24-72h.
Primer Sequence (5’ to 3’)        Sense     Purpose
icTS-LA6S GAAGACGAAGATTCTTATGGTGGTGCTTCC +      mutant icTS-LA6
icTS-LA6A GAAGACGAATCTTCATTAGTGGTTGCCTCCGGC -                  mutant icTS-LA6
nsp10-WS ACAGGGTGGAGTTCCCGTTA +      PCR and
nsp10-WA CCTAAGGGCACTTGGACAAA -      sequencing nsp10
Sg-N1S AAGAGTGATTGGCGTCCGTA +      RT and QPCR
Sg-N1A AGCGCGGTTTACAGAGGAG -      RT and  QPCR
Table 1.  Primers used for engineering nsp10 mutants and RT-PCR
Flasks were examined at regular intervals for cytopathic effect (CPE), and verified by reverse
transcriptase PCR (RT-PCR) of subgenomic RNA using primers targeting the leader
sequence and the 5’ end of the N-gene (Table 1). Rescued virus was plaque purified and the
nsp10 gene was amplified by RT-PCR, cloned into TopoXL vector, and sequenced to
confirm that the correct mutations were present in the recombinant virus (Fig. 2B).  The
sequence verified mutant virus was designated infectious clone of TS-LA6 (icTS-LA6).
Growth kinetics and Temperature shift experiments.  Viral stocks of recombinant
wt-icMHV were propagated in DBTs cells grown at 37°C, while mutant icTS-LA6 was
propagated in DBT cells maintained at the permissive temperature of 32°C.  Titers were
determined by plaque titration in DBT cells, maintained at the appropriate temperature.
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Figure 2.  Verification of viral replication and genotype.  A.  Transfected cells were
harvested in Trizol reagents and total RNA was extracted and reverse transcribed.  The
cDNA was amplified by PCR with primers designed to detect leader-containing cDNAs (N-
gene and leader).  Bands correspond in size to subgenomic mRNAs for N, M, E, and S
(column 3).  B.  Mutants viruses were plaque purified and the nsp10 region was amplified by
RT-PCR and cloned into TopoXL for sequencing.  The sequence read of the PCR product
shows that the mutation was present in the plaque purified virus.
For the temperature specific plaque assay, DBT cells were infected in duplicate with serial
dilutions of wt-icMHV or icTS-LA6 in 60 mm plates with an one-hour adsorption period.
Five milliliters of overlay (.8% LE agar, 10% Fetal clone II, 40% 2x MEM, 1%
Gentamycin/Kanamycin) was added to each culture and the infections were maintained at
both 32°C and 39.5°C until plaques were observed between 24h and 36h.  To visualize
plaques, plates were stained with Neutral Red for 2h at 32°C and counted.
For the growth curve analysis, cultures of DBT cells were infected at an multiplicity
of infection (MOI) of 1 plaque forming unit (PFU) /cell in 60 mm plates with an one-hour
adsorption period, followed by three washes with PBS.  Three milliliters of media was added
to each culture and the infections were maintained at 32°C.  Supernatants were harvested at
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2, 4, 6, 9, 12, and 16 hours post infection (h p.i.) and titers determined by plaque titration in
DBT cells maintained at 32°C.
The temperature shift growth curves were conducted as previously described (49)
with slight modifications.  Briefly, multiple 60mm dishes of DBT cells were infected with
wt-icMHV and mutant icTS-LA6 at an MOI of 5 PFU/cell and incubated at the permissive
temperature of 32ºC for 6h.  At 6 hours, half of the cultures were shifted to the non-
permissive temperature of 39.5ºC.  Supernatant samples were taken from both 32ºC and
39.5ºC cultures at 2, 4, 6, 9, and 12h p.i. and titers were determined by plaque titration in
DBT cells maintained at 32ºC.
RNA analysis. DBT cells were infected in triplicate with wt-icMHV or icTS-LA6 at
an MOI of 1 PFU/cell, and maintained at 32ºC, 37ºC, or 39.5ºC. At 8h.p.i. cells were
harvested in Trizol Reagent (Invitrogen) for isolation of total RNA and probed for viral
mRNA production.  For Northern blot analysis 1μg of total RNA from mutant icTS-LA6 and
wt-icMHV at each temperature was separated by gel electrophoresis on a 1% agarose gel,
transferred to a nitrocellulose membrane, and probed with a 300 nucleotide (nt) biotinylated
RNA probe designed to detect the first ~300 nts of mRNA-7 (N-gene) using an Ambion
(Austin, TX) Northern kit.   Bands were detected using the Bright Star Detection (Ambion)
system, and membranes were exposed to film.
Reverse transcription, RT-PCR, and real time PCR.  Viral RNA was then reverse
transcribed to cDNA using SuperScript III (Invitrogen) with modification to the protocol as
follows:  Random hexamers (300ng) and total RNA (5μg) were incubated for 10 min at
70°C.  The remaining reagents were then added according to manufacturer’s protocol and the
reaction was incubated at 55°C for 1h followed by 20 min at 70°C to deactivate the RT.  For
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RT-PCR, a forward primer in the leader sequence and a reverse primer ~200 nt into the N-
gene (Table 1) were used to generate an ~220 basepair (bp) product by PCR.
Real time PCR was conducted using Smart Cycler II (Cepheid) with SYBR green
(Cepheid, diluted to .25X) to detect subgenomic cDNA with primers (7.5 pM) optimized to
detect ~120 nucleotides spanning from the leader sequence to the 5’ end of N-gene (Table 1)
or genomic cDNA with primers (7.5 pM) optimized to detect ~120 nucleotides of ORF1a
(Table 1).  cDNA template concentrations from the RT reaction were diluted 1:100 and
normalized to housekeeping gene GAPDH concentrations.  Omnimix beads (Cepheid)
containing all reagents except SYBR green, primer, and template were used to standardize
the reaction conditions.  All product sizes were verified by melting curve analysis.
Immunoprecipitation analysis.  DBT cells were infected at an MOI of 2 PFU/cell
for 2h, at which time the media was removed and replaced with media lacking Met/Cys but
containing 20μg/ml of Actinomycin D (Sigma), and incubated at 32°C for icTS-LA6 and TS-
LA6, and 37°C for wt-icMHV for an additional two hours.  At 4h p.i.,
[35S]methionine/cysteine (0.08mCi/ml) was added to the infections and cells were harvested
at 9h. Radiolabeled cells were washed in 1 ml of PBS and then resuspended in 1 ml of ST
buffer (200mM Sucrose, 10mM Tris pH 7.4, cold).  Next, the cells were homogenized by 40
passes through a ball-bearing homogenizer, and transferred to fresh tubes.  Homogenates
were then spun at 6000g for 3 min at room temperature, and supernatant was transferred to
ultracentrifuge tubes and spun at 300,000g for 15 min at 4°C.  The supernatant was then
transferred to a fresh tube (S100), and the pellet resuspended in 1 ml of ST buffer (P100).
Lysates were boiled for 5 min in SDS at a final concentration of one percent, then
combined with protein A-Sepharose beads and a 1:200 dilution of anti-nsp10 antibody
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(VU128) in no-SDS lysis buffer (1% NP-40, 150 mM sodium chloride, 0.5% sodium
deoxycholate, and 50 mM Tris, pH 8.0) supplemented with 1% SDS. After incubation at 4°C
for 4 h, beads were pelleted and washed with low-salt lysis buffer (no-SDS lysis buffer plus
150 mM NaCl) followed by high-salt lysis buffer (no-SDS lysis buffer with 1 M NaCl) and a
final low-salt wash. After rinsing, 30 ml of 2X SDS loading buffer (8% SDS, 0.2 M Tris, pH
8.8, 4 mM EDTA, 0.1% bromophenol blue, 40% glycerol, 0.5 M dithiothreitol) was added to
the pelleted beads and boiled for 5 min prior to electrophoresis of the supernatant on 4 to
12% SDS-PAGE gels.
Temperature shift immunoprecipitation analysis.  DBT cells were infected in
duplicate with mock, wt-icMHV, icTS-LA6, and TS-LA6 at an MOI of 10 PFU/cell at the
permissive temperature of 32°C for 1h, at which time the media was removed and replaced
with media lacking Met/Cys but containing 20μg/ml of Actinomycin D, and incubated at the
permissive temperature for an additional three hours.  At 4h p.i., [35S] labeled Cys and Met
(0.08mCi/ml) media was added to the infected cells, and half the cultures were shifted to the
non-permissive temperature of 39.5°C.  Cell lysates were harvested at 8h p.i. and the
cytoplasmic fraction was processed and prepared for SDS-PAGE as described above, using
antibodies directed against nsp10, nsp8, nsp5, nsp12, nsp2, and MHV (VU128, VU123, SP9,
VU145, VU154, and VU13, respectively).
Analysis of structure.  The crystal structure coordinates of SARS-CoV nsp10 (PDB
code 2FYG(23)) were used to generate a homology model of MHV nsp10 and icTS-LA6
using the program Modeller version 8.2(17, 32) implementing the automodel class. A
pairwise alignment was generated using SARS-CoV nsp10 protein database (PDB) file and
the MHV homologue sequence (Accession number: NP_740615), and five models were
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generated from each alignment, with the best model selected based on the lowest objective
function score.  Corresponding PDB files generated by this program were visualized on
molecular modeling tools MacPyMol (DeLano Scientific) and Chimera(39).  In addition, the
program Rosetta was used to generate a robust structural model of icTS-LA6, using a flexible
backbone as well as relaxed rotameric states to estimate the lowest energy putative
structure(35).
3. RESULTS
Assembling infectious clone TS-LA6.  The Q65E mutation of nsp10 predicted by
sequence analysis to convey a TS phenotype capable of growth only at the permissive
temperature of 32°C(51), was engineered into the infectious clone of MHV (Fig. 1A,B).
This experiment was designed to confirm that a single amino acid substitution could
recapitulate the TS-LA6 phenotype as reported by Siddell, et. al(51).  The mutation was
engineered in the MHV-E fragment using the No See’m approach described previously(60),
and outlined above (Fig. 1B).  The seven fragments of the molecular clone were ligated
together with the appropriate mutant fragment, and full-length cDNAs were transcribed in
vitro, transfected into BHK-MHVr cells, poured onto DBT cells, and monitored for CPE.
For wt-icMHV, transfections were maintained at 37°C, while mutant icTS-LA6 was
maintained at the permissive temperature of 32°C.  Plates were examined at regular intervals
for CPE, indicated by syncytia formation and clearing of the monolayer.
 Rescue of recombinant virus bearing the TS-LA6 genotype.  Wt-icMHV showed
obvious CPE by 6h post-transfection, with the cultures displaying extensive CPE and fusion
by 16h post-transfection.  In contrast, icTS-LA6 was delayed in the onset of CPE, although
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cytopathology was clearly detectable at 24h post-transfection.  The delay in CPE phenotype
was likely associated with the maintenance of the cultures at 32°C, the permissive
temperature for TS-LA6 replication.  Replication was verified by RT-PCR using primers to
detect products that contain the leader sequence and a 5’ portion of N-gene (Fig. 2A, Table
1).  icTS-LA6 was plaque purified, and stocks were grown to high titer for additional
analyses.  Cells infected with plaque-purified virus were harvested and the nsp10 region was
amplified by RT-PCR and sequenced to verify that the Q65E mutation was present.  All five
plaques selected and sequenced showed the correct mutation at position 65 of nsp10 (Fig.
2B).
Wt-icMHV produced clear plaques of about 5mm by 24-36h post-transfection, while
icTS-LA6 produced smaller, less distinct plaques that were harder to see in the monolayer,
and identical to plaques produced by infection with TS-LA6.  Our next step was to verify the
TS phenotype of icTS-LA6.
Characterization of the TS phenotype of icTS-LA6.  First, serial dilutions of
supernatant from plaque-purified virus was used to infect double cultures of DBT cells
maintained at the permissive temperature of 32°C and the non-permissive temperature of
39.5°C, with plaques counted at 36h p.i.  Wt-icMHV produced plaques at both temperatures
and reached a titer of 1x108 PFU/ml under both conditions, while icTS-LA6 produced a titer
of 8x107 PFU/ml at the permissive temperature, but produced no plaques at the non-
permissive temperature (Fig. 3A).  This phenotype was the same as TS-LA6, which has a
known reversion frequency of 1x10-8(46).  Next, DBT cells were infected at an MOI of 1
PFU/cell for one hour and virus growth assayed over 16h, for both icTS-LA6 and wt-icMHV
at the permissive temperature.  IcTS-LA6 and wt-icMHV grew to nearly the same titers at all
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time points, except 12h where wild-type was delayed in replication by one log as compared
to icTS-LA6 (Fig. 3B), and these results were consistent with TS-LA6.
Figure 3.  Growth characteristics of TS mutant icTS-LA6.  A.  A plaque assay was
performed to determine if icTS-LA6 produced plaques at the permissive and non-permissive
temperatures.  Wt-icMHV, hatched rectangle, grew at the permissive and non-permissive
temperatures, while icTS-LA6, solid black rectangle, only produced plaques at the
permissive temperature.  B.  Virus growth was evaluated at the permissive temperature for
wt-icMHV, +, and icTS-LA6, .  Wt-icMHV was delayed in growth at 32°C from 9-14
hours, but recovered by 16 hours.  C and D.  A temperature shift experiment was performed
using double cultures of cells infected at an MOI of 1 PFU/cell with the infection initiated at
32°C.  At 6 hours (indicated by arrow), half the cultures were shifted to the non-permissive
temperature, supernatants were harvested at 2, 4, 6, 9, and 12h p.i. from both cultures, and
titers were determined by plaque assay.  Wt-icMHV grew equally well at both temperatures
(panel C) while icTS-LA6 shows a temperature sensitive phenotype, with growth declining
rapidly after shift to the non-permissive temperature (panel D).  = infections initiated and
maintained at 32°C,  = infections initiated at 32°C and shifted to 39.5°C at 6h p.i.
   
A                                           B
   
C                                           D
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A temperature shift assay was performed to further evaluate the TS phenotype of icTS-LA6.
Dual infections with wt-icMHV and icTS-LA6 were initiated at the permissive temperature
of 32°C at an MOI 5 PFU/cell, and at 6h p.i. half the cultures were shifted to the non-
permissive temperature of 39.5°C(49). Wt-icMHV grew to similar titers at each time point
and at both temperatures (Fig. 3C).  However, after shift to the non-permissive temperature
growth of icTS-LA6 was inhibited, and titers dropped 3 and 4 logs below cultures maintained
at 32°C at the later time points (Fig. 3D).  In all cases tested, icTS-LA6 behaved identically
to published reports characterizing TS-LA6(49).  Clearly, the amino acid change identified
by Siddell, et al. is sufficient for the TS phenotype noted in TS-LA6(51).
RNA synthesis of icTS-LA6 mimics RNA synthesis of wt-icMHV at the
permissive temperature.  DBT cells were infected at an MOI of 1 PFU/cell with wt-icMHV
or icTS-LA6 and maintained at 32°C, 37°C, or 39.5°C for 8h.   Supernatant was removed and
the cells were harvested in Trizol reagents.  Total RNA (1ug) was denatured with glyoxal and
separated on 1% agarose gels.  The RNA was transferred to a nitrocellulose membrane and
probed for virus mRNAs using an RNA probe designed to hybridize to the first 300
nucleotides of the N-gene found at the 5’end of genomic RNA and all subgenomic mRNAs.
IcTS-LA6 and wt-icMHV produced nearly identical levels of subgenomic mRNA at the
permissive temperature (Fig. 4).  We were unable to detect mRNA in cells infected with
icTS-LA6 maintained at 37°C or 39.5°C (Data not shown).
To confirm and extend the Northern blot analysis, real time PCR analysis was used to
quantify viral transcripts using primers to amplify cDNAs from the N-gene or genomic RNA.
Quantitative RT-PCR also demonstrated that mutant icTS-LA6 and wt-icMHV showed
equivalent quantities of genomic and subgenomic mRNA at 8h p.i at 32°C (Fig. 5B,C).
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Figure 4.  Northern blot analysis of icTS-LA6.  Cultures of cells were infected at an MOI
of 1 PFU/cell, and total RNA isolated at 8h p.i. The RNA was separated on 1% agarose gels,
blotted to a nitrocellulose membrane and probed with an MHV-N-gene specific probe. IcTS-
LA6 and wt-icMHV grown at 32˚C result equivalent amounts of subgenomic RNA at 8h p.i.
Numbered bands correspond to mRNAs 1-7.
Both were reduced as compared to wt-icMHV infections initiated and maintained at 37°C
(Fig. 5B-D).  A comparison of ratios of subgenomic N-gene mRNA to genomic RNA
demonstrated that mutant icTS-LA6 had equal reductions in both subgenomic and genomic
mRNA resulting in ratios similar to wild-type (~100-to-1) (Fig. 5D)(46, 47).  These results
suggested that this mutation had little affect on plus or minus strand RNA synthesis at the
permissive temperature.  Little if any subgenomic or genomic RNA was detected by real time
PCR in DBT cells infected with icTS-LA6 maintained at the non-permissive temperature.
Processing of nsp10 is not altered in mutant icTS-LA6 at the permissive
temperature.  We next examined nsp10 processing to determine if nsp10 was cleaved from
the polyprotein at rates equal to wt-icMHV.
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Figure 5.  Real time PCR analysis of icTS-LA6.  Cells were infected in triplicate with wt-
icMHV, icTS-LA6 and mock at an MOI of 1 PFU/cell and maintained at the permissive
temperature of 32˚C and the standard temperature of 37˚C.  Cells were harvested in Trizol at
8h p.i., total RNA was isolated, and 5 μg of RNA was used for Reverse Transcription using
random hexamer primers to generate cDNA.  Viral cDNAs were normalized to the
housekeeping gene GAPDH.  A.  Dilutions were prepared to normalize the total cDNA of all
infections to approximate levels using the housekeeping gene GAPDH.  All four normalized
samples amplified at similar Cycle Threshold values indicating equivalent starting template
concentrations.  B.  Subgenomic mRNAs were detected using primers to leader and the first
122 nucleotides of N-gene.  Cells infected with wt-icMHV and maintained at 37˚C generated
the most subgenomic mRNAs, while cells infected with wt-icMHV and icTS-LA6 and
maintained at the permissive temperature were reduced by ~2.5 logs.  IcTS-LA6 infections
initiated and maintained at 37˚C generated extremely reduced concentrations of subgenomic
mRNAs.  C. Genomic mRNAs were detected using primers to 122 nucleotides of ORF1a.
Cells infected with wt-icMHV and maintained at 37˚C generated the most genomic mRNAs,
while cells infected with wt-icMHV and icTS-LA6 and maintained at the permissive
temperature were reduced by 2-2.5 logs.  IcTS-LA6 infections initiated and maintained at
37˚C generated extremely reduced concentrations of genomic mRNAs.  D.  Comparisons of
the reductions of subgenomic and genomic mRNAs for icTS-LA6 and wt-icMHV suggests
that RNA synthesis is equivalent in both viruses at the permissive temperature.  Black =
subgenomic, white =genomic.
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To evaluate protein processing and expression of nsp10, DBT cells were infected with wt-
icMHV, TS-LA6, or icTS-LA6 and the cultures labeled with 35Cys/Meth for 3h between 7-
9h p.i..   Nsp4-10/11 is expressed as a large precursor of 150kDa (p150), which is
subsequently processed by cis and/or trans cleavage into the individual replicase proteins
nsp4-10.  A band corresponding to the p150 intermediate was detected, as were bands
corresponding to processed nsp10 (Fig. 6A).  TS-LA6 and icTS-LA6, grown at the
permissive temperature 32°C, process similar levels of the p150 intermediate and nsp10, and
both are reduced when compared to wildtype MHV-A59 grown at 37°C (Fig. 6A).  Both TS
mutants processed equivalent structural proteins as compared to wt-icMHV (Fig. 6B).
Figure 6.  Processing of nsp10 and the structural proteins.  Immunoprecipitations were
conducted to evaluate processing of nsp10 and the structural proteins S, M, and N.  Cells
were infected at an MOI of 2 PFU/cell with infections initiated and maintained at the
permissive temperature.  A.  Anti-nsp10 antibody was used to immunoprecipitate proteins
from the cytoplasmic fraction of cells.  Nsp10 is detected and processed at the permissive
temperature, as is the p150 intermediate. B.  Anti-MHV antibody was used to detect
structural proteins in wt-icMHV grown at 37°C, and compared to icTS-LA6 and TS-LA6
grown at 32˚C.
A. B.
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 Mutations responsible for TS phenotype completely block 3CLpro activity at
the non-permissive temperature.  To determine levels of nsp10 processing at the
permissive and non-permissive temperatures, temperature shift immunoprecipitation assays
were designed and conducted to analyze processing of nsp10 at 32°C and after shift to
39.5°C.   DBT cells were infected in duplicate with mock, wt-icMHV, icTS-LA6, and TS-
LA6 at an MOI of 10 PFU/cell at the permissive temperature of 32°C for 1h, after which the
media was removed and replaced with media lacking Met/Cys but containing 20μg/ml of
Actinomycin D, and incubated at the permissive temperature for an additional three hours.
At 4h p.i., [35S] labeled Cys and Met (0.08mCi/ml) media was added to the infected cells,
and half the cultures were shifted to the non-permissive temperature of 39.5°C.  Cell lysates
were harvested at 8h p.i. and the cytoplasmic fraction was probed with antibodies directed
against nsp10 (VU128), separated on SDS-PAGE gels and analyzed by autoradiograph to
detect radiolabeled viral proteins.    At 32°C, nsp10 was processed as expected for infections
with wt-icMHV, TS-LA6 and icTS-LA6 and the p150 intermediate was detected in all cases
(Fig. 7A, lanes 2-4).  However, at 39.5°C there was an accumulation of p150 in TS-LA6 and
icTS-LA6, and nsp10 processing was abrogated in both TS mutants (Fig. 7A, lanes 6 and 7).
Wt-icMHV continued to process nsp10 and p150 at all three temperatures, 32°C, 37°C, and
39.5°C (Fig. 7A, lanes 2, 5, and 8).
To determine if this effect was limited to nsp10, we next examined the processing of
nsp8 under the same experimental conditions. Cell lysates were harvested and the
cytoplasmic fraction was probed with antibodies directed against nsp8 (VU123), separated on
SDS-PAGE gels and analyzed by autoradiograph to detect radiolabeled viral proteins.  As
with nsp10, in the TS mutants TS-LA6 and icTS-LA6, nsp8 was processed at the permissive
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temperature (Fig. 7B, lanes 3 and 4), but not at the non-permissive temperature (Fig. 7B,
lanes 6 and 7), while wt-icMHV processed nsp8 at all temperatures (Fig. 7B, lanes 2, 5, 8).
The absence of nsp8 processing again resulted in an accumulation of the p150 intermediate in
the TS infections shifted to the non-permissive temperature.
To determine the extent of this effect, we next examined the nsp5 (3CLpro) protein,
under identical conditions using anti-nsp5 antibody (SP9)(Fig. 7C).  Again we discovered
that the infection with icTS-LA6 and TS-LA6 completely blocked processing of nsp5 at the
non-permissive temperature after shift (Fig. 7C, lanes 6 and 7), but not before (Fig. 7C, lanes
3 and 4).  These experiments demonstrated that the TS mutation in nsp10 was sufficient to
block processing of the c-terminal nsp5-10 of pp1a.  To determine if the nsp10 mutation
abrogated pp1ab processing, we performed the same experiment using anti-nsp12 antibody
(VU145) to analyze the processing of the RdRp at the permissive and non-permissive
temperatures  (Fig. 7D).  Surprisingly, while wt-icMHV processed nsp12 at both
temperatures (Fig. 7D, lanes 3 and 4), both TS-LA6 and icTS-LA6 did not process nsp12 at
the non-permissive temperature (Fig. 7D, lanes 6 and 7).  This suggested that the TS
mutation was responsible for a complete block of the 3CLpro activity.
 To rule out a complete block in polyprotein processing, we next precipitated nsp2
with an anti-nsp2 antibody (VU154) from the same lysates to determine if nsp2 processing
by PLP1 was affected at the non-permissive temperature (Fig. 7E).   In this case, cells
infected with wt-icMHV, icTS-LA6, and TS-LA6 processed nsp2 at both the permissive and
non-permissive temperatures (Fig. 7E, lanes 3, 4, 6, and 7).  These results demonstrate that
the mutation in nsp10 responsible for the TS phenotype completely blocks 3CLpro activity at
the non-permissive temperature, but has no effect on processing mediated by the PLPs.
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Figure 7.  Temperature shift immunoprecipitations of icTS-LA6.
A.
B. C.
D. E.
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Figure 7 (continued).  Temperature shift immunoprecipitations of icTS-LA6. Double
cultures of DBT cells were infected with mock (M, Lane 1), wt-icMHV (Lanes 2 and 5),
icTS-LA6 (Lanes 3 and 6), and TS-LA6 (Lanes 4 and 7) at an MOI of 10 PFU/cell at the
permissive temperature of 32°C for an hour, media was then removed and replaced with
media lacking Met/Cys but with Actinomycin D, and infections were incubated at the
permissive temperature for an additional three hours.  At 4h p.i., labeled media was added to
the infected cells, and half the cultures were maintained at the permissive temperature (P),
while the other half were shifted to the non-permissive temperature of 39.5°C (NP).
Immunoprecipitations were performed on the cytoplasmic lysates using anitibodies indicated
above each figure.  Wt-icMHV infections initiated and maintained at 37°C were performed
as a control (C).  A. Immunoprecipitation analysis was performed using anti-nsp10 antibody.
At the permissive temperature of 32°C, nsp10 is processed in wt-icMHV, icTS-LA6, and TS-
LA6 (lanes 2-4).  For infections initiated at 32°C, and then shifted to the non-permissive
temperature of 39.5°C, processing of nsp10 was ablated in icTS-LA6 and TS-LA6, while
p150 appeared to accumulate (Lanes 6 and 7).  Wt-icMHV continued to efficiently process
this protein at 37°C and 39.5°C (Lanes 5 and 8).  B. Anti-nsp8 antibody was used to pull
down viral proteins that were processed at the permissive and non-permissive temperatures.
At 32°C, nsp8 is processed in wt-icMHV, icTS-LA6, and TS-LA6 (Lanes 2-4).  For
infections initiated at 32°C and then shifted to 39.5°C, nsp8 was ablated in icTS-LA6 and
TS-LA6, and p150 appeared to accumulate (Lanes 6 and 7).  Wt-icMHV continued to
process this protein at 37°C and 39.5°C (Lanes 5 and 8).  C.  Immunoprecipitation analysis
conducted with anti-nsp5 antibody.  At 32°C, the results show that nsp5 is processed in wt-
icMHV, icTS-LA6, and TS-LA6 (Lanes 2-4). After shift to 39.5°C, processing of nsp5 was
not seen in icTS-LA6 and TS-LA6, while p150 appeared to accumulate (Lanes 6 and 7).  Wt-
icMHV processing of nsp5 was observed at 37°C and 39.5°C (Lanes 5 and 8).  D .
Immunoprecipitation with anti-nsp12 antibody showed that nsp12 is processed in wt-icMHV,
icTS-LA6, and TS-LA6 at the permissive temperature (Lanes 2-4). After shift to the non-
permissive temperature processing of nsp12 was ablated in icTS-LA6 and TS-LA6 (Lanes 6
and 7), while wt-icMHV continued to efficiently process this protein at 37°C and 39.5°C
(Lanes 5 and 8).  E.  Anti-nsp2 antibody was used to pull down viral proteins that were
processed at the permissive and non-permissive temperatures by PLP1 and PLP2.
TS mutation maps to a disordered region of nsp10 which likely plays a role in
3CLpro processing.  Homology models of nsp10 were generated for wt-icMHV and icTS-
LA6.  The backbone of the SARS-CoV nsp10 structure(23) was then compared to the
homology model of MHV nsp10 using the MatchMaker tool under the structure comparison
section of Chimera, resulting in a calculated Root Mean Square Distance of 0.207 Å.   The
homology models of nsp10 of icTS-LA6 and wt-icMHV were then analyzed and compared.
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 In general, the nsp10:Q65E mutation occurs in a loop region distal to both Zinc-
binding fingers (ZnFs)(23), in a disordered region that extends to the surface (Fig.
8)(Donaldson, et. al., in press).  The switch from Gln to Glu, alters the surface charge by
adding a negative charge to the surface.  In addition, both Modeller and Rosetta indicate that
this single amino acid change significantly alters the loop structures in the region resulting in
an extended surface area proximal to the mutation.
4. DISCUSSION
Temperature sensitive mutants have been described for a large number of positive
strand RNA viruses and have provided significant insights into the molecular mechanisms
governing RNA synthesis, genome replication, and subgenomic transcription(11, 18, 19, 25,
26, 28, 29, 41-44, 46, 48, 49, 55).  In this study we introduced the Q65E substitution in nsp10
of MHV predicted to generate a TS phenotype(51) into the molecular clone of MHV (Fig. 1)
and recapitulated TS-LA6 as icTS-LA6 (Fig. 1 and 2).  This confirms that this single amino
acid substitution is sufficient to generate this phenotype, and our characterization
experiments show that it clearly mimics the TS phenotype reported for TS-LA6 (Fig. 3)(46,
48, 49, 51, 59).  The mutation was introduced by altering the codon in two positions to limit
reversion to wildtype and further stabilize the mutant locus.    No plaques were detected in
infections initiated and maintained at the non-permissive temperature (Fig. 3A), while icTS-
LA6 grew with similar growth kinetics as wild-type at the permissive temperature (Fig. 3B).
A temperature shift experiment confirmed that icTS-LA6 replication was similar to wt-
icMHV at the permissive temperature, but replication declined drastically when shifted to the
non-permissive temperature at 6 hours post infection (Fig. 3C,D).  This result was in
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complete agreement with data previously published for TS-LA6 that showed an identical
phenotype (48, 49).
In addition, at the permissive temperature icTS-LA6 behaves similar to wildtype in
processing of nsp10 as detected by immunoprecipitation with anti-nsp10 antibody (Fig. 6A),
and in producing structural proteins as indicated by immunoprecipitation with anti-MHV
antibody (Fig. 6B). Further immunofluorescence assays, conducted at 6.5h p.i. showed that in
both wt-icMHV and TS-LA6 nsp10 co-localized with N to sites of viral replication,
indicating that the TS mutation to nsp10 does not result in a defect in localization (data not
shown).
Analysis of RNA synthesis by real time PCR (Fig. 5) and Northern blot (Fig. 4) show
that icTS-LA6 does not have a specific defect in RNA synthesis as it produces a wild-type
ratio of subgenomic-to-genomic mRNAs at the permissive temperature (Fig. 5B, C, D).
Taken together, these data suggest that the TS defect exhibited by icTS-LA6 has little or no
effect on RNA synthesis, subcellular localization, or nsp10 processing as compared to wt-
icMHV at the permissive temperature.
Complementation studies using TS mutants with mutations in several nsps of MHV,
have purported that nsp10, along with nsp4, nsp5, nsp12, nsp14, and nsp16 are essential for
the assembly of a functional replication/transcription complex (46).  Among these TS
mutants, three have been identified that fall within the peptide sequence of pp1a, and these
include TS-ALB6 in nsp4, TS-ALB16 in nsp5, and TS-LA6 found in nsp10.  Classic
complementation experiments have demonstrated that these mutants do not complement each
other in crosses where each of the TS viruses were used to co-infect cells initiated and
maintained at the non-permissive temperature for a single round of replication (~8
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hours)(46).  By definition, mutations that do not complement each other in the cis-trans test
are defined as a single complementation group and are presumed to occur within a
cistron(14).  This principle was the basis for predicting that nsp4, nsp5, and nsp10 are part of
a single cistron comprised of nsps4-10/11, and known as Complementation group I(46).  A
cistron comprised of nsp4-10/11 has a calculated molecular mass of ~150kDa, and the
hypothesis of nsp4-10/11 acting as a single cistron is supported by the fact that a p150
intermediate is detected in immunoprecipitation experiments using antibody against nsps7-
10(6, 24, 50).
TS-LA6 behaves almost identically to wild-type MHV infections treated with CH to
inhibit protein synthesis(5, 45).  In wild-type MHV-A59 replication, negative strand
synthesis stops within 30 minutes of the addition of CH, which implies the virus requires an
ongoing supply of proteins to form new negative strand replication complexes to continue
negative strand synthesis(5, 45).  Positive strand synthesis continues until all negative strands
are depleted, suggesting that the positive strand replication complex is stable, and does not
require continued renewal of co-factors to function(46).  Sawicki and colleagues reported
that TS-LA6 negative strand synthesis stops almost immediately after shift to the non-
permissive temperature, while positive strand synthesis continues unabated until all negative
strands are likely depleted.  This hypothesis is drawn from two experiments, one evaluating
overall RNA synthesis of several TS mutants and a second using pulse chase experiments
before and after shift of plus and minus strands as compared to infections treated with CH
(46).  The pulse label experiment for TS-LA6 showed no difference in plus strand synthesis
and a rapid reduction in negative strand synthesis(46).  The authors suggested at least two
possibilities to account for TS mutants from complementation group I being defective in
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forming competent replication/transcription complexes capable of generating more negative
strands: 1) The TS mutation altered the ability of p150 to function in negative strand but not
positive strand synthesis; and 2) The TS mutation blocked the ability of negative strands to
be used as templates for positive strand synthesis(46).  Further analysis of RNA synthesis of
the TS-LA6 mutant suggested that negative strands were not made after shift, implying a
defect in negative strand elongation(46, 59).
Our immunoprecipitation results suggest an alternative mechanism for TS-LA6 mode
of action.  Using TS-LA6 and icTS-LA6, we demonstrated that processing of nsp5, nsp8,
nsp10, and nsp12 are ablated after shift to the non-permissive temperature (Fig. 7, A-D),
which strongly implies that 3CLpro function in general is abrogated by this mutation.
Further, our results demonstrate that 3CLpro-mediated processing of pp1a and pp1ab is
blocked by this mutation (Fig.7, A-D), while processing by the PLPs is not compromised
(Fig. 7E).
Blocking the processing of 3CLpro should mimic infections that were treated with
E64d or CH, especially if nsp4-16 encode the labile factors that contribute to the negative
strand replicase.  In fact, there is little difference in viral RNA synthesis of cells treated with
CH and those infected with TS-LA6 at the non-permissive temperature (46).  While CH
would reduce the quantities of proteins translated in general, ablating processing at the non-
permissive temperature as we have demonstrated occurs with TS-LA6, would more closely
mimic treatment of cells with E64d, as translation would continue but unprocessed
polyproteins would likely accumulate(27).  In our immunoprecipitation experiments looking
at nsp5, nsp8, nsp10 we show that p150 accumulates after shift to the non-permissive
temperature (Fig. 7), consistent with this observation.
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In light of these findings, we hypothesize that the TS mutation to nsp10 ablates all
3CLpro processing, similar to treatment with E64d(27), which results in a block of all viral
RNA synthesis at the restrictive temperature.  The noted dominant effects on negative strand
synthesis reflect the sensitivity of the negative strand replicase when new protein
synthesis/processing is blocked while plus strand replicase molecules are less sensitive.
However, all RNA synthesis will eventually stop because continued protein processing is
ultimately required for both.
Complementation studies show that TS-LA6 does not complement with other TS
viruses with mutations in p150, including TS-ALB6 (nsp4), and TS-Alb16 (nsp5), as well as
others (46).  However, TS-LA6 does complement with other TS mutants with changes that
occur in pp1b, although the incorporation rates and complementation indices (CI) for these
crosses are significantly lower(46).  For example, TS-LA6 crossed with TS-ALB22
(mutation in nsp12) has CIs of 11 and 18 and an incorporation rate of 9%, as compared to the
cross between TS-ALB6 and TS-ALB22, which has CIs of 694 and 108, and an
incorporation rate of 41%, respectively(46).  This same result is shown in other crosses
between TS-LA6 and TS mutants that fall in complementation groups other than Group I,
specifically with mutants TS-ALB17 (nsp14) and TS-UT 145 (unknown), with CIs of 3 and
7; and 6, respectively (46).  Our results are consistent with the inability of TS-LA6 to
complement viruses with mutations in p150, as the TS mutation prevents any processing of
these intermediates both in cis and trans(Fig. 9A).  Consequently, viruses with TS mutations
within nsp4-10 would lack the cognitive trans functional factor from TS-LA6.  In contrast, it
is less clear why complementation was noted between TS-LA6 and TS mutants mapping in
ORF1b.  The TS-LA6 mutation appears to block processing of ORF1b, most likely in cis and
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trans as temperature shift experiments demonstrated ablated processing in the presence of
processed 3CLpro (Fig. 7D).  These data suggest that mutant TS-LA6 (icTS-LA6) could not
directly complement with any other TS mutant with mutations that occur within the 3CLpro
cleavage range (nsp4-16).  The fact that low level complementation has been reported to
occur in crosses between TS-LA6 and TS mutants in pp1b suggests that 3CLpro from the
pp1b TS mutants can perform limited processing of ORF1b nsps of TS-LA6 polyproteins in
trans allowing the two viruses to complement (Fig. 9B).  However, we cannot rule out the
possibility that recombination or reversion of TS viruses may be occurring during co-
infection, which would confound the complementation index resulting in slightly higher than
expected indices; and second, the 3CLpro may function less efficiently in trans to process
proteins from the C-terminal region of pp1ab.  We hypothesize that crosses between TS-LA6
and TS-ALB22, TS-ALB 17, and TS-Ut145 are complementing via trans cleavage by the
3CLpro of the pp1b TS mutant, which cleaves the appropriate nsp of TS-LA6 to rescue RNA
synthesis.
Our results also challenge the current paradigm that nps4-11 (p150) functions as a
cistron, as TS-LA6 abrogates 3CLpro activity and therefore synthesizes large uncleaved
polyproteins and should not be capable of complementing other ts mutants spanning nsp 4-16
at the restrictive temperature.  Two additional mutants within the putative nsp4-11 cistron,
TS-ALB6 in nsp4 and TS-ALB16 in nsp5 do not complement with TS-LA6 or each other,
but do robustly complement with TS viruses from other complementation groups.  The
processing patterns of TS-ALB6 and TS-ALB16 need to be investigated in more detail to
determine whether they impact global processing similar to TS-LA6, impact select
processing of specific intermediates (nsp5-6), or impact individual nsp function.  Our data
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suggest that mutants within individual nsps4-10 that do not affect processing may exist, and
these mutants should be capable of complementing other TS mutants in other nsps(49, 53).
The fact that TS-ALB6 and TS-ALB16 do not complement within p150, but do in
other complementation groups raises the possibility that coronaviruses utilize differential
proteolytic processing, cleaving the majority of products translated from pp1a by cis
interactions, while processing less frequent pp1b products in trans.
Interestingly, the icTS-LA6 mutation is adjacent on the inferred structure of MHV
nsp10 to the mutations of nsp10-E2 (Fig. 8), a mutant which demonstrated a delayed
processing phenotype, resulting in replication intermediates not observed in wt-icMHV
(Donaldson, et. al., in press).  The nsp10-E2 mutation removes an aspartate and histidine,
which are replaced with alanine, while the TS mutation adds the negative charge of
glutamate.  Both mutants produce viral RNA in ratios equivalent to wild-type, map from
amino acid positions 50-70 of nsp10, and occur in a disordered loop region proximal to zinc
binding finger-1(23).  This region is altered substantially by both mutations, as predicted by
homology models of nsp10-E2 and icTS-LA6.  In the case of nsp10-E2, substituting alanines
for Asp47 and His48 directly alters hydrogen bonds: Lys43-His48, Asp47-Ala-49, and
Asp47-Cys46, forcing the loop to collapse inward, rearranging the surface.  Substituting a
glutamine to glutamic acid at position 65 as in icTS-LA6, adds a negative charge to the
surface of the protein(23) and forces the loop to extend outward, probably due to repulsion
between Glu65, Asp66, and Glu60, which are in the same proximity.  This allows a new
hydrogen bond to form between Glu65 and His48, which likely extends the loop outward.
These results suggest that the region from amino acids 50-70 comprise a putative interaction
site in wt-icMHV nsp10, and we predict that these mutations significantly alter the binding
177
interface between nsp10 and another co-factor, which is required to facilitate 3CLpro
activity.
Figure 8.  Location of TS mutation on the nsp10 structure.  An homology model of
MHV-A59 nsp10 protein was generated using the co-ordinates of the X-ray crystal structure
of SARS-CoV (PDB code 2FYG), using the program Modeller.  The mutants icTS-LA6
(nsp10:Q65E) and nsp10-E2 (nsp10:D47A, H48A) were mapped onto the structure.  Both
mutations occur within a predicted disordered region, proximal to ZnF-1, and are exposed to
the surface.
Although other reports have shown that polyprotein processing is affected by TS
mutants of MHV-A59(4), this is the first report to demonstrate that the Q65E mutation in
nsp10 of TS-LA6 results in a defect in nsp5 (3CLpro) function at the non-permissive
temperature.  This implicates nsp10 as a critical factor in 3CLpro activity.   In general,
regulation of 3CLpro activity in MHV is poorly understood.  However, one potential
mechanism is that nsp10 allosterically regulates 3CLpro by interacting with another nsp(s) in
the p150 polyprotein to facilitate the proteinase activity by inducing a conformational change
E3:65 Q
E2 :DH 47,48
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necessary for 3CLpro to function in cis.   Two studies have shown that nsp10 interacts with
other proteins including itself, nsp1 and nsp7(6, 36).  Future experiments have been designed
to determine if amino acids 50-70 maintain a site important for interaction with other viral
co-factors.
Figure 9.  Complementation with TS-LA6 revisited.  Sawicki, et. al., established that
crosses between TS mutants within nsp4, nsp5, and nsp10 failed to complement each other as
shown by the Cis-Trans test and Biochemical Complementation Analysis.  This was the basis
for including them in Complementation Group I, and suggests that nsp4-10 acts as a single
cistron.  A. The TS mutation in nsp10 effectively renders the entire pp1ab polyprotein
unprocessed, and therefore it cannot complement with any other TS mutant from
Complementation Group 1.  B.  Our results suggest that TS-LA6 cannot complement with
any virus bearing a TS mutation in pp1ab.  However, limited proteolysis may occur in trans
to process proteins in pp1b.  Complementation between TS-LA6 and TS-ALB22 suggests
that 3CLpro of TS-ALB22 cleaves nsp12 of TS-LA6 in trans to rescue virus replication.  The
dotted line represents trans cleavage of nsp12.  Hatched boxes show proteins potentially
cleaved in trans, = 3CLpro cleavage site.
A second possibility is that nsp10 encodes a flexible disordered region, conserved among all
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coronaviruses, which allows the polyprotein to fold into proper orientation to facilitate
cleavage of p150 by 3CLpro.  Studies conducted with Yellow Fever and Hepatitis A viruses,
have shown that mutagenesis of amino acids distant from the polyprotein cleavage site and
the active site of the viral protease can reduce proteolytic activity, probably by altering
substrate conformation(13, 20).  It is possible that the change to glutamate at position 65 of
nsp10 of TS-LA6 is thermostable at the permissive temperature, but unstable at the non-
permissive temperature, altering the conformation of or rendering the p150 intermediate
insoluble and therefore resistant to 3CLpro cleavage.  A third possibility is that the TS
mutation to nsp10 alters the conformation of p150 at the non-permissive temperature and this
prevents membrane anchoring or dimerization, both of which may be essential to the
activation of 3CLpro function(1, 2, 40, 50, 54, 56, 58).
This is the first study to demonstrate that nsp10 is critical to polyprotein processing,
and suggests that nsp10 plays pleiotropic roles in the coronavirus life cycle, as additional
studies have demonstrated that nsp10 likely plays a role in viral RNA synthesis.
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CHAPTER VI:  DESIGN AND DEVELOPMENT OF TWO FULL-LENGTH
CORONAVIRUS INFECTIOUS CLONES
ABSTRACT
Full-length cDNA constructs of Coronavirus (CoV) genomes have revolutionized reverse
genetic applications in Coronavirology.  The infectious clone allows for detailed genetic
studies into the function of genes in replication and pathogenesis, the rapid production of
candidate vaccine strains and vectors for therapeutic gene delivery in animals and humans.
Here we describe in detail, the design and development of full-length infectious clones for
two newly identified coronaviruses: Human CoV-NL63 and Bat SARS-CoV.  The cloning
strategy was conceptually designed using a bioinformatics approach and synthetic genome
synthesis, and both clones were created by dividing the genome into stable cDNA fragments
flanked by native or engineered type IIs restrictions sites that provided unique ends
facilitating a seamless, unidirectional ligation of the full-length cDNA of the viral genome.
The full-length cDNAs were transcribed and transfected into cells, and recombinant viruses
were rescued and characterized. Rational design of synthetic genomes not only offers
considerable promise toward understanding complex adaptive biological mechanisms but
also provides robust pathways for the production of pharmaceuticals and therapeutics that
could greatly improve human health and economic stability.  Using this rational genome
design, we successfully recovered the largest synthetic replicating life form, a 29.7Kb bat
SARS-like CoV (Bat-SCoV), a likely progenitor to the SARS-CoV epidemic.
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1. INTRODUCTION TO HCOV-NL63 AND BAT SARS-COV
Coronaviruses (CoVs) encode the largest known single-stranded positive-sense RNA
containing 5’ capped, polyadenylated genomes ranging in size from 27-32 kb which is
infectious upon delivery to an uninfected cell.  Taxonomically, CoVs are categorized as
members of the order Nidovirales, family Coronaviridae, genus Coronavirus(13, 32, 40).
The genus is further divided into three primary groups based upon serological and
phylogenetic data. Group 1 consists of human CoVs (HCoV) HCoV-NL63 and HCoV-229E,
Porcine Epidemic diarrhea virus (PEDV), and Transmissible Gastroenteritis Virus (TGEV);
Group 3 is composed of Avian Infectious Bronchitis Virus (IBV); and Group 2 CoVs include
HCoV-OC43, HCoV-HKU-1, Bovine CoV (BCoV), Mouse Hepatitis Virus (MHV) and
Severe Acute Respiratory Syndrome (SARS) CoV (SARS-CoV), which is either an outlier of
group 2, making it a group 2b virus, or a new group 4 virus (13).
Until recently, CoVs were predominantly associated with severe disease in important
domestic animals including bovines (BCoV), swine (PEDV and TGEV), poultry (IBV)(2, 4,
32, 39) and mice (MHV) (42), while infections in humans were primarily associated with
mild upper respiratory tract diseases caused by HCoV-229E and HCoV-OC43 (32).
However, the rapid identification of a CoV as the etiological agent responsible for the
pandemic of SARS, an atypical pneumonia with a mortality rate of nearly 10%(60), indicated
that HCoVs are capable of causing severe disease in humans, and that unidentified HCoVs
continue to exist in nature.
In fact, from the early days of the SARS-CoV epidemic, civet cats and raccoon dogs
were the suspected natural source of the virus, and this culminated in the culling of thousands
of these animals when civet cats and raccoon dogs in the wet markets in Guangdong province
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tested seropositive for SARS-CoV, and viruses isolated from these animals were similar to
SARS-CoV isolated from humans during the SARS pandemic(21).
Further, specimens taken from animals raised on the farms that supplied the live
animal markets demonstrated that many of the farm-raised animals were seropositive.
However, SARS-CoV could not be isolated from any of these animals, suggesting that while
they were susceptible to infection by SARS-CoV, they were unlikely to be the reservoir of
the virus that incited the SARS pandemic (25, 62).
Further efforts to identify the reservoir of the SARS-CoV culminated in the discovery
of several novel coronaviruses, particularly those that infect bats (33, 34, 37, 46).
Interestingly, CoVs found in bats were shown to cluster within all three CoV taxonomic
groups, although, a CoV isolated from the Horseshoe bat shared ~80-90% sequence
similarity with SARS-CoV.  The fact that this virus was readily detectable in the horseshoe
bat, which was reported to have an asymptomatic infection, has led to the hypothesis that the
Horseshoe Bat is the natural reservoir from which the SARS-CoV evolved.  Unfortunately,
the Bat SARS-CoV has not been cultured from bats, and these samples have not been made
available to the research community, and only the sequences of these viruses was determined
by RT-PCR and deposited as electronic signatures.
In addition to SARS-CoV, molecular diagnostics have identified two additional
human CoVs: 1) HCoV-HKU1, which has been associated with chronic pulmonary disease
in humans (35); and 2) HCoV-NL63, which has been associated with both upper and lower
respiratory tract disease in children and adults (47, 64-66), with a worldwide distribution (7,
9-11, 15, 23, 26, 27, 43, 54, 63, 64, 68).  HCoV-NL63 was initially isolated from two
children in the Netherlands suffering from lower respiratory tract infections of unknown
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origin, and since has been identified as one of several viruses associated with the croup (44,
65, 66).
Since Bat SARS-COV and HCoV-NL63 are coronaviruses from different groups, the
genome length, genome organization and the number of accessory proteins differ depending
on the virus (Fig. 1), however conserved genome features include the replicase region, the
Spike, Envelope, Membrane and Nucleocapsid genes (Fig.1).
Figure 1. Comparison of the HCoV-NL63 and Bat SARS-CoV genomes.  Although these
two CoVs cluster in different groups, all CoVs have common structural proteins shown here
as Spike (S), envelope (E), membrane (M), and Nucleocapsid (N).  A. HCoV-NL63 is 27,503
nt in length and encodes the only two accessory genes labeled as ORF3 and ORF6b.  B.  Bat
SARS-CoV is 29,728 nt in length and encodes eight accessory genes shown as ORF3a,
ORF3b, ORF6, ORF7a, ORF7b, ORF8a, ORF8b, and ORF9b. ORF1ab shown in the boxes.
Interestingly, despite large differences in the Spike (S) glycoprotein sequences (less
than 50% identity at the nucleotide level) between HCoV-SARS and HCoV-NL63, both viral
S glycoproteins interact with human angiotensin-converting enzyme-2 (hACE2) as a receptor
for docking and entry into cells (45, 59).  Once a coronavirus is liberated inside the
cytoplasm of an infected cell the RNA genome, which is tightly associated with N protein, is
uncoated and immediately translated by host cell ribosomes resulting in two large
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polyproteins(32, 39).  The first 2/3s of the CoV genome contains the non-structural replicase
genes in a single open reading frame (ORF) (Fig. 1).  The final 1/3 of the genome consists of
the structural genes S, envelope (E), matrix (M) and N, as well as accessory genes specific to
different strains, which are translated from a nested set of co-terminal subgenomic
mRNAs(32, 39).  For HCoV-NL63, there are six genes: Gene 1 encodes the nonstructural
replicase proteins, gene 2 encodes S, gene 3 encodes an unknown accessory protein known as
ORF3, gene 4 encodes E, gene 5 encodes M, gene 6 encodes N, and an overlapping ORF 6b
encodes an additional accessory protein of unknown function.  For Bat SARS-CoV, eight
accessory genes are encoded, most of which have unknown function.  However, recent
studies with SARS-CoV have reported interferon antagonist properties for at least two of
these accessory ORFs (16-18, 28, 67).
Full-length cDNA constructs of CoV genomes have revolutionized reverse genetic
applications in Coronavirology.  The strategy employed by our laboratory has been to divide
the genome into stable cDNA fragments flanked by native or engineered type IIs restrictions
sites that form unique junctions at the ends of each fragment and allow for directed assembly
of full length cDNAs.  In addition, a T7 promoter site is added to the first fragment (at the 5’
end of the genome) to facilitate in vitro transcription of full-length RNAs, and a poly-A tail is
included at the end of the last fragment (at the 3’ end). The individual fragments can be
easily stored and amplified, and the smaller cDNA sizes are more manageable for targeted
mutagenesis studies.  This infectious clone strategy has been successfully employed for
TGEV(69), MHV strain A59(71), and for human CoV SARS-CoV strain Urbani(70).
This chapter is divided into two additional sections.  Section 2 focuses on the strategy
used to design, build, and characterize the first full-length infectious clone of HCoV-NL63
192
(icNL63) and a second icNL63 clone in which we replaced ORF3 with the heterologous
green fluorescence protein gene (icNL63gfp).  In Section 3, we describe the bioinformatics
strategy used to design the Bat SARS-CoV from a published sequence.  In this study, we
combine phylogenetics, large-scale cDNA synthesis, and reverse genetics to reconstruct
viruses with a consensus Bat-SCoV RNA genome. As these viruses were capable of efficient
replication, but not spread, we then paired structural modeling and chimeric gene design to
recover a chimeric Bat-SCoV that contained the Spike glycoprotein receptor-binding domain
(RBD) from human epidemic SARS-CoV. The Bat-SRBD chimeric virus grew
indistinguishably from SARS-CoV, and the recombinant viruses rescued represent the largest
synthetic self-replicating organism to date (Section 3).
2. SYSTEMATIC ASSEMBLY OF A FULL-LENGTH INFECTIOUS CLONE OF
    HCOV-NL63
(Manuscript in preparation: Donaldson, E.F., Yount, B., Sims, A.C., and Baric, R.S. to be
submitted to Journal of Virology)
2. 1 Methods for assembling the HCoV-NL63 and HCoV-NL63gfp infectious clones
Virus and cells.   The HCoV-NL63 virus and LLC-MK2 cells were generously
provided by Dr. Lia van der Hoek.  The LLC-M2 cells were maintained at 37°C in Minimum
Essential Media supplemented with 10% Fetal Clone II (Gibco), 10% tryptose phosphate
broth, and Gentamycin (0.05mg/ml)/Kanamycin (0.25mg/ml).  HCoV-NL63 was propagated
on these cells, and the infections were maintained at 32°C in incubators maintained at 5%
CO2.  In addition, Vero E9 cells, Delayed Brain Tumor-9 (DBT) cells and DBT cells
transgenically expressing hACE2 were maintained in the same media described above.
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Infections in these cell lines were also conducted at 32°C in incubators maintained at 5%
CO2.
Human nasal and tracheobronchial epithelial cells were obtained from airway
specimens resected from patients undergoing elective surgery under UNC Institutional
Review Board-approved protocols by the UNC Cystic Fibrosis Center Tissue Culture Core.
Briefly, primary cells were expanded on plastic to generate passage 1 cells and plated at a
density of 250,000 cells per well on permeable Transwell-Col (12-mm-diameter) supports
(14, 43). HAE cultures were generated by provision of an air-liquid interface for 4 to 6 weeks
to form well-differentiated, polarized cultures that resemble in vivo pseudostratified
mucociliary epithelium (43). Cultures of airway epithelial cells derived from alveolar regions
of the human lung were obtained by plating primary human alveolar cells (ScienCell
Research Labs, CA) or A549 cells on Transwell-Col supports and maintained for 5 days
before viral inoculation in manufacturer-supplied medium or Dulbecco's high-glucose
minimal essential medium, respectively.
Design of the HCoV-NL63 infectious clones, icNL63 and icNL63gfp.  The HCoV-
NL63 coronavirus was amplified from viral cDNA and cloned as a set of five fragments
(Table 1).  The first fragment, NL63-A, was PCR amplified using primer set 5’T7NL63+ (5’-
ggtacctaatacgactcactatagcttaaagaatttttctatctatag-3’) and HCoV-NL63: A- (5’-
gcggccgcgtctccaggagctgtgggttgaacag-3’).  These primers created a T7 RNA promoter at the
5’ end of the fragment and a BsmBI restriction site its 3’ end, respectively.  The PCR product
was gel isolated and then cloned into the pCR-XL TOPO cloning vector (Invitrogen).  The
second fragment, NL63-B, was amplified using primers HCoV-NL63: B+ (5’-
gcggccgcgtctcctcctgcatatgttattattgataag-3’) and HCoV-NL63: B- (5’-
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gcggccgcgtctctgctggggaagaagctattatcaag-3).  Fragment NL63-C was amplified with primers
HCoV-NL63: C+ (5’-gcggccgcgtctcccagcactcgttgatcaacgcac-3’) and HCoV-NL63: C- (5’-
gcggccgcgtctctctttagagacattttcaccatc-3’).  Both of these fragments, which are flanked with
BsmBI sites, were gel isolated and cloned into the Big Easy v2.0 Linear cloning vector
(Lucigen).  Fragment NL63-D, was amplified using primer HCoV-NL63: D+ (5’-
ggtgaaaacgtctctaaagatgg-3’) and primer HCoV-NL63: D- (5’-
cagcagcacagtatgcagaaaaagcaaacc-3’). This primer set created either a BsmBI or a BstAPI
restriction site at the 5’ and 3’ end, respectively.  The last fragment, NL63-E, was PCR
amplified using primers HCoV-NL63: E+ (5’- tttctgcatactgtgctgctgccaactg-3’) and HCoV-
NL63: E- (5’-ttttttttttttttttttttttttgtgtatccatatcaaaaacaatatcattaacaagtacc-3’) and contained a
BstAPI site at its 5’ end.  The last two fragments, C and D, were gel purified and
subsequently cloned into the pCR-XL TOPO vector.
Primer Nucleotide position Comment
5’T7NL63+ 5’ end of genome Creates 5’ T7 RNA polymerase promoter
NL63: A- 6907-6928 Creates BsmBI junction between A and B
NL63: B+ 6922-6948 Creates BsmBI junction between A and B
NL63: B- 13537-13562 Creates BsmBI junction between B and C
NL63: C+ 13556-13579 Creates BsmBI junction between B and C
NL63: C- 19988-20011 Creates BsmBI junction between C and D
NL63: D+ 19991-20014 Creates BsmBI junction between D and D
NL63: D- 23845-23875 Creates BstAPI junction between D and E
NL63: E+ 23854-23882 Creates BstAPI junction between D and E
NL63: E- 3’ end of genome Creates 3’ poly A tail at end of genome
Table 1: Primer positions and sites added by PCR.  The HCoV-NL63 clone was
engineered into five fragments flanked by the restriction sites added by PCR.   A T7
promoter was added at the 5’ end and a poly A tail at the 3’end.
The 5’ approx. 630 bp of the HCoV-NL63 E fragment was PCR amplified using the
primer set HCoV-NL63: E+ and Ngfp2- (5’-ccattattgaacgtggaccttttc-3’).  The gene encoding
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gfp was amplified with primer Ngfp1+ (5’-gaaaaggtccacgttcaataatggtgagcaagggcgagg-3’)
and primer Ngfp3- (5’-ggtcaccttacttgtacagctcgtccatg-3’).  These two amplicons were joined
in an over-lapping extension PCR reaction and the resulting product was cloned into the
pCR-XL cloning vector.A consensus clone was generated using standard recombinant DNA
techniques and the BstAPI to BstEII fragment from this clone was inserted into the NL63-E
fragment, which had also been digested with BstAPI and BstEII.  The resulting plasmid then
contained gfp in place of the HCoV-NL63 ORF3, and this fragment was designated NL63-
Egfp (Fig. 2).
Systematic assembly of full-length HCoV-NL63 cDNAs for icNL63 and
icNL63gfp.  For assembling the infectious clones, plasmids incorporating cDNA fragments
of NL63-A through NL63-E were transformed into chemically competent Top 10 Cells
(Invitrogen) by heat shock at 42°C for 2 min, then plated on Luria Bertani (LB) plates with
appropriate selection (Kanamycin [25mg/ml] or Ampicillin [50 mg/ml]).  Colonies were
picked and grown under appropriate selection conditions in 5ml of LB broth maintained at
28.5°C for 16-24 H, then purified and screened by restriction digestion.   Larger 20 ml stocks
were grown at 28.5°C for 24h for each of the cDNAs.   Purified plasmids were then digested
as follows: NL63-A, NL63-B and NL63-C with BsmBI, NL63-D and NL63-E were digested
under the appropriate conditions with BsmBI and BstAPI.  NL63-Egfp was digested with
BsmBI and BstAPI.
After digestion fragments were electroporated on 0.8% agarose gel, and appropriate
bands were excised and gel purified using a Qiaex II Gel Extraction Kit (Qiagen) with
modifications (71).  Briefly, all fragments were resuspended in 620 μl of QX1 buffer, 11 μl
QIAEX II silica-gel particles and 12.5 μl 3M sodium acetate, and eluted in 35 μl of elution
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buffer heated to 70°C.   Purified fragments, NL63-A through NL63-E were ligated
(Promega) overnight at 4°C, in a total reaction volume of ~200 μl, to generate the wildtype
infectious clone (icNL63).  For the HCoV-NL63 clone expressing gfp (icNL63gfp), the
NL63-Egfp fragment was used instead of the NL63-E fragment.
Transfection of full-length transcripts.  The full-length cDNAs were then further
purified by chloroform extraction and isopropanol precipitation, transcribed using T7
transcription kit (Ambion) and co-transfected into 8x106 LLC-MK2 cells in parallel with the
N-gene driven by an SP6 promoter and transcribed with SP6 transcription kit (Ambion).
LLC-MK2 cells were efficiently transfected at 200V and 950 μferrads with one pulse using a
Bio Rad (Hercules, CA) Gene Pulser Excel electroporator.  Electroporated LLC-MK2s were
plated in T25 flasks and incubated at 32°C for up to 7 days.
Detection of icNL63 and icNL63gfp replication.  To determine if replication
occurred in the icNL63 transfection cultures, cells were examined at regular intervals for
cytopathology.  However, CPE was not definitive at 7 days post transfection, so half of the
cells and supernatants were passed with fresh cells and media, and cultures observed for 7
additional days.  A third passage was conducted in the same manner.  At each passage,
infected cells were harvested in Trizol Reagent, total RNA was isolated, and RT-PCR
targeting subgenomic RNA was conducted using primers specific to the leader sequence and
the 5’ end of the N-gene.  Briefly, viral RNA was reverse transcribed to cDNA using
SuperScript III (Invitrogen) with modification to the protocol as follows:  Random hexamers
(300ng) and total RNA (5μg) were incubated for 10 minutes at 70°C.  The remaining
reagents were then added according to manufacturer’s recommendation and the reaction was
incubated at 55°C for 1 hour followed by 20 minutes at 70°C to deactivate the RT.  For RT-
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PCR, a forward primer in the leader sequence and a reverse primer ~200 nt into the N-gene
were used to generate an ~220 base pair product by PCR.
Real time RT-PCR was also conducted with the same cDNA templates using Smart
Cycler II (Cepheid) with SYBR green (Cepheid, diluted to .25X) to detect subgenomic
cDNA with primers (7.5 pM) optimized to detect ~120 nucleotides spanning from the leader
sequence to the 5’ end of N gene.  The cDNA from the RT reaction of each virus was used, at
a volume of 2μl for each reaction, with a total reaction volume of 25μl.  Omnimix beads
(Cepheid) containing all reagents except SYBR green, primer, and template were used to
standardize the reaction conditions.  In addition, all products were verified by melting curve
analysis.
For the icNL63gfp infectious clone, replication was confirmed by observing
fluorescence.  Infections were passaged as described above until nearly 100% of cells were
fluorescing, at which time the supernatants and cells were harvested.  Replication was further
verified by RT-PCR, using primers specific to subgenomic N transcripts.
Plaque purification and titration of rescued virus.  Supernatants harvested from
passage three of the transfections were diluted 1:10 and 200μl of dilutions from 100 to 10-5
were poured onto LLC-MK2 cells in six well plates.  After an one-hour adsorption period,
five mls of overlay (.8% LE agar, 10% Fetal clone II, 40% 2x MEM, 1%
Gentamycin/Kanamycin) was added to each culture and the infections were maintained at
32°C for 7 days. To help visualize the plaques, the plates were stained with Neutral Red for 1
hr at 32°C and five plaques were picked for each virus.  Each plaque was incubated in PBS at
32°C for 30 minutes and then poured onto fresh LLC-MK2 cells and grown at 32°C for up to
9 days to allow for propagation of purified virus.  For the icNL63gfp recombinant virus
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(icNL63gfp-RV), plaques were clearly visible by fluorescent microscopy, and 5 plaques were
picked and propagated as described above.  Titers for both icNL63-RV and icNL63gfp-RV
were determined by plaque assay using LLC-MK2 cells.  Briefly, LLC-MK2 cells were
infected in duplicate with serial dilutions of icNL63 or icNL63gfp in 6-well plates with an
one-hour adsorption period.  Five milliliters of overlay (.8% LE agar, 10% Fetal clone II,
40% 2x MEM, 1% Gentamycin/Kanamycin) was added to each infection and the plates were
maintained at 32°C until plaques were observed (between 4 and 7 days).  To visualize
plaques, plates were stained with Neutral Red for 2h at 32°C and then incubated overnight
prior to counting.
Detection of marker mutations.  An unique BstAPI restriction endonuclease site
was engineered into both the icNL63 and icNL63gfp clones to facilitate the unidirectional
ligation of the NL63-C and NL63-D fragments.  This engineering introduced a unique, but
silent BstAPI restriction endonuclease site at position 23916 to 23925 of both clones.  This
site was used to verify that the plaque-purified viruses harvested were originated from the
infectious clones.  Primers flanking the marker mutation were used to amplify this region of
the genome by RT-PCR, for wt-NL63, icNL63-RV and icNL63gfp-RV.  In all cases an
~1000bp PCR product was detected by electroporation on a 0.8% agarose gel, and the band
for each virus was excised and gel purified using a Qiaex II Gel Extraction Kit (Qiagen) with
modifications (71).  Briefly, the excised PCR product was resuspended in 620 μl of QX1
buffer, 11 μl QIAEX II silica-gel particles and 12.5 μl 3M sodium acetate, and eluted in 55
μl of elution buffer heated to 70°C.  Analysis of the genotype was conducted by restriction
digestion of the 1000bp DNA with the BstAPI restriction endonuclease.  Briefly, 25μl of
DNA for each virus was incubated with 1μl BstAPI, 3μl of NEB buffer 3 and 1μl ddh20 at
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60C for 2 hours, and then electroporated on a 0.8% agarose gel. The remaining 5μl of DNA
was used to sequence the fragment for genotype verification.
Growth kinetics and RNA analysis.  For the growth curve analysis, cultures of
LLC-MK2 cells were infected at a multiplicity of infection (MOI) of 0.003 plaque forming
units (PFU) /cell in 12-well plates with an one-hour adsorption period, followed by three
washes with PBS.  Two milliliters of media was added to each culture and the infections
were maintained at 32°C.  Supernatants were harvested, 300μl per time point, with the 300μl
of media added back, at 0, 8, 24, 48, 72, 96, 120, 144, 168 and 192 hours post infection (h
p.i.).   The titers for each virus at each time point were determined by plaque titration in
LLC-MK2 cells maintained at 32°C, and described above.
Immunofluorescence assay.  LLC-MK2 cells were grown to 70-80% confluence on
a four well chamber slide and infected with icNL63-RV or mock at an MOI of ~1 PFU/cell.
At 48h p.i., the media was aspirated and the cells were fixed and permeabilized in –20°C
methanol overnight.  Cells were rehydrated in PBS for 30 min, and blocked in buffer
comprised of PBS with 5% bovine serum albumin.  All subsequent IFA steps were conducted
at 25°C in IFA assay wash buffer comprised of PBS containing 1% bovine serum albumin
and 0.05% Nonidet P-40.  After blocking, cells were incubated in primary antibody (anti-
NL63-N, generously provided by Lia van der Hoek), anti-N, 1:1,000 for 1 h.  Cells were then
washed in IFA assay wash buffer three times at 10 min/wash.  Next, cells were incubated in
secondary antibody (goat anti-rabbit-Alexa 488, 1:1,000, Molecular Probes) for 45 min.
Next, cells were washed three times at 10 min/wash, followed by a final wash of 30 min. in
PBS.  Cells were then visualized by fluorescent microscopy.  Images were prepared for
publication using Adobe Photoshop CS.
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Infection of Human Airway Epithelial cultures.  Apical or basolateral virus
inoculations were performed with 200 μl of virus stocks of icNL63-RV or icNL63gfp-RV,
both with titers of 104 PFU/ml, applied to the apical or basolateral surfaces of HAE,
respectively.  Prior to apical inoculation, the apical surfaces of HAE were rinsed three times
over 30 min with phosphate-buffered saline (PBS) at 37°C.  Basolateral inoculations were
performed by inverting the Transwell-Col insert prior to addition of virus.  Following a 2-h
viral inoculation at 37°C, all inocula were removed and HAE were maintained with an air-
liquid interface for the remainder of the experiment.  To generate growth curves at specific
times after viral inoculation, 120 μl of tissue culture medium was applied to the apical
surface of HAE and collected after a 10-min incubation at 37°C.  Basolateral samples were
collected by removing 120 μl of basolateral medium at each time point.  All samples were
stored at -80°C until assayed for plaque formation on LLC-MK2 cells.
2.2 Systematic assembly of icNL63 and icNL63gfp and recovering recombinant viruses
Design and assembly of HCoV-NL63 infectious clones, icNL63 and icNL63gfp.
For icNL63, the HCoV-NL63 genome was divided into five cDNA fragments (NL63-A
through NL63-E) with unique type IIS endonuclease restriction sites flanking each junction
(Fig. 2).  For icNL63gfp, the same strategy was used although the heterologous GFP gene
was inserted in place of the accessory ORF3 in NL63-E, which was designated NL63-Egfp
(Fig. 2).  To assemble the clones, the fragments were cut by restriction digestion to remove
the non-native portion of the restriction site and sequence, leaving unique sticky ends.  The
digested fragments were then ligated to generate the full-length cDNA clones, with NL63-
Egfp being used instead of NL63-E for icNL63gfp (Fig. 2).  A T7 promoter site engineered at
the 5’ end of the genome in fragment NL63-A was used to drive in vitro transcription of the
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full-length cDNA to infectious RNA (Fig. 2).  LLC-MK2 cells were transfected with the full
length RNA for each clone and the cells were monitored for cytopathology.
Figure 2: The gene order of HCoV-NL63 and the strategy used to generate both
infectious clones.  A.  The HCoV-NL63 genome is of 6 genes, with ORF1a/b containing the
viral non-structural proteins involved primarily in replication.  Genes 2-6 encode the
structural and accessory proteins, with only ORF3 encoding a protein of unknown function.
B.  The HCoV-NL63 genome was divided into five cDNA fragments (designated NL63-A to
HCoV-NL63 E) flanked by unique type IIS restriction sites that enable the seamless,
unidirectional assembly of the entire genome.  Fragment NL63-A contained a T7 promoter
sequence and NL63-E a poly A tail.  In addition, ORF3 was deleted and heterologous gfp
gene inserted in its place in the NL63-E fragment to form NL63-Egfp, which was used to
engineer an HCoV-NL63 clone with a unique marker of infection.
Detection of icNL63-RV and icNL63gfp-RV replication.  To determine if
replication occurred in the icNL63 transfection cultures, cells were examined at regular
intervals for cytopathology, which in LLC-Mk2 cells was reported to be discernible as
rounded cells that appear on top of the monolayer. In the case of icNL63-RV, CPE was not
definitive at 7 days post transfection, so half of the cells and supernatants were passed with
fresh cells and media, and cultures observed for 7 additional days.  A third passage was
conducted in the same manner.  At each passage, supernatants were saved, and infected cells
were harvested in Trizol Reagent for isolation of total RNA.
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Figure 3: Detection of replication in cells transfected wit icNL63.  A.  Supernatants from
the transfection flask were used to inoculate a 4 well chamber slide with LLC-MK2 cells to
assay for the presence of HCoV-NL63 N protein by IFA.  In mock infected cells, there was
no sign of viral Nucleocapsid protein.  B.  In cells infected with supernatants from the
icNL63 transfection, Nucleocapsid protein was evident, showing the same perinuclear
localization pattern as N exhibits in cells infected with MHV and SARS-CoV.  C.  While
CPE was not convincing, the supernatants from the icNL63 transfection resulted in
differential sized plaques.  D.  Subgenomic transcription was verified by real time RT-PCR,
by assaying for leader containing transcripts only detectable if viral replication had occurred.
Amplification of the viral cDNA for wt-NL63 () and recombinant icNL63 () occurred at
nearly identical cycle thresholds, suggesting that recombinant icNL63 generated similar
quantities of subgenomic N-gene as wt-NL63.  LLC-MK2 cells () and the no template
control () showed no amplification.
While CPE was not conclusive at any time, icNL63-RVp3 replication was verified using
IFA, plaque titration, and staining of the overlay with neutral red to show plaques, and by
real-time RT-PCR (Fig. 3).
D
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For icNL63gfp-RV, replication was confirmed by observing fluorescence (Fig. 4).
While fluorescence was observed as early as day one, the p3 infections were maintained for 9
days, but the LLC-MK2 cells were fed by replacing half the supernatants with fresh media at
day 5. By 7 days post infection of p3, there was obvious CPE in the icNL63gfp-RV infected
cells, characterized by rounded cells that grew on top of the monolayer (Fig. 4A).
Figure 4. Detection of replication in LLC-MK2 cells transfected with icNL63gfp.  A.
Cytopatholgy was evident in cells transfected with icNL63gfp after passage 3, indicated by
rounded clumps of cells that grew on top of the monolayer forming long continuous
striations.  B.  Fluorescence was detected as early as 24 hours post infection, although it was
obvious that the number of recombinant viruses resulting from the original transfection was
low.  Fluorescence increased daily through three passages, and finally by day 23 nearly 100%
of cells appeared to be infected.  Interestingly, the fluorescence did not correlate with CPE,
as both photos above are of the same field, one taken by bright field and the other by
fluorescent microscopy.
Cells and supernatants were harvested on day 9 when nearly 100% of cells showed strong
evidence of GFP fluorescence.  Replication and the presence of mRNA encoding viral
structural proteins or GFP was further verified by RT-PCR (data not shown).
Plaque purification and titration of rescued virus.  Viruses rescued from the
icNL63 and icNL63gfp transfections were harvested after p3, between 21 and 24 days post
transfection.  Supernatants were serially diluted 1:10, and multiple dilutions were
individually placed on LLC-MK2 cells, and covered with overlay media.  Infections were
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maintained at 32°C for 7 days.  To help visualize the icNL63-RV plaques, the plates were
stained with Neutral Red for 1 hr at 32°C, the stain was then removed, and five plaques were
picked for each virus. Each plaque was incubated in PBS at 32°C for 30 minutes and then
poured onto fresh LLC-MK2 cells and grown at 32°C for up to 9 days to allow for
propagation of purified virus.  For icNL63gfp-RV, plaques were clearly visible by
fluorescent microscopy (Fig. 5), and 5 plaques were picked and propagated as described
above.
Titers for both icNL63-RV and icNL63gfp-RV were determined by plaque assay
using LLC-MK2 cells.  Viral titers derived from icNL63-RV plaques reached 2x104 PFU/ml
in LLC-MK2 cells, while titers for icNL63gfp-RV were higher, ranging from 5-8x104
PFU/ml.  Of note, the wt-NL63 virus titer was 2x105 PFU/ml.
Figure 5:  Detection of plaques generated by recombinant icNL63gfp.  Fluorescence
generated by icNL63gfp-RV was readily detectable at early times of infection, and plaques
comprised of icNL63gfp-RV were visible by fluorescent microscopy.  A. Cells infected with
recombinant icNL63 or wt-NL63 virus generated no detectable fluorescence beyond the
normal background.  B.  Cells infected with icNL63gfp-RV and covered with overlay media
formed plaques distinguished by fluorescent islands within the monolayer.
Detection of marker mutations in the rescued viruses.  As part of the cloning
strategy, a silent BstAPI restriction endonuclease site was engineered into both the icNL63
and icNL63gfp clones at the NL63-D and NL63-E or NL63-Egfp junction to facilitate the
205
unidirectional ligation of the NL63-C and NL63-D fragments.  Therefore, upon ligation, this
site would be present in both clones, but not in the wt-NL63 genome.To verify that each
clone had this marker mutation present, viral RNA was harvested from plaque purified
infections, and the ~1000 nt region flanking the BstAPI site was amplified by RT-PCR (Fig.
6).  In all cases an ~1000 nt PCR product was detected by electroporation, and the band for
each virus was excised and gel purified (Fig. 6).  The purified 1000nt DNA from each virus
was digested with the BstAPI restriction endonuclease.  Viral cDNA harvested from icNL63
and icNL63gfp recombinant viruses was digested to form two bands of 600 and 400 nts (Fig.
6), while the wt-NL63 viral cDNA was not cleaved by this enzyme (Fig. 6).  Further, this
region was sequenced to verify that the site of the marker mutation was present in the two
clones, and this was the case for both recombinant viruses (Fig. 6).
Figure 6: Identification of the marker mutation in rescued virus from icNL63 and
icNL63gfp. A.  A silent BstAPI site introduced into both clones at the NL63-D and NL63-E
or NL63-Egfp junctions was used to verify that the viruses rescued from the transfection
flasks were generated from the cloned cDNA.  This region was amplified and verified.  Lane
1, marker; lane 2, wt-NL63; lane 3, icNL63 recombinant virus; and lane 4, icNL63gfp
recombinant virus. B and C.  Further, the region was sequenced and in both cases the
recombinant virus had the correct genotype.  icNL63 (B) and icNL63gfp (C).
Growth kinetics and RNA analysis.  To determine if the recombinant viruses
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generated from the two clones grew with similar growth kinetics as wt-NL63, cultures of
LLC-MK2 cells were infected at a multiplicity of infection (MOI) of 0.003 PFU/cell with
each virus infection repeated in triplicate, and supernatants were harvested at 0, 8, 24, 48, 72,
96, 120, 144, 168 and 192 h p.i.  The titers for each virus at each time point were determined
by plaque titration in LLC-MK2 cells maintained at 32°C, as described above.  For the most
part, viral growth was similar for wt-NL63 and both recombinant viruses, although icNL63-
RV appeared to have less of a delay than the other two (Fig. 7).
Figure 7.  Growth kinetics of wt-NL63 and recombinant viruses of icNL63 and
icNL63gfp.  All three viruses grew with similar growth kinetics, although recombinant
icNL63 virus () appeared to have a shorter lag phase.  Wt-NL63 () and icNL63gfp-RV
() were nearly identical at every time point until day 7 (168h p.i.) when wt-NL63 reached
peak titers of 5x10
5
PFU/ml.  IcNL63-RV reached a peak titer of 3x10
5
 on day 6 (144h p.i.)
and icNL63gfp-RV reached titers of 1.5x10
5
 PFU/ml on the same day.  All virus titers at
each time point fall within one standard deviation, suggesting that all titers are similar.
Infection of Human Airway Epithelial cultures.  Apical or basolateral virus
inoculations were performed with 200 μl of virus stocks of icNL63 or icNL63gfp, both with
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titers of 105 PFU/ml, applied to the apical or basolateral surfaces of HAE, respectively.
Following a 2-h viral inoculation at 32°C, all inocula were removed and HAE were
maintained with an air-liquid interface for 7 days.   Recombinant icNL63gfp was detected by
fluorescence on day 1 (24h p.i.), and fluorescence was observed, and increased during every
time point of the experiment (Data not shown).  To determine titers, supernatants were
collected at 24 hour intervals, and plaque assays were performed in LLC-MK2 cells (Data
not shown).  icNL63 and icNL63 recombinant viruses reached peak titers of 1-2x105 in LLC-
MK2 on day 6 (144 hp.i.), while wt-NL63 reached slightly higher titers of 5-6x10
5
 in LLC-
MK2 cells on day 7 (168 h p.i.).
2.3 Discussion of Human Coronavirus NL63 Expression Vectors for Human Health
NL63 is a worldwide public health threat, associated with croup.  Acute lower
respiratory tract infections (LRTIs) in children less than five years of age are among the most
frequent diseases during early childhood, and the World Health Organization
(http://www.who.int/fch/depts/cah/resp_infections/en/) reports that acute LRTIs are fatal
20% of the time.  In 2005, it was reported that among children 3-years of age and younger
who presented with LRTIs, HCoV-NL63 was one of the most commonly isolated viruses,
following only Respiratory Syncytial Virus and Human Parainfluenza Virus-3, respectively.
More intriguingly, it was determined that HCoV-NL63 viral loads were higher in patients not
co-infected with other viruses, and that among those patients with high viral loads of HCoV-
NL63, 43% had croup(44, 65).  Croup is a group of conditions, that can be caused by a
variety of viruses, resulting in inflammation of the upper airway, which is characterized by a
whistling, obstructive stridor as the child breathes in followed by a “barking” cough.  Croup
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results in 250,000 hospitalizations each year in the United States, and cases severe enough to
require hospitalization can be fatal if treatment is not sought. Because Croup is caused by
more than one pathogen, it cab be difficult to diagnose, therefore no accurate mortality rate
can be determined.
 Having a reverse genetics system available for HCoV-NL63 provides a platform for
studying the virus in depth, and will likely be a necessary component toward the
development of vaccine candidates and therapeutics designed to reduce the burden of this
virus on children all over the world.  The benefits of such a vaccine would be to reduce the
overall LRTI disease burden in children, reducing cases of Croup, and Croup-related
hospitalizations.
The availability of icNL63 and icNL63gfp provides unique research opportunities,
which will advance our understanding of in vivo tropisms, and allow for the development of
small animal models of infection.  We are currently in the process of passing icNL63 in mice
to develop a mouse adapted variant of the virus, following a strategy that was successful in
SARS-CoV(70), which uses the same receptor as icNL63.  An infectious clone of NL63 is a
powerful vaccine platform, as CPE can be detected, it uses the same receptor as has been
described for SARS-CoV and that is present in mice, it readily adapts to grow more
efficiently in vitro, resulting in higher peak titers in less time.  These characteristics are in
contrast to HCoV-229E clone, which grow poorly, and are difficult to detect(61).
To generate the reverse genetics system of NL63, he NL63 genome was divided into
five fragments (NL63-A through NL63-E) with unique class IIS restriction sites flanking
each end.  The sticky ends generated by digestion of these sites facilitate a seamless
unidirectional ligation of a full-length viral cDNA, as has been described for TGEV(69),
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MHV(71), and SARS(70).  The cDNA is transcribed, driven by a heterologous T7 promoter
added at the 5’end, and the full-length infectious viral RNA is transfected into LLC-MK2
cells.  The only difference between icNL63 and icNL63gfp is that the latter has heterologous
gfp inserted into the NL63-E fragment in place of ORF3.  The junction between NL63-D and
both NL63-E variants was created by adding a silent BstAPI restriction site, upon ligation,
this silent site is present in, providing a unique marker indicative of viral RNA generated
from the cDNA clone.
Recombinant viruses rescued from icNL63-RV and icNL63gfp-RV contain the
marker mutation.  Amplification of a 1000nt region flanking the NL63-D and NL63-E or
NL63-Egfp junction was used to verify that the input cDNA was that assembled from the
infectious clone and not introduced by contamination.  Once amplified by PCR the band was
excised, purified, and digested with BstAPI.  In both cases, the reverse transcribed viral RNA
harvested from infections with plaque purified recombinant virus generated from each clone
contained the BstAPI site, and was digested by the enzyme (Fig. 6).  Wt-NL63, which does
not contain the site, was not digested.  This region was also sequenced and showed that clone
genotype containing the silent BstAPI site was present in both recombinant viruses (Fig. 6).
Detection of cytopathology in recombinant icNL63 and icNL63gfp infected LLC-
MK2 cells.  Cytopathology in LLC-MK2 cells infected with wt-NL63 is generally
observable between days 4 through 7 post infection, and it presents as rounded cells that
grow on top of the monolayer.  Cells usually dissociate from the plate after 7 days post
infection.  This type of cytopathology was present in both recombinant viruses, but not
definitively until after passage 3, 21-25 days post transfection.  However, fluorescence was
observed in the recombinant icNL63gfp as early as 24 h p.i.  We continued to observe the
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fluorescence throughout the course of the experiment, and the recombinant icNL63gfp virus
continued to spread until nearly all cells displayed clear GFP fluorescence.  These same cells
exhibited the same rounded cytopathology as observed in the icNL63 recombinant virus
infections (Fig. 4).  Interestingly, although the cytopatholgy was not obvious to the untrained
eye, wt-NL63 and recombinant icNL63 and icNL63gfp readily formed plaques in LLC-MK2
cells (Fig. 3).
Differential plaque morphology in recombinant icNL63 and icNL63gfp infected
LLC-MK2 cells.  In general, plaque purified wt-NL63 and recombinant icNL63 viruses
generated nearly round plaques of 2-3 mm in diameter, in LLC-MK2 cells covered in overlay
agarose medium and incubated for 7 days at 32C with 5% CO2.  While plaques were barely
discernible to the naked eye, Neutral Red stain was applied to the plates to facilitate the
characterization of the plaques, and to improve the accuracy of counting for determining viral
titers.  Interestingly, the infections with plaque purified recombinant icNL63gfp virus,
generated plaques that were slightly smaller (1.5-2.5mm in diameter), had irregular borders,
and were considerably less clear (data not shown) than wt plaques.  However, the difference
in plaque phenotype did not correlate to a reduction in growth kinetics (Fig. 7).
Recombinant viruses rescued via icNL63 and icNL63gfp have similar growth
kinetics as wt-NL63.  Growth curve analysis was conducted in triplicate for each of the
recombinant viruses and wt-NL63.  Viral growth was assayed over 10 days, but peak titers
were reached by day 6 for icNL63 and icNL63gfp recombinant viruses and by day 7 for wt-
NL63, although all titers at all time points were within the range of error for the experiment.
In all cases, peak titers reached low to mid 105 PFU/ml in the LLC-MK2 cells tested (Fig. 7).
While icNL63 appeared to have a shortened lag phase, this is likely due to differences in cell
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culture and not a real difference in the recombinant icNL63 virus (Fig. 7).  Interestingly,
growth of wt-NL63 and recombinant icNL63gfp virus was nearly identical in cell culture
(Fig. 7).
The ORF3 protein is non-essential for replication in vitro.  In HCoV-NL63, the
gene order is 5’-replicase-S-ORF3-E-M-N-3’ (lia and krystov), with the ORF3 protein
product being of unknown function.  Interestingly, ORF3 encodes a 225 amino acid protein
that shares homology with ORF4 of HCoV-229E (53% similarity), which has the same
genome organization as HCoV-NL63, and with ORF3A of SARS-CoV (23% similarity)
(Muller, MA, thesis).  Removal of ORF3, and replacing it with the heterologous gfp gene,
resulted in infected cells that fluoresce, and viral titers and growth kinetics that were
essentially identical to wt-NL63 in LLC-MK2 cells (Fig. 7).  The only difference noted, was
in plaque morphology.  Interestingly, the ORF4 protein in HCoV-229E (van der Hoek, 2006,
JV) and ORF3a in SARS-CoV (Yount SARS non-ess paper) have been shown to be
nonessential in cell culture.   However, HCoV-229E ORF4 is thought to play an important
role in vivo (van der Hoek, 2006, JV).  We are in the process of generating icNL63ORF3,
which is designed to remove ORF3 while preserving the TRS elements necessary for
subgenomic transcription of all down stream mRNAs.  This construct will allow us to further
investigate the role of ORF3 in HCoV-NL63 replication and pathogenesis.
icNL63 and icNL63gfp recombinant virus infects primary human airway
epithelium.  In addition to LLC-MK2 cells, recombinant icNL63 and icNL63gfp viruses
were used to infect primary human airway epithelium.  Since HCoV-NL63 infects the upper
and lower respiratory tract, the HAE cells are likely a more authentic model for studying this
virus.  Not surprisingly, both recombinant viruses grew similarly in HAEs (data not shown),
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and icNL63gfp recombinant virus was detectable by fluorescence starting at 24 hours post
infection, and progression of the infection to different cells was observed over the course of
the experiment.
icNL63gfp provides a novel reagent that allows monitoring of infections in real
time.  A fluorescent marker for HCoV-NL63 infection is an important reagent that allows an
investigator to monitor infections in real time.  In LLC-MK2 cells, we could visualize viral
spread throughout the culture.  This same monitoring was available in the HAE cultures,
providing a platform to monitor infections of primary HAEs in real time.  Detection of CPE
in HAEs is difficult, and nearly undetectable in wt-NL63 infections.
Infectious clones of HCoV-NL63 provide a platform to develop vaccines against
this human threat. The discovery of HCoV-NL63 as an important viral pathogen of children
and adults worldwide coupled with the identification of SARS-CoV as the agent responsible
for the atypical pneumonia that nearly crippled the economy of Southeast Asia, asseverate
human coronaviruses as important human pathogens.  These discoveries underscore the need
to further our understanding of and our ability to control this family of viruses by continued
research and development of systems capable of immediately addressing an emerging threat.
The infectious clones described in this report provide a unique reverse genetics platform that
can be used to further the research effort toward candidate vaccine strains that might one day
eliminate HCoV-NL63 as a formidable respiratory pathogen that infects nearly every child,
worldwide.
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3. DEVELOPMENT OF A BAT SARS-COV INFECTIOUS CLONE
(Manuscript in preparation:  Becker, M., Graham, R., Donaldson, E., Rockx, B., Sims, A.,
Baric, R., and Denison, M.  To be submitted to Nature Biotech)
3.1 Introduction
During the SARS pandemic, the etiologic agent was rapidly identified and studied, in
part due to its robust growth in cell culture (29, 30, 53). Although viruses similar to SARS-
CoV were isolated from civets and raccoon dogs in the wet markets of Guangdong province
(21, 25, 62), the epidemic likely originated from strains circulating in bats (33, 37, 46).
Surprisingly, subsequent studies demonstrated that Bat-SCoVs cluster in both major
mammalian CoV taxonomic groups (12, 56), suggesting that these animal strains may be
progenitors to the four major pathogenic human CoVs. While robust sequence information is
available, no Bat-SCoV has been successfully cultivated in vitro or in vivo (12, 56). Bats are
predicted to function as general reservoirs for emerging human and animal CoVs (37, 46),
thus providing a rationale for developing key methodologies to reconstruct and study
zoonotic strains.
Reverse genetic systems have been established for a number of viruses, including
CoVs, facilitating the study of viral replication, virus-host interaction, pathogenesis and
virulence. We previously developed plasmid cassette-based reverse genetics systems to
genetically manipulate transmissible gastroenteritis virus (TGEV), a group 1 CoV (69),
murine hepatitis virus (MHV), a group 2a CoV (71), and SARS-CoV, a group 2b CoV (70).
Engineered type IIs restriction sites allow for the seamless ligation of 6-7 cDNA fragments
into full-length genomic cDNA from which recombinant viruses can be readily isolated (69,
71, 72). These systems have been used to define functions of individual viral proteins, test
temperature-sensitive and other viral mutants, and assess determinants of virulence in
animals.
In this study, we combine phylogenetics, large-scale cDNA synthesis, and reverse
genetics to reconstruct viruses with a consensus Bat-SCoV RNA genome. As these viruses
were capable of efficient replication, but not spread, we then paired structural modeling and
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chimeric gene design to recover a chimeric Bat-SCoV that contained the Spike glycoprotein
receptor-binding domain (RBD) from human epidemic SARS-CoV. The Bat-SRBD chimeric
virus grew indistinguishably from SARS-CoV in cultured cells, but did not replicate well in
young or senescent mice.
3.2 Methods used to computationally design the Bat SARS-CoV clone
Determining the Consensus Sequence For Synthetic Bat SARS-CoV.  Bat SARS-
CoVs isolated from nature have been sequenced, but the virus has not been made available to
the scientific research community.  To circumvent this limitation, we utilized synthetic
biology to reconstruct the 3’ end of the Bat SARS-CoV genome and then the entire genome
itself, based upon a consensus sequence of the published Bat SARS-CoV available in
GenBank.
First, the 3’end of the Bat SARS-CoV was designed so that it could be incorporated
into the SARS-CoV (Urbani) infectious clone such that the non-structural genes would be
entirely comprised of the Urbani genomic sequence and the structural and accessory ORFs
would be entirely from the Bat SARS-CoV genome.  At the time this study was initiated,
only four full-length Bat SARS-CoV sequences were available, including: HKU3-1, HKU3-
2, HKU3-3, and RP3 (accession no.s).  These sequences were downloaded and aligned using
ClustalXv1.83.  The three HKU sequences shared 99.936% sequence identity (19 changes
between all three), while the RP3 sequence had only 89.7% identity with the HKU
sequences.  SARS-CoV Urbani shared 88.3% sequence identity with the HKU viruses, and
92.7% identity with RP3.  These analyses indicated that the three HKU viruses were the most
appropriate for determining a consensus sequence for the 3’end.  Only seven differences
were noted between the HKU sequences in the 3’end of the genome (Table 2).
215
Table 2: Differences between the 3’ end of the HKU Bat SARS-CoV sequences.  Seven
sites differed between HKU3-1, HKU3-2 and HKU3-3 sequences from the beginning of the
spike gene through the end of the genome.  The nucleotides at these positions in Urbani and
RP3 were also used to determine consensus at each position.  Gray boxes mark the consensus
residue for each column.  Numbering is based upon the HKU3-1 sequence.
Since the 3’ end of CoV genomes encode overlapping ORFs, the nucleotides at these
positions in RP3 and Urbani were also included for determining consensus.  In all cases, a
minimum of 3-out-of-5 nucleotides agreed at each position and the dominant nucleotide was
selected as the consensus residue.To determine the consensus sequence for the 5’ end of the
Bat SARS-CoV genome, we employed a more rigorous strategy (Fig. 8). In all cases, two of
the three HKU sequences agreed at each position.  Therefore, consensus was determined by
simple majority (the nucleotide represented twice was selected) for nucleotide differences
that would result in a synonymous amino acid replacement.  If the variation would result in a
non-synonymous change, the nucleotide at the same position in RP3 was included in the
analysis, and if this resulted in a tie, the nucleotide at the same position in Urbani was
included.  The predominant nucleotide at each position was selected as the consensus residue
(Fig. 8).
Conceptual Design of the SARS-CoV/Bat SARS-CoV Chimera.  A full-length
infectious clone of SARS-CoV Urbani has been developed (70) whereby the entire
2
3
0
1
8
2
3
4
2
2
2
3
4
2
7
2
4
9
3
2
2
7
2
7
5
2
8
2
0
7
2
8
9
8
6
HKU3-1 C C C A A A T
HKU3-3 C C C A A A T
HKU3-2 T T T C G G C
RP3 T C T C A G C
Urbani T C T C A G C
Consensus T C T C A G C
216
genome of Urbani was divided into six fragments named SARS-A through SARS-F. The 3’
end of the Bat SARS-CoV was designed to ligate directly into that infectious clone (Fig. 9).
Figure 8: Determining Consensus between the Bat SARS-CoV sequences.  Nineteen sites
differed between the HKU3-1, HKU3-2 and HKU3-3 sequences, and 12 of these fell within
the 5’ end of the genome, which encodes the non-structural genes.  Changes resulting in non-
synonymous amino acid replacements were further evaluated using the Bat SARS-CoV RP3
and SARS-CoV Urbani sequences to more rigorously determine which nucleotide was best
for consensus.
In icSARS, an unique AflII restriction endonuclease site occurs beginning at position 2450 of
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the SARS-E fragment, which is 114 nucleotides upstream of the initiating methionine for the
spike gene. This AflII site was engineered onto the 5’ end of the Bat SARS-CoV consensus
sequence encoding the structural and accessory ORFs, along with the 114 nucleotides from
Urbani, which were kept to ensure the entire non-structural gene-1 was from Urbani (Fig. 9).
Figure 9: Designing the Urbani/Bat Chimeras and the full-length BATicSARS clone.  A.
The 3’end of the Bat SARS-CoV comprised of all of the structural and accessory ORFs was
divided into two fragments called Bat-E2 and Bat-F, and a unique BglI site was engineered
into each fragment using the icSARS fragments as a template.  A 114 nucleotide linker
region identical to the Urbani nucleotide sequence was added at the 5’end of the Bat-E2
fragment, to incorporate an unique AflII site.  This was designed so that the SARS-E and
Bat-E2 fragments could be digested with AflII and ligated such that the gene1 would be
strictly Urbani and genes 2-9 would be Bat SARS-CoV.  However, the linker region is
strictly conserved at the amino acid level, indicating that nsp16 function would not be
altered.  B.  The BATicSARS clone was designed using the icSARS clone as a template.
BglI sites were engineered into the sequence to match those of icSARS, allowing for
swapping of different fragments. The constructs include: icSARS, the Urbani infectious
clone; Urbani/Bat 3’end, Urbani non-structural gene1 and Bat SARS-CoV structural and
accessory ORFs (genes 2-9); Urbani/Bat F, Urbani gene1 and part of gene 2 including the
RBD and Bat SARS-CoV from the 3’end of gene2 through gene 9; and BATicSARS, the Bat
SARS-CoV clone.
A
B
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This 114 Bat SARS/Urbani linker region is over 90% identical between Urbani and the Bat
sequences (11 differences out of 114 nucleotides) at the nucleotide level, and is strictly
conserved (100% identity) at the amino acid level (Table 3).  The 3’ end of the Bat SARS-
CoV sequence was then divided into two regions based upon the icSARS cloning strategy
such that a unique BglI site was engineered to correspond with the icSARS clone.  This
resulted in two BATicSARS fragments, named Bat-E2 and Bat-F, which were completely
compatible with the icSARS clone of Urbani.  Bat-E2 and Bat-F together comprise the entire
3’end of Bat SARS-CoV (with the linker), and Bat-F independently includes the spike gene
down stream of the receptor binding domain and all of the other structural and accessory
ORFs (Fig. 9).
Table 3: A comparison of the differences between the Bat SARS-CoV sequences,
Urbani and BaticSARS.  This table outlines the strategy used to design the full length
BATicSARS clone.  Consensus positions are noted, with only bases used to determine
consensus shown.  Engineered sites are also shown, with the corresponding alteration noted
at the top.  Nucleotide position numbering is based upon the BATicSARS clone sequence,
which includes 23 additional nucleotides at the 5’end and 47 additional bases at the 3’end as
compared to HKU3-1.  The Urbani/Bat linker region is highlighted in black.  The linker is
identical at the amino acid level between Urbani and HKU3-1, and 92% identical at the
nucleotide level.  Synonymous versus nonsynonymous amino acids are noted to show that at
some positions there was heterogeneity in the peptide sequence between viral sequences.  In
these cases, RP3 and if necessary Urbani sequences were used to provide further support for
consensus.  Type of change: s, synonymous; n, nonsynonymous.
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In addition, several unique restriction endonuclease sites were engineered into the Bat-E2
fragment to allow for easy removal and replacement of alternate receptor binding domains.
Silent nucleotide changes were made that either added unique sites or ablated sites such that
only unique sites remained (Table 3).
Conceptual design of the full-length BATicSARS infectious clone.  The full-length
infectious clone of SARS-CoV Urbani was used as a template for designing the Bat SARS-
CoV clone.  The consensus Bat SARS-CoV sequence was aligned with each of the fragments
of the icSARS clone and corresponding BglI sites were designed such that all fragments of
the Bat SARS-CoV were compatible with the icSARS clone.
Synonymous changes were made to incorporate the BglI sites necessary for junctions
between the Bat-A:Bat-B, Bat-B:Bat-C, Bat-C:Bat-D, and Bat-D:Bat-E1.  At the 5’end of the
Bat SARS-CoV genomes there was not consensus among the HKU sequences.  In fact, two
of the three sequences were provided with missing information at this site.  The HKU3-1
sequence was the most complete, but it differed from the SARS Urbani sequence.  Since the
icSARS clone was the most reliable source of sequence information, we utilized the 5’ most
region of the icSARS to incorporate the T7 promoter site onto the 5’end of the Bat-A
fragment.
Molecular phylogenetics of the Bat SARS-CoV spike protein.  The spike protein
sequences of 36 SARS-CoV viruses representing the early, middle, and late phases of the
human epidemic, as well as representative viruses isolated from Palm Civets and Racoon
Dogs were aligned along with the four Bat SARS-CoV spike sequences using the program
ClustalXv1.83.  The alignment was analyzed and exported in the nexus format, and a
phylogenetic tree was generated using the program MrBayesv3.2.  Briefly, the amino acid
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substitution model was set to Dayhoff using the lset command, and Markov chain Monte
Carlo simulation was used to approximate the posterior probabilities of trees with sampling
conducted on four chains over 500,000 generations. Trees were sampled every 100
generations, and the 5001 trees collected were summarized with the sumt command set to a
burnin of 1000, which generated a consensus tree using the 50% majority rule.  The burnin
value was determined using the sump command with an arbitrary burnin of 250 which,
demonstrated that stationarity occurred prior to the 100,000th generation, indicating that a
burnin of 1000 was appropriate for the sumt command.  The tree was visualized using the
program TreeView.
Cells and viruses. VeroE6 (African green monkey kidney, hereafter Vero) cells were
maintained in minimal essential medium (Invitrogen) containing 10% fetal calf serum,
penicillin (100 U/ml) and streptomycin (100 μg/ml), and amphotericin B (0.25μg/ml). DBT
(delayed brain tumor, murine astrocytoma) cells were maintained in Dulbecco’s minimal
essential medium (Invitrogen) supplemented with 10% fetal calf serum, 10 mM Hepes,
penicillin (100 U/ml) and streptomycin (100 μg/ml), and amphotericin B (0.25μg/ml). DBT
cells stably transected with the human or civet angiotensisn converting enzyme 2 (ACE2),
DBT-hACE2 and DBT-cACE2 cells, were cultured as DBT cells with 0.5 mg/mL G418 to
maintain selection. SARS-CoV Urbani strain (hereafter, SARS-CoV) and Bat-SCoV wild-
type and chimeric viruses were propagated and all plaque assays performed on Vero cells.
All virus work was performed in a biological safety cabinet in a biosafety level 3 laboratory
containing redundant exhaust fans; personnel were dressed in Tyvek suits, full hoods, and
powered air-purifying respirators with high-efficiency particulate air (HEPA) and organic
vapor filters and were double-gloved.
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Construction of chimeric Spike variants. Insertions of SARS-CoV sequence in
place of Bat-SCoV sequence were engineered using PCR and specific primers. PCR
amplicons for Bat-SRBD and Bat-SARS-CoV-Receptor Binding Motif (SRBM) were
generated using fragments Bat-E2, which consists of nts 21355-24000 of the consensus Bat-
SCoV sequence; and SARS-E, which consists of nts 18937-24051 of the SARS-CoV
sequence. For PCR ABCDEF primer sets, primers A and B generated an AB product,
primers C and D generated a CD product, and primers E and F generated an EF product.
Amplicons AB, CD, and EF were ligated into an ABCDEF product using the class IIs
restriction enzyme method described in (71), and ligation products were cloned into the Bat-
E2 plasmid using unique 5’-BstB I and 3’-Msc I. Successful insertions of SARS-CoV
sequence were confirmed by restriction digestion screening of individual colonies and
sequencing across the regions of PCR amplification. PCR amplicons for Bat-Hinge (Bat-
SRBM plus six additional residues from SARS-CoV Spike) were generated using Bat-SRBM
as template, and utilized a primer set AGHF strategy, where primers A and F were from the
ABCDEF strategy utilized above. Primers A and G generated an AG amplicon, and primers
H and F generated a HF amplicon. Ligation of AG and HF amplicons generated an AGHF
product, which was then cloned into the Bat-E2 as described above. Successful mutagenesis
was confirmed by restriction digestion screening of individual colonies and sequencing
across the region of PCR amplification.
Generation of SARS-CoV and Bat-SCoV mutant viruses. Viruses containing
PCR-generated insertions within the viral coding sequence were produced using the
infectious cDNA assembly strategies for MHV-A59 and SARS-CoV as previously described
(20, 57, 70) with the following modifications. Briefly, for SARS-CoV containing Bat-F,
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plasmids containing the five (A-E) cDNA cassettes of the SARS-CoV genome as well as the
sixth (F) plasmid of the Bat-SCoV genome were digested using Mlu I and Bgl I for SARS-A,
Bgl I for SARS-B through SARS-E, and Bgl I and Not I for Bat-F. For Bat-SCoV and Bat-
SRBD, -SRBM, or -Hinge, plasmids containing the seven cDNA cassettes of the Bat-SCoV
genome were digested using Bgl I forBat-A, -B, -C, and -D, Bgl I and Afl II for Bat-E1 and -
E2, and Bgl I and Not I for Bat-F. Digested, gel-purified fragments were simultaneously
ligated together in a total reaction volume of ~100 uL overnight at 16oC. Chloroform-
extracted, isopropanol-precipitated cDNA as well as PCR-generated N cDNA were used to
drive transcription of viral genomes and N transcripts and using a T7 mMessage mMachine
kit (Ambion) as previously described (20, 70).  N transcripts and mutant viral transcripts
were then mixed and electroporated into 800 μL of 1 x 107 cells/ml of Vero cells via 4 pulses
at 850 V, 50 μF using a Bio-Rad Gene Pulser Xcell electroporator. Electroporated cells were
then seeded onto a layer of 106 uninfected Vero cells in a 75 cm2 flask (or on layers of 3 x 105
Vero cells in 3 25 cm2 flasks for leader-containing transcript assay, see below) and incubated
at 37oC for 30-90 h. Virus viability was determined by cytopathic effect (cell rounding and
detachment) and progeny viruses were passaged at low MOI. RNA was recovered from
infected cell monolayers using TRIzol (Invitrogen) according to the manufacturer’s
instructions, and retention of introduced mutations was verified by RT-PCR and sequencing.
Leader-containing transcript assay for Bat-SCoV electroporated cells and mouse
lungs. At days 2 and 5 post-electroporation (p.e.), generation of leader-containing N (ORF9)
and genome (ORF1) transcripts was determined by RT-PCR. Briefly, electroporated cells
seeded into 25 cm2 flasks were harvested using TRIzol (Invitrogen) according to
manufacturer’s instructions. RNA was purified, and RT-PCR was performed. Following an
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initial denaturation at 70oC for 5 minutes, first-strand cDNAs were generated from harvested
RNA stocks using Random Hexamers (ABI) and Superscript III (Invitrogen) at an extension
temperature of 55oC for 1h. The reverse transcriptase was inactivated by heating at 70oC for
15 min, and leader-containing cDNAs were amplified by PCR using Taq with Thermopol
buffer (NEB) and the following primers: 5’- CAGGAAAAGCCAACCAACCTTG and 5’-
CGCTACGACCGAACTGAATGCC to detect Bat-SCoV ORF1; and 5’-
CAGGAAAAGCCAACCAACCTTG and 5’- GTGAGAGCTGTGAACCAAGACG to
detect ORF9. Presence or absence of PCR products was assessed by electrophoresis on a
1.5% agarose gel stained with ethidium bromide.
Growth assay. Vero, DBT, DBT-hACE2, or DBT-cACE2 cells were plated in 25
cm2 flasks. The next day cells were infected at a multiplicity of infection (MOI) of 1 or 0.01
plaque forming units (PFU)/cell in duplicate (DBT) or triplicate (all others). The inocula
were allowed to adsorb to cells for 1 h at 37°C. Inocula were removed, cells washed three
times, and then replaced with prewarmed media. Samples were obtained at 1, 4, 8, 12, 16, 20,
24, 30, 36, and 48 h post-infection (p.i.). Samples of SARS-CoV on DBT cells were taken at
1, 24, and 48 h p.i. Samples were serially diluted, and titers were determined in duplicate on
Vero cell monolayers by plaque assay.
Plaque assay.  Samples were serially diluted, inoculated onto Vero cell monolayers
in 6-well plates for 1 hour, and overlaid in complete media plus 1.0% agar. Plaques were
visualized between 48-52 h p.i. following staining with neutral red (Sigma) for 3-4h.
3.3 Phylogeny of Bat SARS-CoV
Molecular phylogenetics of the spike amino acid sequences.  The Bayesian
phylogenetic tree of 36 SARS-CoVs which included viruses from various phases of the
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human epidemic as well as SARS-CoVs from Palm Civets, Racoon Dogs, and Bats
demonstrated that the Bat SARS-CoV spike sequence is more similar to human isolates than
it is to any of the other animal sequences (Fig. 10).  This implies that the route of
transmission during the human epidemic may have been from bat to human and then to
Civet, in contrast to reports in the literature.  Interestingly, isolate GD03, which is a human
isolate that clusters with the Civet/Racoon Dog sequences, may represent a rare
Civet/Racoon Dog to human transmission.
Figure 10: Bayesian Inference of the Spike amino acid sequence of representative SARS
viruses. The spike protein sequences of 36 SARS-CoV viruses representing the early,
middle, and late phases of the human epidemic, as well as representative SARS-CoVs
isolated from Palm Civets, Racoon Dogs and Bats were aligned and analyzed using
MrBayes.  The tree, rooted with the bat sequences, suggests that the Bat SARS-CoV is more
closely related to the human SARS-CoV strains than those isolated from Civet or Racoon
Dogs.  This implies that the emergence of SARS-CoV may have occurred by Bat-to-Human
transmissions, and that Civets and Racoon Dogs may have been subsequently infected by
humans.  The GD03 human outlier case may be an isolated case of a Civet (or Racoon Dog)-
to-Human transmission.  Node confidences are shown as posterior probabilities.
3.4 Rescuing recombinant BATicSARS viruses
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Viable recombinant BATicSARS virus requires Urbani RBD.  In collaboration
with the Denison Lab at Vanderbilt, the BATicSARS clone was assembled, transcribed,
transfected into competent Vero E6 cells, and viable recombinant virus was rescued.  Initial
experiments showed that while replication of the BATicSARS recombinant virus occurred,
there was no CPE detected, and the virus did not spread to other cells in the culture.
However, when the Urbani receptor binding domain was placed into the BATicSARS
backbone, this chimeric virus was viable and readily spread in culture to neighboring cells,
substantiating our hypothesis that the Bat SARS-CoV spike is not adapted to the Vero ACE2
receptor (See Chapter VII).
Generation of consensus Bat-SCoV sequence. To generate a functional reagent to
study the evolution of coronaviruses, we compared reported Bat-SCoV sequences. When this
study was initiated, four Bat-SCoVs had been identified, HKU3-1, HKU3-2, HKU3-3, and
RP3, which constituted the hypothetical reservoir from which SARS-CoV emerged (33, 36,
47, 56, 64-66).  Comparing SARS-CoV and the four Bat-SCoV strains, we devised a
consensus Bat-SCoV sequence and then designed fragments with junctions that aligned
precisely with the existing SARS-CoV reverse genetics system (70) (Fig. 9). These fragments
were synthesized by Blue Heron Biotechnology, Inc. and inserted into compatible vectors.
Reverse genetic construction and recovery of virus. Initial attempts to recover
virus from assembled Bat-SCoV cDNA yielded evidence of genome and leader-
containing subgenomic transcripts on day 2, but not 5, p.e. (Fig. 11), but progeny virions
could not be successfully passaged onto new cultures. However, we successfully recovered
infectious virus consisting of fragments SARS-A through SARS-E and Bat-F (data not
shown).
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Figure 11: Presence of genomic and subgenomic transcripts following electroporation of
in vitro transcribed viral RNA. Cells electroporated with the viruses indicated were
collected on day 2 or 5 following electroporation. RNA was extracted, treated with DNase,
amplified by RT-PCR with genomic (ORF1) or subgenomic transcript (ORF9) specific
primers, then subjected to agarose gel electrophoresis. Band corresponding to ORF1
indicates the presence of genomic RNA, either electroporated genomic RNA or progeny
genomic RNA, and the presence of a band corresponding to ORF9 indicates the presence of
leader-containing subgenomic RNA, indicative of viral transcription.
This virus, Bat-F, encodes a chimeric Spike, with the amino-terminal two-thirds, including
the RBD, originating from SARS-CoV, and the carboxy-terminal third originating from Bat-
SCoV.  These results indicate that the chimeric SARS/Bat-SCoV Spike and downstream Bat-
SCoV ORFs are sufficient, but not whether there are critical regions in SARS-A through -E
necessary for viral replication and propagation in Vero cells. To thoroughly test this, we
replaced the Bat-SCoV Spike RBD (aa 323-505) with the RBD (aa 319-518) (6, 8, 36) of
SARS-CoV (See Chapter VII for the structural analysis).
Following electroporation of the Bat/SARS-CoV RBD chimera (Bat-SRBD), genome
and leader-containing subgenomic transcripts were detected, and progeny virions were
successfully passaged to fresh cultures (Fig. 11).  Following two additional passages in Vero
cells, the nucleotide sequence of the entire viral genome was determined and no changes
from the synthesized or engineered fragments were noted, although four nts (none within the
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RBD) exhibited a dual peak on the electropherograms suggesting quasispecies variation or
selection for adaptive mutations at these positions.
The crystal structure of SARS-CoV RBD complexed with its receptor, hACE2 (37)
implicated 13 residues within carboxy-terminus of the RBD (aa 426R-518D) likely essential
for ACE2 engagement.
Figure 12. Growth of SARS-CoV and bat-SRBD in three different cell types.  A) Vero
cells, B) DBT-hACE2 cells, or C) DBT-cACE2 cells were infected with SARS-CoV at an
MOI=1 () or MOI=0.01 ( ) or bat-SRBD at an MOI=1 ( ) or an MOI=0.01 ().
Infected cultures were sampled, in triplicate, at the times indicated and viral titer was
quantified by plaque assay on Vero cells. Error bars indicate standard deviation.
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Homology modeling indicated that this receptor-binding motif (RBM) from SARS-CoV may
be sufficient to allow ACE2 engagement in the Bat spike background (See Chapter VII), and
chimeric Bat-SCoV genomes were constructed containing the RBM (Bat-SRBM).  However,
electroporation yielded genome and subgenomic leader-containing transcripts at day 2, but
not 5, p.e. (Fig. 11), and progeny virions could not be successfully passaged onto new
cultures.
Viral growth and replication in vitro: To compare growth of SARS-CoV and Bat
SRBD, Vero, DBT, DBT-hACE2 and DBT-cACE2 cells (55), were infected with Bat-SRBD
or SARS-CoV at an MOI of 0.01 or 1, and titers at various times were determined by plaque
assay on Vero cells (Fig. 12). In all cell types, growth of Bat-SRBD and SARS-CoV was
indistinguishable.  DBT-hACE2 and DBT-cACE2, but not DBT, cells supported infection of
SARS-CoV and Bat-SRBD (data not shown). These data indicate that SARS-CoV and Bat-
SRBD are capable of entering cells using ACE2 from humans, nonhuman primates, or civets
as receptor and that once entry is achieved, multiple cell lines are capable of supporting
productive CoV infection.
Enhanced replication of Bat-SRBD virus including mouse-adapted Spike
substitution.  We next assessed replication and pathogenesis of Bat-SRBD in vivo. SARS-
CoV replicates in mouse lungs, but causes little reproducible morbidity (49, 50). However,
replication and pathogenesis are enhanced in infections of BALB/c mice with MA15, a
mouse-adapted SARS-CoV (49), containing six amino acid substitutions, including one
(Y436H) in the SARS-CoV RBD.  Modeling predicts that this mutation enhances RBD-
mACE2 receptor engagement (See Chapter VII), although SARS-CoV and MA15 both
replicate efficiently in mouse lungs.
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To test the hypothesis that Y436H enhances interaction with mACE2, Bat-SRBD was
constructed with this substitution (Bat-SRBD-MA).  As with Bat-SRBD, electroporation with
Bat-SRBD-MA RNA resulted in production of infectious virus with titers similar to Bat-
SRBD (data not shown). Next, 14-month-old BALB/c mice were infected with Bat-SRBD,
Bat-SRBD-MA, or SARS-CoV.  Mice were weighed and monitored for morbidity daily, and
on days 2 and 4 p.i., mice were euthanized and lungs harvested (Fig. 13).  Mice did not
exhibit significant weight loss or morbidity following infection.  However, while Bat-SRBD
replicated to low titers in infected lungs, Bat-SRBD-MA replicated more significantly more
efficiently (p<.005 at day 2, Student’s T-test) (Fig. 13).
Fig. 13.  Weight loss and viral replication of Bat-SRBD, Bat-SRBD-MA, and SARS-
CoV Urbani in aged BALB/c mice.  Ten 14-month-old female BALB/c mice were infected
intra-nasally with 10
5
 PFU of the indicated virus or an equivalent volume (50 ml) of PBS. On
days 2 and 4 post-infection, 5 mice per group were euthanized and lungs were harvested.
Lung homogenates were titered on Vero-E6 monolayers.  Circles represent titers of
individual mouse lungs.  Bars represent the average titer of each infection group.
0
1
2
3
4
5
6
7
8
9
B
a
t-
S
R
B
D
B
a
t-
S
R
B
D
-
M
A
U
r
b
a
n
i
B
a
t-
S
R
B
D
B
a
t-
S
R
B
D
-
M
A
U
r
b
a
n
i
Day 2 Day 4
T
it
e
r
 
(
L
o
g
1
0
P
F
U
/g
)
230
Replication of Bat-SRBD-MA was also significantly enhanced compared to SARS-
CoV (p<.001 at day 2, Student’s T-test). Bat-SRBD-MA plaques closely resembled SARS-
CoV in size and definition, but Bat-SRBD plaques were intermediate in size with ill-defined
boundaries (not shown), providing support for the hypothesis that the Y436H substitution in
Bat-SRBD-MA may improve mACE2 receptor engagement.
3.5 Discussion of the Bat-SCoV
Reverse genetic systems have revolutionized our understanding of the molecular basis
of virus-host interactions, viral replication, assembly, pathogenesis and vaccine design.
While powerful, extreme applications, such as the emergence of new pathogenic viruses, are
restricted due to technical limitations involved in constructing molecular clones, introducing
single and sequential mutations, and characterizing and testing recombinant viruses and
vaccines.  Consequently, rapid advances in sampling environmental microorganisms,
analysis, synthesis, and reverse genetic systems represent a confluence of techniques that
provide a paradigm shift in public health intervention strategies and promote rapid responses
to natural or deliberately initiated outbreaks of emerging pathogens.  Previous work has
fostered incremental steps toward the goal of synthetic reconstruction of large microbial
genomes.  The 7.5- and 5.6-kb genomes of poliovirus and X174, respectively, were
reconstructed from known infectious sequences using commercially synthesized cDNA
fragments and PCR assembly (5, 58).  Sequences of ancient human endogenous retroviruses
were assembled by PCR-directed assembly of a battery of synthetic oligonucleotides into a
consensus proviral sequence (1). Finally, approaches for full-scale commercial synthesis,
assembly and cloning of the 580-kb microbial genome of Mycoplasma genitalium have been
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reported using transformation-associated recombination of fragments ligated from synthetic
oligonucleotides, though this has not yet yielded a replicating organism (19).
Our approach to systematically assemble large DNA genomes using recursive ligation
of class IIs restriction sites accommodates theoretical genome sizes exceeding several million
base pairs (69-71).  Using these techniques and employing a rational design strategy, we have
compiled a functional consensus sequence from Bat-SCoVs and have synthetically recovered
a member of the largest and most complex RNA virus family in nature.  Additionally, we
have used this strategy to alter receptor specificity, unearth additional information about
virulence determinants, define residues important for viral adaptation and growth in animals,
and identify therapeutic windows that will help control zoonotic viruses emerging by
mutation, recombination, or deliberate design.
Bat-SCoV was capable of efficient replication, as evidenced by subgenomic
transcription, but progeny virions were not successfully amplified, likely due to a defect in
docking or entry.  Bat-SRBD, however, efficiently recognized human, primate and civet
receptors, demonstrating that the RBDs of related bat and human CoVs are interchangeable
and confer growth in different cell types.  These findings confirm and extend a previous
report (48).  Not surprisingly, our experiments fall under the category of “experiments of
concern” as described by the Fink Report(14), as we have identified and refined an approach
that could be used to alter the host range of an animal coronavirus. Since even minor
instances of recombination- and mutation-driven evolution are known to rapidly alter the
population structure of the Coronaviridae, and thus promote emergence (41, 51, 55), these
results provide the first opportunity to address whether existing therapeutics and vaccines
will work against newly emerged or deliberately designed CoVs.  As recommended,
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experimental oversight was approved by institutional biosafety committees at Vanderbilt
University and UNC-Chapel Hill, and all experiments were conducted under proper BSL3
conditions.
Human mAbs show great promise in the treatment of human diseases.  We have
identified several hmAbs that bind distinct, conserved locations in the Spike RBD and
neutralize infectivity of SARS-CoV strains that originate from civets, raccoon dogs or human
hosts (55) providing a panel of broad spectrum therapeutics.  Previous studies have shown
that the ectodomains of CoV Spike are interchangeable and alter host range specificity (22,
31).  In this manuscript, we demonstrate that the RBD is the major regulator of host range
and that hmAbs targeting SARS-CoV RBD sequence motifs efficiently neutralize Bat-SRBD
(data not shown).  Our data suggest that these hmAbs may provide robust protection against
other CoVs that emerge either by natural recombination or deliberate design.
However, since mutation-driven evolution rapidly selects for host range variants of
CoVs, (3, 24, 55), we must develop other novel high-throughput approaches to rapidly
respond to emerging pathogens.  Several groups have used computer simulations to
successfully remodel protein structures or the interface between two interacting proteins (73,
74), allowing for informed selection of mutations predicted to modify host range through
alterations in virus-receptor interactions.  Our studies indicate that the SARS-CoV RBM
could not function properly in the context of the Bat-SCoV Spike.  Molecular dynamic
modeling of the RBM/hACE2 interaction predicted the presence of a 6-aa motif that
functions as a putative molecular hinge, but is sterically “frozen”; substitution of the
corresponding SARS-CoV residues might allow Spike to shift into a tighter interaction with
hACE2 following initial binding (for details see Chapter VII).  Direct testing of this model
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did not yield infectious virus (Bat-Hinge), reinforcing the difficulty of predicting interactions
of fluid proteins when structural data represents a single, stable conformation.  Clearly,
modeling the range of interactions necessary for a virus to enter a cell, many of which may
be subtle or involve multiple protein domains, remains in its infancy.  Even so, coupling
empirical data from viruses carrying Spike variants with known structural ACE2/RBD
interaction data will comprise a vigorous model system to probe the role of specific
alterations that allow for subtle short- or long-range interactions and can drive efficient
docking and entry.
To protect against future emergent pathogenic virus strains, developing animal
models to test therapeutics with broad-spectrum activity is crucial.  In this instance, Bat-
SRBD replicated efficiently in HAE cultures, providing a robust human airway model to
evaluate existing drugs that target proteases, replicase enzymes and other enzymatic
machinery.  However, Bat-SRBD replicated poorly in vivo, calling for additional design
modifications to facilitate studies in mouse models.  Fortunately, robust structural
information exists on the RBD-ACE2 interaction (38), mutations affecting this interaction
have been identified (52, 55), and Rosetta-modeling of short range RBD-mACE2 receptor
interfaces can identify key residues essential for retargeting the host specificity of Bat-SRBD
(36, 38) (See Chapter VII for details).  Previous studies identified a mutation in the RBD of
the MA15 strain, Y436H, but its exact role in vivo was not clear (49).  Using structural
modeling algorithms, we predicted that the Y436H mutation would enhance the interaction
of Bat-SRBD with mACE2, facilitating binding of key residues (details provided in Chapter
VII).  Our hypothesis was supported when Bat-SRBD-MA grew to substantially higher titer
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in aged mice than Bat-SRBD.  These data provide the foundation for further experiments to
confirm that the Y436H mutation enhances mACE2 binding and entry.
Successful recovery of these viruses demonstrates the utility of rational design paired
with our powerful reverse genetics system in that sequence and structural information was
integrated to recover a zoonotic precursor virus that: a) could not be cultivated from field
samples; b) exhibited cross-reactivity with previously identified therapeutics; and c)
demonstrated the potential ease of CoV host-range adaptation.  This information will be
foundational to building a platform in which essential viral components are left intact and
those involved in virulence and adaptation are remodeled for stable attenuation of
pathogenesis, facilitating the construction of a multivalent vaccine comprised of viruses
bearing different Spike or other immunogenic epitopes.  Paired with the greater availability
of reagents and therapeutics, this will allow an enhanced rapid response to newly emerging
coronavirus diseases.
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CHAPTER VII:  CORONAVIRUS STRUCTURAL STUDIES
ABSTRACT
In this chapter, several smaller structural projects are highlighted.  For the most part
these are not complete stories, but structural studies were used to model hypotheses that were
subsequently tested utilizing a reverse genetics approach to study the effect mutation had on
structure and function.  The chapter is divided into eight sections, the first of which is a
general introduction, followed by a section for each study.  In sections 2-4, non-structural
protein projects are discussed, and in the later sections 5-8 spike structural studies are
discussed.  In all cases, theoretical models were generated by homology modeling or by the
use of Rosetta Design, and these models were used to discuss hypotheses about what effects
the mutations played on the structure.  Several of these observations have been published as
parts of larger manuscripts and are listed below.
1. INTRODUCTION
The core functional coronavirus genome contains five conserved open reading frames
that encode a replicase polyprotein (Orf1a/b), the spike glycoprotein (S), a small envelope
protein (E), the membrane protein (M), and the nucleocapsid protein (N), which is tightly
associated with the viral RNA(18, 25).  These genes are conserved in this order from the 5’
end, although there may be additional accessory genes that occur between them in the
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different phylogenetic groups(18, 25).  In general, the replicase polyprotein is the most
conserved region among the CoVs, and this polyprotein is processed by two viral encoded
proteases, PLP1/PLP2 (nsp3) and Mpro (nsp5) into the 15 non-structural proteins that form
the replication complexes in the cell(18, 25).
2. MHV REPLICASE PROTEIN NSP5 STRUCTURAL STUDIES
Submitted to Journal of Virology: Identification of a Novel Mutation in Murine Hepatitis
Virus nsp5 that Causes Temperature-Sensitive Defects in Viral Growth and Protein
Processing.  Jennifer S. Sparks, Eric F. Donaldson, Xiaotao Lu, Ralph S. Baric, and Mark R.
Denison
2.1 Introduction
Nsp5 (Mpro) cleaves all proteins beyond nsp4, with pp1ab being cleaved at 11
conserved sites following sequences (Table 1), including the autoproteolytic cleavage of
itself (Mpro) from the nascent polyprotein(12, 23, 24, 28, 35).   It has been demonstrated that
continuous translation and processing of the replicase polyprotein(s) is essential for RNA
synthesis during MHV replication(32).  However, it is currently unclear as to processing
order, and to what extent intermediates containing several of the unprocessed proteins
participate in cleavage and/or replication complex formation and activity.
 Protein Amino acid sequence of indicated cleavage site
P5 P4 P3 P2 P1 P1' P2' P3' P4' P5'
nsp6-nsp7 V S Q I Q S R L T D
nsp7-nsp8 L Q A L Q S E F V N
nsp8-nsp9 T V V L Q N N E L M
nsp9-nsp10 T V R L Q A G T A T
nsp10-nsp11 G S Q F Q S K D T N
Table 1: Mpro cleavage sites.  Cleavage sites for cleaving nsp6-11.  Cleavage occurs
between P1 and P1’, just after a conserved Gln (11).
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The X-ray crystal structure of the SARS-CoV Mpro has been solved by multiple
groups, under multiple conditions (2, 38, 41, 43), and it has been reported to form a
homodimer both in the crystal and in solution (3, 44), although it has been described to
function as both a homodimer and to a lesser extent as a monomer (7, 9).  The Mpro
protomer can be divided into three domains (44), of which domains I (residues 1-99) and
domains II (residues 100-183) resemble chymotrypsin, while domain III (residues 184-302)
is a comprised of five anti-parallel -helices (2, 14) (Figure 1A).  The catalytic dyad has
been identified as amino acids His41 and Cys145 (44), and the substrate-binding pocket has
been mapped to a cleft between domains I and II (Figure 1A,B).  An YMH motif from
positions 161-163 has been identified as the substrate-binding region (44).
The MHV and SARS-CoV Mpro amino acid sequences share 50% sequence identity,
and in CoV Mpro sequences from all three groups the His41 and Cys145 are strictly
conserved, as well as the Tyr-Met-His motif that comprises the core of the active site cavity
where the protease binds its substrate.   Mutating either residue of the catalytic dyad
completely abolished the proteolytic activity of Mpro.
Many temperature-sensitive (TS) mutations have been identified, and a few of these
have been predicted by complementation studies to fall within in the replicase proteins of
MHV (36).  In this study, we set out to characterize a TS virus, known as Alb ts6, which was
reported to contain a single nucleotide mutation in nsp4 (A4949C, Asn258Thr) that resulted
in a TS phenotype (32).  However, upon sequencing the provided TS Alb ts6 virus, the
originally identified mutation in nsp4 was not present.  Rather, a mutation was identified in
the Mpro (T10651C, Val148Ala).  The different genotypes of Alb ts6 and the newly
identified TS mutant designated Albts6-6189 (named after the label on the tube that read: Alb
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ts6 6-1-89) demonstrate that the preparation contained two different potential TS alleles,
which represent two different lineages, and likely have two different TS defects.
The new TS mutation (in nsp5: T10651C, Val148Ala) was introduced into the MHV
infectious clone and resulted in recovery of a virus that displayed a TS phenotype.  Further,
this TS virus demonstrated reduced Mpro activity at the non-permissive temperature.
Passing the newly identified TS virus resulted in second-site mutations within nsp5, which
when introduced into the background of the Mpro TS virus, compensated for growth and
protein processing at the non-permissive temperature.  Modeling of the MHV wild type, TS,
and second-site revertant Mpros suggests that Val148 is critical for stabilization of the
substrate-binding residue Met162, and that the second-site revertant viruses are capable of
partially compensating for the destabilization of Mpro resulting from the Val148Ala
mutation.  These results demonstrate the identification of a novel mutation in MHV Mpro
that confers a TS phenotype and reduces Mpro processing at the non-permissive temperature.
2.2 Methods
Computer modeling of MHV Mpro, Albts6-6189, and the two second site
revertants.  The crystal structure coordinates of SARS Mpro (PDB code 2H2Z, chain A,
(42)) were used as a template to generate a homology model of the MHV Mpro using the
online program 3DJigsaw in the automatic mode (4, 5, 10).  The Root Mean Square Distance
between the template and the model was determined to be 0.708 Angstroms, using the
molecular modeling tool Chimera (27).
The MHV Mpro model was then used as a template for introducing the TS genotype
of Albts6-6189 as well as the genotypes of each of the second site revertant mutants using the
Rosetta Design web server (http://rosettadesign.med.unc.edu/ (15, 17, 22).  In each case, the
246
MHV Mpro model was analyzed using the molecular modeling tool, MacPyMol (DeLano
Scientific), to determine which amino acids were proximal to the amino acid(s) being
targeted for replacement.
Figure 1: Structural model of wild type MHV nsp5.  A homology model of MHV nsp5
was generated with the program 3D-Jigsaw using the crystal structure of the SARS-CoV
nsp5 as a template.  A) The MHV nsp5 model contains three domains shown as: Domain I,
red; Domain II, blue; and Domain III, green.  The substrate-binding region is shown in
orange, with the catalytic dyad shown in purple. Other critical residues in the substrate cavity
are shown in cyan.  Resides that compensated for the TS phenotype are shown in pink.  B)
Expanded view of the putative active site cavity of this structural model shows that the
catalytic dyad consists of His41 and Cys145, which are highlighted in purple.  Critical
substrate-binding residues Tyr161, Met162, and His163, orange.  Additional important
substrate cavity residues His172 and Tyr182, cyan. TS residue, Val148, yellow.  Revertant
sites Ser133 and His134, pink.
Briefly, each amino acid to be altered was highlighted and all other amino acids
within an interaction distance of 5 angstroms were identified.  Using the Rosetta Design
website, the amino acid replacements were incorporated and all amino acids within the 5
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angstrom interaction distance were relaxed to allow the program to repack the side chains to
an optimal energetic state.  This process was repeated with each mutation and series of
mutations.  Ten models were generated for each set of mutations, and the best model, based
on lowest energy score, was selected and further evaluated using Mac Pymol.
In addition, an online version of the program WHAT_IF was used to identify the
optimal hydrogen bonding networks for the MHV Mpro model, Albts6-6189, and the two
revertant mutants.
2.3 Results
Generation and Comparison of Computational Models.  A structural model of the
MHV Mpro was generated based on the crystal structure coordinates of the SARS-CoV
Mpro (PDB code 2H2Z, (42)) and analyzed for differences.  In general, the two structures
were similar (RMSD of 0.7Å), even though they share only 50% sequence identity (44).
Rosetta Design was used to model the Albts6-6189 genotype by introducing the Val148Ala
substitution into the MHV Mpro template and relaxing the constraints to allow repacking of
all side chains within a 5Å interaction distance.   The resulting Albts6-6189 model was
superimposed upon the Mpro model, and two changes were observed.  In the MHV model,
Val148 interacts with Met162 (Figure 2A) by hydrophobic interactions (3.9Å), however this
interaction was ablated by the replacement of Val with Ala (Figure 2B).  This resulted in a
rotameric shift in Met162 (Figure 2B).  A second change in rotameric position of Val157 was
also noted (Figure 2A and 2B), suggesting that interruption of the hydrophobic interaction
network resulted in subtle changes to the structure.
Superimposing the revertant mutant models upon the Albts6-6189 template revealed
that each mutation resulted in local remodeling near the replaced amino acid (Fig. 2C, D).
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Figure 2: Modeling MHV-nsp5, Albts6-6189-nsp5, V148A/S133N-nsp5, and
V148A/H134Y-nsp5.  A homology model of the MHV nsp5 protein was generated using the
coordinates of the x-ray crystal structure of SARS-CoV (PDB accession number 2H2Z) using
the program 3D-Jigsaw.  Rosetta Design was used to model the remaining mutations. A)
Model of the substrate-binding pocket of MHV nsp5. Domain II residues are shown as a
ribbon diagram in blue.  Residues 40-42 of nsp5 Domain I are shown as His41.  The catalytic
dyad, consisting of His41 and Cys145, is shown in red.  The substrate-binding site, consisting
of Tyr161, Met162, and His163, is shown in orange.  Val148 is highlighted in yellow.  B)
Model of the substrate-binding pocket of Albts6-6189-nsp5.  The substrate-binding site,
consisting of Tyr161, Met162, and His163, is shown in purple.  Ala148 is highlighted in
yellow.  C) Model of the substrate-binding pocket of S133N/V148A-nsp5.  Domain II
backbone residues of nsp5 V148A are shown in green, the catalytic dyad in red, and the
substrate-binding motif in orange.  Changes between nsp5 V148A and S133N/V1438A-nsp5
are shown in purple.  A148 and S133 is shown in yellow and N133 is shown in purple.  D)
Model of the substrate-binding pocket of H134Y/V148A- sp5.  Domain II backbone residues
of nsp5 V148A are shown in green, the catalytic dyad in red, and the substrate-binding motif
in orange.  Changes between nsp5 V148A and H134Y/V148A-nsp5 are shown in blue.  H134
is shown in yellow and Y134 is shown in blue.
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In the case of S133N, neighboring residues Arg131, Val195, Tyr196 and Asp 197 were
predicted to repack to account for the replacement (Figure 2C).   Mutant H134Y also resulted
in repacking of the region proximal to residue 134, but this site was closer to the substrate-
binding region.  Residues Leu130, Arg131, Ser132, Tyr134, Ile136, His172 and Tyr182
(Figure 2D).
Of note, His172 has been identified as a residue, which interacted with an Mpro
inhibitor to block the substrate-binding pocket (44).  Interestingly, none of the alterations of
either second site revertant occurred proximal to the definitive mutation of Albts6-6189 at
position 148.
Analyses of the calculated optimal hydrogen bonding network for each model
indicated that much of the side chain rearrangements which occurred in the regions proximal
to the replacements were due to adjustments in the local hydrogen bonding network (data not
shown).
2.4 Discussion
Generating computational structural models of MHV Mpro, Albts6-6189 and the two
revertant mutants allowed us to predict how these mutations might impact function.  Analysis
of the Albts6-6189 model in comparison to the MHV Mpro model showed that changing
Val148 to alanine likely ablated a hydrophobic interaction between it and Met162, one of the
residues of the substrate-binding motif (Figure 2A).   Knocking out this interaction would
likely increase the frequency of additional rotameric positions of Met162, many of which
might be less favorable to substrate-binding.  However, at reduced temperatures hydrophobic
interactions are known to increase in strength, suggesting that Met162 likely adopts a
favorable, but less stable rotameric position at the permissive temperature. Another intriguing
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possibility is that the predicted rotameric shift in Met162 places its side chain within
interaction distance of Pro39, which interacts with His41 of the catalytic dyad (Figure 1A,B
and 2A).  It is possible that juxtapositioning of Met162 alters the positioning of Pro39 and
His41, resulting in disruption of the catalytic dyad and a block in proteolytic activity.  As
mentioned above, reduced temperatures likely increase the likelihood of unfavorable
hydrophobic interactions, which would allow Met162 to adopt a more favorable rotameric
position, allowing the dyad to function at the permissive, but not the non-permissive
temperature.
Interestingly, the mutations which led to revertants of the TS phenotype did not occur
in or near the site of the TS mutant (Val148Ala).  Both of these mutations occurred in loops
distal to the substrate-binding region and even further from residue 148.  While these
mutations had an impact on the local environment (Figure 2C,D), they did not appear to
directly alter the catalytic dyad or the region of substrate-binding.  However, in the case of
mutant H134Y, His172 was predicted to assume a different rotameric position (Figure 2D),
and this residue has been identified as one that is important to inhibitor binding (44).  In
addition, hydrogen bonding in the regions where the replacements occurred changed
significantly, suggesting that subtle conformational changes may have resulted in remodeling
of the substrate-binding region, by altering the hydrogen bonding network of some residues
which bind to others in the substrate-binding region.  Based on the positioning of the
mutations, we predict that those conformational changes increased substrate-binding capacity
by altering the binding cleft to allow the juxtapositioning of Met162.  While bioinformatics
tools and computational models provide significant insights into the structure-function
relationship of mutants, we realize that they are limited by a number of constraints.
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3. SARS-COV REPLICASE PROTEIN NSP8 STRUCTURAL STUDIES
3.1 Introduction
Nsp7 and nsp8 have recently been crystallized and shown to interact to form a
supercomplex(48), which is predicted to function as a processivity factor during the
transcription of coronavirus RNAs(48). The nsp7 structure is described as a three helical
bundle, which acts as the mortar to hold together the supercomplex, while the nsp8 structure
takes one of two conformations.  The first conformation of nsp8, nsp8I, is an extraordinarily
long a-helical protein, whereas in second conformation, nsp8II, the long helix is disrupted by
a loop in the middle, which allows nsp8II to bend around nsp8I (Fig. 3A,B)(48).  Nsp8 is
described as the bricks in the superstructure, and both conformations interact with nsp7 in
exactly the same way utilizing the same interaction residues (Fig. 3A,B)(48).
Figure 3: The structures of nsp7 and nsp8.  A.  Nsp8 is found in two distinct
conformations.  Here the long helical form, nsp8I, is shown. Nsp8I, green; nsp7, red.  B.
Here then nsp8II conformation is shown, where the long helix is interrupted by a loop which
allows nsp8II to wrap around nsp8I.  Both conformations of nsp8 interact the same with
nsp7.  nsp8II, blue; nsp7, yellow.
The biological unit of the supercomplex is a hexadecamer, composed of two
asymmetric units, which are comprised of four copies of nsp7 and four of nsp8 (two nsp8I
A                                                     B
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and two nsp8II) (Fig. 4A,B)(48).  The formation of the hexadecamer supercomplex results in
a large round structure with a hollow channel through the center (Fig. 4B), which is
postulated to accommodate viral dsRNA in the cytoplasm, and protect the dsRNA during
viral transcription/replication(48).
Figure 4: Assymetric and biological units of the nsp7/nsp8 superstructure.  A.  The
asymmetric unit is comprised of four copies of nsp7, which interact with the two different
conformations of nsp8 to for the asymmetric unit.  The nsp7/nsp8 interaction is identical in
both conformations.  Nsp8I, green; nsp8II, blue; nsp7 interacting with nsp8I, red; nsp7
interacting with nsp8II, yellow.  B.  The biological unit is comprised of two asymmetric
units, which interact by stacking one on the other, forming a positive channel through the
middle of the superstructure.
The diameter and electrostatic properties of the hexadecamer are similar to those of
PCNA and beta-subunit, two processivity factors of DNA polymerase, which encircle the
dsDNA and confer high processivity on it(48).  The main feature of the hexadecameric
superstructure is the fact that the channel through the middle is positively charged, while the
predominant charge on the outside of the channel is negative (Fig. 5A,B)(48).
Gel shift assays using purified nsp7 and nsp8 indicated that these proteins bind
specifically to dsRNA.  Taken together with the charge distribution, this would suggest that
A                                                                   B
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the positively lined channel attracts the viral RNA, and may act to protect it from degradation
by host defenses, or promote high processivity during RNA synthesis.
   
Figure 5: Positive charge lines the channel formed by the nsp7/nsp8 superstructure.  A.
The interior of the asymmetric unit is lined with positive charge, shown in blue, while the
negative charges, shown in red, localizes to the exposed surface.  B.  Mapping the
electrostatic potential onto the superstructure shows the distribution of charge, indicating a
positive potential through the channel with negative potential on the surface.
In a different study, biochemical experiments with the SARS-CoV nsp8 have
demonstrated that this protein contains a second non-canonical RdRp activity, which may
produce primers that are utilized by the primer-dependent primary RdRP, found in
nsp12(16).  It is not clear if nsp8 could provide this activity as part of the supercomplex(16).
Mutations predicted to knockout the primase activity were engineered into the nsp8 protein
and it was demonstrated that the activity was indeed reduced or ablated.   Interestingly, the
addition of nsp9 to the nsp7-8 supercomplex reduced disorder in the supercomplex,
suggesting that nsp9 interacts with nsp7 or 8 in the structure. However, it is not clear if this
association is as a monomer, a dimer, or as a higher ordered structural subunit.
A                                                                 B
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The purpose of this study was to design a series of mutations that would disrupt the
activity of the supercomplex in three distinct ways: 1) By forcing nsp8 to assume more of an
nsp8I conformation than nsp8II, and thus reduce the number of superstructures present; 2) By
removing the positive charge in the channel, resulting in superstructures defective in
attracting viral RNA; and 3) By disrupting the interaction of nsp7 and nsp8, which would
likely greatly compromise or completely block the formation of the superstructure.  Fifteen
mutants were designed and designated M1-M15, and each of these was synthesized and
dropped into the reverse genetics system for SARS-CoV, to determine if recombinant virus
could be rescued and characterized.
3.2 Methods
Sequence and structural analysis.  The amino acid sequences of the SARS-CoV
nsp7 and nsp8 proteins were analyzed in detail, by multiple alignment using ClustalX(1, 8,
13, 39) and by domain searching via prosite and SMART(19, 33).  A secondary structure
analysis was conducted using the program Chimera.  The crystal structure coordinates were
downloaded from the Protein Database (Protein Database Accession code: 2AHM), and the
structure was visualized and analyzed using molecular visualization programs PyMOL and
SwissPdbViewer.
Designing mutants.  Mutants were designed by: 1) identifying residues which
would remove a disordered region in nsp8II, forcing it to assume the nsp8I conformation; 2)
targeting residues with a positive charge that protruded into the open channel in the structure;
and 3) targeting residues in nsp8 which interact with nsp7.  In each case, the targeted amino
acids were changed to Ala by changing at least two nucleotides in the codon.
Mutant construct design and synthesis.  The mutants were designed such that
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single and multiple changes would be tested in the SARS-CoV infectious clone (icSARS).
Fifteen mutants were selected for synthesis, and all mapped within 300 nucleotides of one
another in the SARS-D fragment.  Utilizing convenient restriction sites that flanked this
region, a 717 nt cassette was designed, which could be cut out of the wild type SARS-D
fragment and replaced with the mutant cassette of choice.  The cassettes for all fifteen
mutants were designed and submitted to BioBasic for synthesis.  The total cost for the
synthesis was $1800.00, which included all fifteen mutant cassettes sequenced and inserted
into plasmids.  In addition, they included enough purified DNA to do the digestions upon
arrival.  This synthesis took two weeks to complete.
Generating viruses bearing the fifteen mutant cassettes.  Once the cassettes
arrived, they were digested with the appropriate enzymes and ligated into the SARS-D
fragment, which had the wt cassette removed.  This process left the SARS-D vector intact,
allowing for immediate transformation and growth of the plasmids bearing each of mutant
constructs in E. coli.  Transformation was conducted by heat shock at 42C for two minutes,
and transformed E. coli was plated on LB plates with appropriate selection.  Plates were
grown at room temperature for 48 hours, after which five colonies were picked and amplified
in 5 ml of LB broth incubated at room temperature, under appropriate selection, and with
agitation.  After 24 hours, the plasmids were purified, and digested with restriction enzymes
to determine if the DNA resembled wild type by restriction screening.  Plasmids that digested
correctly were amplified in 20 ml of LB broth with the appropriate antibiotic and grown for
24 hours at room temperature with agitation.  The plasmids were again purified and three of
each mutant was sequenced to verify that the mutant cassette was incorporated into the wt
SARS-D fragment.
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Assembling the mutant viruses.  The infectious clone of the Urbani strain of
SARS-CoV was used as the backbone for this project, and mutated SARS-D fragments
containing each of the mutants of interest were dropped into the infectious clone as described
previously(45-47).  Briefly, icSARS fragments A through F were amplified in E. coli,
purified and screened by restriction digestion.  Large stocks of each fragment that screened
correctly were established, and digested with the appropriate enzyme.  The digested bands
were electroporated, excised, and purified; and ligation reactions were set up using
equivalent molar ratios of each fragment.  Wild type fragments were ligated to generate the a
full-length cDNA of wt SARS-CoV, and the SARS-D fragment bearing the mutant cassette
for each mutant was used to generate full-length cDNAs for each mutant.  The ligation
reactions were purified by chloroform extraction and isopropanol precipitation, and then
transcribed in vitro, and transfected into Vero cells.   Transfections were monitored for 3
days, and passed if necessary.  All recombinant icSARS strains were propagated on Vero E6
cells in Eagle’s minimal essential medium (Invitrogen, Carlsbad, CA) supplemented with
10% fetal calf serum (HyClone, Logan, UT), kanamycin (0.25 μg/ml) and gentamycin (0.05
μg/ml) at 37ºC in a humidified CO2 incubator. All work was performed in a biological safety
cabinet in a biosafety level 3 (BSL3) laboratory containing redundant exhaust fans. Personnel
were equipped with powered air-purifying respirators with high-efficiency particulate air and
organic vapor filters (3M, St. Paul, MN), wore Tyvek suits (DuPont, Research Triangle Park,
NC) and were double gloved.
Verification of viral replication.  The cells were analyzed daily for CPE, and
viral replication was verified by RT-PCR of leader containing transcripts of the S gene.
Briefly, primers were designed to amplify the leader sequence and ~300 nt into the S gene,
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identifying the presence or absence of leader-containing subgenomic mRNAs that encode the
S glycoprotein gene as a marker of transcription.  Total RNA was harvested from transfected
cells using TriZol reagent, and purified RNA was reverse transcribed using random hexamer
primers and Superscript III reverse transcriptase, following the manufacturer’s protocol.
cDNA was amplified by PCR using the primers to detect the presence of cDNA containing
leader sequence, which would only be present if replication occurred.
3.3 Results
Mutational design.  Fifteen mutants were designed based on three criteria.  First,
mutants were designed that would promote the nsp8I conformation.  A secondary structure
analysis indicated that the extraordinarily long helix in nsp8I contained a disordered region in
the middle where the loop interrupts the helix in nsp8II (Fig. 6).
Sars nsp 8 AIASEFSSLP SYAAYATAQE AYEQAVANGD SEVVLKKLKK SLNVAKSEFD
Struture CCCCCCCCCH HHHHHHHHHH HHHHHHHCCC HHHHHHHHHH HHDDDDDDDD
Sars nsp 8 RDAAMQRKLE KMADQAMTQM YKQARSEDKR AKVTSAMQTM LFTMLRKLDN
Struture DDDDDDDDDD DDDDDDDDDD DDDDDDDDDD DDDDDHHHHH HHHHHHHHCH
Sars nsp 8 DALNNIINNA RDGCVPLNII PLTTAAKLMV VVPDYGTYKN TCDGNTFTYA
Struture HHHHHEEECC CCCCCCCCCC CCHHHHHEEE EECCCCEECC CCCCCCEEEC
Sars nsp 8 SALWEIQQVV DADSKIVQLS EINMDNSPNL AWPLIVTALR ANSAVKLQ
Struture HHHHHHHHHH CCCCHHHHHH HCCCCCCCCC CCHHHHHHHH HHHCEEEC
Figure 6.  The Disordered region that disrupts the helix in nsp8II.  The disordered region
is shown in blue.  Sites that have similar charges that occur adjacent to each other often cause
a region to be disordered.  These sites, indicated above in teal, were targeted for mutagenesis,
as changing these to Ala would likely increase the helical character of this region.  C, coil; H,
helix; D, disordered; E, beta-sheet.
Charges adjacent to each other in the disordered region were targeted as potential disordering
residues and these were changed to Ala to force the structure to be more helical.
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The second strategy was to design mutations that would alter Lys and Arg residues,
which contain positive charges and which are shown to provide positive potential to channel
(Fig. 5).  In this case, Arg and Lys were changed to Ala to remove the positive side chain
while preserving the structural property, as these changes occurred on helices, and alanine is
favorable for the formation of helices.
Site 1                                                      Site 2
Figure 7:  The nsp7 and nsp8 interaction sites.  Site 1 and Site 2 show the residues, which
interact between nsp7 and nsp8 to allow the formation of the superstructure.  Some of these
residues were targeted to hypothetically disrupt this interaction.
The third group of mutations targeted the sites of interaction between nsp7 and
nsp8 (Fig.7).  These were designed to reduce the affinity of the interaction such that fewer
superstructures could form and therefore we predicted that this would result in a reduction in
replication efficiency.  In addition, three mutations were designed to knockout or reduce the
putative primase activity recently reported.  Fifteen mutants were designed (Table 2), and
these were designated M1-M15.
Detection of viral replication.  The fifteen mutants were designed as cassettes that
could be incorporated into the wt SARS-D fragment.  The cassettes were synthesized by
BioBasic, Inc., and the 15 mutant SARS-D fragments were assembled, amplified, sequence
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verified, and placed into the infectious clone of SARS-CoV.  The full-length cDNAs were
then transcribed and transfected into Vero cells and monitored for CPE.
Mutant Site targeted Position (AA)
1 DO that defines nsp8I/II 57 & 58
2 DO that defines nsp8I/II 77 & 78
3 DO that defines nsp8I/II 79 & 80
4 DO that defines nsp8I/II 77 to 80
5 positive charge in channel 75
6 positive charge in channel 82
7 positive charge in channel 75, 79, & 80
8 positive charge in channel 79, 80, & 82
9 positive charge in channel 75, 79, 80, & 82
10 Interaction with nsp7 site 1 90 & 91
11 Interaction with nsp7 site 1 94 & 98
12 Interaction with nsp7 site 1 90, 91, 94, & 98
13 Interaction with nsp7 site 2 103 & 106
14 Interaction with nsp7 site 2 106 & 110
15 Interaction with nsp7 site 2 103, 106, & 110
Table 2: Mutants designed for this study.  DO, disordered region; *, mutant also targets
the putative primase.  Mutants were designated M1-M15.
However, detection of CPE was not definitive.  CPE in SARS-CoV infected cells generally
presents as rounded cells that begin to lift off the monolayer between 24-48 hours post
infection.  In the case of the 15 mutants, there was observable cell rounding in every case,
however, it was delayed and not obvious until day 3 or 4 post transfection.  To verify viral
replication, RT-PCR was conducted to assay for leader containing transcripts that encoded
the S gene, which would only be present if subgenomic RNA synthesis occurred, which
requires a functional viral replication complex (Fig. 8).
The RT-PCR results of assaying for the presence of subgenomic S gene was
positive for mutants: M2, M3, M5-to-M7, and M9-to-M15, as all contained subgenomic
transcripts indicative of viral RNA synthesis (Fig. 8).  Mutants M1 and M4 showed no
*
*
*
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evidence of subgenomic RNA synthesis, while M8 generated a faint band indicative of only a
minute amount of subgenomic RNA.  An important caveat, the RNA for this assay was
harvested from the transfection flasks, and therefore the differential observed in band
luminosity does not correlate to increased replication, as the transfection efficiency was not a
variable that could be appropriately controlled.
Figure 8: RT-PCR results for the nsp8 mutants.  RT-PCR assaying for the presence of
subgenomic S gene indicated that mutants M2 (lane 4), M3 (lane 5), M5 (lane 8), M6 (lane
9), M7 (lane 10), M9 (lane 13), M10 (lane 14), M11 (lane 15), M12 (lane 16 and 18), M13
(lane 19), M14 (lane 20), and M15 (lane 21) all generated subgenomic transcripts indicative
of viral RNA synthesis.  Only mutants M1 (lane 3) and M4 (lane 6) showed no evidence of
replication.  M8 (lane 11) generated only a minute amount of subgenomic RNA, as this band
is very faint.
Rescuing recombinant virus.  Attempts to rescue the mutant recombinant viruses
failed.  The supernatants were harvested from the RT-PCR positive flasks and plated in an
attempt to passage the recombinant viruses, but no CPE was ever detected.  In addition, each
virus was plated in an attempt to detect plaques, but none produced plaques.  Frustratingly,
cells infected with supernatants from the transfection flasks resulted in negative results by
RT-PCR.  All of these experiments performed in parallel with the icSARS recombinant virus
resulted in CPE, plaques, and was positive after passage as assayed by RT-PCR.
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3.4 Discussion and Future Directions
The hexadecamer supercomplex as an RNA processivity factor.  It is an
intriguing hypothesis that the nsp7/nsp8 supercomplex forms a structure similar to PCNA
and beta-subunit, two processivity factors of DNA polymerase, known to encircle dsDNA
and confer high processivity upon it(48).  If the same activity is occurring in the
hexadecamer with CoV RNA, then it provides an important clue as to how the CoV
replication complex forms, and which proteins are key players.  We know that the structure
of the hexadecamer was more stable in the presence of nsp9, which implies that nsp9
interacts with a disordered region and this interaction further stabilizes the supercomplex(48).
Interestingly, nsp9 has been identified as a unique ssRNA binding protein(37).  Further, nsp7
has been shown to interact with nsp10, an important regulator of viral RNA synthesis, which
also interacts with nsp1(6).  All of these replicase proteins are essential to viral replication,
and are predicted to be involved in formation of the replication complex.  If nsp7/8 are key
components in replicase complex formation with complex interaction networks with other
replicase proteins, then it may prove very difficult to isolate defined mutants.
Therefore, we hypothesized that utilizing a reverse genetics system to engineer
mutations in nsp8 and then assaying for viral replication, RNA processivity, and perhaps
even crystallography of mutants would provide important clues that would either verify or
refute the supercomplex formation and the RNA processivity it was proposed to provide.  In
addition, knocking out the putative non-canonical RdRp activity, would likewise test the
hypothesis that it generates the primers required for the primer-dependent primary RdRp
(nsp12)(16).
 With this in mind, we designed fifteen mutants created to answer four distinct
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questions: 1) If nsp8 conformation was skewed to reduce the in the number of
supercomplexes formed, would this reduce the rate of viral RNA synthesis?  2) If the
supercomplex formed, but did not have a positive potential in the channel, would there be a
decrease in viral RNA synthesis?  3) Is the supercomplex biologically relevant or just an
artifact of crystallography?  And finally, 4) Is the primase activity essential for viral
replication?  Fifteen mutants were designed to provide a reverse genetics approach to
answering these questions.
First, four mutants were designed to target the disordered region that determines
which conformation nsp8 will assume.  Pairs of charges in the disordered region where
changed to Ala in an attempt force the nsp8I conformation in higher quantities than the
nsp8II conformation.  Second five mutants were designed such that the Lys and Arg residues
observed to extend positively charged side chains into the channel, thus providing positive
potential, were changed to Ala which preserved the helical nature of the residue, but removed
the positive potential.  Third, six mutations were designed to interrupt the hydrophobic
interactions at site 1 and site 2 where nsp7 and nsp8 interact.  The interacting residues were
changed to Ala to reduce the hydrophobicity of the interaction, and we predicted that these
would mutations would reduce the nsp7 and nsp8 interaction, either preventing the formation
of the supercomplex or reducing the efficiency with which it assembles.   Fourth, in addition,
residues which were shown to ablate or reduce the non-canonical primase activity of nsp8
were changed to Ala (M1, M5 and M6) to assay the effect of the primase activity on viral
replication.
Engineering this panel of mutations into the infectious clone of SARS-CoV to
generate mutant recombinant viruses, culminated in mixed results.  While viral transcription,
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as verified by RT-PCR was detected in 12 or perhaps 13-out-of-15 of the mutant viruses (Fig.
8), the isolation of recombinant viruses has proven more elusive.  The fact that subgenomic S
was present, suggests that RNA synthesis occurred, but we could not measure differential
defects, as we were unable to quantify virus and control for viral titer differences, which may
have skewed the transfection results.  (Note processivity factor might be more critical for
genome length synthesis and (gradient by size) preferentially disrupt genome replication.
Mutants specific for genome but not subgenomic mRNA have been reported in arteriviruses.
Multiple attempts were made to recover virus from the transfection supernatants, but nothing
was ever detected in any case except for the recombinant wt SARS-CoV virus, which was
used as a control.
Future directions.  Although multiple attempts were made to recover virus from
the mutant transfection flask supernatants, it is sill possible that virus is present there, and
that with the right cell conditions recombinant viruses will be recovered.  This is the first
step, to verify that nothing can be recovered.  Secondly, it is possible that the defects in RNA
synthesis are significant, and that allowing the original transfections to go only 4 days was
too soon to harvest them.  If no recombinant mutant viruses can be rescued, then each will be
assembled back into the infectious clone system a second time, and the transfections will be
passaged and maintained for several days to determine if a recombinant virus is detected.
While more passages can lead to second site reversions, those types of mutations might be
very useful in identifying further interaction partners.
If the second attempt fails to generate recombinant virus, we plan to transfect these
cells into stable cell lines expressing nsp7 and nsp8, to see if we can rescue the mutant in the
presence of the protein expressed in trans.
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4. SARS-COV REPLICASE PROTEIN NSP9 STRUCTURAL STUDIES
4.1 Introduction
The structure of nsp9 has also been solved and this protein was reported to be an
unique single-stranded RNA binding protein with an oligosaccharide/oligonucleotide fold-
like fold(37).  This single-stranded RNA binding protein does not appear to be related to any
protein found in any other virus(37).  In solution, nsp9 forms a dimer, although it is currently
not known if it assumes this oligermization state in vitro or in vivo (Fig. 9A,B)(37).
Figure 9: The structure of nsp9.  A.  The reported crystal structure of nsp9 identified it as a
dimer which binds to single-stranded RNA.  B. Sites targeted in the dimer interface, shown in
red, were targeted for mutagenesis.  Purple, chain A; yellow, chain B.
In this study, in collaboration with the Wayne Shultz Laboratory at the Hauptman-
Woodward Institute, State University of New York they determined by structural analysis
and confirmed with biochemical assays that three mutations would likely interrupt or ablate
the formation of the dimer.  The amino acid residues targeted were both Glys on the helical
interface (Fig.9A), which interact between the two monomers to form the dimer.  These Glys
          
A                                       B
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were mutated to either Val or Glu, both of which add bulky side chains to the interaction
region, and thus were designed to prevent the concise interface interaction.
Experiments in our lab have indicated that introducing these mutations, which force a
monomeric state without disrupting overall structure, to the nsp9 protein results in a lethal
phenotype.  Interestingly, low-level replication occurred in one mutant, but no mutant virus
was ever isolated.  This provides evidence that nsp9 dimerization is essential to viral
replication in vitro.
4.2 Methods
Mutant design and synthesis. To determine the effects of mutations G100E,
G104E and G104V on SARS-CoV replication the three mutations were individually
engineered into the molecular clone of SARS-CoV, replacing the wild-type codons as
follows: G100E: GGT to GAG, G104V: GGC to GTG, and G104E: GGC to GAA.  This was
accomplished using the No See’m approach whereby primers were designed utilizing type
IIS restriction endonuclease sites which allowed sticky ends to be generated with non-native
nucleotides present (See Chapter III).  This was used to introduce the mutations into the
codons described above, using the wt SARS-D fragment from icSARS as the backbone.  The
full-length mutated D-fragments were digested, purified, and ligated back into the original
vector.  Transformation was conducted by heat shock at 42C for two minutes, and
transformed E. coli was plated on LB plates with appropriate selection.  Plates were grown at
room temperature for 48 hours, after which five colonies were picked and amplified in 5 ml
of LB broth incubated at room temperature, under appropriate selection, and with agitation.
After 24 hours, the plasmids were purified, and digested with restriction enzymes to
determine if the DNA resembled wild type by restriction screening.  Plasmids that digested
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correctly were amplified in 20 ml of LB broth with the appropriate antibiotic and grown for
24 hours at room temperature with agitation.  The plasmids were again purified and three of
each mutant was sequenced to verify that the mutation was incorporated into the wt SARS-D
fragment.
Assembling the mutant viruses.  The infectious clone of the Urbani strain of
SARS-CoV was used as the backbone for this project, and mutated SARS-D fragments
containing each of the mutations of interest were dropped into the infectious clone as
described previously(45-47).  Briefly, icSARS fragments A through F were amplified in E.
coli, purified and screened by restriction digestion.  Large stocks of each fragment that
screened correctly were established, and digested with the appropriate enzyme.  The digested
bands were electroporated, excised, and purified; and ligation reactions were set up using
equivalent molar ratios of each fragment.  Wild type fragments were ligated to generate a
full-length cDNA of wt SARS-CoV, and the SARS-D fragment bearing each mutation was
used to generate full-length cDNAs for each mutant.  The ligation reactions were purified by
chloroform extraction and isopropanol precipitation, and then transcribed in vitro, and
transfected into Vero cells.   Transfections were monitored for 3 days, and passed if
necessary.  All recombinant icSARS strains were propagated on Vero E6 cells in Eagle’s
minimal essential medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf
serum (HyClone, Logan, UT), kanamycin (0.25 μg/ml) and gentamycin (0.05 μg/ml) at 37ºC
in a humidified CO2 incubator. All work was performed in a biological safety cabinet in a
biosafety level 3 (BSL3) laboratory containing redundant exhaust fans. Personnel were
equipped with powered air-purifying respirators with high-efficiency particulate air and
organic vapor filters (3M, St. Paul, MN), wore Tyvek suits (DuPont, Research Triangle Park,
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NC) and were double gloved.
Verification of viral replication.  The cells were analyzed daily for CPE, and
viral replication was verified by RT-PCR of leader containing transcripts of the S gene.
Briefly, primers were designed to amplify the leader sequence and ~300 nt into the S gene.
Total RNA was harvested from transfected cells using TriZol reagent, and purified RNA was
reverse transcribed using random hexamer primers and Superscript III reverse transcriptase,
following the manufacturer’s protocol.  cDNA was amplified by PCR using the primers to
detect the presence of cDNA containing leader sequence, which would only be present if
replication occurred.
4.3 Results
Mutational Design.  Three mutants were designed and engineered to determine the
effect of dimerization on SARS-CoV replication in vitro.  The strategy employed was to
replace Gly residues in the dimerization interface with amino acids bearing larger, more
bulky side chains.  Two key interaction sites were targeted, the Gly at position 100 in the
nsp9 protein and a Gly at position 104.  In both cases, the Gly was changed to Glu, which
was verified to ablate dimer formation in solution, and position 104 was also changed from
Gly to Val, which was shown in solution to reduce the number of dimers, but to not ablate
the interaction altogether.
Detection of viral replication.  The three mutants were designed for and
incorporated into the wt SARS-D fragment.  The three mutant SARS-D fragments were
assembled, amplified, sequence verified, and placed into the infectious clone of SARS-CoV.
The full-length cDNAs were then transcribed and transfected into Vero cells and monitored
for CPE.  Detection of CPE was not evident.  To determine if low-level RNA synthesis
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occurred, RT-PCR was conducted to assay for leader containing transcripts, but no bands
were detected, suggesting that no RNA synthesis was occurring.
Mutants G100E and G104E was introduced into the infectious clone three times, and
in all three cases no recombinant mutant virus was detected or rescued.  However,
recombinant wt icSARS, prepared in parallel did produce CPE and subgenomic mRNA
synthesis was detected by RT-PCR.  For mutant G104V, the experiment was repeated four
times.  The first two times there was no evidence of viral replication by cytopathology or by
RT-PCR.  The third time, however, CPE was evident and subgenomic S was detected by RT-
PCR.  In addition, the recombinant virus was successfully passaged in Vero cells and also
produced wt-sized plaques.  Total viral RNA was harvested and the region flanking the
mutation site was amplified by RT-PCR, electroporated on a 0.8% agarose gel, gel purified,
and sequenced.  Interestingly, sequence analysis revealed that the G104V mutation had
reverted to wt-SARS-CoV at that position.  However, since two changes were originally
introduced and only one change was sufficient to revert it to wt sequence at that site, the
other mutation was present, indicating that it was indeed a revertant and not an accidental
contamination with wt-SARS D-fragment.  The G104V mutant was generated and tested a
fourth time, with results identical to the first two trials.
4.4 Discussion
Dimerization is essential to SARS-CoV replication in Vero E6 cells. To determine
the effects of mutations G100E, G104E and G104V on SARS-CoV replication the three
mutations were individually engineered into the molecular clone of SARS-CoV, replacing
the wild-type codons as follows: G100E: GGT to GAG, G104V: GGC to GTG, and G104E:
GGC to GAA. The infectious clone was assembled in parallel for wild type and each of the
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three mutants, and full-length cDNAs were transcribed in vitro, transfected into replication
competent cell lines, and monitored for cytopathology.  For all three mutants, no cytopathic
effect was observed in the transfected cells, which were monitored for 4 days and then passed
onto fresh cells for 4 more days.  To determine if any of the mutants synthesized viral RNA,
RT-PCR was conducted to amplify leader-containing transcripts, which are only present in
cells experiencing a productive viral infection.  No leader-containing transcripts were present
in any of the mutants.  In contrast, cytopathology was obvious in the wild type transfection
within 2 days, and RT-PCR confirmed RNA synthesis by amplifying cDNAs corresponding
to subgenomic S mRNAs of SARS-CoV.  Each transfection was repeated three times for
Ga100E and G104E, with the same results.  This suggests that Glu at positions 100 and 104
blocks dimer formation, and that dimer formation is required for viral replication, although
we cannot conclusively rule out the possibility that these sites may also encode some other
unidentified critical function in replicase complex formation, interactone networks or RNA
synthesis.
There were slightly different results for the G104V mutant.  G104V was originally
predicted to just alter dimer formation, without completely knocking it out.  Interestingly,
although three of four trial transfections resulted in no indication of viral infection, but one
trial resulted in a revertant, changing one site in the mutated codon to revert the amino acid
back to Gly at the position.  Of note, this change was not a revertant to the wt nucleotide
sequence, indicating that the virus utilized a new codon to achieve the required amino acid
substitution necessary for propagation.  The only way for this evolution to occur would be if
viral RNA synthesis were occurring at low level.  This suggests the G104V mutant was
greatly debilitated in its ability to generate viral RNA, but not completely deficient.
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Dimerization of nsp9 appears to be essential for viral replication in vitro, provided the
dimerization states predicted in solution are the same as occur in vitro.  Because viral
replication was either too low to be detected by RT-PCR, or non-existent, or only occurred in
the case of the revertant, we could not determine if the G104V mutant still formed dimers of
nsp9.
5. SARS-COV SPIKE RECEPTOR BINDING DOMAIN STUDIES
Sheahan, T., B. Rockx, E. Donaldson, A. Sims, R. Pickles, D. Corti, and R. Baric. 2008.
Mechanisms of zoonotic severe acute respiratory syndrome coronavirus host range expansion
in human airway epithelium. J Virol 82:2274-85.
5.1 Introduction
This project was in collaboration with Tim Sheahan from the Baric Lab, and
theresearch was primarily conducted by Dr. Sheahan and his co-authors.  My contribution
was the structural bioinformatics analyses focused on defining the molecular mechanisms
that explain zoonotic SARS-CoV adaptation to human airway epithelial cells (ref).
SARS-CoV is a zoonotic viruses that likely originated in bats, civet cats, raccoon
dogs and other species.  Among Coronaviridae, the S glycoprotein gene is known to play a
key role in receptor interaction and entry and in determining host range.  The amino acid
sequence of the S glycoproteins of the different SARS-CoV isolates segregate
phylogenetically into four distinct clusters, which have been labeled: zoonotic, early, middle,
and late phase clusters.  A total of 23 amino acid changes occurred between the zoonotic and
all human phases over the course of the epidemic (31).
A crystal structure of a late phase SARS-CoV RBD in complex with the human
ACE2 molecule showed that18 amino acids in ACE2 interact with 14 residues in the RBD of
SARS-CoV (20), and two amino acids in the RBD at positions 479 and 487 have been
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described as critical for binding to ACE2, and a third site, position 472, has also been noted
(20).  Interestingly, analysis of these amino acids at those interaction positions in the
zoonotic S glycoproteins revealed that position 479 changed from Lys or Arg in the zoonotic
strains to Asn in the human strains, while position 487 was Ser in the zoonotic strains, and
changed to Thr in all human strains.  Using pseudotyped viruses encoding different S
glycoproteins and reporter cells expressing the hACE2 receptor, Asn479 and Thr487 were
found to be key regulators of host range expansion(34).
To determine if these mutations had similar effects in the context of infectious virus,
the S protein of SZ16 containing the Lys at position 479, was placed in the Urbani infectious
clone and the resulting construct resulted in replication as detectable by RT-PCR, however,
no virus was recovered with passage, and no CPE was detected, suggesting a block at the
level of attachment or entry (34). However, mutating the Lys at position 479 to Asn resulted
in viable viruses indicating that a single point mutation (K479N) in the SZ16 S improved
binding to ACE2, although the mutation was insufficient for robust growth (34).
Interestingly, passing the SZ16-K479N recombinant virus in human airway epithelial
cultures resulted in adaptations within the RBD, which allowed for efficient attachment,
entry and viral replication that were ~3 logs higher than the parent virus.  The sites in the S
glycoprotein that adapted were at positions Y442F and/or L472F, sites known to interact with
hACE2 but reported to play minor roles in mediating robust interactions.  Based on structural
analyses and as discussed below, we predicted that these changes allowed the zoonotic RBD
to efficiently utilize the human ACE2 for attachment and entry into host cells.
5.2 Methods
Generating structural models of the RBD for SZ16, SZ16-K479N, SZ16-
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K479N.D8, and SZ16-K479N.D22.  The crystal structure coordinates of SARS RBD
interacting with the hACE2 receptor (PDB code 2AJF)(20) were used as a template to
generate each set of mutations using the Rosetta Design web server
(http://rosettadesign.med.unc.edu/)(15, 22).  In each case, the SARS RBD structure was
analyzed using the molecular modeling tool, MacPyMol (DeLano Scientific), to determine
which amino acids were proximal to the amino acid(s) being targeted for replacement.
Briefly, each amino acid to be altered was highlighted and all other amino acids within an
interaction distance of 5 angstroms were identified.  Using the Rosetta Design website, the
amino acid replacements were incorporated and all amino acids within the 5 angstrom
interaction distance were relaxed to allow the program to repack the side chains to an optimal
energetic state.  This process was repeated with each mutation and series of mutations.  Ten
models were generated for each set of mutations, and the best model, based on lowest energy
score, was selected and further evaluated using Mac Pymol.
5.3 Results
Rosetta Design modeling of S RBD and ACE2 interactions. Rosetta Design was
used to model hACE2's interactions with the RBDs of the parental SZ16 K479N
recombinant, and viruses passaged for 8 and 22 days in HAE, designated SZ16-S K479N D8,
and SZ16-S K479N D22, respectively. In contrast to the epidemic strain N479 residue, the
SZ16 K479 residue appears to electrostatically clash with the ACE2 binding partners K31
and H34. After a point mutation (K479N) is introduced in the civet S RBD, the repulsive
forces of the civet K479 are eradicated, allowing for S and ACE2 binding (Fig. 10A, B, and
C). The Urbani RBD residues 442 and 479 are predicted to have single hACE2 binding
partners (residue 442 interacts with H34; residue 479 interacts with K31) (Fig. 10A). Though
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residues 442 and 479 of the SZ16 K479N RBD are identical to Urbani, residues 442 and 479
are predicted to compete for hACE2 binding partner H34, and residue 442 is also predicted to
interact with H34 and K31 of hACE2 (Fig. 10C). The difference in binding efficiencies of
the seemingly similar Urbani and K479N RBDs is likely due to subtle alterations of the RBD
hydrogen bonding network created by mutations at the peripheral RBD residue 487. Residue
S487 of the SZ16 K479N RBD binds to one ACE2 residue, but T487 of Urbani binds to three
residues of ACE2, thereby enhancing S and ACE2 binding interactions (Fig. 10C). The
Rosetta Design model predicts that the Y442F mutation within the icSZ16-S K479N D8 S
protein creates an RBD architecture similar to that of SARS Urbani, where S residues F442
and N479 have singular and unique hACE2 binding partners (residue 442 binds K31 of
hACE2, and residue 479 binds H34 of hACE2) while retaining the S487 and Y41 interaction
and the hydrogen bonding network (Fig. 10C and D). Finally, while the icSZ16-S K479N D8
L472 residue is predicted to have only two potential ACE2 binding partners (L79 and M82),
the L472F mutation of the icSZ16-S K479N D22 S protein is predicted to increase the
numbers of possible binding partners of ACE2 to three residues (L79, M82, and Y83),
thereby strengthening S binding (Fig. 10D and E).
5.4 Discussion
To determine the potential impact of the mutations acquired during passage, we used Rosetta
Design to generate structural models of the SZ16, SZ16-S K479N, SZ16-S K479N D8, and
SZ16-S K479N D22 RBDs and then superimposed these models onto the existing crystal
structure of the SARS Urbani RBD bound to hACE2 (PDB code 2AJF) (Fig. 10A). Similarly
to Li et al., we observed that residue K479 of the SZ16 S inhibited binding to hACE2 by
sterically clashing with residues K31 and H34 (Fig. 10B).
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Figure 10: Rosetta Design modeling of "evolved" mutations that enhance spike protein
binding to ACE2. Rosetta Design was used to generate structural models of SZ16 and
mutant RBDs that were then superimposed onto the existing crystal structure of the SARS
Urbani RBD bound to ACE2.  A. Epidemic strain and hACE2 RBD architecture.  B. SZ16
and hACE2 interaction is inhibited by steric clashing, shown as red dots, of K479 of S and
residues K31 and H34 of hACE2.  C. Electrostatic repulsion at residue 479 is eradicated,
allowing S and ACE2 binding, but local remodeling within the RBD due to hydrogen
bonding differences at residue 487 creates cross-reactions whereby residues 442 and 479 of
K479N compete with each other for interaction partners H34, K31, and D32 of hACE2.
275
Figure 10 (continued): D. The Y442F mutation of SZ16-S K479N D8 restores an optimal
RBD, allowing for favorable packing to create an architecture similar to that of the wild type.
E.  Leucine 472 of the SZ16-S K479N and SZ16-S K479N D8 S interacts with L79 and M82
of ACE2. The icSZ16-S K479N D22 L472F mutation is predicted to have hydrophobic
interactions with three potential partners, L79, M82, and Y83, of hACE2 that will increase
the stability of the binding. Green dots on hACE2 indicate residues which are within 4
angstroms and thus are predicted to interact with the S residues shown in red.
After the K479N mutation, the electrostatic repulsion at residue 479 is eradicated, but
Rosetta Design predicts that local remodeling within the RBD creates cross-reactions
whereby residues 442 and 479 of the K479N RBD compete with each other for interaction
with partners H34, K31, and D32 of ACE2 (Fig. 10C). It appears that Y442 could interact
with all three hACE2 residues, but N479 is predicted to interact only with H34 of hACE2.
We predict that this network of competing interactions reduces the avidity between the
K479N RBD and the hACE2 receptor by misaligning other key residues in the RBD. Of
note, the only difference in the RBDs of SZ16 K47N and Urbani occurs at position 487. The
fact that SZ16 K479N is compromised in growth compared to Urbani suggests that the
hydrogen bonding differences between S487 of SZ16 K47N and Thr487 of Urbani influence
the receptor interaction.  During the 2003 epidemic, S487T likely evolved to eliminate this
putative inhibitory effect.  Interestingly, the icSZ16-S K479N D8 Y442F mutation also
restores an optimal RBD by allowing for favorable amino acid packing that recreated an
RBD architecture similar to that of the wild type (Fig. 10A and D). In this case, the icSZ16-S
K479N D8 RBD residues 442 and 479 have distinct and unique interaction partners in
hACE2, which likely restores avidity to near wild-type levels and may explain why the
icSZ16-S K479N D8 virus grows more efficiently than the icSZ16-S K479N virus in cells
expressing hACE2 (Fig. 10D). Thus, at least two independent routes of evolution could
increase S RBD and human ACE2 interactions. Leucine 472 of the icSZ16-S K479N RBD
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and the icSZ16-S K479N D8 RBD interacts with L79 and M82 of ACE2. The icSZ16-S
K479N D22 virus RBD is mutated at position 472 from leucine to phenylalanine, which
Rosetta Design predicts will induce strong hydrophobic interactions between F472 and
partners L79, M82, and Y83 of ACE2 (Fig. 10E). The icSZ16-S K479N D22 virus F472
mutation likely strengthens the binding interface of the icSZ16-S K479N D22 virus over the
icSZ16-S K479N D8 strain, which may explain why the icSZ16-S K479N D22 virus has a
growth advantage over the icSZ16-S K479N D8 virus in HAE, Vero E6, and DBT-hACE2
cells. Of note, it is possible that these viruses acquired replication-enhancing mutations in
structural or nonstructural genes that we did not sequence. Nevertheless, these data
demonstrate the plasticity of the RBD-ACE2 interface site and its ability to subtly remodel
the RBD and hACE2 binding interface to promote efficient entry and growth. Clearly,
multiple genetic pathways likely exist to allow for zoonotic SARS-CoV host range
expansion, and it will be interesting to determine if other contact interface point mutations
can enhance zoonotic virus infection of HAE cell cultures.
6. MONOCLONAL ANTIBODY ESCAPE MUTANT ANALYSIS WITH SARS-COV
Rockx, B., D. Corti, E. Donaldson, T. Sheahan, K. Stadler, A. Lanzavecchia, and R. Baric.
2008. Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody
Protection Against Lethal Human and Zoonotic SARS-CoV Challenge. J Virol.
6.1 Introduction
This work was in collaboration with Dr. Barry Rockx, who performed all of the
escape mutant analyses.  My contribution to this work was in modeling the mutations onto
the structure of SARS-CoV RBD interacting with hACE2, focused on determining the likely
mechanisms of virus escape for neutralization.
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Human monoclonal antibody provides an important therapeutic for the treatment and
control of severe viral infections and a large panel of human mAB have been generated that
neutralize the epidemic strain of SARS-CoV(40).  A panel of isogenic SARS-CoV bearing
human and zoonotic S glycoproteins was used to categorize several human monoclonal
antibodies into six distinct neutralization profiles, with the goal of identifying antibodies that
neutralized all human and animal strains(30).  Importantly, four of these human monoclonal
antibodies neutralized all zoonotic and human strains tested, and we showed that three of
these mAbs engage unique epitopes in the S glycoprotein.   Further, these broad-spectrum
therapeutics protected young and senescent mice from lethal homologous and heterologous
challenge.  These studies demonstrate that a cocktail of these antibodies would provide
robust protection from lethal SARS-CoV infection in humans(30).
Further, escape mutants were generated in the presence of these neutralizing
antibodies, and the adaptive sites that allowed escape were mapped onto the structure of the
SARS-CoV RBD.  The escape mutants were called S109.8, S230.15 and S227.14, reflecting
the nomenclature of the mAB used in the selection process.  A fourth mAb was not used to
generate an escape mutant.  Intriguingly, two newly identified epitopes were mapped to the
binding interface, while a third was mapped to a region distal to the interface.  We
hypothesized that antibodies binding to the distal epitope likely neutralized the virus by
preventing the RBD from adopting the conformation that allowed binding to the ACE2(30).
6.2 Methods
Structural Analyses. The crystal structure coordinates of SARS-CoV RBD
interacting with the human ACE2 receptor (PDB code 2AJF)(20) were used as a template to
generate each set of mutations using the Rosetta Design web server
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(http://rosettadesign.med.unc.edu/)(22). In each case, the SARS-CoV RBD structure was
analyzed using the molecular modeling tool, MacPyMol (DeLano Scientific), to determine
which a.a. residues were proximal to the a.a. being targeted for replacement.  Briefly, each
a.a. to be altered was highlighted and all other a.a. residues within an interaction distance of 5
angstroms were identified. Using the Rosetta Design website(22), the a.a. replacements were
incorporated and all a.a. residues within the 5 angstrom interaction distance were relaxed to
allow the program to repack the side chains to an optimal energetic state. This process was
repeated with each mutation and series of mutations. Ten models were generated for each set
of mutations, and the best model was selected based on the lowest energy score and further
evaluated using Mac Pymol. In all cases, the lowest energy score was identical between
several of the predicted models, suggesting an optimal folding energy of the chosen model.
6.3 Results
Structural modeling of cross-neutralizing epitopes. Recently the structure of the
SARS-CoV RBD complexed with its receptor ACE2 was resolved, allowing for structural
modeling of a.a. changes within the RBD. Two different mutations were identified in
different S109.8 escape mutants that flank the side of the RBD in a loop that is not in direct
contact with the receptor, ACE2 (Fig. 11A). The T332I change results in a protrusion from
the surface due to the additional CH3 group as well as becoming strongly hydrophobic.
Alternatively, the a.a. change from Lys to Asn at position 333 removes a positive charge.
Both mutations clearly affect binding of the S109.8 mAb. The mechanism of neutralization
by S109.8 is unknown but may either involve structural changes to the RBD after binding or
provide steric hindrance that antagonizes receptor binding in some unspecified manner.
Structural analysis of the S230.15 escape mutant showed that subtle remodeling of the
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receptor binding pocket did not impact binding of the hACE2 The Arg residue is likely
forced into the binding pocket by surrounding positive charged amino acids. At this site, a
binding pocket exists that can accommodate the larger side chain without disrupting interface
site interactions (Fig. 11B).
Figure 11: Location and effects of neutralization escape variant 1007 mutations on the
structure of the SARS-CoV RBD.  A. The S109.8 escape variant mutations T332I and
K333N B. S230.15 escape variant mutation L443R was mapped onto the structure of the
SARS-CoV RBD. The changed a.a. residues are shown in red.  C. In addition the locations of
all the important a.a. residues associated with the cross neutralizing mAbs were highlighted
in the SARS-CoV RBD. A.A. residues associated with S109.8, yellow; a.a. residues
associated with S227.14, red; and a.a. residues associated with S230.15, purple.
280
However, the presence of arginine at this position likely ablates binding of S230.15.  These
data support the hypothesis that the S230.15 mAb neutralizes SARS-CoV by directly
blocking the interaction with its receptor, ACE2.
6.4 Discussion
The combined results from the sequence analysis, competition assays, and escape
mutant analysis allowed us to identify the a.a.s that were associated with the neutralization
efficacy of the 3 different cross-neutralizing mAb.  By mapping the location of these a.a.
onto the crystal structure of the SARS-CoV Urbani strain RBD bound to ACE2, putative
locations of the cross-neutralizing epitopes could be identified (Fig. 11C).  S230.15 likely
recognizes an epitope that includes a.a. 443 as shown by escape variant analysis as well as
a.a. 487 as shown by reduced in vitro neutralization of an SZ16 spike variant with a T487S
change (58). The epitope recognized by the S227.14 mAb partially overlaps with that of
S230.15 but is not affected by the L443R change identified in the S230.15 escape mutant.
Finally, the epitope recognized by S109.8 includes a.a. 332 and 333 as shown by escape
mutant analysis.
7. BAT SARS-COV RECEPTOR BINDING DOMAIN STUDIES
Recovery and growth of a Bat SARS-Like Coronavirus.  M.M. Becker, R.L. Graham, E.F.
Donaldson, X.T. Lu, R.S. Baric, and M.R. Denison.  Manuscript in preparation for Nature
Biotech
7.1 Introduction
This project was a collaborative venture between Mark Denison’s lab at Vanderbilt
and UNC researchers.  The first part of the project was to design a Bat SARS-CoV(21)
molecular clone using the Urbani SARS-CoV as a template.  This work is discussed in detail
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in Chapter VI.  After the molecular clone fragments were designed and synthesized, the
Denison lab assembled the full-length infectious clone and determined that replication
occurred, but that it was limited to cells that had the viral RNA transfected into it.
Supernatants collected from those transfections were not able to infect Vero cells.
This indicated a similar barrier as describe in section 5 above, that being a block at
the level of attachment and entry.  The resurrected Bat SARS-CoV was unable to infect Vero
cells with the Bat SARS-CoV RBD, but when the Urbani S glycoprotein RBD was placed
into the Bat SARS-CoV backbone, the rescued virus was capable of replication and spread to
neighboring cells, indicating the primary block was at the level of viral attachment and entry
(see Chapter V).  Interestingly, inserting only the receptor binding motif (e.g., the 76 amino
acids that directly interact with ACE2 at a.a. positions 426-502) that interacts with the human
ACE2 was insufficient to overcome this barrier.  This observation, taken together with the
distal mAb epitope described in section6 above, led us to speculate that sites distal to the
interaction region regulate binding affinity of the RBD to the ACE2 receptor.
The second phase of the project was to model the chimeras that were built to help
determine what was happening at the structural level.  Several models were generated and
analyzed including: Bat-SRBD, Bat SARS-CoV with the Urbani RBD; Bat-SRBM, Bat
SARS-CoV with a minimal segment of the Urbani RBD, the RBM, that directly interacts
with hACE2; and Bat-SRBD-MA.  This latter virus is Bat SARS-CoV with the Urbani RBD
that is further altered by mutating one amino acids Tyr to His at position 436, which was
shown the only residue in the spike gene to change during passage in mice during selection
for a mouse-adapted strain of SARS-CoV(29).
7.2 Methods
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Homology Modeling of the Bat RBD and different Bat constructs.  The crystal
structure coordinates of SARS-CoV RBD interacting with the human ACE-2 receptor (PDB
code 2AJF) were used as a template to generate homology models using the program
Modeller (version 8.2)(26) for each of the Bat constructs including: Bat-RBD, Bat-SRBD,
Bat-SRBM and Bat-SRBM-MA.  Briefly, chain E of the 2AJF template was aligned to each
of the mutant sequences and five models of each were generated under the automodel class.
The model with the lowest objective function score was selected for further analyses.  The
PDB files generated by this program were visualized on molecular modeling tools
MacPyMol (DeLano Scientific) and Chimera(27).  This same process was used to generate a
structural model of the mouse ACE2.  In addition, Rosetta Design(22) was used to
incorporate the single Y to H change (residue 436) in the Urbani RBD to generate the mouse
adapted version of the RBD.  This single a.a. replacement was incorporated and all a.a.
residues within the 5 angstrom interaction distance were relaxed to allow the program to
repack the side chains to an optimal energetic state.  Ten models were generated for this
mutation, and the best model was selected based on the lowest energy score and further
evaluated using Mac Pymol.  In all cases, the lowest energy score was identical between
several of the predicted models, suggesting an optimal folding energy of the chosen model.
7.3 Results
Comparison of the SARS RBD structure to the Bat RBD Models.  Homology
models were generated for Bat-RBD, Bat-SRBD, Bat-SRBM and Bat-SRBD-MA, and these
predicted structures were compared to the structure of the SARS-CoV spike RBD in complex
with hACE2 (PDB code: 2AJF).  The residues which interact between the SARS-CoV RBD
and the hACE2 have been identified as: Leu472 of the RBD interacts with Met82 and Leu79
283
of hACE2, RDB residue Gln442 interacts with Lys31 of hACE2, RBD residue Asn479
interacts with His34 of hACE2, and RBD residue Thr487 interacts with Glu41 and Lys353 of
hACE2 and these interactions allow the RBD to bind to a-helices 1 and 2 of hACE2
(Fig.12A) (20).
The homology model of the Bat RBD superimposed upon the Urbani RBD/hACE2
structure showed that the Bat RBD is likely incompatible with hACE2 as there were several
deletions that altered the structure, shortening the loop that allows residue 472 to extend
toward -helix 1 of hACE2 (Fig. 12B).  In addition, three of the four interaction sites had
amino acid replacements, while the residue at position 472 was ablated (Fig. 12A and B).
This model predicts that the Bat S would be incapable of binding to hACE2.
The homology model of Bat-SRBM. The homology model of Bat-SRBM
superimposed on the Urbani RBD/hACE2 suggested that while the two structures are
predicted to share significant structural similarities, the loop that contains Leu472 will not
fold correctly to allow interaction with binding partners Met82 and Leu79.  This model
predicts that this minor structural remodeling would be sufficient to hinder the overall Bat-
SRBM:hACE2 interaction (Fig. 12C). The juxtapositioning of this loop would likely result
from distal interactions that prevent the loop with Leu472 from fully extending to interact
with Met82 and Leu79 (Fig. 12C).  Since the sequence in this interaction region is identical
between Urbani and Bat-SRBM, this implies that sites distal to the residues that interact
directly with hACE2 may regulate receptor binding. Superimposing Bat-SRBM on the
Urbani RBD shows that bat-SARS and Urbani RBDs are significantly different in regions
distal from the interaction interface (Fig. 12D).  We hypothesize that these differences limit
the flexibility of the interaction interface, and therefore may limit the ability of the loop
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containing Leu472 to engage its interaction partners.
Modeling the mouse ACE2.  Modeling the interaction of SARS-CoV RBD with the
mouse ACE2 receptor suggests that differences in mACE2 would reduce or ablate binding
with the Urbani RBD.  Concordant with these findings, SARS-CoV does not readily infect
mice and infection results in a limited replication model.  In the model of SARS-CoV Urbani
interacting with mouse ACE2 (Fig. 12E), residue Asn472 of RBD does not appear to interact
with the mACE2, and RBD residue Thr487 was predicted to interact with a single binding
partner, His353 on mACE2.
However, modeling the mouse adapted RBD interacting with mACE2 predicts that
the single change from Tyr to His at position 436 in the RBD of Urbani, will restore binding
of all four key residues.  Further, the interaction of residue Thr 487 was increased to include
residues Asp355 and Tyr41.  Of note, residue 436 is predicted to interact with Asp38 and
Gln42 of mACE2 in both cases, however when 436 is a His as in MA15, it is predicted to
interact with neighboring residues Gly482 and Phe483.  We hypothesize that His436 allows
subtle remodeling near the Thr487 interaction residue, which increases its ability to bind to
its interaction partners (Fig. 12 F).
7.4 Discussion
In this study, we modeled the Bat RBD interacting with the hACE2 receptor,
and determined that these two proteins are not likely to interact to allow the Bat SARS-CoV
to attach to and enter cells expressing hACE2.  The chimera Bat-SRBD, containing the
Urbani RBD in the Bat-SARS-CoV backbone, was predicted to interact as expected, and in
fact this was shown to be the case in vitro, as recombinant Bat-SRBD virus was rescued and
was competent to infect and spread in Vero cells.
285
Figure 12.  Modeling the interactions of SARS-CoV and the bat-SARS mutants with the
human and mouse receptor.  A.  Four residues from the SARS-CoV RBD interact with
residues of hACE2 to facilitate binding.  These include Leu 472 of RBD interacting with Met
82 and Leu 79 of hACE2, Tyr 442 interacting with Lys 31, Asn 479 interacting with His 34,
and Thr 487 of RBD interacts with Tyr 41 and Lys 353 of hACE2.  Bat-SRBD produced
nearly identical models as the one presented here.  B. The bat-SARS RBD is significantly
different from that of Urbani RBD, with no conserved residues in similar positions.  The
structure near Leu 472 of Urbani is completely different in the bat model.
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Figure 12 (continued) Based on this model we hypothesized that wt-bat-SARS could not
interact with hACE2.  C.  A model of bat-SRBM suggests that while the interacting residues
are present in similar conformation as in Urbani, Leu 472 is not capable of interacting with
Met 82 and Leu 79 of hACE2.   D. Superimposing Bat-SRBM on the Urbani RBD shows
that bat-SARS and Urbani RBDs are significantly different in regions distal from the
interaction interface. E. Modelling the interaction of SARS-CoV RBD with the mouse Ace2
receptor suggests that differences in mACE2 would reduce or ablate binding with the Urbani
RBD.  Asn 472 was predicted to not interact, and Thr 487 was predicted to interact with a
single binding partner, His 353.  F. Modelling the MA15 RBD interacting with mACE2
predicts that the single change from Y to H at position 436 in the RBD of Urbani, will restore
binding of all four key residues.
Interestingly, we also modeled Bat-SRBM, and although it contained all of the residues
important for interacting with hACE2, this virus was not viable.   Analysis of the structure
suggested that sites distal to the binding interface potentially regulate receptor attachment, as
all residues that interact with hACE2 were present and predicted to assume a conformation
favorable for binding.  The only discrepancy noted by the homology model was the loop that
contains binding residue 472 was not in proper orientation for that residue to interact
appropriately with its binding partner on hACE2.  This observation led us to hypothesize that
sites distal to the binding interface are involved in binding, probably by allowing the RBD to
bend into position to bind hACE2.
To further validate this hypothesis, we utilized an online molecular dynamics
simulator (El nemo: http://www.igs.cnrs-mrs.fr/elnemo) to analyze the flexibility of the RBD
in seven common planes of motion.  Interestingly, this program predicted that the loop in
question would flex back and forth, and hypothetically could flex inward to engage the
receptor.  In order for this flexibility to occur, other sites distal to this loop would be
important for maintaining the conformation necessary to allow flexibility in the loop.
In addition, it has been reported that SARS-CoV RBD does not interact well with
mACE2, however a mouse adapted SARS-CoV virus, with a single amino acid change in the
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RBD, is able to efficiently replicate in mice.  We substituted the single amino acid
substitution into the Bat-SRBD and generated and analyzed a homology model of the
interaction.  The structural model predicted that this change would likely increase binding at
the bat-SRBD|mACE2 interface, allowing the Bat-SRBD-MA to replicate in mice.
Recombinant viruses bearing the Bat-SRBD-MA mutation were rescued from mice,
indicating that this single site is sufficient for host expansion from human to mouse.
8. STUDIES WITH THE CIVET ACE2 RECEPTOR
8.1 Introduction
This study was done in collaboration with Tim Sheahan.  Dr. Sheahan observed that
the SZ16-K479N mutant designed to interact with human ACE2, lost the ability to infect
cells expressing the civet ACE2, while the opposite was true for the wild type SZ16, which
was capable of infecting cells expressing cACE2, but not hACE2(34).   Interestingly, SARS-
CoV RBD was able to infect cells expressing cACE2, nearly as efficiently as cells expressing
hACE2.  This indicates that the SARS-COV RBD had adapted to efficiently utilize both
human and civet ACE2 receptors.
8.2 Methods
Homology Modelling of the Civet ACE2.  The crystal structure coordinates of
SARS-CoV RBD interacting with the human ACE-2 receptor (PDB code 2AJF, Chain A)
were used as a template to a generate homology model for the civet ACE2 using the program
Modeller (version 8.2)(26).    Briefly, chain E of the 2AJF template was aligned to the civet
ACE2 sequence and five models were generated under the automodel class(26).  The model
with the lowest objective function score was selected for further analyses.  The PDB files
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generated by this program were visualized on molecular modeling tools MacPyMol (DeLano
Scientific) and Chimera(27).
Figure 13: Difference between human and civet ACE2 in the binding region.  Comparing
the hACE2 structure to a homology model of civet ACE2 indicates that two residues
differences in the binding interface likely determine which SARS-COV RBDs can bind. A.
D30 and H34 interact with residues 442/479 in hACE2 to stabilize binding.  B.  However, in
the civet ACE2 E at position 30 and Y at position 34 add methyl groups to the side chain
which appears to add surface area to the 442/470 binding interface, which likely blocks some
interactions.  Red, hACE2; blue cACE2.
8.3 Results
Comparison of the hACE2 structure with the Civet ACE2 model indicated that
residues E30 and Y34 on cACE2 add surface area to the 442/479 binding interface (Fig. 13).
The SZ16 RBD and the Urbani RBD can accommodate this additional surface area (Fig. 14),
but SZ16-K479N and SZ16-K479N D22 cannot bind to cACE2 because of clashes with
V404 and F440, which interact with those residues (Fig.15).  Juxtaposition occurs in this
region of civet ACE2 because of charge changes that result in E30 extending directly into the
binding interface.
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Figure 14: Binding to the native receptors. A. The SARS-CoV RBD interacts with hACE2
to allow attachment of the virus to cells with this receptor present. B. SARS-CoV RBD is
also capable of interacting with cACE2. C. A model of the SZ16 RBD interacting with the
cACE2.  Red, hACE2; blue, cACE2; green, Urbani RBD; brown, SZ16 RBD.
8.4 Discussion
Perhaps the most interesting observation with this experiment was that the late
phase epidemic SARS-CoV RBD had adapted to efficiently utilize both human and civet
ACE2 receptors (34). This result leaves open the possibility that it was the human SARS-
CoV and not the Civet SARS-CoV that may have first evolved from the Bat reservoir.  This
observation was further corroborated by phylogenetic analysis, which suggests that the Bat
SARS-CoV spike is more closely related to the middle phase human SARS-CoV spike than
to the civet or raccoon variants of the virus (See Chapters 2 and 6).  Importantly, we have
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demonstrated that an alternative pathway exists for specifically interacting with the hACE2,
but not cACE2 receptor.  Incorporation of such changes into vaccine vectors would prevent
establishment of persisting vaccine strains in animal reservoirs and likely improve safety.
Figure 15: Adaptation of SZ16 RBD to hACE2 results in loss of affinity for cACE2.  A.
SZ16-K479N RBD is predicted to interact with hACE2.  B. Changing residue 479 from K to
N would cause SZ16-K479N RBD to lose the ability to interact with cACE2.  This is likely
due to clash between N479 and E30 and Y34, which prevents L472 and S487 from engaging
the appropriate binding partners.  C.  SZ16-K479 D22 was further adapted to bind efficiently
to hACE2.  D.  SZ16-K479N D22 which also contains the N at 479, would similarly block
binding to cACE2 due to a clash between N479 and E30 and Y34, which prevents L472 and
S487 from engaging the appropriate binding partners.
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CHAPTER VIII: NOROVIRUS INTRODUCTION
1. GENERAL INTRODUCTION
1.1 Noroviruses and Human Disease
While noroviruses infect other important domestic animals such as bovine and swine,
human norovirus outbreaks have had a devastating impact on public health morbidity in the
United States and worldwide.  The Centers for Disease Control and Prevention report that
noroviruses account for over 96% of all viral gastroenteritis cases, with at least 23 million
infections occurring annually in the United States alone (62).   Worldwide, noroviruses cause
up to half of all outbreaks of gastroenteritis (4), making this virus the most common cause of
sporadic diarrhea in community settings (78).  Although all populations are susceptible to
infection, the elderly are more susceptible, and outbreaks commonly occur in retirement
communities (36, 37).  In addition to increased susceptibility, the elderly are at increased risk
for more severe disease and death, as are the very young and the immunocompromised (61,
64, 69).
Noroviruses infections have most often been associated with consuming
contaminated food or water, although spread during an outbreak is predominantly by person-
to-person transmission via direct contact, exposure to aerosols, or the fecal-oral route (72).
More often than not, outbreaks occur in institutions such as schools, nursing homes,
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retirement communities, hospitals, or day care centers; or in settings where close human
contact is difficult to avoid such as aboard cruise ships or in military barracks.
There are at least two factors that contribute to the virus’ ability to cause outbreaks.
First, norovirus infections require a very low infectious dose of <10 virions per individual to
infect 50% of those individuals (ID50).  Second, the virus is extremely stable in the
environment, showing resistance to freezing, heating to 60ºC, disinfection with chlorine,
acidic conditions, vinegar, alcohol, and high sugar concentration.  An ID50 of <10 virions
coupled with increased viral stability in the environment, contribute to a high transmissibility
rate for these viruses, as it is often extremely difficult to eradicate the virus from the outbreak
setting, and only a few viruses are necessary to seed the next outbreak.
The incubation period for norovirus infection is generally 24-48 hours, with clinical
symptoms typically lasting for 12-72 hours, although presentation of symptoms may be
prolonged in some cases, particularly among the elderly or immuno-compromised (66). The
symptoms of norovirus infection include: vomiting (69%), diarrhea (66%), nausea (79%),
low-grade fever (37%), and abdominal cramping (30%) (42).  Viral shedding has been
detected for up to three weeks post resolution of symptoms, which provides an extended
opportunity for transmission of the virus to other hosts. Because noroviruses establish an
infection with a low infectious dose, are extremely stable in the environment, exhibit an
extended period of viral shedding, and are readily spread from human-to-human, they have
been named class B select agents (18, 33).
1.2 Genomic organization
Noroviruses belong to the family Caliciviridae, genus Norovirus and are small non-
enveloped, icosahedral viruses with a diameter of ~38 nm.   Noroviruses encode a ~7.5
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kilobase positive-sense, single-stranded RNA genome with three open reading frames
(ORFs), which encode both the structural and the non-structural genes.  The viral RNA is
likely covalently linked to a viral protein, known as Vpg, at its 5’ end; and it is speculated
that this protein may play a role in transporting the genome to sites of negative strand
synthesis.  The 3’ end of the genome contains a poly A tail  (Fig.1)(100).  ORF1 is over 5kb
and makes up the first two-thirds of the genome.  It encodes an ~200 kDa polyprotein, which
is autoprocessed by a virally encoded protease to yield the non-structural viral replicase
proteins essential for viral replication.
The final 1/3 of the genome is comprised of the two structural proteins: 1) ORF2 is
1.8kb and encodes the 57 kDa major structural capsid protein, VP1; and 2) ORF3 is 0.6 kb
and encodes a 22 kDa minor basic structural protein that has been hypothesized to function in
packaging the genome into virions (23)(Fig. 1).
Figure 1: The Norovirus genomic structure.  The norovirus genome is comprised of three
open reading frames: ORF1 encodes the non-structural proteins (blue), ORF2 encodes the
major capsid protein, VP1, (yellow) and ORF3 encodes the minor structural protein, VP2,
(brown). This figure was downloaded from PathoSystems Resource Integration Center
(PATRIC) (website: http://patric.vbi.vt.edu/organism/).
1.3 Translation, processing, and function of the viral proteins
Translation of ORF2 is thought dependent upon a -2 frameshift, which is necessary
for the start codon of ORF2 to be aligned in frame with ORF1, and thereby translated.  A
single nucleotide overlap between the ORF2 stop codon and the ORF3 initiating codon
restores the reading frame of ORF3 to that of ORF1 (23), allowing translation of ORF3 to
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proceed.  However, others have detected both a large genomic RNA of ~7.6kb and a ~2.3kb
positive strand subgenomic RNA (44, 98), in studies with murine Norovirus.
ORF1 is translated into a large polyprotein, which is autocleaved into six replicase
proteins by the virally encoded 3C-like viral cysteine proteinase.   The processed protein
products from N-terminus to C-terminus include: 1) An N-terminal protein (p48) of between
37-48 kDa in mass; 2) A 2C-like nucleoside triphosphatase (NTPase) of ~40 kDa in size; 3)
A 20 kDa 3A-like protein (p20); 4) The VPg protein (16 kDa) that is attached to the 5’ end of
the genome; 5) The 3C-like proteinase (Pro) which is 19 kDa in size; and 6) A 3D-like RNA-
dependent RNA polymerase (Pol) which is ~57 kDa (83).
The function of the N-terminal protein, p48, is unknown; however, p48 expressed in
vitro has been shown to localize to the Golgi apparatus in transfected cells where it is
hypothesized to play a role in membrane rearrangement and intracellular protein trafficking
(19, 21).  The norovirus NTPase has been shown to bind and hydrolyze NTPs, similar to the
picornavirus 2C protein, although it does not appear to unwind DNA.   The Vpg protein,
which is covalently attached to the 5’ end of the norovirus genome, is thought to be
important for priming transcription, and may play a role in the initiation of translation, as it
has been shown to bind to translation initiation factors in both an in vitro expression system,
and following infection of cultured cells (16, 17, 80, 81).
Pro shares structural similarity with the cellular chymotrypsin-like serine proteases
(10), and contains the same amino acid sequence motifs found in the picornavirus 3C
proteases.  Pro processes the norovirus ORF1 polyprotein into the individual non-structural
proteins at cleavage sites: QG, EG, or EA (53, 54, 82, 86) (Fig. 2).  Two stable processing
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intermediates have been detected including Pro-Pol which retains enzymatic activity (8), and
VpG-P20.   The role these intermediates play in replication is currently unknown (8).
Figure 2.  Cleavage sites for proteolytic processing of the norovirus ORF1 polyprotein
into individual functional proteins (9).
The Pro active site is comprised of the catalytic triad defined as amino acids His30, Glu54,
and Cys139, which is located at the center of a deep cleft between the N- and C-terminal
domains and is stabilized by hydrogen bonds between conserved residues (65, 85, 95).
His157 is essential for substrate binding (102).  In addition to its role in processing the viral
proteome, Pro also inhibits cellular translation by cleaving specific domains of cellular poly-
A binding proteins that bind translation initiation factors and RNA.   
The norovirus Pol has been shown to be essential for in vitro viral replication.  It is
classified as part of the Gly-Asp-Asp (GDD) polymerase family, and members of this family
are found in many plus-strand RNA viruses (22).  The viral Pol functions in viral genome
replication by utilizing a VPg-priming mechanism and the poly A tail for RNA synthesis
from the genomic template.  Interestingly, RNA synthesis from the nascent negative strand
RNA does not require priming or utilize a poly A tail (22, 80, 81).
1.4 Replication of the viral RNA
Although noroviruses were first described in 1972 (40, 41), replication of this virus
still remains largely uncharacterized due to the lack of a culture system or small animal
model.  The exact mechanism of norovirus replication is yet to be elucidated, however, it is
hypothesized that genomic RNA serves as a template for negative strand synthesis, which
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likewise serves as a template for transcription of full-length positive strand genomic RNA for
packaging and subgenomic RNA for structural protein synthesis.  It has been proposed that
during positive genomic and subgenomic strand replication, Pol uridylates VPg in the
presence of the polyadenylated genomic RNA, and the uridylated VPg then primes initiation
of negative strand synthesis.  In contrast, no primer is required for replication of the negative
strand RNA by Pol.   Following replication, genomic RNA localizes to the site of assembly,
probably driven by a localization signal identified in ORF1 (3), where it gets packaged into
the virion.
While human noroviruses have yet to be cultured, murine noroviruses have been
shown to replicate in dendritic cells in vitro and in macrophages in vivo and in vitro (98).
These modes of culturing the murine norovirus will provide the tools necessary to further
advance the study of norovirus replication.
1.5 Molecular phylogenetics of the Noroviruses
The Norovirus genus contains more than forty different virus strains, which are
divided into five genogroups based on sequence similarity (20, 26, 43, 71).  Genogroup I
(GI), GII, and GIV viruses are primarily human pathogens, although there is a porcine-
specific virus within GII.  GIII and GV viruses infect bovines and murines, respectively.
Each genogroup is further subdivided into genoclusters, based on sequence similarity and
phylogenetic analysis (Fig. 3).
The GI genogroup is divided into eight genoclusters, GII contains at least seventeen
genoclusters, GIII has two genoclusters, and GIV and GV each contain one genocluster (103)
(Fig. 3).  The different norovirus genoclusters and genogroups are designated numerically
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with the genocluster indicated first as a roman numeral followed by the genogroup number.
For example a virus from genogroup II and genocluster 4 would be designated GII.4.
Figure 3: Phylogeny of the norovirus genus.  Five Genogroups are designated by GI, GII,
GIII, GIV, and GV.  Genoclusters within each genogroup are numbered inside boxes(103).
Strains within a genocluster can be further subdivided based on sequence similarity and
phylogeny (Fig. 3).  Norovirus strains are commonly named for the location of the identified
outbreak (i.e. the Norwalk virus strain was first isolated from an outbreak in Norwalk, Ohio),
and individual isolates routinely use strain/year/country nomenclature (i.e. NV/93/USA).
Analyses of the full-length genomic sequences of several noroviruses indicated that
viral strains within a genogroup share 69-97% nucleotide similarity, while strains in different
genogroups are only 51-56% similar (45).    More importantly, the ORF2 major capsid
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protein sequence can diverge by as much as 60% between genogroups and ~20-30% between
genotypes within a genogroup.  Within a genocluster, viral capsid sequences are often very
similar.  In the case of the GII.4 viruses, there are five distinct subclusters that differ from
each other by approximately 2% at the nucleotide level.  The divergence within this
genocluster is approximately 10% overall.
While most phylogenetic studies of the noroviruses are based upon a small segment
of sequence within ORF1, between the Pol and the Pro, a much more interesting and relevant
means of classifying these viruses is by using the full-length capsid sequence.   Because the
capsid gene is found on the outside of the virion, not surprisingly it is the most variable gene
in the norovirus genome.  Surface exposed residues often change frequently to evade the host
immune response, increase virion stability or alter tissue or host tropisms, and thus the
environment provides selective pressure, which drives viral adaptation.  Because we were
interested in studying the evolution of the GII.4 viruses over time in response to the human
immune response, all of the phylogenetic studies we conducted were with the full-length
viral capsid protein.  Of note, even different regions of this protein evolved at different rates,
with surface exposed residues changing more frequently than those buried in the proteins
interior (PLOS paper).
1.6 Norovirus epidemiology
The GI and GII genogroups, and the more than 25 different genoclusters that
comprise these two genogroups, account for the majority of human norovirus cases.
However, outbreaks of the GII.4 genocluster occur much more frequently than any other
genocluster within the GII genogroup, and GI outbreaks occur even less frequently (20, 36,
96).  Thus, the majority of norovirus outbreaks are caused by the GII.4 genotype, and
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pandemic spread was first recognized in the mid-1990’s (68). During 1995-96, strain
US95/96 was responsible for ~55% of the norovirus outbreaks in the USA and 85% of the
outbreaks in the Netherlands (94).  Between 2000 and 2004, US95/96 was replaced by two
new GII.4 variants.  In the USA, Farmington Hills (FH) (97) was ultimately associated with
~80% of norovirus acute gastroenteritis outbreaks (20).
Simultaneously in Europe, a new GII.4 variant, GII.4b, emerged and caused
outbreaks during the winter, spring and summer (56-58, 63, 74). The incidence of norovirus
outbreaks during the winter of 2002-03 is the highest on record, as reported in the United
States and Europe(1, 36, 92).  In 2004, the Hunter GII.4 variant was detected in Australia,
Europe and Asia (11, 47, 74).  This strain was replaced in early 2006 by two new co-
circulating GII.4 variants in the US, Europe and Asia (2).  One of these was Sakai, which
represents a neoteric GII.4 outbreak strain, associated with outbreaks in healthcare facilities
in Southeast Asia (69), although strains that cluster with Sakai have also been identified in
the United States and the Netherlands.  The second 2006 outbreak strain was Minerva, which
was identified in the US and which is identical to strains identified in the Netherlands (84).
During 2006, the National Calicivirus Laboratory at CDC tested 761 stool specimens from
126 outbreaks in the United States for norovirus by RT-PCR.  Norovirus was confirmed in
114 (90%) of these outbreaks, and 87 (76%) of these were associated with two new GII.4
norovirus variants (Minerva and Laurens(13).
1.7 The norovirus capsid protein
A major limitation to human norovirus research has been the lack of a functional cell
culture system or small animal model.  Therefore, recombinant expression systems have been
developed to generate copious amounts of norovirus capsid protein, which spontaneously
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self-assembles into virus-like particles (VLPs).  VLPs, which are morphologically and
antigenically indistinguishable from native norovirus (5, 25), contain the major immunogenic
and antigenic properties of the norovirus strains they represent, and when generated in
sufficient quantities are important reagents for studying virus-ligand interactions, immune
responses and as vaccines against norovirus infection.  Two recombinant expression systems
have been well characterized and these include the Baculovirus replicon system and the
Venezuelan equine encephalitis (VEE) replicon system (6, 38).  The VEE replicon system is
described in detail in Chapter I of this dissertation.  In the Baculovirus expression system,
wild-type Baculovirus DNA is co-transfected with transfer vector DNA containing a cDNA
copy of a norovirus ORF2 gene of interest.
The Baculovirus replicon system was used to generate a VLP of the Norwalk virus
(NV; a GI.1 virus) by co-transfecting the ORF2 major capsid cDNA into the system, and the
resulting VLP was characterized by electron cryomicroscopy, x-ray crystallography, and
computer imaging to reveal the structure of the intact norovirus capsid (75, 76).   The NV X-
ray crystal structure indicated that the viral capsid is assembled utilizing 180 copies of the
capsid protien organized into 90 dimers in a T = 3 icosahedral symmetry (76) (Fig. 4).
Further, two distinct dimer formations were required to form the higher order structure (75).
In all cases, dimers were formed from identical monomers, with the difference between the
different dimers being one of overall orientation.  C:C dimers were determined to be
important for forming the interior capsid shell (Fig. 4A, B), while the A:B dimers extend
further from the surface (Fig. 4C).  The intact viral capsid (Fig. 4D) utilizes this strategy to
form a tight viral capsid with the necessary protrusions on the surface, which interact with
the cellular receptor for viral attachment and entry (Fig. 4D).
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Figure 4.  Structural subunits of the Norwalk virus VLP.  A.  Two different dimer
interactions are required for formation of the VLP (76).  These include the C:C interaction
(B) which forms a tight shell for the A:B dimers (C) to insert into creating a tight capsid with
protusions (D). Red, A monomer; blue, B monomer; yellow, C monomer. 180 monomers
form the VLP.  This figure was generated using Chimera (see Chapter 1).
The monomer is further divided into two domains known as the shell domain (S)
(residues 1-125), which forms the inner core and the protruding domain (P), linked by a
flexible hinge (Fig.5).  The P domain forms prominent protrusions that extend away from the
structure (75) and is subdivided into two subdomains (Fig. 5).  These include P1 (residues
226-278 and 406-520) which acts as a stem region between S and the second P subdomain,
P2, which is the most surface exposed region of the capsid protein (residues 279-405) (75)
(Fig.5).  The sequence of the P2 subdomain is most variable region in the norovirus genome,
and it contains the receptor binding site(s), and a motif resembling an RNA binding domain
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(12, 75, 87, 93).  Immune pressure and variant HSBG carbohydrate-receptor interactions
likely drives the evolution of the distal regions of P2 as well as some surface exposed P1
residues, which can result in novel patterns of evolutionary and structural changes in the
protein (52, 66)
Mutational analysis of the surface exposed P2 subdomain supports its role in HBGA
binding (55, 88, 90), suggesting that it contains the determinants of strain specificity,
receptor binding (15, 75, 87, 89, 93) and potential neutralizing antibody recognition sites (14,
55).
Figure 5: The domains and subdomains of the NV capsid monomer.  The monomer is
divided into two domains, the Shell (S) and the Protruding (P) domains.  The P domain is
divided further into subdomains P1 and P2.  P1 is important for dimer interaction, while P2 is
the most surface exposed region of the virus.  The flexible hinge region between S and P,
allows flexibility for forming the capsid superstructure (76).
More recently, the complex structures of the P-domain of a GII.4 virus, VA387, in complex
with HBGA trisaccharide A- and B- antigens revealed a ligand interaction site in the P2
subdomain where specific capsid residues form a strong hydrogen bond network with the -
fucose group of the trisaccharide (12) (Fig. 6).  A second interaction site on the VA387 P2
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domain was predicted to stabilize binding and enhance ligand affinity by weaker, long
distance interactions with the -Gal ring of the trisaccharide (12) (Fig. 6).
Figure 6: The P domain structure of a GII.4 capsid in complex with the receptor.  For
each A:B dimer that interacts, there are two identical receptor binding domains formed, by
two distinct sites on the exposed surface.  Site 1, shown in purple, interacts directly with the
fucose group of B-trimer, forming strong hydrogen bonds, whiles site 2, shown in pink,
provides long distant interactions which stabilized binding.  The B trimer is shown in green.
Figure generated in PyMOL from PDB code 2OBT (12).
1.8 The polymorphic norovirus receptor
Norovirus VLPs have been shown to bind to the ABH histoblood group antigens
(HBGAs), and these carbohydrates moieties are likely important receptors for virus infection
in vivo (28-30, 35, 51, 60).  HBGAs are a family of complex glycans found on the surfaces
of red blood cells, expressed in the gut, and on respiratory epithelia.  They are also found in
many biological secretions of humans, including saliva (59).  HBGA expression is regulated
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by several genes that determine which of three biosynthetic pathways is followed, and this
variation leads to polymorphic ABO, Lewis, and secretor phenotypes (Fig. 7).
Figure 7: HBGA Type 1/3 (A) and Type 2 (B) synthesis pathways with enzymatic
modifications by FUT2 and FUT3 genes (51).
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HBGA synthesis begins with a disaccharide precursor (Gal1-3GlcNAc for the Type 1
pathway), and monosaccharides are sequentially added by different glycosyltransferases.
The FUT3 gene, also known as the Lewis enzyme, encodes a fucosyltransferase that adds
fucose residues in -1,3 or -1,4 linkages to the precursor, leading to synthesis of a
trisaccharide of the Lewis A (Lea) phenotype, also known as the non-secretor phenotype.
The alternative pathway to the secretor phenotype, requires the action of the FUT2 gene,
which encodes a fucosyltransferase that adds monosaccharides to the precursor in an -1,2
linkage, creating the H type 1 antigen.  Further activity on the trisaccharide by FUT3 or the A
and B enzymes lead to synthesis of tetrasaccharides Leb, A type 1, and B type 1, respectively
(Fig. 7).  The A and B enzymes add N-acetylgalactosamine or galactose in an -1,3 linkage,
respectively.  The Type 2 pathway begins with the Gal1-4GlcNAc precursor and is also
acted on by FUT2, FUT3, A and B enzymes in a parallel fashion, resulting in the production
of H type 2, Lex, Ley, A type 2, and B type 2, respectively (Fig. 7).  The Type 3 precursor
Gal1-3GalNAc is catalyzed by FUT2, resulting in the H type 3 product that can be further
modified by the A and B enzymes. (Reviewed in (59), The presence or absence of the FUT2
and FUT3 alleles in an individual can determine if that individual is susceptible to norovirus
infection in a strain-specific manner (49).
Epidemiology of outbreaks and human challenge studies following norovirus
infection have provided strong evidence for HBGAs as the natural receptor for norovirus
infection (31, 34, 51, 79).  Further, there appears to be a direct link between expression of
HBGAs and human susceptibility to infection.  Early studies with Norwalk virus
demonstrated that some individuals could not be infected with Norwalk virus upon challenge,
and that these resistant individuals typically clustered in families.  It was further
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hypothesized that the presence of pre-existing antibody did not correlate with protection (39,
46, 73).  More recent studies showed that individuals of blood type O appeared to be more
susceptible to Norwalk virus infection, than other blood type groups (34), and it was
demonstrated that Norwalk VLPs bound to gastroduodenal epithelial cells from secretor-
positive individuals, while VLPs did not bind to the cells of secretor-negative individuals
(60).  The FUT2 gene, carried by secretor positive individuals, encodes a fucosyltranferase
responsible for generating the H type 1 and H type 3 antigens from the disaccharide
precursor, and these are known to be expressed on mucosal surfaces and been shown to bind
Norwalk VLPs (60).  Norwalk VLP does not bind to precursors modified by the A- and B-
enzymes, resulting in the A and B blood types.
Additional studies with other norovirus strains have revealed that susceptibility to
norovirus infection is complicated compared to the Norwalk virus.  A study with the GII.2
Snow Mountain Virus demonstrated that blood type and secretor status did not correlate with
susceptibility to infection (50).  A different study demonstrated that secretor-negative
individuals had significantly lower antibody titers to GII.4 norovirus strains than those of the
secretor-positive phenotype, suggesting that non-secretors are less likely to become infected
with the predominantly circulating norovirus strains than secretors, however, blood type was
irrelevant to infection status (48).  In another report, individuals with blood type B appeared
to have a lower incidence of infection with GI viruses (79).
These observations indicate that while individual norovirus strains may be capable of
infecting only a subset of the human population, however, the diverse binding profiles found
within the GI and GII genogroups may collectively allow nearly all individuals to be
susceptible to a norovirus infection.
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1.9 Receptor binding
The ability of noroviruses to attach to HBGAs is most likely determined by specific
residues encoded in a binding pocket found on the P2 subdomain of capsid, as demonstrated
with the P domain structure of VA387 strain in complex with synthetic A and B
trisaccharides (12) (Fig. 6 and 8).  It is likely that both strain-specific and non-specific
interactions occur between virus and CHO to stabilize binding.  Strain-specific interactions
occurred in site 1 where the alpha-fucose group of the CHO hydrogen bonded with residues
Thr344, Arg345, Asp374, and Gly442 of VA387 (Fig.6 and 8) (101).
Figure 8: The binding pocket found on the VA387 dimer surface.  A.  Chain A and Chain
B form a dimer, which creates two identical receptor-binding domains on the surface.  These
RBDs are further characterized as having two sites that interact with the CHO receptor,
known as site 1 and site 2.  In addition, several other residues proximal to those sites form a
pocket comprised of several residues that likely play a role in engaging and binding the CHO
receptor.   B.  The residues in VA387 that interact in each site.  White represents residues
that likely interact, but in non-specific ways, while pink and purple are sites 1 and 2,
respectively (12). White residues make up the blue/red arms of the pocket.
Interestingly, Cao et al. and Tan et al. had predicted that Thr338 was essential for
receptor binding, and although this residue was not found to interact directly with the CHO,
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it does hydrogen bond with Thr344 which does (12, 87).  Previous studies suggesting the
presence of Asp302 near the receptor binding site and a conserved C-terminal arginine
cluster were important for efficient receptor binding (87, 89) appear to be incorrect, as these
residues are on the opposite side of the structure, although we cannot rule out the possibility
that there are more than one receptor binding sites on the surface.
Long distance interactions between additional non-specific residues are likely necessary for
further stabilization of virus-receptor interactions.  Residues in site 2 provide stabilizing
interactions over long distances.  However, several residues surrounding site 1 and site 2
likely contribute to CHO binding (Fig. 8).
Interestingly, the receptor-binding interface of the Norwalk virus (GI.1) P domain has
also been crystallized, and it is distinctly different from VA387.  In addition, a comparison of
the P domain structures of the GII.3, GII.4, and GI.1 suggest that significant structural
differences occur in the P2 subdomain (Fig. 9).  Such differences may explain why different
norovirus strains exhibit diverse binding profiles to different or multiple members of HBGA
family (Fig. 9).
1.10 Differential receptor usage among norovirus strains
Carbohydrate binding specificities of norovirus strains have been reported and while
genetically related strains can share binding patterns, specific binding profiles are not
exclusive to a given genogroup (32).  Noroviruses can generally be divided into two binding
profile groups: 1) strains that bind A/B and/or H antigens, and 2) strains that bind Lewis
and/or H antigens.  Although no strains had been known to bind both A/B and Lewis
antigens simultaneously, we recently described a Farmington Hills strain from 2002 which
bound to A and Lea and Ley (See Chapter IX).
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Figure 9: Comparing structures of the GII.4 protruding domain with that of GII.3 and
GI.1.  A.  The GI.1 P domain structure (light blue) superimposed upon the GII.4 structure
(green) reveals that the GII.4 contains three additional loops in the P2 domain.  B.  A
homology model of the GII.3 norovirus, dark blue, superimposed upon the GII.4 structure
suggests that while they are very similar, the GII.3 structure contains a long loop inserted in
the P2 region.  The molecules are shown in different orientations to highlight the differences.
Figure generated using PyMOL.
Many strains from either of the two binding groups can bind H antigens, and in fact the H
epitopes have been shown to be independent docking sites for virus attachment. In addition,
blockade studies have shown that H antigens can inhibit binding of strains that also bind A/B
or Lewis antigens, but the A/B or Lewis antigens cannot block each other. These data argue
that strains in the two binding profile groups have distinct binding sites on the viral capsid.
A third binding group contains noroviruses that do not bind to any known HBGA ligands.
This observation suggests that additional receptors may be used by noroviruses, or that the
appropriate carbohydrate has yet to be identified.
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1.11 Human immunity to the noroviruses
Norovirus outbreaks and human challenge studies have provided the only available
reagents with which to study norovirus immunity in humans.  While susceptibility studies
have demonstrated that some individuals are resistant to infection with a specific norovirus
(51); these observations are likely confounded by previous exposure history and the variable
immune response generated by different individuals.  Early human challenge studies
suggested that individuals with high serum or fecal antibody titers to Norwalk virus prior to
challenge, had a greater chance of becoming infected with the virus than individuals with low
pre-existing antibody titers (7, 24, 39, 70).  Furthermore, most of these individuals were
resistant to subsequent infection with the same virus six months later, although some did
become infected.  Interestingly, less than half of the immune individuals maintained high
antibody titers six months after secondary challenge (39).
Studies looking at long-term immunity have showed that all of the individuals
initially infected with Norwalk virus were re-infected, with symptoms, upon challenge with
the same virus 27-42 months later (73).  Another study showed that individuals without
common pre-exposure factors, who were genetically susceptible to Norwalk virus infection,
never became infected (51).  These findings are contradictory, making it difficult to discern
the exact role of antibodies in preventing norovirus infection.  While there is evidence for
short-term immunity, a long-term persistent immune response is most likely confounded by
pre-exposure to the large number of circulating norovirus strains and the frequency with
which many humans are exposed to them.
Results from a cross-challenge study of volunteers infected with Norwalk virus (GI.1)
who were still susceptible to subsequent infection with Hawaii virus (GII.1) suggests that
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immunity to one strain is unlikely to confer cross-genogroup protection against infection with
another strain (99).  In addition, cross-reactivity studies have demonstrated that antibodies
can recognize heterologous norovirus antigens, particularly within a genogroup (27, 50, 67,
77, 79, 91).  However, while homotypic antibodies from human antisera following infection
can completely block VLP binding to synthetic HBGA receptors, heterotypic antisera to
strains within the same genogroup are less able to do so (30, 77, 79).
1.12 Evolution of the capsid within a genocluster
While many studies have compared strains from different genogroups and/or different
genoclusters to determine human susceptibility, very little work has been done with strains
found within a specific genocluster.  The paradigm has suggested that strains within a
genocluster are similar enough that the differences between them would be insufficient to
generate an unique immune response.  However, the predominance of the GII.4 cluster as the
leading cause of norovirus infections over the past 20 years, and the ability of this
genocluster to generate pandemic outbreaks of norovirus, has stimulated more interest in
determining the features of this genocluster that make it so successful.   Sequence analysis
and molecular phylogenetics of the GII.4 viruses has demonstrated that this genocluster can
be further divided into subclusters, each of which is related to a specific pandemic outbreak
strain (Fig. 10).
These subclusters include: (1) the Camberwell cluster, which ranges from
1987–1995; (2) the Grimsby cluster from 1995 to 2002; (3) the Farmington Hills cluster from
2002–2004; (4) the Hunter cluster from 2004–2006; and (5) the Sakai cluster, which includes
viruses isolated 2004–2006.  A new Den Haag/Minerva cluster has recently been identified.
The Camberwell cluster was ancestral, so little is known about this cluster.  All of the other
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clusters represent viral strains that caused pandemics.  This tree suggests an epochal
evolution, whereby some clusters persisted for several years, followed by burst of evolution,
followed by more stasis (52, 84).
 
Figure 10: Variation within the GII.4 genocluster result in additional subclusters.  A.
The sites of variation in the GII.4 capsid were exported to this table and ordered by time.
Each color represents amino acids changes that were acquired in within the subcluster.  B.  A
Bayesian tree of the entire capsid amino acid sequence demonstrates that the amino acid
differences resulted in different subclusters. The subclusters include: Camberwell, yellow;
Grimsby, red; Farmington Hills, blue; Hunter, green; Sakai, orange.  Purple indicates new
viruses of the Den Haag/Minerva cluster (See Chapter IX).
Mapping the variation between the clusters on the VA387 structure indicated that
much of the variation observed between these subclusters occurred in or near the receptor
binding domains (Fig. 11).  From these observations we speculated that: 1) The variable sites
allowed the different GII.4 viruses to evade the immune response by changing antibody
recognition sites on the surface; and 2) That this variation would result in differential binding
patterns to different CHO receptors.  In Chapter IX, we describe this work in detail and show
that the GII.4 genocluster is evolving in response to herd immunity, and as a consequence of
A                                                                              B
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this evolution, each cluster acquires unique immunologic properties, and expanded host
range, or both (52, 84).
Figure 11: Variation within the GII.4 viruses mapped onto the dimer.  The structures are
arranged from left-to-right, followed by top-to-bottom such that row one is Camberwell
(1987), Grimsby (1997), Farmington Hills (2002), and row two contains Hunter (2004) and
Sakai (2005).  Changes are cumulative, with each clusters changes being added onto the
structure in a time ordered fashion.
1.13 Summary
In contrast to assertions in many textbooks, Noroviruses are important human
pathogens, which infect millions of people each year in the United States, and worldwide.
Although the duration of the symptoms is short-lived (24-72 hours), the onset and
presentation of this severe form of gastroenteritis is painful.  Since noroviruses require a low
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ID50 of 10-100 virions to establish an infection, are highly stable in the environment, and are
readily spread human-to-human; eradicating these viruses from an outbreak setting can be
nearly impossible.
Diversity among the norovirus genus likely contributes to the virus’ ability to persist
in human populations.  While humans are polymorphic in expressing the HBGAs, thought to
serve as the receptors for entry into cells, different genogroups and genoclusters appear to
bind to different arrangements of HBGA, which implies that some individuals may be
resistant to some norovirus strains, but probably not all.
Studies with different genoclusters and genogroups have shown that norovirus
immunity is complicated, and probably confounded by pre-existing exposure histories and
variable immune responses.  While, there is some evidence for both short term and long-term
immunity to a given strain, in most cases there is also evidence to the contrary.
The crystal structure of the protruding domain of a GII.4 virus has shown how the P2
subdomain interacts with the B-trimer.  This interaction is important, as it identifies key
residues that likely define how the virus interacts with the wide range of glycans that are
processed as HBGAs.  Studies within the GII.4 cluster show that variation within that cluster
occurs near these receptor-binding domains, and probably results in differential binding
profiles and an altered immune response.  These observations suggest that the norovirus
capsid is capable of evolving several solutions to the single problem of evading the immune
system while retaining its ability to bind to some HBGA.  In the next chapter, we show that
even minimal evolution with a single amino acid difference in the capsid can have profound
impacts on receptor usage and immune response.
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ABSTRACT
Noroviruses are the leading cause of viral acute gastroenteritis in humans, noted for causing
epidemic outbreaks in communities, the military, cruise ships, hospitals, and assisted living
communities.  The evolutionary mechanisms governing the persistence and emergence of
new norovirus strains in human populations are unknown.  Primarily organized by sequence
homology into two major human genogroups defined by multiple genoclusters, the majority
of norovirus outbreaks are caused by viruses from the GII.4 genocluster, which was first
recognized as the major epidemic strain in the mid-1990’s. Previous studies by our laboratory
and others indicate that some noroviruses readily infect individuals who encode a functional
alpha 1,2 fucosyltransferase gene (FUT2) and are secretor-positive because they express
ABH histoblood group antigens (HBGAs), a highly heterogeneous group of related
carbohydrates on mucosal surfaces.  Individuals who encode defects in the FUT2 gene, are
termed secretor-negative, don’t express the appropriate HBGA necessary for docking and are
resistant to Norwalk virus infection.  These data argue that the FUT2 gene and other enzymes
that regulate processing of the HBGA carbohydrates function as susceptibility alleles.
However, secretor-negative individuals can be infected with other norovirus strains and re-
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infection with the GII.4 strains are common in human populations.  In this manuscript, we
reveal the molecular mechanisms governing GII.4 epidemiology, susceptibility and
persistence in human populations.
Phylogenetic analyses of the GII.4 capsid sequences suggested an epochal evolution
over the last twenty years with periods of stasis followed by rapid evolution of novel
epidemic strains. The epidemic strains show a linear relationship, whereby serial
replacements emerge from the previous cluster.  Five major evolutionary clusters were
identified and representative ORF2 capsid genes for each cluster were expressed as virus-like
particles (VLPs).  Using salivary and carbohydrate binding assays, we show that GII.4 VLP-
carbohydrate ligand binding patterns changed over time and included carbohydrates
regulated by the human FUT2 and FUT3 pathways, suggesting that strain sensitivity to
human susceptibility alleles will vary.  Variation in surface exposed residues and in residues
that surround the fucose ligand interaction domain suggested that antigenic drift may
promote GII.4 persistence in human populations.  Evidence supporting antigenic drift was
obtained by measuring the antigenic relatedness of GII.4 VLPs using murine and human sera
and demonstrating strain specific serologic and carbohydrate binding blockade responses.
These data suggest that the GII.4 noroviruses persist by altering HBGA carbohydrate binding
targets over time, which not only allows for escape from highly penetrant host susceptibility
alleles, but simultaneously allows for immune driven selection in the receptor binding region
to facilitate escape from protective herd immunity.
Our data suggest that the surface exposed carbohydrate ligand binding domain in the
norovirus capsid is under heavy immune selection and likely evolves by antigenic drift in the
face of human herd immunity.  Variation in the capsid carbohydrate-binding domain is
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tolerated because of the large repertoire of similar, yet distinct HBGA carbohydrate receptors
that are available on mucosal surfaces that could interface with the remodeled architecture of
the capsid ligand binding pocket.  The continuing evolution of new replacement strains
suggests that, like influenza virus, vaccines can be targeted that protect against norovirus
infections and that continued surveillance and reformulations of norovirus vaccines will be
essential components in controlling future outbreaks.
1. INTRODUCTION
Globally, noroviruses are the 2
nd
 most important cause of severe viral gastroenteritis
in young children, cause 20% of endemic diarrheal disease in families, cause travelers
diarrhea in all ages and are especially virulent in the elderly, as evidenced by recent reports
of 19 deaths associated with norovirus acute gastroenteritis in 2006 in long-term care
facilities in the United States (1, 19, 33, 40).  In addition to human costs, norovirus infections
cause severe economic loses as a single 3 month hospital outbreak may incur expenses that
approach or exceed $650,000 in supplies, staff time off and closed beds (37).  Although
noroviruses were first observed in 1968, the basic principles governing their molecular and
evolutionary epidemiology and persistence in human populations is unclear, but is critically
important for devising intervention strategies, therapeutics and vaccines which could
minimize the high morbidity, low mortality and extensive economic burdens associated with
disease outbreaks.
Noroviruses are ~38 nm iscosahedral viruses and contain a ~7.5 Kb single-stranded,
positive-sense RNA genome that encodes three large open reading frames including the
ORF1 replicase polyprotein and the major and minor structural ORFs 2 and 3, respectively.
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These highly heterogeneous viruses have been genetically grouped into five different
genogroups (GI-GV) of which the GI and GII genogroups are further subdivided into more
than 25 different genotypes (for example GII.4 is genogroup II genotype 4), and account for
the majority of human cases.  The ORF2 major capsid protein sequence can diverge by as
much as 60% between genogroups and ~20-30% between genotypes within a genogroup.
The majority of norovirus outbreaks are caused by the GII.4 genotypes and pandemic spread
was first recognized in the mid-1990’s (56). During 1995-96, strain US95/96 was responsible
for ~55% of the norovirus outbreaks in the USA and 85% of the outbreaks in the Netherlands
(91).  Between 2000 and 2004, US95/96 was replaced by two new GII.4 variants. In the
USA, Farmington Hills (FH) (93) was ultimately associated with ~80% of norovirus acute
gastroenteritis outbreaks (20).  Simultaneously in Europe, a new GII.4 variant, GII.4b,
emerged and caused outbreaks during the winter, spring and summer (50, 54, 65).  In 2004,
the Hunter GII.4 variant was detected in Australia, Europe and Asia (7, 42, 65).  This strain
was replaced in early 2006 by two new co-circulating GII.4 variants in the US, Europe and
Asia (1).  One of these was Sakai which represents a neoteric GII.4 outbreak strain associated
with outbreaks in healthcare facilities in Southeast Asia (58), although strains which cluster
with Sakai have also been identified in the United States and the Netherlands.  The second
2006 outbreak strain was Minerva, which was identified in the US and which is identical to
strains identified in the Netherlands (1).
Norwalk virus (NV, a GI.1 virus) readily infects individuals who encode a functional
FUT2 1,2 fucosyltransferase enzyme that allows expression of histo-blood group antigens
(HBGAs) on mucosal surfaces and a secretor-positive phenotype (46).  Individuals who
encode defects in the FUT2 enzyme are secretor-negative; don’t express the appropriate
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HBGAs necessary for docking and perhaps entry, and are resistant to infection.  The
association between HBGA expression and norovirus susceptibility has been confirmed for
NV and other select GI and GII strains, including GII.4 (32, 34, 39, 43, 87).  However, other
enzymes may serve as susceptibility factors as well since secretor-negative individuals have
antibodies against human noroviruses, although at lower titers than secretor positive
individuals (43, 45, 46), and develop clinical illness after challenge with SMV (GII.2)(45).
The evolutionary mechanisms governing the persistence and epidemic spread of the GII.4
viruses in human populations are unknown.
Expression of the norovirus ORF2 major capsid protein produces virus-like particles
(VLPs) and the NV X-ray crystal structure indicates that dimer formation is required to form
the higher order structure comprised of 180 subunits (67).  The monomer has two domains
known as the shell domain (S) which forms the inner core and the protruding domain (P),
linked by a flexible hinge.  P domain forms prominent protrusions that extend away from the
structure (67) and is subdivided into two subdomains.  These include P1(residues 226-278
and 406-520) which structurally flanks P2, which is the most  surface exposed region of the
capsid protein (residues 279-405) (67).
Mutational analysis of the surface exposed P2 subdomain supports its role in HBGA
binding (49, 82, 84), suggesting that it contains the determinants of strain specificity,
receptor binding (11, 67, 83, 85, 90) and potential neutralizing antibody recognition sites (10,
49).  More recently, the complex structures of the P-domain of a GII.4 virus, VA387, in
complex with HBGA trisaccharide A- and B- antigens revealed a ligand interaction site in the
P2 subdomain where specific capsid residues form a strong hydrogen bond network with the
-fucose group of the trisaccharide (9).  A second interaction site on the VA387 P2 domain
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was predicted to stabilize binding and enhance ligand affinity by weaker, long distance
interactions with the -Gal ring of the trisaccharide (9).
In this manuscript, we study the molecular mechanisms governing the emergence and
persistence of novel epidemic strains in human populations.
2. MATERIALS AND METHODS
2.1 Sequences and Sequence Analysis
One-hundred and sixty-seven full-length GII.4 capsid sequences were downloaded
from GenBank, six sequences were obtained from our collaborators at the CDC, and three
were included from our own in-house collection, for a total of 176 full length amino acid and
nucleotide capsid sequences.  The amino acid sequences were aligned by ClustalXv1.83 (13)
using the PAM distance matrix and default parameters.  A variety of parameters and
substitution matrices for the alignment were evaluated using the program TuneClustalv1.0
(generously provided by Dr. Barry G. Hall) and the PAM series matrix was determined to be
the most appropriate, with default gap opening and extension values.  The alignment was
refined manually, and 211 sites of variation, defined as any site with a quality score of less
than 100, were exported in table format and ordered by sequence identity, and then by date of
isolation.  The sequences were divided into clusters defined as groups of sequences
containing a minimum of 98% sequence identity with each other, as determined by the
Blastclust program provided on line by the Max Planck Institute
(http://toolkit.tuebingen.mpg.de).  Clusters were further divided into subclusters, which were
defined as a smaller cluster of sequences that shared a minimum of five identical sites that
differed from the main cluster.  Each cluster and subcluster was ordered by year of isolation.
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The 211 variable sites were further refined to identify informative sites, such that columns in
the table were removed based on the following criteria: 1) columns with single amino acid
replacements; 2) columns containing multiple single incongruous amino acid replacements;
3) columns containing random amino acid replacements not associated with a geographic
lineage or specific cluster; and 4) lineage specific replacements that were noninformative.
This reduced the 211 variable sites to 59 informative sites.  Major clusters were defined as
those that contained a minimum of five sequences.  One sequence representative of each of
the major clusters was selected and aligned with VA387, the reference strain.
In addition to the amino acid multiple alignment, the nucleotide sequences were
aligned as codons using the program PAL2NAL (79) which aligned the corresponding
nucleotide sequences based on the amino acid alignment.
2.2 Positive Selection Analyses
To determine if positive selection occurred during the evolution of the GII.4 strains
over the past 20 years, five codon sequences from each of the five major clusters were
selected and aligned. The Model Selection tool of the HyPhy Package (41, 66) was used to
determine that the TrN model of evolution was the most appropriate for conducting the
analyses, and three different codon-based maximum likelihood methods were used to
estimate the dN/dS ratio at every codon position in the alignment to determine if positive
selection occurred.  These methods included: 1) single-likelihood ancestor counting (SLAC),
2) fixed effects likelihood (FEL), and 3) random effects likelihood (REL).
2.3 Recombination Analysis
In addition the Genetic Algorithms for Recombination Detection (GARD) and the
Single Break Point (SBP) methods of the HyPhy Package were utilized to determine if
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recombination occurred within the capsid sequences.  Further, the Recombination
Identification Program (RIP) version 1.9 beta (http://www.hiv.lanl.gov/content/hiv-
db/RIPPER/rip_test.html) was used as an alternative approach to determine if recombination
was a factor in capsid sequence evolution.
2.4 Phylogenetic Analyses
 Phylogenetic analyses were conducted using two different approaches and by three
different strategies.  In all cases, amino acid alignments were used to generate trees by both
Bayesian inference (BI) of phylogeny using Mr. Bayesv3.12 (71) and by two Maximum
Parsimony (MP)(18) methods: 1) Molecular Evolutionary Genetics Analysis (MEGA) 4.0
package (81) and 2) Phylogenetic Analysis Using Parsimony (PAUP) version 4.0b10 (80).
For MrBayes, the alignment was exported in the nexus format, the amino acid substitution
model was set to Dayhoff (16)using the lset command, and Markov chain Monte Carlo
simulation (25, 29, 31) was used to approximate the posterior probabilities of trees with
sampling conducted on four chains over 500,000 generations (72). Trees were sampled every
100 generations, and the 5001 trees collected were summarized with the sumt command set
to a burnin of 1000, which generated a consensus tree using the 50% majority rule (72).  The
burnin value was determined using the sump command with an arbitrary burnin of 250
which, demonstrated that stationarity occurred prior to the 100,000
th
 generation, indicating
that a burnin of 1000 was appropriate for the sumt command (72).
For the Maximum Parsimony analysis (18)using Mega 4.0, a bootstrap consensus tree
inferred from 100 replicates was generated to represent the evolutionary history of the taxa
analyzed (21). Branches corresponding to partitions reproduced in less than 50% bootstrap
replicates were collapsed. The percentage of replicate trees in which the associated taxa
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clustered together in the bootstrap test (100 replicates) were shown next to the branches (21).
The MP tree was obtained using the Close-Neighbor-Interchange algorithm (55)with search
level 3 (21, 55) in which the initial trees were obtained with the random addition of
sequences (10 replicates). The trees were drawn to scale, with branch lengths calculated
using the average pathway method (55) and were displayed in the units of the number of
changes over the whole sequence.  All positions containing gaps and missing data were
eliminated from the dataset.
Maximum Parsimony trees were also generated utilizing the tree bisection-
reconnection branch-swapping method under the heuristic search option of the parsimony
program of PAUP 4.0b10 (80).  Since bootstrapping under the heuristic search option of the
parsimony criterion of PAUP4.0b10 for MP trees comprised of greater than 150 taxa is
computationally intensive, the consensus trees from the PAUP4.0b10 analyses were
compared to the less robust bootstrapped trees generated by MEGA4.0. Only the most
relevant P2 alignment was bootstrapped under PAUP4.0b10.
In the first strategy, all 176 full length capsid amino acid sequences were used to
generate trees by each method.  Using the second strategy, all full length amino acid
sequences were divided into groups based upon geographic isolation and trees were
generated by both methods.  In the third strategy, the capsid amino acid sequence of all 176
sequences was divided into the three structurally defined domains and subdomains of Shell,
P1 and P2, and trees were generated for each of these alignments by both methods.  All trees
generated were viewed using TreeViewPPC version 1.6.6 (60) or with tools from the
MEGA4.0 package.
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Further, the bootstrapped MP trees generated by MEGA 4.0 for the entire capsid,
Shell and P1 were compared to trees generated utilizing the tree bisection-reconnection
branch-swapping method under the heuristic search option of the parsimony program of
PAUP 4.0b10 (80).  For the P2 subdomain, bootstrapped trees were generated and compared
using both methods.  In addition, ancestral sequences were generated for selected nodes
using the ANCECON program at the Max Planck Institute(http://toolkit.tuebingen.mpg.de/).
2.5 Mapping informative sites onto the predicted structure
The X-ray crystal structure of the P domain of GII.4 virus VA387 in complex with
the B-trisaccharide (9) (PDB accession no. 2OBT) was used to generate comparative models
of each representative sequence using the program 3D-Jigsaw (3, 4, 15), with default
parameters, and Modeller version 8.2 using the automodel class (22, 52).  Five models of
each were generated and the model with the lowest objective function score was selected for
analyses.  The PDB files generated by these programs were visualized on molecular
modeling tools MacPyMol (DeLano Scientific) and Chimera (63).  The evolving sites were
mapped onto each model and onto the tertiary and quaternary structures of the P domain of
VA387 in complex with A and B trisaccharides (9). Rosetta Design (47) was used to generate
relevant biological units for GII.4-1987 based upon the VA387 biological unit PDB file
(accession no. 2OBT).  Briefly, the changes that define GII.4-1987 were made on both chains
of the VA387 template using the Rosetta Design web server (http://Rosetta
Design.med.unc.edu/index.html) with default parameters. In addition, residues within 5
Angstroms of the variable sites were relaxed to allow repacking of side chains in the
presence of the engineered mutations.  Ten Models were generated, with all ten predicting
nearly identical structures.
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2.6 VEE Replicon Particles (VRPs) and norovirus Virus-like Particles (VLPs)
Capsid gene constructs for each of the representative strains were designed and
synthesized as reported previously (17).  Briefly, the ORF2 genes of GII.4-1997 (LV-NC1)
(48) and GII.4-2002 and 2002a were derived from RT-PCR products from outbreak stool
samples collected in 1997, 2002 and 2004 (92) while the ORF2 genes of GII.4-1987, GII.4-
2004 and GII.4-2005 were synthesized commercially by BioBasic
(https://www.biobasic.com/index.php).  To create GII.4-1987 D393G, a primer was designed
to replace the Asp395 of GII.4-1987 with Gly395 of GII.4-1997 and the amino acid change
introduced by PCR.  All ORF2 constructs were then inserted directly into the VEE replicon
vector for the production of VRPs (VRP-GII.4-1987, VRP-GII.4-1997, VRP-GII.4-2002a,
VRP-GII.4-2002, VRP-GII.4-2004, VRP-GII.4-2005) (2, 48). The VLPs were expressed in
VRP-infected BHK cells, purified and visualized by negative staining EM (2, 48).
2.7 Carbohydrate Binding Assays
VLP binding to HBGA-phenotyped salivary samples was determined as reported (28,
48), with the exception of the use of mouse anti-VLP anti-sera (either strain-specific or
cocktails) followed by anti-mouse- alkaline phosphatase (Sigma Aldrich, St. Louis, MO) and
pNPP (Sigma Aldrich) for VLP binding detection.  VLP binding to synthetic HBGAs was
determined using Neutri-avidin coated plates (Pierce, Rockford, IL) treated with 10μg/ml
biotinylated carbohydrate (Glycotech, Gaithersberg, MD and the Consortium for Functional
Glycomics Grant number GM62116) for one hour and washed with PBS-0.05% Tween 20
before the addition of 1-2μg/ml VLP for 1.5 hours at 37 oC or room temperature.  VLP
binding was detected as described above.  Blockade assays included serum pretreatment of
the VLP for 1 hour at 37 
o
C or room temperature before addition to the carbohydrate-bound
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plate.  Assays using mouse antisera for blockade used rabbit polyclonal anti-GII VLP
antisera followed by anti-rabbit IgG-AP (Sigma) for VLP binding detection.  Blockade titer
50% (BT50) titers were defined as the lowest percentage of sera tested that blocked 50% of
binding compared to levels determined in the absence of antibody pretreatment.  Serum
samples that did not reach a BT50 by the maximum % sera tested were assigned a BT50
value equal to 2X the maximum % sera tested for statistical analysis.
2.8 Serology
Samples from an archived GII.4 outbreak occurring in 1988 were obtained from the
National Calicivirus Laboratory of the CDC, (Atlanta, GA) and are summarized in Table 1.
Any serum pair with a norovirus-positive stool sample or a 4-fold increase in anti-LV87 or
LV97 IgG response between acute and convalescent samples (seroconversion) was studied
for IgG reactivity and HBGA-VLP blockade across the panel of VLPs. Mice were
immunized with VRP constructs as described (48).  Geometric mean titers of both human
and murine VLP-reactive serum IgG were measured by ELISA (45, 46, 48) using VLP-
binding detection methods as described above.  Human and mouse anti-VLP serum IgG was
compared to a purified IgG of known concentration for quantitation.
2.9 Statistical Analysis
The Mann-Whitney 2-tail test (M-W test) was used to compare the median IgG
responses between groups and linear regression analysis was used to compare trends of IgG
reactivity across the VLP panel for human serum samples. The One-way ANOVA (ANOVA)
was used to compare responses between murine immunization groups.
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Table 1: Characteristics of the GII.4 outbreak samples used in this study.
3. RESULTS
3.1 Sequence Analyes and Molecular Phylogeny of the GII.4 Capsid
An amino acid multiple alignment of 176 full length GII.4 capsid sequences was
generated and columns of heterogeneity were exported as a table, and ordered by time.  The
211 variable sites were refined to 59 informative sites, and six distinct clusters were
identified based upon sequence identity.  The five major evolutionary clusters were
associated with and named according to outbreak strains.  These five clusters include:  1) the
Camberwell cluster which ranges from 1987-1995, 2) the Grimsby cluster from 1995 to
Outbreak Name 1988
Date April 1988
Location SD
Setting VA Hospital
Transmission Mode Person to Person
Mean Age 64
% Female 16
# Stool collected 25
# Stool PCR positive 5/18
# Sequenceda 1/5
Genoclusterb GII.4 Camberwell
# Serum pairsa,c 17/25
Stool HBGA binding
a H type 3 (4/4)
a # of samples positive / # of samples tested
b Determined by sequence of region C.
c 
acute (days 2-5 post-exposure) and
convalescent (days 20-22 days post-
exposure) serum pairs stored at -20
o
C since
collection.
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2002, 3) the Farmington Hills cluster from 2002 to 2004, 4) the Hunter cluster from 2004 to
2006, and 5) the Sakai cluster which includes viruses isolated from 2004 to 2006.
One representative sequence was selected from each major cluster, and these were named
according to the date of isolation. For the Camberwell cluster MD145_12.1987.US
(gb|AY032605.1) was selected and named GII.4-1987; for the Grimsby cluster, an in-house
Lordsdale 1997 (LV-NC1)(48) isolate was used as the representative sequence and it was
named GII.4-1997; two sequences were used, based upon two in-house isolates, to represent
the Farmington Hills clusters, and these were named GII.4-2002 for the cluster
representative, and GII.4-2002a for a variant that differs by two replacements, one at position
226 (Pro in GII.4-2002 and Ser in GII.4.2002a) and one at site 395 (Ala395 in GII.4-2002
and Thr395 in GII.4.2002a); the Hunter cluster representative is Hunter284E.04O.AU
(gb|DQ078794.2), and it was named GII.4-2004; and the Sakai.04_179.2005.JP
(dbj|AB220922.1) sequence was selected as the representative sequence for the Sakai cluster
and was referred to as GII.4-2005.  These sequences were aligned with VA387 as a reference
sequence and informative sites were exported to a table (Fig. 1).  In addition, interaction sites
identified in a recent structural study of the VA387 P domain were included (Fig. 1).
The sixth cluster, named Den Haag, was comprised of three viruses isolated in 2006,
and also contains Minerva, one of the co-circulating GII.4 strains that caused the GII.4
pandemic in the winter of 2006 (1).    The extent of diversity among the clusters of GII.4
viruses is approximately 2%, with a total sequence identity of ~90% occurring between the
earliest cluster, Camberwell, and the extant clusters, Hunter, Sakai, and Den Haag.  While
variation was noted in the S, P1, and P2 regions of the capsid; the majority of heterogeneity
occurred within the P2 subdomain (Fig. 1).  Of the two receptor interaction sites recently
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reported, site 1 was strictly conserved in all clusters, while the second site was highly
variable at positions 393 through 395 (VA387 numbering) (Fig. 1).  Of note, strains
occurring after the Grimsby cluster encoded an inserted amino acid between positions 393
and 394 of VA387 (Fig. 1).
Figure 1:  Evolutionary analysis of representative GII.4 strains from 1987 to present.
Five major evolutionary patterns were observed in the mutational profiles of the GII.4
sequences, and these are represented by: GII.4-1987, GII.4-1997, GII.4-2002, GII.4-2004,
and GII.4-2005.  Amino acids present in the late 1980s Camberwell cluster (GII.4-1987) are
highlighted in yellow, changes that occurred to form the Grimsby (GII.4-1997) cluster are
noted in red, changes associated with the Farmington Hills (GII.4-2002) cluster are blue,
changes specific to the Hunter cluster (GII.4-2004) are green and substitutions important for
the Sakai cluster (GII.4-2005) cluster are orange.  A second GII.4.2002a sequence is included
as it encodes a single amino acid replacement at positively select position 395 in the P2
subdomain as compared to GII.4.2002.  The P2 region is highlighted in dark blue beneath the
amino acids, with the N-terminal and C-terminal flanking regions of heterogeneity noted in
black for the Shell domain and brown for P1.  Lavender sites represent residues that
hydrogen bond to the ligand at site 1, framed residues have been predicted to interact in a
second stabilization domain. Amino acids operating under positive selection are marked
below the column with a plus sign.  Residues that are not colored represent single amino acid
changes that were not seen in other strains in the cluster. Strain VA387 is included for
comparison, as it is a Grimsby-like virus with a solved crystal structure of the P domain.
Bold residues represent amino acids which reverted to a residue from a previous cluster.
The fact that most amino acid replacements occurred in the surface-exposed P2
subdomain indicated that the different regions of the capsid protein were evolving under
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different evolutionary constraints, suggesting that the P2 region may be evolving by positive
selection in response to herd immunity (61, 74).  To determine if positive selection occurred
during the evolution between the earliest cluster, Camberwell, and the extant clusters, five
sequences were selected from each major cluster, the 25 codon sequences were aligned, and
the alignment was analyzed using HyPhy to detect positive selection by three methods.
Table 2: Detection of positive selection.  A codon alignment was generated using five
sequences from each major cluster, and the dN/dS ratio was determined at every codon
position in the alignment to determine if positive selection occurred using: 1) single-
likelihood ancestor counting (SLAC), 2) fixed effects likelihood (FEL), and 3) random
effects likelihood (REL) methods of the HyPHY package. This table presents the 10 sites that
are predicted to be operating under positive selection.  dN/dS ratios and p-values are shown
for the SLAC and FEL methods and the Bayes factor is shown for the REL analysis. P-value
for SLAC was 0.2, FEL was 0.1, and the minimum Bayes factor value was set at 40.  Gray
boxes indicate residues that were significant for each method.  In addition, this analysis was
repeated three times using random selections of five sequences from each major cluster and
the residue positions indicated by an asterick (*) were predicted to be operating under
positive selection in all cases.
Only five unique sequences were selected per cluster, as this was the maximum number of
sequences available for the smallest major cluster, the Camberwell cluster.  This approach
indicated that 10 sites evolved by positive selection and these included residues at positions
6, 9, 355, 372, 393, 394/395 (site 394 in viruses of the Camberwell and Grimsby clusters and
position 395 of all later clusters), 412, 505, and 534 (Table 2).   Of note, this analysis was
Codon SLAC dN-dS SLAC p-value FEL dN-dS FEL p-value REL dN-dS REL Bayes Factor
6 2.128 0.481 2.294 0.095 0.502 72.757
*9 3.204 0.33 2.908 0.056 0.632 159.935
*355 2.128 0.481 1.682 0.138 0.41 48.935
365 3.315 0.298 2.223 0.079 0.626 149.129
*372 2.128 0.481 1.941 0.117 0.455 58.71
393 1.845 0.516 2.738 0.253 0.127 40.072
*395 5.422 0.146 4.786 0.015 0.685 231.954
412 2.198 0.451 1.498 0.148 0.38 42.047
*505 2.15 0.478 2 0.114 0.46 60.32
*534 4.428 0.198 3.043 0.118 0.466 85.438
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repeated three times using different random selections of five sequences from each of the five
major clusters, and in all cases residues 9, 355, 372, 394/395, 505 and 534 were indicated as
operating under positive selection (Table 2).
3.2 Origin of Outliers
Five outlier sequences were identified that did not appear to be associated with any
cluster, and all of these had amino acid replacement patterns similar to two different clusters
in different regions of the protein, as would be expected in the event of recombination, which
has been reported for several genogroups of noroviruses (64).  Recombination analyses using
the HyPhy package and RIP identified a putative breakpoint at position 794 of ORF2, and
four of the five outlier sequences appear to be recombinants based on analyses performed by
both methods (Table 3).
Table 3: Recombination detection analysis.  Genetic Algorithms for Recombination
Detection (GARD) and the Single Break Point (SBP) methods of the HyPhy Package were
utilized to determine if recombination could explain the occurrence of the outlier sequences,
which did not fall within any identified cluster.  These methods predicted that a breakpoint
occurred at position 794 and showed that trees generated using nucleotides 1-794 and 795-
1620 produced different evolutionary relationships of the outliers.   Further, the
Recombination Identification Program (RIP) version 1.9 beta was used to determine amino
Table 3: (continued) acid sequence similarity by comparing the known clusters to the
potential recombinants.  CM, Camberwell; GR, Grimsby; FH, Farmington Hills; SK, Sakai;
R, recombinant; M, mosaic.
   GARD/SBP    breakpoint (794)       RIP1.9 Analysis
Virus Cluster 1-794     Cluster 795-1620 from: to: to: Status
Erfurt/007/00/DE Outlier of GR Outlier of CM CM GR FH R
Lanzhou/35666/02/CHN SK Outlier of SK CM FH R
Richmont/94/US CM Outlier of CM CM GR R
EmmenE006/02/NL CM Outlier of CM CM/GR CM/GR M
GA04/2004/US Outlier of FH FH CM FH R
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These include Lanzhou 35666.2002.CHN, Ga04.2004.US, Richmont.94.US and
Erfurt.007.00.DE. In addition, two sequences were identified with sequence anomalies:
EmmensE006.NL that appears to be mosaic (Table 3), and Beijing.CR2905.CHN which
contains many unique mutations and a deletion which may be the result of sequencing error.
3.3 Patterns of Molecular Evolution
Analyses of the Bayesian and Maximum Parsimony phylogenetic trees suggested that
GII.4 capsid evolution was complex.  Analysis of the full length capsid amino acid sequences
by these two approaches identified similar, but not identical trees in which all six identified
clusters were represented (Fig. 2 A and B).  However, evolutionary patterns from the earliest
to the latest cluster were confounded.  While the Camberwell cluster was predicted to give
rise to the Grimsby cluster, all extant clusters arose from a single last common ancestor
(LCA) that likely evolved from the Grimsby cluster.  However, no single evolutionary
pattern was discernible, suggesting a complex evolutionary pattern in ORF2.  In addition,
there were several outliers that did not cluster with any specific group (Fig. 2 A and B).
To rule out the possibility that geographic variation confounded the overall
phylogeny, we employed a second approach where the sequences were separated by
geographic region of isolation and analyzed by BI and MP.  Four major groupings were
analyzed with sequences derived specifically from the Netherlands, the United Kingdom,
Germany, and the United States.  However, sampling biases and lack of sequences over the
course of the 20-year time frame for each region resulted in trees that for the most part were
incomplete, or those that provided inconsistent evolutionary patterns (data not shown). Only
the Netherlands tree showed a linear-like progression from the earliest cluster to extant
clusters, consistent with a recent report from this country (74).
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Figure 2. Phylogenic reconstruction of the GII.4 capsid sequence.   A multiple alignment
was generated using 176 full length capsid amino acid sequences and trees were generated
using Bayesian Inference and Maximum Parsimony analysis.  The , clusters are marked as
follows: yellow, sequences from Camberwell cluster; red, sequences from Grimsby cluster;
blue, sequences from the Farmington Hills cluster; green, sequences from the Hunter cluster;
orange, sequences from the Sakai cluster; and purple, sequences from the Den Haag cluster.
The trees are drawn to similar scales and are rooted with the earliest Camberwell cluster.  A.
Bayesian inference predicts that Camberwell gave rise to Grimsby, which gave rise to a LCA
from which Farmington Hills and a LCA for the three extant clusters evolved independently.
B.  The Maximum Parsimony boot strapped tree generated by MEGA 4.0 was similar to the
Bayesian tree with the exception that the Grimsby cluster gave rise to the Farmington Hills
cluster, and a LCA of all extant clusters arose from Farmington Hills.  A MP tree generated
by PAUP4.0b10 predicted similar results.
Virus proteins contain multiple functional domains and protein domains are
recognized as the units of molecular evolution (61).  Not surprisingly, different domains
within a protein may evolve at different rates based on structural and functional constraints of
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the specific domain, potentially masking informative evolutionary patterns (61).  Analysis of
the sequence variation of the three different domains of the GII.4 capsid showed that of the
59 informative sites noted, 11 occurred in the Shell domain (~5% of sites 11/225 S
alterations), 18 occurred in the P1 subdomain (~11% of sites 18/166 P1 alterations), and 30
were noted in the P2 subdomain (~24% of sites 30/126 P2 alterations), the surface exposed
region of the capsid protein.  This observation suggested that the different domains were
evolving under different evolutionary constraints.  Therefore, we employed a more
sophisticated approach whereby the capsid amino acid sequences were divided into the three
structurally defined domains and subdomains of Shell, P1 and P2 and each region was
analyzed separately.  Analysis of the phylogeny of Shell, which is the most conserved
domain, showed only two predominant clusters represented by Camberwell and everything
else (Fig. 3 A and B).  The P1 domain phylogeny indicated a linear-like progression from
Camberwell to Grimsby to later strains, but the tree did not resolve the evolution of the later
clusters of Farmington Hills, Hunter, Sakai and Den Haag and more information is necessary
to resolve contemporary patterns (Fig. 3 C and D).  Intriguingly, the surface exposed P2
domain phylogeny suggests that the P2 region has evolved in a linear fashion, punctuated by
periods of stasis, over the last twenty years similar to influenza (8).  Both BI and MP
confirmed that the evolution of each cluster was correlated with time, with the Camberwell
cluster being near the root of the tree, and with the Grimsby cluster having origins in the
Camberwell cluster (Fig. 3 E, F and G).  Further, the Farmington Hills and all later clusters
appeared to have arisen from the Grimsby cluster.  Evolution beyond the Farmington Hills
cluster is less clear, as a LCA from the Grimsby cluster gave rise to all four later clusters.
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Figure 3. Phylogenic reconstruction of the GII.4 shell domain, P1 and P2 subdomains.   
Independent multiple alignments were generated using 176 amino acid sequences divided
into the Shell, P1 and P2 regions of the capsid, and trees were generated for each alignment
using three different methods, with clusters marked as follows: yellow, Camberwell cluster;
red, Grimsby cluster; blue, Farmington Hills cluster; green, Hunter cluster; orange, Sakai
cluster; and purple, Den Haag cluster.  Branches not marked represent sequences that did not
group with any specific cluster.  The trees are drawn to similar scales and are rooted with the
earliest Camberwell cluster.  A. Bayesian inference of the Shell domain predicts only two
distinct clusters with Camberwell as the first, while everything else groups into a single large
cluster.  B.  The MEGA4.0 MP tree of the shell predicted similar results as the Bayesian tree,
although there are two non-distinct clusters arising from the LCA derived from the
Camberwell cluster. A MP tree generated by PAUP4.0b10 predicted similar results. C.
Bayesian inference of the P1 domain predicted that the Camberwell cluster gave rise to
Grimsby cluster from which the Farmington Hills cluster and all later clusters emerged,
although the extant clusters were not fully resolved.  D.  The MEGA4.0 MP tree of P1
predicted similar results, although it showed that Grimsby gave rise to the Farmington Hills
cluster, from which the later clusters emerged.  However, the Den Haag cluster falls within
the Farmington Hills cluster. An MP tree generated by PAUP4.0b10 predicted similar results.
E. Bayesian inference of the P2 subdomain predicts that Camberwell gave rise to Grimsby,
which gave rise to a LCA from which Farmington Hills and a LCA for the three extant
clusters evolved independently.  All six clusters are distinct.  F.  The MEGA4.0 MP
bootstrapped tree agreed with the Bayesian tree. G.  The MP bootstrapped tree generated
using PAUP4.0b10 predicted a nearly identical tree as the Bayesian tree. The fact that all
three methods generated similar trees, with distinct clusters suggests that the P2 subdomain is
the most appropriate region to determine phylogeny for the GII.4 noroviruses.
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However the Bayesian posterior probability at this node was only 57/100 and an MP (PAUP)
bootstrap value of 65/100, suggesting that there was not enough information to fully define
this branching order.  Therefore, we computed the predicted ancestral sequence for this node
and compared this sequence to the Farmington Hills, Hunter, and Sakai cluster sequences.
The LCA sequence was definitively more Farmington Hills-like, which implies that the
Farmington Hills cluster is ancestral to the extant clusters.  This suggests that the GII.4
viruses evolved in a linear manner, with each subsequent cluster giving rise to the next (Fig.
1) from Camberwell to Farmington Hills.
While some clusters persisted for ~8 years, contemporary clusters appear to have
evolved from subsequent populations in much shorter intervals, characteristic of epochal
evolution.  Taken together, these analyses suggest that the P2 region of the GII.4 viruses
evolved in a linear direction over the last twenty years, with intense heterogeneity within the
P2 region of the capsid sequence facilitating the emergence of new predominant strains.
To further evaluate this hypothesis, homology models of each of the five
representative sequences were generated using the VA387 P domain as a template, and these
models were analyzed to determine if microevolution in the P2 subdomain altered the capsid
structure.
3.4 Structural Modeling of GII.4 Evolution
Homology models of the P domain of the capsid monomer of each of the
representative viruses were generated and the changes that defined the emergence of each
cluster were highlighted on each predicted structure, as well as the VA387 wildtype structure
(9).   The majority of heterogeneous sites mapped 180 degrees distal to a previously reported
putative receptor binding domain (83), with many of the mutations flanking the two receptor
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interaction sites identified recently (9).  The biological unit for the GII.4 capsid is a dimer,
and dimerization creates two identical receptor-binding domains, each of which contains the
two sites shown to be important for receptor binding.  Many of the sites that evolve
differences between the GII.4 clusters map to regions surrounding both of these domains
(Fig. 4).  In general, these residues map to the most distal edge of P2 where they  protrude
from the surface (Fig. 4).
Figure 4. Variation mapped to the VA387 Dimer.  Capsid dimerization creates two
identical Receptor Binding Domains (RBDs), which have been shown to bind to
carbohydrate receptors.  Each domain contains two sites that facilitate binding, with site 1
directly binding the -fucose of B-trimer, shown in RBD#1 in this depiction.  The second
interaction site likely governs specificity as it provides weak, long distance interactions to the
-gal group of the B-antigen.  Site 1, purple; site 2 pink; sites that have changed over 20
years of evolution, yellow; Chain A monomer, gray; Chain B monomer, blue.  B-trimer
carbohydrate is shown in green.
Evolutionary analyses showed that the fucose ligand binding residues reported for site 1(9)
were strictly conserved in the GII.4 viruses, while one amino acid position in the second
interaction site at position 393 was highly variable among the representative viruses.
RBD #1
RBD #2
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Further, many of the P2 sites operating under positive selection occur near the two
interactions sites, with position 395 being an important residue adjacent to the second
interaction site.
These observations suggest that the heterogeneity most likely to interfere with
receptor binding occurs in or near the second interaction site.  In particular, residues at
positions 393-395, which change with each cluster, likely play a distinct role in carbohydrate
binding affinity and/or avidity.  Comparison of a structural model for the GII.4-1987
biological unit predicted by Rosetta Design which contained an Asp at position 393, to the
VA387 structure (Fig. 5A, B), which contains Asn at position 393 predicts that this amino
acid difference exerts two profound effects upon the second interaction site.  First, an Asp at
position 393 adds negative potential to the second site, which may inhibit some carbohydrate
interactions (compare Figure 5C and 5D).  Second, the side chain of Asp393 is likely
repelled by a conserved Asp at position 391, resulting in subtle remodeling of the second
interaction site (Fig. 5C, D), which potentially alters carbohydrate binding. Our model
predicts that changes in the second interaction site between GII.4-1987 and GII.4-1997
would alter carbohydrate binding and/or specificity. Thus, we introduced the Gly393 of
GII.4-1997 into the backbone of GII.4-1987 by PCR mutagenesis creating GII.4-1987
D393G to study the effect of a single amino acid on HBGA interaction.
To further examine this region homology models of GII.4-2002 (containing Ala395)
and GII.4-2002a (containing Thr395), which differ by two amino acids at positions 226
(within the P1 subdomain) and 395 (within the P2 subdomain), were compared and shown to
have an RMSD of 0.201 Angstroms.
354
      
Figure 5. Subtle changes in the second interaction site govern HBGA binding.  A.  Two
identical receptor-binding domains are formed upon dimerization of two capsid proteins
(chain A, gray; chain B, black), with each RBD containing two sites important for HBGA
carbohydrate binding.  Site 1 (cyan) directly interacts with the ligand, while site 2 (purple)
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Figure 5 (continued): provides weak, long range interactions which may regulate receptor
specificity. B. In VA387, B-trimer binds to site 1 by a strong hydrogen bond network. B-
trimer is noted in yellow.  C and D.   Electrostatic differences between RBDs of VA387
(Panel C) and Rosetta predicted RBD of GII.4-1987 (Panel D) show that changing an Asp at
393 present in GII.4-1987 to Asn393 found in the GII.4-1997 cluster significantly alters the
second interaction site.   Repulsion between Asp 393 and a conserved Asp391 forces the side
chain of Asp393 away from the pocket.  These alterations likely lead to differences in
binding between GII.4-1987 and the GII.4-1997 cluster. E.  Molecular remodeling by
mutation in GII.4-2002 cluster. Homology models for the P domain of GII.4-2002 and GII.4-
2002a were generated by Modeller using the coordinates from 2OBT (from VA387 from
cluster GII.4-1997), and the structures were superimposed upon one another and analyzed for
differences.  The predicted structures had an RMSD of 0.201 Angstroms, with the only
change in the structures occurring at position 395, where GII.4-2002 has an alanine residue,
and GII.4-2002a encodes a threonine. The addition of threonine at position 395 remodels the
second interaction site, increasing the pocket by 1.111 Angstroms.  We predict that this
subtle change in site 2 will be sufficient to alter HBGA binding.
The two putative structures were superimposed and the region of the mutation was
characterized (Fig. 5E).  Mutating Ala395 to Thr remodels the second interaction site by
increasing the size of the pocket by 1.1 Angstroms (Fig. 5E).  In addition, this change is
predicted to direct the negative side chain of Asp391 toward the pocket. The change at
position 226 (Pro to Ser) occurs at the bottom of the P1 subdomain where the protruding
domain and the shell domain are connected by the hinge region.  This change occurs within 5
residues of one of the dimer interface sites. Although these changes are subtle, they may have
profound influences on carbohydrate binding. From these two models, we hypothesize that
microevolution in site 2 alters carbohydrate binding specificity, and we predict that GII.4-
2002 and GII.4-2002a will have different binding characteristics, facilitated by a single
amino acid difference in the P2 subdomain.
To further characterize the binding characteristics of the GII.4-2002 viruses as well as
the other representative viruses, the Camberwell GII.4-1987, GII.4-1987 D393G, Grimsby
GII.4-1997, Farmington Hills GII.4 2002 and 2002a, Hunter GII.4-2004 and Sakai GII.4-
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2005 ORF 2 sequences were inserted directly into the VEE replicon vector and all seven
replicons produced abundant 30-40nm VLPs following visualization by negative strain EM
techniques (26, 44, 68).
3.5 Carbohydrate Binding Profiles
GII2.4-1987, GII.4-1997 and GII.4-2002/2002a demonstrated binding to secretor-
positive saliva from individuals of blood type O, A, and B (27), although binding of GII.4-
2002a was temperature dependent(Fig. 6A and B).
Figure 6.  GII.4 VLP-salivary binding patterns.  GII.4 VLPs were assayed for ability to
bind to saliva samples phenotyped for secretor status (Se) and ABO bloodtype by ELISA.
The mean optical density is indicated by the line in the box.  The upper and lower boundaries
of the box represent the maximum and minimum values.  A.  VLP binding at 37
o
C. B. VLP
binding at room temperature.
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These data are consistent with previously published salivary binding data for VLPs from
Grimsby strains isolated in 1997 and 1998 (36, 48).  GII.4-2002a also bound weakly to some
secretor-negative saliva at 37
o
C, suggesting that this strain may bind through the Lewis
antigens.  In contrast, GII.4-2004 and GII.4-2005 strains bound only weakly (2X
background) to secretor-positive, blood type B saliva at room temperature.   Since saliva is a
complex biological fluid containing many carbohydrates in varying amounts dependant upon
both the donor’s genetics and sample integrity, this assay cannot positively identify specific
carbohydrate binding partners or identify subtle differential binding patterns within the GII.4
VLP panel (51).   However, in agreement with salivary binding assays, synthetic HBGA
binding assays revealed 3 patterns of carbohydrate binding for the six VLPs (Fig. 7A-D).
Although tested, none of the VLPS bound to any of the core chain precursor molecules (data
not shown).  The first pattern exhibited by GII.4-1987, GII.4-1997 and GII.4-2002 utilized
known FUT2-dependent HBGAs.  GII.4-1987 VLPs bound strongly to H type 3 and less well
to Le
y
, GII.4-1997 bound H type 3, but also bound efficiently to Le
y
, A and B and GII.4-2002
bound to Le
Y
 and less efficiently to H type 3 and B.  The second pattern exhibited by GII.4-
2002a, utilized Lewis enzyme products, Le
a
 and Le
x
, as well as the FUT2-dependent A
antigen.  GII.4-2002a is the first GII.4 strain reported to bind FUT2-independent products
indicating a possible pathway for infection of secretor-negative individuals.  GII.4-2004 and
GII.4-2005 did not bind strongly to any of the carbohydrates tested (Fig. 7A-D), depicting
the third binding pattern.  Particularly interesting, GII.4-1987 D393G had an intermediate
binding phenotype between GII.4-1987 and GII.4-1997.  Replacement of GII.4-1987 Asp393
with GII.4-1997 Gly393 resulted in the addition of binding to B antigen to GII.4-1987 but
not the ability to bind A antigen, indicating that position 393 is important in determining
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HBGA binding but that other surrounding residues must also play a role.  Concordant with
the predicted remodeling of the receptor binding pocket, these data support the hypothesis
that sequence variation in and around the second carbohydrate stabilizing domain of ORF 2
alters VLP structure and modulates HBGA binding patterns within a genotype, resulting in
changes in VLP-carbohydrate ligand binding over time (Fig. 7).
Figure 7.  GII.4 VLP-carbohydrate binding patterns at room temperature. VLPs were
assayed for ability to bind to synthetic biotinylated HBGA bound to avidin-coated plates. The
mean optical density is indicated by the line in the box.  The upper and lower boundaries of
the box represent the maximum and minimum values. A. VLP binding to core chains
including an 1,2-fucose.  B.  VLP binding to either core chains or H antigens modified with
the Lewis antigen.  C.  VLP binding to A or B antigen trimer.  Panel D.  Comparison of
binding of GII.4-1987, GII.4-1987 D393G and GII.4-1997 VLPs to select HBGAs.
3.6 Serologic Relationships among the GII.4 VLPs
As the most prominent surface projection, the P2 subdomain may be a major
antigenic determinant (67).  Thus, it is possible that the noted sequence variation across time
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in the GII.4 ORF2 protein could alter the affinity of antibodies to the individual outbreak
strains and help explain the continued prevalence and emergence of new GII.4 strains,
worldwide. Consonant with this idea, modeling of the noted GII.4 variation indicates
significant changes throughout the surface exposed P2 domain which would be predicted to
alter the serologic relationships (Fig. 4).  To test this hypothesis, stools and sera collected
from infected subjects from an 1988 human GII.4 outbreak were studied for HBGA binding
and VLP reactivity and blockade.  Characteristics of the outbreak and samples collected from
it are described in Table 1.  Taken in 1988, these serum and stool samples were collected
during the emergence phase of the GII.4 strains and potentially represent a baseline (pre-
global spread) immune response to the future global epidemic strains.
Both acute and convalescent serum samples cross-reacted with each of the time-
ordered VLPs.  Figure 8 shows the percentage of subjects who seroconverted to each VLP
and the geometric mean titer of acute and convalescent serum samples.  While reactivity to
GII.4-1987 and GII.4-1997 VLPs was similar (geometric mean fold increase 16.3 and 15.1),
convalescent sera titer to GII.4-2002 (geometric mean fold increase 13.0, P=0.02), GII.4-
2002a (geometric mean fold increase 3.1, P<0.001, M-W test), GII.4-2004 (geometric mean
fold increase 10.1, P<0.01, M-W test) and GII.4-2005 (geometric mean fold increase 7.8,
P<0.01, M-W test) was significantly and proportionately reduced as compared to GII.4-1987
(Fig. 8).   Comparison of the IgG titer across VLPS also demonstrated a significant negative
trend in reactivity of 1988 outbreak convalescent sera and VLPs circulating at later times
(P<0.001, linear regression analysis).  Of note, reactivity to GII.4-2002a was lower than
reactivity to all of the other VLPs.   Intriguingly, GII.4-2002 and 2002a only differ at P226S
and A395T in the ORF2 capsid protein and yet they vary in antibody reactivity, suggesting
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that one or both of these sites may encompass strong immunodominant epitopes.
Figure 8.  Anti-GII.4 VLP IgG titers.  The geometric mean titer of anti-VLP IgG (μg/ml)
for acute (dotted bars) and convalescent (shaded bars) serum samples collected from a 1988
GII.4 outbreak and the percentage of subjects who seroconverted to each VLP.  The mean
titer is indicated by the line in the box.  The upper and lower boundaries of the box represent
the maximum and minimum values.  * Significant increase in titer between acute and
convalescent samples.  ^ Significant difference between convalescent titers compared to
GII.4-1987.
To evaluate the extent of IgG cross-reactivity induced by the 1988 GII.4 infection,
five randomly–chosen serum pairs were assayed for reactivity to NV, a genogroup 1 strain
(70). The IgG titers were less reactive across genogroup (45) (data not shown).  Significant
changes between the reactivity of acute and convalescent serum pairs to NV VLP were not
detected, none of the five tested pairs had a 4-fold increase in anti-NV titer (data not shown)
indicating that the increased response to all of the GII.4 strains is cluster or genogroup
specific, not a broad spectrum increase in total IgG in response to viral infection.
3.7 Blockade Titer Varies Over Time
Blockade experiments provide a biological measure of the ability of antisera to block
the interaction of a specific VLP with a carbohydrate ligand partner, a surrogate assay for
neutralization (28, 48), in the absence of a cell culture system for noroviruses.   Figure 9A
shows the mean % control binding of VLP in the presence of sera compared to the binding of
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VLP in the absence of antibody pretreatment. Although the acute serum samples reacted with
GII.4-1987, GII.4-1997, GII.4-2002 and GII.4-2002a in the IgG EIA, none of the acute
samples collected blocked the VLP-HBGA interactions, even at high serum concentrations
(data not shown).  However, convalescent serum collected in 1988 blocked GII.4-1987 and
GII.4-1997 interaction with H type 3 but was significantly less able to block GII.4-2002 VLP
interaction with Le
y 
and was completely unable to block GII.4-2002a interaction with Le
a
(Fig. 9A).    The mean concentration of sera needed to block VLP-HBGA binding by 50%
(BT50) was 0.27% for GII.4-1987 and 0.24% for GII.4-1997 interaction with H type 3 (Fig.
9B).  These titers were significantly different from the sera titer (0.52%) needed to block
GII.4-2002-Le
y
 interaction (P=0.03, M-W test) and GII.4-2002a-Le
a
 interaction (>1%)
(P<0.001, M-W test), suggesting that the early Camberwell and Grimsby strains share
common possible neutralization epitopes with each other that are not common to the later
Farmington Hills GII.4 strains.
GII.4-1997 and 2002a VLPs both bind to multiple HBGA in vitro.  Thus, antibody
blockade was compared for GII.4-1997 binding to B trimer, Le
y
 and H type 3 and GII.4-
2002a binding to A trimer and Le
a
 to determine if the antibody blockade was effective
against additional potential carbohydrate binding partners.  Convalescent serum samples
from the 1988 GII.4 outbreak similarly blocked GII.4-1997 with each of the potential binding
partners (Fig. 10), indicating that binding sites for additional HBGAs are physically close to
each other on the GII.4-1997 VLP.  In agreement with blockade of GII.4-2002a interaction
with Le
a
, GII.4-2002a interaction with A trimer was unaffected by the 1988 sera (Figs 9 and
10).
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Figure 9.  Blockade of GII.4 VLPs binding to HBGA by outbreak sera. Convalescent
serum samples collected from a GII.4 outbreak in 1988 were assayed for blockade of GII.4-
1987 and GII.4-1997-H type 3, GII.4-2002-Le
y
, and GII.4-2002a-Le
a
 interaction and the
mean % control binding calculated compared to the no-serum control binding (A).  Error bars
represent SEM.  The floating bar plot (B) shows the mean % sera needed for BT50 for each
VLP.  The mean titer is indicated by the line in the box.  The upper and lower boundaries of
the box represent the maximum and minimum values.  Outbreak sera BT50 responses
significantly different from GII.4-1987 are marked with an *.
To test if the blockade antibody generated after GII.4 infection could block a distant
norovirus strain interaction with HBGA, five randomly selected serum pairs from each
outbreak were tested for blockade of NV-H type 3 binding.  There was no difference in the
mean % control binding between acute and convalescent serum samples (data not shown).
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Figure 10.  Blockade of alternative HBGA ligands by outbreak sera. Convalescent serum
samples collected from a GII.4 outbreak in 1988 were assayed for blockade of GII.4-1997-H
type 3, Le
y
 and B antigen trimer interaction (A) as well as GII.4-2002a-Le
a
 and A antigen
trimer interaction (B)and the mean % control binding calculated compared to the no-serum
control binding.  Error bars represent SEM.  The floating bar plot (C) shows the mean % sera
needed for BT50 for each VLP and alternative HBGA ligand.  The mean titer is indicated by
the line in the box.  The upper and lower boundaries of the box represent the maximum and
minimum values.
3.8 GII.4 Serologic Relationships Using Murine Sera
Analyzing human serum samples is complicated as norovirus exposure histories are
unknown and serologic relationships between strains are not well defined (48), making it
more complex to decode the antigenic relationship between the time-ordered GII.4 strains in
humans.  As mice are not susceptible to human norovirus infection, they provide a clean
background in which to study antigenic relatedness between unique time-ordered norovirus
VLPs. Therefore, we immunized naive mice with VRPs encoding the variant ORF2 of each
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of the GII.4 strains and collected sera for testing IgG cross-reactivity and blockade ability.
As seen with human outbreak sera, antisera from mice immunized with VRP- GII.4-
1987 or GII.4-1997 reacted similarly to GII.4-1987 and GII.4-1997 VLPs and to a
significantly lesser degree to GII.4-2002, GII.4-2002a, GII.4-2004 and GII.4-2005 VLPs
(ranging from 1.6-24% of GII.4-1987 and 0.5-8% of GII.4-1997 homotypic responses for
later GII.4 strain, P<0.05, ANOVA), indicating that antigenic sites are maintained more
completely in early GII.4 strains while becoming variable in later emergent strains (Fig. 11).
Figure 11.  Murine antisera cross-reactivity to GII.4 VLPs.  Mice were immunized by
footpad inoculation on day 1 and day 21with 2.5 x 10
6
 IU VRPs expressing GII.4-1987,
GII.4-1997, GII.4-2002, GII.4-2002a, GII.4-2004, GII.4-2005 ORF2 (N=4 per inoculation
group).  Antisera were collected on day 35 and analyzed for homotypic and heterotypic IgG
responses to each VLP by ELISA.  Antibody titers are represented as geometric mean μg/ml
serum IgG. Error bars represent SEM.   * denotes VLPs with significantly different reactivity
within an immunization group.
Immunization with VRP-GII.4-2002 or 2002a, GII.4-2004 or GII.4-2005 elicited a strong
homotypic response with weaker cross-reactivity (ranging from 0.03%-16% homotypic
response) to all of the other strains tested (P<0.01, ANOVA), although GII.4-2002 had cross-
reactivity to GII.4-1997 that was significantly higher than the other cross-reactive responses
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(P<0.05, ANOVA) (Fig. 11).  Immunization with any of the GII.4 VRPs did not result in a
substantial antibody response cross-reactive to NV (data not shown).
Murine cross-reactive IgG data support the trend seen with human serum samples
indicating clear serologic differences between the early and late GII.4 strains.  To further test
this hypothesis, blockade experiments were performed using mouse sera, and BT50 values
were compared.  Antisera raised against GII.4-1987 and GII.4-1997 reacted similarly and
effectively blocked both GII.4-1987 and -1997 interaction with H type 3 and both sera were
unable to block GII.4-2002/2002a interaction with HBGA ligands (BT50 P<0.01, ANOVA;
Figure 12).  Conversely, antisera raised against GII.4-2002 or 2002a effectively blocked
2002/2002a interactions with HBGAs but were significantly less able to block GII.4-1987
(BT50 P<0.05, ANOVA) and GII.4-1997 (BT50 P<0.01, ANOVA) interactions with H type
3, again suggesting that the earlier strains share common blocking epitopes not found in the
later Farmington Hills strains.  GII.4-1987 and GII.4-1997 interaction with H type 3 was
weakly blocked by sera against GII.4-2004 and GII.4-2005 (Fig. 12).  GII.4-2004 and GII.4-
2005 sera efficiently blocked GII.4-2002-Le
y
 interaction but were significantly less able to
block GII.4-2002a interaction with Le
a
 (BT50 P<0.01 and P<0.05, ANOVA, respectively;
Figure 12).  In fact, GII.4-2002a-Le
a
 interaction was not efficiently blocked by any sera
except the GII.4-2002/2002a samples, supporting observations with human sera (Fig. 12).
Our inability to identify carbohydrates that efficiently bound GII.4-2004 and GII.4-2005
precluded the testing of sera from historic strains to block the binding of contemporary
strains to HBGAs.  None of the antisera generated to the GII.4 panel blocked NV-H type 3
interactions at any of the serum concentrations tested (data not shown).  These data support
the hypothesis that not only does antigenic drift occur in the capsid region of GII.4 norovirus
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strains over time, but that the variation significantly influences the ability of pre-existing herd
immunity to neutralize extant strains, based on carbohydrate blockade assays.
Figure 12.  Murine antisera blockade of GII.4 VLP binding to HBGAs.  Antisera
collected from mice immunized against each GII.4 ORF2 were assayed for blockade of
GII.4-1987 and GII.4-1997-H type 3, GII.4-2002a-Le
a
 and GII.4-2002-Le
y
 interaction and
the mean % control binding calculated compared to the no-serum control.  The floating bar
plot shows the mean % sera needed for BT50 for each antisera and each VLP; the mean titer
is indicated by the line in the box.  The upper and lower boundaries of the box represent the
maximum and minimum values.  Antisera groups that did not block 50% VLP-HBGA
binding at the highest serum concentration tested (5%) were assigned an arbitrary value of
10%.  * denotes VLPs with significantly different BT50 titer compared to the homotypic
antisera-VLP BT50 titer.
4. DISCUSSION
 In this manuscript, we show that GII.4 norovirus evolution is epochal, with periods of
stasis followed by the emergence of novel epidemic strains which evolve in a linear manner
over time, and we map the antigenic variation onto the surface exposed P2 capsid structure.
Using a time-ordered panel of GII.4 VLPs from 1987-2005, we demonstrate that specific
changes proximal to the 2
nd
 interaction site regulate carbohydrate binding patterns, which
change over the 20 year interval.  Using serum from a human outbreak in 1988 and murine
antisera, we use ELISAs and an in vitro carbohydrate blockade as a surrogate neutralization
assay to demonstrate that the noted variation alters the serologic and blockade responses
367
consistent with a model of antigenic drift.  Our data suggest a model of molecular evolution
in which norovirus GII.4 strains persist by evolving novel carbohydrate binding domains
over time in response to immune driven selection and antigenic drift in the receptor binding
regions of the P2 subdomain.
  Evolution in the norovirus capsid gene is complex and our data are in agreement with
other recent studies that underscore the critical importance of using structure to guide
molecular phylogenetic analyses based on the hypothesis that protein domains evolve at
different rates dependant on structural and functional constraints and environmental selective
pressures (61).  In our analyses, the Shell domain appears to be evolving by random drift, as
only 5% of changes are informative (i.e. became fixed in the population).  The P1 to a limited
extent, and in particular the P2 subdomain are evolving at higher evolutionary rates
consistent with our hypothesis that surface exposed residues are evolving in the presence of
immune selection.  High rates of evolution in surface exposed residues have also been
reported in chronological sets of HIV samples within individual patients (38).  As the
majority of the 176 ORF2 sequences included in our study belonged to the Grimsby and
Farmington Hills clusters, the limited sequence information for contemporary clusters
reaffirms the critical need for continued surveillance, the collection of full length capsid
sequence information and detailed studies on the ORF2 evolutionary patterns of change
noted in 2005 and beyond.
Our phylogenetic and evolutionary analyses of the P2 domain of ORF2 suggest that
the GII.4 viruses have evolved linearly over the last twenty years in a similar fashion as
influenza, with serial replacements occurring sporadically, suggesting an epochal evolution
where periods of stasis are followed by sudden transitions (88, 89).  The periods of stasis are
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likely the result of entropy barriers which generally occur in highly degenerate genotype-to-
fitness populations where many genotypes give rise to the same phenotype (88, 89).  During
the evolution of the GII.4 viruses, a long period of stasis of ~ 8 years or more has occurred
within the ancestral Camberwell cluster, prior to the emergence of the epidemic Grimsby
cluster.  Of note, the majority of informative sites within the S domain occurred during the
emergence of the Grimsby cluster and these sites became fixed in the population.  With our
analyses, we cannot rule out the possibility that these changes to S were the key changes
structurally necessary to facilitate the emergence of the GII.4 cluster as the predominant
epidemic strain.  The Grimsby cluster endured a shorter period of stasis, after which
subsequent clusters appear to have evolved from the previous cluster in a linear manner.
Later clusters appear to emerge every 1-2 years from 2002 to present.  Although all six
clusters are distinct, there is overlap between some clusters and the dates of isolation of some
strains that group with ancestral clusters clearly occur after the emergence of later clusters.
This suggests that strains from earlier clusters may continue to circulate, but likely cause
asymptomatic disease, or persist at low levels in the population prior to going extinct.
Analyses of the evolutionary profiles of the GII.4 viruses suggest that many of the
outlier sequences are recombinant viruses, consistent with earlier reports by other groups
(64).  The recombination breakpoint is predicted to occur near the first P1/P2 boundary
(nucleotide position 794/amino acid 265), suggesting that viable recombination may be
restricted to crossover sites which preserve essential protein domain function (Table 3). In
addition, some sites in the P2 region appear to revolve between a select subset of amino acid
replacements.  These sites include: 329, 333, 340, 355, and 365.  We predict that these sites
are important sites of antigenic variation, but are structurally limited in that they must
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maintain a specific physiochemical property important for the overall capsid structure, the
interaction with carbohydrate, or structurally constrained by entry mechanisms.
Sites of heterogeneity predominantly occurred in the exposed P2 subdomain in and
around the two carbohydrate interactions sites that form the receptor binding pocket (9, 49,
67).  Site 2 was the most variable region in our model and changes in this region affected
carbohydrate binding profiles. Our empirical studies suggest that escape from herd immunity
may represent the selective force that drives antigenic variation within and around the
receptor binding pocket on the surface of the GII.4 P2 domain of ORF2.  Variation within the
receptor binding domain in ORF2 variants is likely under strong co-selection to maintain
recognition of one or more HBGA carbohydrate receptors for docking and perhaps entry,
allowing the GII.4 noroviruses to persist and simultaneously circumvent highly penetrant
susceptibility alleles that are common in human populations.  Alternatively as the current
contemporary strains don’t bind any carbohydrates tested, the receptor binding pocket may
evolve to recognize other fucosylated carbohydrates or proteins for docking.
In influenza, herd immunity, mediated primarily by neutralizing IgG antibodies (14),
positively selects for antigenic variation in HA, although the exact effect of individual
mutations on antigenicity is complex.  Mutations may occur in one or more of five
neutralizing epitopes or in the sialic acid binding site in the HA glycoprotein, thus selecting
for replacement strains that circumvent antibody neutralization (8).  Among noroviruses, the
concept of herd immunity is controversial as early human challenge studies had suggested
that strain specific long-term immunity can be elicited following challenge, as 50% of
volunteers did not become infected after multiple challenges with NV.  However, this same
study demonstrated that in some volunteers only short term immunity is evident (62, 95).  In
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more recent studies, we and others have argued that long-term immunity is possible and that
pre-exposure history may influence the duration of the protective immune response against
individual strains (45, 46, 73).   Although early mucosal IgA (46) and T cell (45) responses
may include components of a long-term protective immune response in uninfected,
challenged volunteers, the role of serum IgG in protective immunity remains controversial.
Norovirus challenged volunteers or outbreak patients mount strong serum IgG antibody
responses that block carbohydrate-VLP interactions in a genogroup-specific manner in a
surrogate neutralizing assay potentially representing a component of a long-term protective
immunity (27, 48).  However, IgG antibody levels are usually too low in pre-challenge sera,
or in salivary or fecal samples for assaying by these methods.  Importantly, the years
following the emergence of a new epidemic strain in Europe were characterized by decreased
numbers of outbreaks, speculated to be associated with increased herd immunity (73, 74).  If
herd immunity drives GII.4 norovirus evolution, these data predict that serologic
relationships among temporal GII.4 epidemic strains should change over time.
Although GII.4-1987 and GII.4-1997 VLPs differed by seven amino acids, no
significant differences in antibody reactivity were noted with sera derived from humans and
experimentally immunized mice, suggesting that the few amino acid changes didn’t
significantly alter variation between the two strains during the long period of stasis.  We
speculate that pre-1995 Camberwell-like strains typically produced low level endemic
disease in human populations.  By the mid 1990’s, a series of mutations evolved that
promoted epidemic spread of the post 1996 Lordsdale/Grimsby strains in human populations,
perhaps by allowing for more efficient binding with additional HBGA ligands on mucosal
surfaces, altering the stability of the capsid, or promoting transmissibility.  The epidemic
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spread of the GII.4-1997-like strains in human populations may have subsequently allowed
for higher levels of herd immunity and selected for more rapid antigenic changes in future
strains.  Influenza virus shows similar trends in that genetic variation oftentimes, but not
always, tracks with antigenic variation, because some mutations result in disproportionately
large antigenic changes (75).  However, global serologic responses between GII.4-
1987/1997, and GII.4-2002/2002a, demonstrated significant antigenic differences, reflecting
the increased number of variant residues.  Concordant with these findings GII.4-2004 and
GII.4-2005 epidemic strains were also serologically quite distinct from GII.4-1987 and GII.4-
1997 and to a lesser extent distinct from GII.4-2002, but not 2002a.  Thus, epidemic
replacement strain ORF2 capsid sequences were antigenically related yet distinct due to
antigenic drift.
Given the high amount of GII.4 cross reactivity, it is clear that one or more highly
conserved epitopes define the serology of this genocluster.  Immunodominant neutralizing
epitopes have been described for a number of viruses including West Nile virus (6), HIV-1
(96) and foot-and-mouth disease virus, (53).  Findings with the GII.4-2002 and 2002a ORF 2
capsid proteins support the possibility that GII.4 noroviruses may also encode a limited
number of strong immunodominant epitopes.  Compared to GII.4-2002, the GII.4-2002a
norovirus ORF2 protein differs by two residues, defined by changes in P1 (P226S) and P2
(A395T), yet is antigenically quite distinct from all other strains tested (Fig.s 8,9, 11 and 12).
Previous work with FMDV, demonstrated that a single amino acid change in an
immunodominant epitope resulted in two antigenic specificities and a lack of virus cross-
neutralization (5).  Although speculative, the noted P2 variation is unlikely to encode this
strong serologic change in GII.4-2002a, as other time-ordered VLPs encode amino acid
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changes at this position as well.  Rather, we predict that the alteration in P1 (P226S) might
well define a major immunodominant epitope.  Experiments are in process to test this
interesting hypothesis.  On the structural model, the side chain of Ser226 is much smaller
than the Pro side chain and it extends away from the surface into an open cavity below the
dimer interface region.  This may alter the final conformation of the viral capsid by relaxing
the constraints on the hinge movement.  Clearly, detailed structure analyses of the time-
ordered GII.4 VLP set will likely prove informative.
All convalescent outbreak sera blocked carbohydrate binding of GII.4-1987 and
GII.4-1997 VLPs but was less capable of blocking GII-4-2002/2002a binding.  Interestingly,
the mouse anti-GII.4-2004 and GII.4-2005 sera more efficiently blocked binding of GII.4-
1987 and GII.4-1997 to H type 3 than GII.4-2002/2002a binding to Le
y 
 and A.  Of note,
amino acids at positions 329, 355, and 365 in GII.4-2004 and GII.4-2005 are the same as
GII.4-1987 and GII.4-1997, but not GII.4.2002/2002a, which implies that these sites may
account for the cross blockade of anti-GII.4-2004 and anti-GII.4-2005 sera to GII.4-1987 and
GII.4-1997 carbohydrate binding.  These sites may also be important determinants of
antigenic variation within the GII.4 genocluster.
     The absence of a robust cell culture model for noroviruses prevents the
development of classical neutralization assays.  However, studies with numerous virus
families have indicated that antibodies that block virus receptor-ligand interactions, provide
one mechanism to neutralize virus infectivity (12, 57, 86).  Previous studies by our group and
others have demonstrated that noroviruses bind to HBGA and that HBGAs are necessary for
infection since the FUT2 gene is a susceptibility allele for Norwalk virus infection in vivo
(32, 46).  Although a GII.4 human challenge model does not exist, some GII.4 noroviruses
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have been reported to bind specifically to H type 3 and to a lesser extent the A and B
carbohydrates suggesting usage of HBGAs in infection (30, 48). Further, GII.4 outbreak
investigations have established a strong correlation between a secretor positive phenotype
and symptomatic infection (39).  However, carbohydrate binding patterns within a temporal
panel of norovirus VLPs have not been reported until now.  Consonant with clear variations
in overall serologic identity among the GII.4 VLP panel, we have also demonstrated that the
GII.4 VLPs display variant binding patterns to carbohydrates typically regulated by FUT1
(Le
x
, Le
y
), FUT2 (H Type 3), the Lewis Enzyme (Le
a
, Le
y
) and the A and B enzymes.  These
findings suggest that some GII.4 noroviruses not only bind carbohydrates regulated by the
FUT2 susceptibility allele, but also can bind carbohydrates regulated by FUT1, FUT3 and the
A and B alleles as well.  However to date, FUT1 expression has not been demonstrated in the
gut mucosa (69).  As fucosyltransferase enzymes lack tight core chain fidelity in vitro, it is
possible that the FUT2 enzyme, or another fucosyltransferase may express typically FUT-1
regulated carbohydrates in the gut, as has been observed in saliva where FUT2 activity
produces both Le
x
 and Le
y
 from type 2 core chain (69).   Further, we and others have not
seen in vivo evidence of core chain usage by alternative fucosyltransferases, as FUT2-
negative individuals were completely resistant to NV infection (46) and more likely to be
asymptomatic after GII.4 exposure (39), regardless of the presence of other
fucosyltransferases.  Most surprisingly, the GII.4-2004 and GII.4-2005 strains didn’t bind
any HBGA carbohydrates or saliva tested, suggesting that their carbohydrate ligands are
either not represented within the panel of biotinylated HBGA carbohydrates available for
testing, carbohydrate patterns differ in saliva and in intestinal mucosa, or they utilize non-
HBGA mediated pathways for entry.  Thus, over time, it is reasonable to predict that
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noroviruses have the capacity to utilize the large number of related HBGAs as ligands.  The
potential plasticity in the carbohydrate binding site would likely accommodate sufficient
amounts of antigenic drift to escape herd immunity, while simultaneously preserving
carbohydrate binding potential and altering strain susceptibility to the many different human
alleles that regulate HBGA expression.
Fucose ligand binding site 1 was strictly conserved in the GII.4 viruses, including
paradoxically, extant strains that only weakly bind saliva and do not bind any carbohydrate
tested.  In contrast, the secondary interaction site appears to facilitate carbohydrate specificity
as binding characteristics of the time ordered VLP panel varied extensively.  In the secondary
interaction site, positions 390, 391, 392 and 443 were conserved throughout the GII.4 strains
while sites 393, 394 and 395 were variable.  In two instances, binding characteristics could
be directly correlated to residue changes within this region. First, structural models predicted
that carbohydrate binding would differ between the Camberwell cluster and the Grimsby
cluster (including VA387) based primarily upon an Asp to Asn change at position 393 in site
2 (Fig. 5).  In agreement with our hypothesis, binding between GII.4-1987 and GII.4-1997
was different.  The substitution of an Asp at position 393 was predicted and then empirically
demonstrated to sterically hinder or otherwise alter binding of the larger tri-saccharide
moieties of A- and B- antigens, as the Camberwell representative VLP binds H type 3 and Le
Y, but not A or B (Fig. 7).  In contrast, both GII.4-1997 and VA387 bind H type 3, Le
 
Y, A,
and B (35, 48); and they encode Gly and Asn at the 393 position, respectively.  Interestingly,
our data suggest that the primary impact of the mutations that occurred between the
Camberwell and Grimsby clusters led to an expansion of HBGA usage as representative
strains GII.4-1987 and GII.4-1997 were indistinguishable antigenically.  In the second case, a
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Thr at position 395, as exhibited by GII.4-2002a (Fig. 5E) altered the receptor binding
pattern as this mutant bound to Lewis enzyme products, Le
a
 and Le
x
, as well as the FUT2-
dependent product, A antigen.  GII.4-2002a is the first GII.4 strain reported to bind FUT2-
independent products indicating a possible pathway for infection of secretor-negative
individuals.  Alanine at this position facilitates binding of H type 3 in GII.4-2002.  These
results are also in agreement with our hypothesis that microevolution in site 2 alters
carbohydrate binding interactions and more detailed genetic studies should confirm this
hypothesis.  Of note, the synthetic HBGAs used in this study lack the complex structures
often found in vivo.  Larger polysaccharide moieties likely play a crucial role in carbohydrate
affinity and avidity, by interacting directly with the second interaction site.
Taken together, our structural models (Fig. 5) suggest that heterogeneity in the second
receptor interaction site likely determines HBGA affinity and avidity and subtle changes in
this region may govern HBGA specificity.  Tan et al., demonstrated that binding of VA387
to HBGAs could be ablated by mutating the Thr at position 338 to Ala (83).  While Thr338 is
not directly involved in ligand binding, it does form hydrogen bonds to Arg345, which
directly hydrogen bonds to the ligand (9, 49, 67).  It seems likely that hydrogen bonding
patterns also influence which ligands the virus can bind.  Subtle changes to residues that form
hydrogen bonds with the primary ligand interaction residues may drastically alter ligand
affinity and avidity.  In addition, the length and charge of the side chain of a given residue
likely allosterically regulates the site, by sterically hindering some interactions (Fig. 5).
Studies with Foot and Mouth Disease virus have demonstrated that this virus contains a
conserved shallow pocket on its surface which is predisposed to evolve a high affinity for its
Heparin Sulfate receptor.  Mutations remodel the surface increasing the positive charge,
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which results in an increased affinity for its receptor (23).  Differences in electrostatic
potential may regulate HBGA affinity in GII.4 viruses as well, as the addition of a charge at
position 393 alters the surface charge and binding of the GII.4-1987 virus (Fig. 5A-D).
Studies with influenza virus have shown broad serologic differences between temporally
distinct strains consistent with a phenotype of antigenic drift and variation especially in
antigenic sites, receptor-binding sites and in codons previously identified as under positive
selection (8).
Virus recognition of variant carbohydrate receptor moieties is not unprecedented as
influenza virus recognizes variant sialic acid moieties for infection of aquatic birds (2-3
sialic acid) and humans (2-6 sialic acid), and other viruses utilize similar mechanisms (76,
77, 94).  However, the recognition specificities are much more subtle and complex than
originally appreciated.  Recent glycan microarray tools have demonstrated different human
and avian flu strains binding to different glycan ligands depending upon downstream
fucosylation, sulphation and additional sialylation processing patterns although the biological
significance of these interactions are not fully appreciated (78).  Our data and that of others
(73, 74) suggest that antigenic drift in noroviruses ORF2 (HBGA antigens) and perhaps
influenza viruses (sialic acid-containing antigens) HA may evolve by similar mechanisms.
The combined flexibility of the ligand binding pocket and the wide range of variant, yet
related carbohydrate ligands, may provide the necessary plasticity in both the receptor targets
and viral attachment proteins to allow for extensive antigenic drift in the face of herd
immunity.
The data presented in this manuscript provide support for the hypothesis that
antigenic drift and receptor switching may function as one mechanism to maintain the GII.4
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noroviruses in the presence of human herd immunity.  Our data suggest that strain specific
protective immunity is possible and that vaccines and immune prophylaxis must be
formulated to protect against contemporary strains.  As shown with influenza virus, new
therapeutic formulations will be necessary.  Moreover, continued norovirus surveillance will
be an essential component necessary for maintaining vaccine and drug effectiveness.
At this time, it is unclear whether GII.4 noroviruses will continue to predominate as
the major cause of epidemic gastroenteritis worldwide, or like influenza virus, undergo an
antigenic shift to a variant GI or GII genocluster that is currently circulating at low levels in
human populations, or a new strain introduced from zoonotic pools.  However, important
caveats must be considered when evaluating this work.  While it is clear that the mucosal
compartment has high concentrations of IgG, carbohydrate-VLP blockade assays use serum
IgG while mucosal IgA and IgG responses may be more important in protective immunity
(46, 48). Unfortunately, the mucosal antibody concentrations are usually not only insufficient
for blockade studies, and were not obtained during norovirus outbreaks, preventing the
testing of this possibility.  In the absence of a robust cell culture model, blockade studies
themselves represent a surrogate assay for neutralization and it is likely that antibodies might
neutralize virus infectivity by binding to regions distinct from the carbohydrate binding
pocket or even outside of P2 and inhibit other steps in entry as shown with West Nile virus
among others (59).  Research is clearly needed to define the number and location of the
neutralizing sites in the norovirus particle and the impact of positively selected mutations on
the neutralization phenotype. Structural studies solving variant carbohydrate binding
characteristics in the time-ordered VLP set will be imperative for understanding the role of
the secondary sites in receptor specificity and binding affinity. Further, the VLPs used in this
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study are composed of ORF2 major capsid protein, whereas native virions would also include
1-2 copies of the ORF3 protein (24).  The function of the ORF3 protein is still unclear and its
effect on virus structure and interaction with ligands is unknown.  Although no examples of
norovirus VLP post-translational modifications have been reported, any such modifications
may impact ligand interaction.  In this study VLPs were produced in a mammalian
expression system, thus post-translational modifications should be reflective of natural
processing. Finally, although HBGAs clearly function as ligands for Norwalk virus entry,
clear evidence that HBGAs function for GII.4 docking and entry is less robust, but indicated,
and it is not clear whether differential binding patterns noted in vitro reflect in vivo binding
and susceptibility phenotypes (39, 87).   In the absence of time-order GII.4 human challenge
inocula, it will be difficult to definitively prove that contemporary strains circumvent
immune responses to pre-existing strains.  Additional studies will be needed to determine if
the evolutionary patterns are unique to the GII.4 noroviruses or represent a general
evolutionary pattern of the norovirus family.  Our study, however, clearly articulates a
predictive model for future empirical studies investigating the relationship between antigenic
change, norovirus pathogenesis, vaccine design, and human disease.
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CHAPTER X: DISCUSSION AND FUTURE DIRECTIONS
1. GENERAL OVERVIEW OF THE DISSERTATION
The primary objective was to combine the power of bioinformatics with synthetic
genomics, reverse genetics and molecular genetic approaches as a platform technology,
which empirically tests well-informed hypotheses towards understanding complex
mechanisms of viral pathogenesis and replication.  This integrative strategy was used to: 1)
identify unique sequence signatures that were associated with aberrant or altered gene
function, focusing on replicase and structural proteins of the Coronavirus family and the
capsid protein of the Norovirus family; 2) use these sequence signatures to generate
hypotheses and predictions about gene function or evolution; and then 3) empirically test
these models using reverse genetics, synthetic biology, molecular genetics, and biochemistry
in the laboratory setting.  Applying this strategy allowed us to generate informative models
on the evolutionary epidemiology of SARS-CoV emergence from zoonotic reservoirs, and
the molecular mechanisms governing the persistence of the GII.4 noroviruses in human
populations.
Using these computational methods, we were able to address several important
questions:  1) Can bioinformatic predictions be used to elucidate the function of a protein?  2)
Can bioinformatics guide rationale design of site-directed mutagenesis targets? 3) Can
structural bioinformatics be used to predict mutational impacts on putative or solved protein
structures?  4) Can sequence analyses be used to design synthetic genes and even genomes
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that have not been isolated in nature? 5) Does mapping mutations on a crystal structure allow
predictions that correlate to phenotype? and 6) Does structural modeling of evolution over
time provide insights into how a virus persists in human populations?  In the five sections
below, we highlight the power of this the integrative strategy and discuss future directions.
2. APPLYING SEQUENCE ANALYSIS STRATEGIES TO CORONAVIROLOGY
2.1 The pleiotropic roles of nsp10 in Coronavirus replication
In the study presented in Chapter IV and V(5-7), we employed a bioinformatics
approach to investigate coronavirus non-structural protein, nsp10, an 15kDa replicase
protein, which is conserved throughout the coronavirus genus.  Initial sequence analysis
demonstrated that nsp10 did not share homology with any proteins of known function.  In
fact, the only proteins in the database to be retrieved by BLAST were other nsp10 protein
sequences.  For proteins of unknown function and structure, searching for known protein
domains and functional motifs can provide important clues as to function.  This strategy was
used to identify targets in the amino acid sequence of this protein that could be mutated by
site-directed mutagenesis in a reverse genetics system to help elucidate the protein’s
function.  To identify interesting and informative targets, a Prosite search and SMART(10,
23) tool analysis were conducted on the protein sequence to identify functional domains and
motifs that were conserved, and PONDR(20, 21) was used to identify disordered regions that
might play an important role in protein:protein interactions.
These methods identified a highly active region from amino acids 50-70 which
contained multiple predicted protein functional motifs and a disordered region potentially
indicative of an interaction domain (Fig. 1).  Interestingly, the disordered region was not
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conserved at the amino acid level, however the same amino acid motif was always predicted
by PONDR to be disordered in all CoVs, indicating that the conserved disordered region may
play an important role in nsp10 function.  Therefore, this region of nsp10 was specifically
targeted for alanine mutagenesis as a potential protein:protein or protein:nucleic acid
interaction site (Fig.1)(21).
Figure 1: Bioinformatic predictions for nsp10.  A variety of conserved motifs and a
disordered region were predicted to occur from position 50-75 of the nsp10 amino acid
sequence.  This region was specifically targeted for site-directed mutagenesis.
In addition to the bioinformatics based mutations, pairs and triplets of charged amino acids
were targeted for mutagenesis, since charged residues often provide electrostatic surface
potential required for interaction of the protein with other proteins or nucleic acids.  In all
cases the wild-type residue(s) was changed to Ala by altering two positions in each codon.
A total of 17 mutations were engineered into the MHV reverse genetics system to
generate mutants of nsp10 in the context of the entire virus to help define the functions of
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nsp10 in CoV replication/transcription, including a single glutamine to glutamic acid
substitution at position 65 of nsp10 that conferred a TS phenotype (Chapter V).
The results of these two papers(5-7) demonstrated that rescued viruses with mutations
in nsp10 globally reduce viral RNA synthesis.  Mutations resulting in lethal phenotypes
mapped a central core of nsp10 which is resistant to mutation, and verified that the zinc-
binding fingers (ZFs)(9, 29), including the surrounding residues to which they hydrogen
bond, are critical to nsp10 function and coronavirus viability.  In addition, mapping the
viable mutants identified a region that likely interacts with other proteins or nucleic acids.
The mapping of the mutations on the crystal structure allowed us to predict which regions of
nsp10 are essential to function, which can tolerate mutation, and it allowed us to call into
question a report that suggested that nsp10 functioned as a dodecamer(29).  The mutational
analysis that we performed indicated that mutations that would almost certainly ablate the
dodecamer were viable and replicated nearly as efficiently as wild type MHV.
In addition, mutations in nsp10 affected processing of the ORF1a/1ab polyprotein as
a TS mutant of nsp10 was characterized by a complete block in Mpro cleavage of the viral
polyprotein at the non-permissive temperature.  This finding refutes the paradigm in the field
that concluded that p150 was an intermediate that functioned in the RNA replication
complex, indicating that it is premature to jump to such a conclusion based upon the weak
complementation assay data that has been published(22).
This finding implicates nsp10 as a critical co-factor in Mpro activity.   In general,
regulation of Mpro activity in MHV is poorly understood.  However, one potential
mechanism is that nsp10 allosterically regulates Mpro by interacting with another nsp(s) in
the p150 polyprotein to facilitate the proteinase activity by inducing a conformational change
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necessary for Mpro to function in cis.   Two studies have shown that nsp10 interacts with
other proteins including itself, nsp1 and nsp7(4, 29).  Future directions will be to determine if
amino acids 48-70 maintain a site important for interaction with other viral co-factors.
The role of nsp10 in processing is likely by cis interactions with a binding partner
within the precursor polyprotein.  A putative binding site between amino acid positions 50 to
70, which includes the conserved disordered region, may facilitate this interaction.
 A second possibility is that nsp10 encodes a flexible disordered region, conserved
among all coronaviruses, which allows the polyprotein to fold into proper orientation to
facilitate cleavage of p150 by Mpro.
A third possibility is that the TS mutation to nsp10 alters the conformation of p150 at
the non-permissive temperature and this prevents membrane anchoring or dimerization, both
of which may be essential to the activation of Mpro function(1, 2, 16, 30, 32, 33).
2.2 Future directions with this project
Work presented in this dissertation has demonstrated that nsp10 plays a dual role in
MHV infection, as both a regulator of viral RNA synthesis and as an important component of
polyprotein processing(5, 7).  Mapping 17 engineered mutations onto the solved crystal
structure of nsp10 suggested that a region on the exposed surface of this protein, identified as
a disordered region, is a key site, which may interact with other proteins in the replication
complex, may interact with the Mpro, or both.  This disordered region would be targeted
extensively in a follow up study to determine what role it plays in proteolytic processing,
RNA replication, and protein:protein interactions by generating a panel of disordered region
mutants and determining: 1) what role the region plays in RNA replication; 2) what role this
disordered region plays in proteolytic processing at the permissive and non-permissive
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temperatures; and 3) if nsp1, nsp7, and nsp10 continue to interact to form hetero- or
homodimers, respectively.
In addition, pathogenesis studies would be performed in mice to determine if any of
the viable mutants that exhibited moderate phenotypic differences in RNA replication in vitro
had more profound phenotypes in murine pathogenesis.  Single amino acid mutations in
MHV have resulted in lethal phenotypes in mice, and have deduced that some of the nsps
could be virulence factors in vivo(27).
Furthermore, using the TS mutant background, experiments would be designed to
express the Mpro and nsp10 from ORF4 of the TS MHV genome.  ORF4 encodes a protein
that is non-essential for MHV replication in vitro, and removing this and replacing it with the
Mpro or nsp10 would allow us to determine if cleavage could be rescued upon shift to the
non-permissive temperature by either of these two proteins working in trans.
3. CORONAVIRUS INFECTIOUS CLONE DEVELOPMENT
3.1 Generating a bioinformatics platform for designing infectious clones
The development of three full-length infectious clones is described in detail in
Chapter VI of this dissertation.  The first of these attempts was to develop an infectious clone
of HCoV-NL63 starting with genomic sequences deposited in the NCBI genomic database to
generate a consensus sequence, and then using that consensus sequence to determine the
fragments for the construction of a molecular clone.  This initial design of a full-length
molecular clone of HCoV-NL63 from synthetically derived sequences downloaded from the
NCBI genomic sequence database did not result in rescued recombinant virus.  After much
troubleshooting, it became apparent that the reported sequences were so riddled with errors
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that synthetic reconstruction of this virus via molecular clones was not possible.   A problem
that may account for the difficulty in working with the HCoV-NL63 nucleotide sequence is
the fact HCoV-NL63 is more AT rich than any other CoV, which may have complicated
sequence determinations.  Amplifying the plasmids containing HCoV-NL63 fragments
almost inevitably introduce T to C transitions, which suggests that the E. coli polymerase is
likely geared toward replicating genomes of high GC content.  These types of transition
errors likely resulted in many of the sequence errors that are contained in the sequence
database.  Importantly, a hierarchical bioinformatic driven strategy to identify likely
sequence errors was somewhat successful as the eventual consensus sequence that was
successful at reconstituting recombinant virus was nearly identical with our predicted
consensus sequence.    This resulted in a molecular clone of HCoV-NL63 and in addition, a
clone was developed that generates GFP from ORF3.
We were more successful on our second try at generating a full-length synthetic
genome.  In the case of the bat SARS-CoV, there were three nearly identical sequences
available, along with a closely related outlier, and the SARS-CoV clone, which we knew was
viable.  This made it much easier to generate a reliable consensus sequence, and icSARS
provided a similar design platform with which to determine the fragment boundaries.   Using
the same hierarchical approach that we pioneered in conceptually designing the HCoV-NL63
synthetic clone, we were able to successfully design a Bat SARS-CoV, that was synthesized
by Blue Heron Biotechnology, Inc, and that resulted in viable virus.  Further modifications
were made to the spike protein of Bat SARS-CoV, which resulted viable viruses that
replicates as efficiently as SARS-CoV (See Chapters VI and VII).
395
Molecular clones are available for many RNA and DNA viruses, and this technology
provides a platform for generating synthetic reconstructions of the viral genome, allowing for
the rapid development of important reagents and attenuated candidate vaccine strains.  In
addition, having access to the entire viral genome, a small fragment at a time, provides a
simple and rapid process for engineering appropriate mutations to answer basic science
questions.  These features make this technology a valuable resource for generating reagents
in rapid response to emerging or deliberately designed pathogens.
3.2 Future directions with HCoV-NL63 and BATicSARS
Having an infectious clone for a given virus provides a reverse genetic platform
through which a number of hypotheses can be tested.  Viral proteins can be removed singly
and in combination to determine which play important roles in viral replication, assembly,
egress, and attachment/entry.    Further, attenuating mutations can be introduced and studied
to develop candidate live vaccine strains for testing, and a variety of studies can be done to
determine which viral proteins encode virulence factors, or otherwise play a role in evading
the immune system.
Since HCoV-NL63 did not reach high titers in vitro, we adapted virus growth in
LLC-MK2 cells by serial passage, reasoning that this would select for viruses capable of
more efficient growth.  After 11 passages in these cells, NL63p11 grew to ~2 logs higher titer
(Fig. 2).  This was a significant increase in efficiency, and we are currently sequencing the
spike gene of the p11 virus to determine which changes allowed the adaptation.  Similar
experiments are being performed in primate airway cultures and in mice expressing the
human ACE2 receptor to identify virus strains that allow for robust animal model
development for pathogenesis and vaccine studies.
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Figure 2: Growth kinetics of wt-NL63 versus HCoV-NL63p11.  Wt-NL63 reaches a peak
titer of 2x105 on day 7 (168h p.i.), while NL63p11 showed a 1-2 log increase in growth at
every time point, reaching a peak titer of 2x106 at 6 days post infection (168h p.i.).
Future directions that can be taken with HCoV-NL63 include: 1) Generating vaccine
candidate strains, by identifying attenuating mutations; 2) Rewiring of the TRS elements of
the genome such that a vaccine strain could not recombine with a natural strain(35); 3)
introduction of heterologous antigens into the ORF3 site, creating a double hit vaccine
vector; 4) Investigation of the role of the ORF3 protein in pathogenesis, perhaps as an
interferon antagonist; 5) Adapting the virus to mice, creating a mouse model of infection and
potentially of pathogenesis(19), for testing candidate vaccine strains; and 6) Generating a
passage mutant to Vero cells, and then engineering these mutations back into the infectious
clone to determine which are important for the increased efficiency in binding the hACE2
receptor.
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Benefits of an NL63 based vaccine vector.  The availability of icNL63 and
icNL63gfp provides unique research opportunities, which will advance our understanding of
in vivo tropisms, and allow for the development of small animal models of infection.  We are
currently in the process of passing icNL63 in mice to develop a mouse adapted variant of the
virus, following a strategy that was successful in SARS-CoV(34), which uses the same
receptor as icNL63.  An infectious clone of NL63 is a powerful vaccine platform, as CPE can
be detected, it forms plaques, it uses the same receptor as has been described for SARS-CoV
and that is present in mice(17), and it readily adapts to grow more efficiently in vitro,
resulting in higher peak titers in less time.  These characteristics are in contrast to the only
other human coronavirus clone that would be suitabHCoV-229E clone, which grows poorly,
and is difficult to detect in cells(31).
The importance of the BATicSARS Clone.  The BATicSARS clone will be an
essential tool in furthering our understanding of the emergence of SARS-CoV from the
animal reservoir, and in identifying mechanisms by which CoV host range can be
deliberately targeted to different species.  To date no Bat SARS-CoV viruses have been
isolated and cultured from nature, making it impossible to experiment with and learn more
about this important virus(13, 18).  Therefore, in generating the BATicSARS clone, we
simultaneously resurrected a putative virus and generated the largest reported self-replicating
system to date.  In Chapter VI, we describe how the BATicSARS virus was resurrected from
a sequence database to a viable recombinant virus competent to infect Vero cells.  In Chapter
VII, we show that swapping the Bat RBD with the human RBD was sufficient to allow the
BATicSARS recombinant chimera to replicate as efficiently as wild type SARS-CoV.  The
BATicSARS clone is a valuable reagent that will be indispensable for determining how
398
SARS-CoV evolved from the animal reservoir into the human population.  Opportunities
now exist for testing a wide range of hypotheses, which will likely result in: 1) Identification
of the sequence differences between Bat SARS-CoV and SARS-CoV which are the
determinants that allowed the virus to infect humans; 2) Testing of future vaccine strains to
ensure that they are capable of neutralizing viruses in nature capable of reemerging; and 3)
Understanding how this virus adapted to cross the species barrier.
This work, in conjunction with the spike structural studies discussed below, has
demonstrated that the RBD is the minimal unit for host range shift, and it is apparent from
the structural models that many of the mutations that occur in the binding interface of the
RBD are to allow the virus to adapt to different ACE2 receptors.
4. CORONAVIRUS STRUCTURAL STUDIES WITH REPLICASE PROTEINS
4.1 Structure guided analysis of the coronavirus replicase proteins
Having a solved crystal structure of a protein of unknown function can provide
important clues as to the function of the protein, and the mechanism by which select
mutations and their revertants impact function.  While, a crystal structure provides evidence
of what structure a molecule assumes, biological molecules are dynamic, and thus a structure
is simply a snapshot of an instance or phase of the protein’s structure.  It is more difficult to
determine which interactions are interrupted or altered in the presence of a mutation, and
therefore genetic support is often required to verify and or refute structural predictions.
4.2 Structural analysis of nsp5
In Chapter VII, we present the results of a study that identified a new TS mutant in
nsp5, the main proteinase of Coronaviruses.  A single change in the Mpro resulted in a TS
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phenotype, which was rescued by second site mutations that occurred away from the binding
cleft and distal to the TS mutation.  We speculated, based on structural analysis, that the TS
mutation was caused by the interruption of hydrophobic interactions, which were restored
sufficiently in the revertants.
Future directions with this TS mutant and the revertants will focus on furthering our
understanding of how the two revertant mutants compensate for the TS mutation.
Interestingly, in SARS-CoV the catalytic dyad, the substrate binding residues, the Val at
position 148, and the His at position 134 are identical, but the Ser at position 133 in MHV is
Asn in SARS-CoV.  This is the exact amino acid replacement that allows the TS virus to
revert to a wt phenotype in MHV.  Hypothetically, introducing the V148A TS mutation into
the icSARS would not have a TS effect, as this change allowed the MHV Mpro to regain full
function at the permissive and non-permissive temperatures.
In addition, it would be informative to revisit some of the old complementation assays
that were used to predict that p150 functions in replication.  In those assays they used TS
mutants with mutations in nsp4, nsp5 and nsp10(3, 22, 26, 28).  Alb ts6 was the one
representing the nsp4 TS mutant, and this TS mutant was co-infected with TS-LA6 of nsp10
that did not complement.  However, in section 2 above and in Chapter IV, we show that the
nsp10 TS defect actually shuts down the Mpro, as does the TS mutant described here.  If the
Alb ts6 used in that complementation study was the same as the one we used (presumed to be
a defect in nsp4, but really found to be in nsp5)(3, 22, 26, 28), then those complementation
assays really tested two TS mutants in nsp5, and one in nsp10, all of which blocked nsp5
Mpro activity.  Clearly the entire issue regarding the role of the p150 precursor as a
functional intermediate is not supported by empirical studies to date, and cis acting sequences
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distal to the Mpro have a major impact on protease function.  Detailed studies on Mpro
interaction with precursor substrates, defined in vitro cleavage assays and modeling of larger
precursor structures will provide informative windows into the dynamic interactions that
regulate processing of the large coronavirus replicase polyprotein.
4.3 Structural analysis of nsp7 and nsp8
It has been proposed that the nsp7/nsp8 supercomplex forms a structure similar to
PCNA and beta-subunit(36), two processivity factors of DNA polymerase, known to encircle
dsDNA and confer high processivity upon it(36).  If the same activity is occurring in the
hexadecamer with CoV RNA, then it provides an important clue as to how the CoV
replication complex forms, and which proteins are key players. In this study, detailed in
Chapter VI, we designed fifteen mutants created to answer four distinct questions: 1) If nsp8
conformation was skewed to reduce the in the number of supercomplexes formed, would this
reduce the rate of viral RNA synthesis?  2) If the supercomplex formed, but did not have a
positive potential in the channel, would there be a decrease in viral RNA synthesis?  3) Is the
supercomplex biologically relevant or just an artifact of crystallography?  And finally, 4) Is
the primase activity essential for viral replication(8)?
While viral replication, as verified by RT-PCR occurred in 12 or perhaps 13-out-
of-15 of the mutant viruses, no recombinant virus for any mutant was ever detected by CPE
or plaque assay, and therefore no viruses were rescued.  Multiple attempts were made to
recover virus from the transfection supernatants, but nothing was ever detected in any case
except for the recombinant wt SARS-CoV virus, which was used as a control.  Future
directions with this project will focus on verifying that these mutations are lethal by
evaluating ratios of genome length and subgenomic length mRNAs after transfection, and/or
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assisting the recovery of defective mutants by trans-complementing in cells constitutively
expressing nsp7 and nsp8 delivered from expression plasmids.  In our hands, neither of these
genes were deleterious in eukaryotic cells, potentially providing a mechanism for recovering
debilitated viruses in sufficient titers for detailed studies on the block in replication.
Understanding the complexities of this unique RNA processivity factor will be
important in determining Coronavirus replication strategies in molecular detail.
5. CORONAVORIS SPIKE STRUCTURAL STUDIES
5.1 Structure guided analysis of the coronavirus spike protein
The SARS-CoV spike RBD structure has been solved interacting with its binding
partner human ACE2, and this structure has provided useful information about how these two
molecules interact to stabilize binding.   While there are a 18 amino acids in ACE2 that
contact 14 residues in the RBD of SARS-CoV (11), only 3 of these amino acids, 472, 479,
and 487 have been shown to be critical in binding of the RBD to ACE2 in epidemic strains
that emerged during the 2003 outbreak.  Among these, residue 472 has been described as
being less important than the other two (12, 14).  In the studies discussed here and presented
in detail in Chapter VII, we utilized structural bioinformatics to predict the impact of a
specific genotype on the RBD of SARS-CoV or on the different ACE2 species to predict
specific binding relationships, and the putative effects on the structure.
5.2 Generating an SARS-CoV-SZ16 spike chimeric virus
In this study, the SZ16 spike was placed into the icSARS clone and this recombinant
virus did not replicate in vitro(24, 25).  The SZ16 spike was then mutated at position K479N,
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a change was defined during the emergence of SARS-CoV from civet to human.  This
increased viral replication, but it still was not efficient.  The recombinant virus was passed in
human airway epithelial cultures and by day replication efficiency increased.  By day 22 in
passage the virus have acquired the adaptations necessary to replicate nearly as efficiently as
wt icSARS.  To determine the potential impact of the mutations introduced into the SZ16
spike or that were acquired during passage, we generated structural models of the SZ16,
SZ16-S K479N, SZ16-S K479N D8, and SZ16-S K479N D22 RBDs and then superimposed
these models onto the existing crystal structure of the SARS Urbani RBD bound to hACE2.
Similarly to Li et al., we observed that residue K479 of the SZ16 S inhibited binding to
hACE2 by sterically clashing with residues K31 and H34.  After the K479N mutation, the
electrostatic repulsion at residue 479 was eradicated, however, local remodeling within the
RBD created cross-reactions whereby residues 442 and 479 of the K479N RBD competed
with each other for interaction with partners of ACE2.  We predicted that this network of
competing interactions reduces the avidity between the K479N RBD and the hACE2 receptor
by misaligning other key residues in the RBD(24, 25).
Interestingly, the icSZ16-S K479N D8 Y442F mutation also restores an optimal RBD
by allowing for favorable amino acid packing that recreated an RBD architecture similar to
that of the wild type. In this case, the icSZ16-S K479N D8 RBD residues 442 and 479 have
distinct and unique interaction partners in hACE2, which likely restores avidity to near wild-
type levels and may explain why the icSZ16-S K479N D8 virus grows more efficiently than
the icSZ16-S K479N virus in cells expressing hACE2 . Thus, at least two independent routes
of evolution could increase S RBD and human ACE2 interactions. Leucine 472 of the
icSZ16-S K479N RBD and the icSZ16-S K479N D8 RBD interacts with L79 and M82 of
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ACE2. The icSZ16-S K479N D22 virus RBD is mutated at position 472 from leucine to
phenylalanine, which Rosetta Design predicts will induce strong hydrophobic interactions
between F472 and partners L79, M82, and Y83 of ACE2. The icSZ16-S K479N D22 virus
F472 mutation likely strengthens the binding interface of the icSZ16-S K479N D22 virus
over the icSZ16-S K479N D8 strain, which may explain why the icSZ16-S K479N D22 virus
has a growth advantage over the icSZ16-S K479N D8 virus in HAE, Vero E6, and DBT-
hACE2 cells. These data demonstrate the plasticity of the RBD-ACE2 interface site and its
ability to subtly remodel the RBD and hACE2 binding interface to promote efficient entry
and growth. Clearly, multiple genetic pathways likely exist to allow for zoonotic SARS-CoV
host range expansion, and it will be interesting to determine if other contact interface point
mutations can enhance zoonotic virus infection of HAE cell cultures.
When these mutants were tested in a cell line stably expressing the human and civet
ACE2, there were some very interesting observations.  Perhaps the most interesting was that
the late phase SARS-CoV RBD had adapted to efficiently utilize both human and civet
ACE2 receptors(24, 25), while the SZ16 chimeras that had been adapted to the hACE2 could
no longer bind to civet ACE2 or use this receptor, but the original icSARS-SZ116 spike virus
did. Coupled with bioinformatic analysis of sequence information, our data argues that
human SARS-CoV, and not the Civet SARS-CoV, that may have first evolved from the Bat
reservoir.  This observation was further corroborated by phylogenetic analysis, which
suggests that the Bat SARS-CoV spike is more closely related to the middle phase human
SARS-CoV spike than to civet or raccoon variants of the virus (See Chapters II and VI).
5.3 Modeling the Bat SARS-CoV RBD and chimeras
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In this study described in detail in Chapter VII, we modeled the Bat RBD
interacting with the hACE2 receptor, and determined that these two proteins are not likely to
interact to allow the Bat SARS-CoV to attach to and enter cells expressing hACE2.  The
chimera Bat-SRBD, containing the Urbani RBD in the Bat-SARS-CoV backbone, was
predicted to interact as expected, and in fact this was shown to be the case in vitro, as
recombinant Bat-SRBD virus was rescued and was competent to infect and spread in Vero
cells.  Interestingly, we also modeled Bat-SRBM, and although it contained all of the
residues important for interacting with hACE2, this virus was not viable.   Analysis of the
structure suggested that sites distal to the binding interface potentially regulate receptor
attachment, as all residues that interact with hACE2 were present and predicted to assume a
conformation favorable for binding.  The only discrepancy noted by the homology model
was the loop that contains binding residue 472 was not in proper orientation for that residue
to interact appropriately with its binding partner on hACE2.  This observation, in conjunction
with the observation described in the previous section, led us to hypothesize that sites distal
to the binding interface are involved in binding, probably by allowing the RBD to bend into
position to bind hACE2.
To further validate this hypothesis, we utilized an online molecular dynamics
simulator (El nemo: http://www.igs.cnrs-mrs.fr/elnemo/) to analyze the flexibility of the
RBD in seven common planes of motion.  Interestingly, this program predicted that the loop
in question would flex back and forth, and hypothetically could flex inward to engage the
receptor (Fig. 3).  In order for this flexibility to occur, other sites distal to this loop would be
important for maintaining the conformation necessary to allow flexibility in the loop.
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Figure 3: Flexible binding of the SARS-CoV RBD with hACE2.  A.  The RBD (blue)
interacts with residues to recognize the hACE2 receptor (green).  B. Upon interaction, the
RBD changes conformation to wrap around the hACE2 receptor.  C.  The binding is
completed when all three interaction sites (red) come into contact with the appropriate
binding partners of hACE2.  Distal sites likely provide the flexibility to allow this
conformational change.
Further support for the hypothesis that the spike RBD flexes and bends around the hACE2
receptor has can been derived by looking at the structure of the SARS-CoV RBD from its
bound state as compared to its unbound state (Fig. 4).
Figure 4: The unbound versus bound structures of SARS-CoV RBD.  In the unbound
state the SARS-CoV RBD assumes an open conformation, whereby interaction residue L472
and the loop within which it resides is extended away from the interaction site.  In the bound
state, L472 and the loop extend down and in toward the binding partners that would be
present in hACE2.
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In the unbound state the RBD is has an open conformation, whereas in the bound state reside
L472 drops into position to interact with the hAVE2 residues.
In addition, it has been reported that SARS-CoV RBD does not interact well with
mACE2, however a mouse adapted SARS-CoV virus, with a single amino acid change in the
RBD, is able to efficiently replicate in mice.  We substituted the single amino acid
substitution into the Bat-SRBD and generated and analyzed a homology model of the
interaction.  The structural model predicted that this change would likely increase binding at
the bat-SRBD|mACE2 interface, allowing the Bat-SRBD-MA to replicate in mice.
Recombinant viruses bearing the Bat-SRBD-MA mutation were rescued from mice,
indicating that this single site is sufficient for host expansion from human to mouse.
6. NOROVIRUS PERSISTENCE IN HUMAN POPULATIONS
6.1 Evolution in the GII.4 genocluster
In Chapter IX, we demonstrated that within the GII.4 norovirus genocluster, evolution
has occurred over the ~ 20 years that these viruses have been isolated from outbreaks(15).
Interestingly, there is no evidence that this genocluster existed prior to the mid 1980’s while
other genogroups and genoclusters have isolates that date back to the 1960’s when
noroviruses were first being collected.  And even when the GII.4 genocluster did emerge
onto the scene in the 1980’s it appears that it evolved by epochal evolution, with the early
clusters undergoing long periods of stasis, followed by the emergence of novel epidemic
strains, which evolved rapidly and in a more linear manner (Fig. 5).
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Figure 5: Epochal evolution characterized by periods of stasis followed by sudden
bursts which give rise to novel epidemic strains.  FH, Farmington Hills; M, Den
Haag/Minerva.
However, six clusters were identified and each of these was distinct.  Next, we
mapped the antigenic variation onto the surface exposed P2 capsid structure and generated
and compared homology models of representative sequences for each cluster.  These
analyses suggested that variation in an around the receptor binding domain was subtly
altering the RBD structure in ways that we predicted would alter receptor binding and
antigenicity of the VLP.  Positive selection analysis identified five residues that were
changing more frequently than any other, and these were also mapped onto the structure (Fig.
6).
Interestingly, the sites operating under positive selection occurred in distinct epitopes,
and in regions where other variation was also present.  This suggested that these sites might
be antibody binding epitopes on the capsid (Fig. 6).  The overall results of the structural
modeling and comparison indicated that subtle rearrangements were occurring on the surface,
near the binding pocket(15).  Some of these changes appeared to be more drastic, for instance
the Asp to Gly change at position 393 that occurred during the emergence of the Camberwell
like strains to the Grimsby like viruses.  This change forced rotameric positioning in the
pocket such that it would assume a different form in Grimsby than the earlier cluster.
Another difference noted was between two strains in the Farmington Hills cluster that
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differed by only two amino acids, one in the P2 and the other in the P1 subdomain.  The
remodeling in this case was predicted to be subtle, but sufficient to account for altered
receptor binding.
Figure 6: Putative epitopes on the surface of the GII.4 viruses.  A.  Sites of positive
selection and variation were mapped onto the protruding domain structure, and these sites
occur adjacent to the receptor binding pockets on the most exposed edge of the capsid.   B.
Comparing the residues which change between the clusters at the most exposed positions
reveals that the Camberwell and Grimsby viruses are more similar than the other clusters,
although Hunter and Sakai share more similarity to each other than to Farmington Hills.
Camberwell, yellow; Grimsby, red; Farmington Hills, blue; Hunter, green; and Sakai, orange.
A, B, C, D, E are putative epitopes.
To assay the differences between representative sequences from each of these
clusters, we designed the capsid gene sequence of each strain not already present in our
collection, designed the gene to drop into the VEE replicon system, and had these genes
synthesized by BioBasic, Inc.  Utilizing this time-ordered panel of GII.4 VLPs from 1987-
2005, we demonstrated that specific changes proximal to the 2nd interaction site regulate
carbohydrate-binding patterns, which changed over the 20-year interval.  Using serum from a
human outbreak in 1988 and murine antisera, we used ELISAs and an in vitro carbohydrate
blockade as a surrogate neutralization assay to demonstrate that the noted variation alters the
serologic and blockade responses consistent with a model of antigenic drift.  Our data
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suggest a model of molecular evolution in which norovirus GII.4 strains persist by evolving
novel carbohydrate binding domains over time in response to immune driven selection and
antigenic drift in the receptor binding regions of the P2 subdomain (Fig.
7)(15).
Figure 7: A Model of persistence.  The GII.4 viruses persist in the human population by
two mechanisms.  First, adaptation, driven by herd immunity, results in viruses capable of
binding different and sometimes novel CHO receptors, allowing an expansion of host range
or penetrance into a previously naïve population.  Second, the variation allows escape from
the predominant herd immunity, resulting in a virus competent to infect the same population.
6.2 Future directions
The results of this study may help explain why norovirus immunity is complex.  First
of all, it clearly argues that minor sequence and structural differences allow these viruses to
escape pre-existing herd immunity.  Therefore, new strains emerge via selection by herd
immunity, and the result is a new variant, which is competent to infect the same individuals
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that experienced infection with the previous strain.  Second, as a consequence of this
selection, these viruses may evolve to engage different HBGAs, which indicates that
individuals resistant to one pandemic strain, may be susceptible to the next.  This is
particularly compelling in the case of the Farmington Hills strains, where two amino acid
differences resulted in significant and unexpected differences in receptor usage and VLP
antigenicity.  In this case, the single change in the P2 subdomain occurred on the perimeter of
the second interaction site at position 395, very near to the 393 residue that was shown to
allow for host range expansion during the rise of the Grimsby cluster.  The Farmington Hills
2002 strain, which encodes an Ala at position 395, does not bind any synthetic CHO that was
tested.  Changing this residue to Thr as in the 2002a strain of Farmington Hills, resulted in a
VLP capable of binding to Lea, Ley and surprisingly, A-antigen.  This is the first known
example of a VLP capable of binding both secretor and non-secretor HBGAs, and it implies
that this virus would be capable of infecting a previously resistant population.   Further, the
2002a strain is antigenically quite distinct from all other strains tested.  However, the single
change near the binding pocket is unlikely to encode this strong serologic change in the
2002a VLP, as other time-ordered VLPs encode amino acid changes at this position as well.
Rather, we predict that the alteration in the P1 subdomain, a change of Pro at position 226 to
Ser, might well define a major immunodominant epitope.
These observations suggest that just a few amino acid changes within the P2 or even
the P1 subdomains can result in profound differences in receptor usage and antigenicity.
Future directions with this project would focus on furthering our understanding of the impact
the variation has on CHO binding and VLP antigenicity, by designing mutants to test specific
hypotheses.  Proof of concept was shown with the 1987-D393G mutant, which incorporated
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a single amino acid change acquired during the emergence of the 1997 Grimsby cluster back
into the 1987 Camberwell VLP.  This result indicated that this position is important in VLP
binding to synthetic CHOs, as the binding pattern was altered to allow the mutant to expand
its host range.  It also showed that different residues are likely involved.  Testing subsets of
these different variable sites in the 1987 VLP background would allow us to elucidate which
residues are important for binding and which are important for escape.
In addition, monoclonal antibodies directed against each one of the representative
VLPs would provide a valuable panel of reagents for mapping the epitopes that allow escape.
This would be particularly powerful using a panel of mutants generated by swapping the
putative epitopes identified by mapping the sites of positive selection and variation on the
structure (Fig. 6).  Interestingly, it appears that at some positions the extant clusters “recycle”
amino acids observed in previous clusters.  For example, at position 355 in the1987 and 1997
clusters the residue was Ser, which changed to Asp in 2002, and then back to Ser in 2004 and
2005.  This happens at a handful of sites, and it suggests specific amino acids physiochemical
properties are required at specific positions, which limits the variation to a subset of residues.
Understanding which sites allow which residues, and how these positions influence receptor
binding and antigenicity would be valuable for directing vaccine design against the GII.4
genocluster.
And finally, something major happened between 1987 and 1995 that allowed the
GII.4 viruses to become the predominant pandemic norovirus outbreak strain in circulation.
In the second epidemic wave of the GII.4s, the Farmington Hills cluster of 2002 acquired a
one amino acid insert at position 394 in the ORF2 capsid structure.  This observation, taken
together with our observations from above which shows that altering positions 393 and 395
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results in differences in CHO binding, suggests that this region 393-395 of the capsid may
hold the key to how these viruses escape and persist.  Generating mutant VLPs to test the
impact of the insertion within the context of the Camberwell 1987 backbone would provide
significant insights into virus adaptability.
In addition, understanding why the GII.4 genocluster evolved into the pandemic
strains, when other genoclusters were present, begs the question why the GII.4s?  Why not
the GII.3s or the GI.1s?  Both of these genoclusters were circulating at that time and continue
to circulate in human populations.  Comparing the evolutionary profiles and structural
models of these different viruses will likely provide significant insights into how the GII.4
viruses became so successful.
7. THE FUTURE OF BIOINFORMATICS IN VIROLOGY
The work presented in this dissertation would not have been possible without utilizing
the many bioinformatics tools available.  From searching for sequences to aligning them and
determining the variation over time to generating trees to predicting characteristics of the
sequences at the nucleotide and protein levels, all of these tools were used in one form or
another.  And the field of structural bioinformatics, from visualization to model generating to
mutational impacts on a structure, these tools provided important clues, seeded hypotheses,
and allowed for the integration of bioinformatics, molecular biology, classic virology and
synthetic genomics.
The combined power of bioinformatics and synthetic genomics is staggering.  In this
dissertation we described the process of resurrecting the largest self-replicating organism to
date, and we generated dozens of genes to be dropped into various replicon systems for
413
expression.   However, this is just the beginning.  By integrating bioinformatics with
synthetic genomics, we are within reach of rational design of synthetic vectors for gene
therapy, vaccine candidate strains that are efficacious against multiple pathogens, and
eventually synthetic life forms designed for a specific purpose.
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